US20150238473A1 - Methods and compositions for treating infection - Google Patents

Methods and compositions for treating infection Download PDF

Info

Publication number
US20150238473A1
US20150238473A1 US14/431,031 US201314431031A US2015238473A1 US 20150238473 A1 US20150238473 A1 US 20150238473A1 US 201314431031 A US201314431031 A US 201314431031A US 2015238473 A1 US2015238473 A1 US 2015238473A1
Authority
US
United States
Prior art keywords
infection
lower alkyl
virus
phenyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/431,031
Inventor
Paul M. Dunman
Damian J. Krysan
Daniel P. Flaherty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kansas
University of Rochester
Original Assignee
University of Kansas
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kansas, University of Rochester filed Critical University of Kansas
Priority to US14/431,031 priority Critical patent/US20150238473A1/en
Assigned to UNIVERSITY OF KANSAS reassignment UNIVERSITY OF KANSAS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FLAHERTY, Daniel P.
Assigned to UNIVERSITY OF ROCHESTER reassignment UNIVERSITY OF ROCHESTER ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DUNMAN, Paul M., KRYSAN, DAMIAN J.
Assigned to UNIVERSITY OF ROCHESTER reassignment UNIVERSITY OF ROCHESTER ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DUNMAN, Paul M., KRYSAN, DAMIAN J.
Assigned to UNIVERSITY OF KANSAS reassignment UNIVERSITY OF KANSAS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FLAHERTY, Daniel P.
Publication of US20150238473A1 publication Critical patent/US20150238473A1/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF ROCHESTER
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • a method of treating or preventing an infection in a subject with or at risk of developing an infection comprising administering to the subject
  • R represents hydrogen or hydroxyl and R 1 represents hydrogen, or R and R 1 taken together form a second bond between the carbon atoms bearing R and R 1 ;
  • R 2 represents hydrogen or phenyl;
  • n is zero or a positive whole integer of from 1 to 4;
  • X represents CH 2 , CHOH, NH, C ⁇ O, CHNR 3 R 4 , where R 3 and R 4 independently are hydrogen or lower alkyl;
  • Z represents thienyl, pyridinyl, substituted pyridinyl, phenyl or substituted phenyl wherein the substituents on the substituted pyridinyl or substituted phenyl are selected from phenyl, pyridinyl, nitro, a halogen atom, such as chlorine, fluorine, bromine, or iodine, a straight or branched lower alkyl chain of from 1 to 4 carbon atoms, a lower alkoxy group of from 1 to 4 carbon atoms, amino,
  • R 5 is hydrogen or lower alkyl
  • R 6 and R 7 independently are hydrogen or methyl or a pharmaceutically acceptable salt thereof.
  • R 1 and R 2 are independently selected from ethyl or methyl, n 1 or 2, R 3 and R 4 are both phenyl or substituted phenyl, wherein the substituent can be halo (for example, fluoro-, chloro-, iodo- or bromo-), hydroxyl, a lower alkyl or a substituted lower alkyl wherein the substituent can be halo, hydroxy, or lower alkoxy, and R 5 is hydrogen, a halogen, a lower alkyl from about 1 to 4 carbon atoms or a substituted alkyl wherein the substituent can be halo, hydroxy, or lower alkoxy.
  • R 1 and R 2 are independently selected from ethyl or methyl, n 1 or 2
  • R 3 and R 4 are both phenyl or substituted phenyl, wherein the substituent can be halo (for example, fluoro-, chloro-, iodo- or bromo-), hydroxy
  • R 1 is a lower alkyl group having from 1 to 4 carbon atoms being substituted with one or several halogen atoms
  • Z is hydrogen or a lower alkyl group having from 1 to 4 carbon atoms
  • m is 2 or 3
  • X 2 is the ethylene imino group or the group having the formula:
  • R is hydrogen or a lower alkyl group having from 1 to 4 carbon atoms which can be substituted with a chlorine atom or a hydroxy group
  • Z and m have the above-given meaning
  • R represents a lower alkyl or a lower alkenyl group, a phenyl group which can be substituted by halogen, methyl or lower alkoxy groups, or a benzyl group which can be nuclear substituted by halogen, methyl or lower alkoxy groups
  • X represents —O—, —S—, —SO—, or —SO 2 —
  • n represents an integer from 1-4
  • Aryl represents a phenyl group which can be substituted by lower alkoxy or lower alkylmercapto groups
  • R and R 6 are the same or different and are hydroxy, lower alkoxy, lower alkenoxy, dilower alkylamino lower alkoxy (dimethylaminoethoxy), acylamino lower alkoxy (acetylaminoethoxy), acyloxy lower alkoxy (pivaloyloxymethoxy), aryloxy, such as phenoxy, arloweralkoxy, such as benzyloxy, substituted aryloxy or substituted arloweralkoxy wherein the substitutent is methyl, halo or methoxy, amino, loweralkylamino, diloweralkylamino, hydroxyamino, arloweralkylamino such as benzylamino;
  • R 1 is hydrogen, alkyl of from 1 to 20 carbon atoms which include branched and cyclic and unsaturated (such as allyl) alkyl groups, substituted loweralkyl wherein the substituent can be halo, hydroxy, lower alkoxy, aryloxy such as phenoxy, amino, diloweralkylamino, acylamino, such as acetamido and benzamido, arylamino, guanidino, imidazolyl, indolyl, mercapto, loweralkylthio, arylthio such as phenylthio, carboxy or carboxamido, carboloweralkoxy, aryl such as phenyl or naphthyl, substituted aryl such as phenyl wherein the substituent is lower alkyl, lower alkoxy or halo, arloweralkyl, arloweralkenyl, heteroarlower alkyl or heteroarlower alkenyl
  • R 2 and R 7 are the same or different and are hydrogen or lower alkyl
  • R 3 is hydrogen, lower alkyl, phenyl lower alkyl, aminomethyl phenyl lower alkyl, hydroxy phenyl lower alkyl, hydroxy lower alkyl, acylamino lower alkyl (such as benzoylamino lower alkyl, acetylamino lower alkyl), amino lower alkyl, dimethylamino lower alkyl, halo lower alkyl, guanidino lower alkyl, imidazolyl lower alkyl, indolyllower alkyl, mercapto lower alkyl, lower alkyl thio lower alkyl;
  • R 4 is hydrogen or lower alkyl
  • R 5 is hydrogen, lower alkyl, phenyl, phenyl lower alkyl, hydroxy phenyl lower alkyl, hydroxy lower alkyl, amino lower alkyl, guanidino lower alkyl, imidazolyl lower alkyl, indolyl lower alkyl, mercapto lower alkyl or lower alkyl thio lower alkyl;
  • R 4 and R 5 can be connected together to form an alkylene bridge of from 2 to 4 carbon atoms, an alkylene bridge of from 2 to 3 carbon atoms and one sulfur atom, an alkylene bridge of from 3 to 4 carbon atoms containing a double bond or an alkylene bridge as above substituted with hydroxy, loweralkoxy, loweralkyl or diloweralky;
  • R 1 is H, alkyl, acyl or silyl(alkyl) 3 ;
  • R 2 is H and R 3 is OH, O-acyl, O-alkyl or O-silyl (alkyl) 3 or
  • R 3 is H and R 2 is OH.
  • R 1 might also represent a substituted alkyl such as e.g. methoxy ethoxy methyl;
  • PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents
  • R is hydrogen, lower-alkyl or lower-hydroxyalkyl
  • Q is nitro, carbamyl, halo, amino, lower-alkylamino, di(lower-alkyl)amino, or NHAc where Ac is lower-alkanoyl or lower-carbalkoxy;
  • a method of treating or preventing an infection in a subject with or at risk of developing an infection comprising administering to the subject a compound selected from the group consisting of: Didanosine, Norcyclobenzaprine, Niridazole, Ifosfamide, Cefalonium, Tamoxifen citrate, Butoconazole, Suloctidil, Clomiphene, Sulconazole, Miconazole, Mefloquine, Sulfinpyrazone, Terfenadine, Lisinopril, Econzaole, Clofazimine, Equilin, Felodipine, dacarbazine, Furazolidone, Perhexiline maleate, Oxethazaine, Pimozide, Trifluoperazine, Ellipticine, Fluspirilen, Hexestrol, Dienestrol, Zidovudine, Metoprolol, Napelline, Methimazole, Amrinone, Iopanoic acid,
  • Also provided is a method of removing or preventing biofilm formation on a surface comprising administering to a biofilm containing surface or a surface susceptible to biofilm formation an effective amount of a compound selected from the group consisting of:
  • R represents hydrogen or hydroxyl and R 1 represents hydrogen, or R and R 1 taken together form a second bond between the carbon atoms bearing R and R 1 ;
  • R 2 represents hydrogen or phenyl;
  • n is zero or a positive whole integer of from 1 to 4;
  • X represents CH 2 , CHOH, NH, C ⁇ O, CHNR 3 R 4 , where R 3 and R 4 independently are hydrogen or lower alkyl;
  • Z represents thienyl, pyridinyl, substituted pyridinyl, phenyl or substituted phenyl wherein the substituents on the substituted pyridinyl or substituted phenyl are selected from phenyl, pyridinyl, nitro, a halogen atom, such as chlorine, fluorine, bromine, or iodine, a straight or branched lower alkyl chain of from 1 to 4 carbon atoms, a lower alkoxy group of from 1 to 4 carbon atoms, amino,
  • R 5 is hydrogen or lower alkyl
  • R 6 and R 7 independently are hydrogen or methyl or a pharmaceutically acceptable salt thereof.
  • FIG. 1 depicts the adenylate kinase (AK) assay described in the Examples.
  • Bactericidal agents compromise bacterial cell integrity, releasing cellular adenylate kinase.
  • Extracellular AK is measured by the addition of a commercial ToxiLight AK cocktail containing ADP and luciferase, resulting in luminescence.
  • FIG. 2 shows AK assay development.
  • A AK assay measures of E. coli lysed cell supernatants. E. coli DH5 ⁇ cells (1 ⁇ 10 9 ) were heat inactivated by boiling and diluted, and the AK assay was used to measure adenylate kinase release. Background signal is also shown (mock-treated cells (right-hand column in FIG. 2A ). “*” indicates a significant difference between results for boiled and mock treatment (Student's t test; P ⁇ 0.05).
  • B AK assay results for colistin-treated A. baumannii strain 98-37-09.
  • FIG. 3 shows AK assay measures of S. aureus strain RN4220 treatment with bacteriostatic and bactericidal antibiotics.
  • Standard MIC testing determined the MIC of each antibiotic class (in parentheses).
  • Graphed are the fold changes in AK signal of cells treated with 0.5 ⁇ or 1.0 ⁇ the MIC value (left hand column and right hand column, respectively) for each antibiotic, in comparison to untreated control cells; “*” indicates a significant change in signal as determined by Student's t test; P ⁇ 0.05 (compared to results for untreated cells).
  • FIG. 4 shows AK assay measures of antibiotic-treated biofilms and small-colony variants.
  • A Graphed are AK signals generated by static biofilm-associated cells following mock or antibiotic treatment: colistin ( P. aeruginosa ) or ciprofloxacin ( S. aureus and A. baumannii ).
  • B Fold change of AK measures of S. aureus SCV UAMS-1112 cells following treatment with 1 ⁇ and 10 ⁇ ciprofloxacin, meropenem, and vancomycin, compared to results for mock treated cells. “*” indicates a significant change in signal in comparison to results for mock-treated cells (Student's t test, P ⁇ 0.05).
  • FIG. 5 shows AK-based HTS development and screening.
  • A Z′ factor assay results for Klebsiella pneumoniae . Three-hundred-eighty-four-well microtiter plates were seeded with K. pneumoniae , and alternating rows were mock treated (DMSO) or treated with 50 ⁇ M colistin. Following 3 h of incubation, AK release was measured and plotted. DMSO-treated well measures are shown at the bottom of FIG. 5A ; colistin-treated wells are shown at the top of FIG. 5A .
  • B Prestwick library Klebsiella pneumoniae screening results. In total, 26 compounds were determined to result in a 3-fold increase in AK signal, in comparison to results for DMSO-treated cells. Included among this list were polymyxin, cephalosporins, aminoglycosides, fluoroquinolones, and detergents; the complete Prestwick screening results for K. pneumoniae and all other organisms screened are provided in Table 4.
  • FIG. 6 shows antimicrobial properties of terfenadine and tamoxifen.
  • A Fold changes in AK signal of terfenadine-treated (10 ⁇ MIC) S. aureus strain UAMS-1 static biofilms and the SCV strain UAMS-1112, compared to those for mock (DMSO)-treated populations, are plotted. “*” indicates a significant increase in signal over that with mock-treated cells (Student's t test, P ⁇ 0.05).
  • B Plotted are the percent survival of G. mellonella larvae at 48 h post- E. faecium inoculation.
  • Groups of larvae were treated at 2 h and 24 h with either PBS (mock), DMSO, 80 mg kg ⁇ 1 tamoxifen, 160 mg kg ⁇ 1 tamoxifen, or 20 mg kg ⁇ 1 vancomycin.
  • R represents hydrogen or hydroxyl and R 1 represents hydrogen, or R and R 1 taken together form a second bond between the carbon atoms bearing R and R 1 ;
  • R 2 represents hydrogen or phenyl;
  • n is zero or a positive whole integer of from 1 to 4;
  • X represents CH 2 , CHOH, NH, C ⁇ O, CHNR 3 R 4 , where R 3 and R 4 independently are hydrogen or lower alkyl;
  • Z represents thienyl, pyridinyl, substituted pyridinyl, phenyl or substituted phenyl wherein the substituents on the substituted pyridinyl or substituted phenyl are selected from phenyl, pyridinyl, nitro, a halogen atom, such as chlorine, fluorine, bromine, or iodine, a straight or branched lower alkyl chain of from 1 to 4 carbon atoms, a lower alkoxy group of from 1 to 4 carbon atoms, amino,
  • R 5 is hydrogen or lower alkyl
  • R 6 and R 7 independently are hydrogen or methyl.
  • the substituents on the substituted phenyl may be attached at the ortho, meta or para positions of the phenyl ring.
  • Compounds of Formula I include compounds of Formula II,
  • R represents hydrogen or hydroxyl and R 1 represents hydrogen, or R and R 1 taken together form a second bond between the carbon atoms bearing R and R 1 ;
  • n is zero or a positive whole integer of from 1 to 4;
  • Z represents thienyl, pyridinyl, substituted pyridinyl, phenyl or substituted phenyl wherein the substituents on the substituted pyridinyl or substituted phenyl are selected from phenyl, pyridinyl, nitro, a halogen atom, such as chlorine, fluorine, bromine, or iodine, a straight or branched lower alkyl chain of from 1 to 4 carbon atoms, a lower alkoxy group of from 1 to 4 carbon atoms, amino, a mono or di(lower)alkylamino group, a saturated monocyclic heterocyclic group such as pyrrolidino, piperidino, morpholino, or N-(lower)al
  • Compounds of Formula I also include terfenadine and derivatives thereof, including, but not limited to the following compounds.
  • the compounds are identified by structure, name and registry number.
  • the registry number for each compound is also set forth in Table 6 as an additional identifier for each compound.
  • the compounds of Formula III include, tamoxifen and derivatives
  • the infection can be an infection, wherein the infection is not a fungal infection or a parasitic infection.
  • R 1 is a lower alkyl group having from 1 to 4 carbon atoms being substituted with one or several halogen atoms
  • Z is hydrogen or a lower alkyl group having from 1 to 4 carbon atoms
  • m is 2 or 3
  • X 2 is the ethylene imino group or the group having the formula:
  • R is hydrogen or a lower alkyl group having from 1 to 4 carbon atoms which may be substituted with a chlorine atom or a hydroxy group
  • Z and m have the above-given meaning, or a pharmaceutically acceptable salt thereof.
  • lower alkyl group containing from 1 to 4 carbon atoms means methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tertiary butyl, and I-methylpropyl.
  • halogen means chlorine, bromine, fluorine, and iodine. Included herein are compounds of formula IV that correspond to formula VI:
  • R 2 is a ⁇ -chloroethyl or a ⁇ -chloropropyl group
  • R 3 is hydrogen, a methyl group or an ethyl group, optionally substituted in the ⁇ -position with a chlorine atom or a hydroxy group.
  • the compound of formula VIII is 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide or ifosfamide. Ifosfamide is also known as IFEX.
  • R represents a lower alkyl or a lower alkenyl group, a phenyl group which can be substituted by halogen, methyl or lower alkoxy groups, or a benzyl group which can be nuclear substituted by halogen, methyl or lower alkoxy groups
  • X represents —O—, —S—, —SO—, or —SO 2 —
  • n represents an integer from 1-4
  • Aryl represents a phenyl group which can be substituted by lower alkoxy or lower alkylmercapto groups; or a pharmaceutically acceptable salt thereof.
  • R represents a lower alkyl or a lower alkenyl group, a phenyl group which can be substituted by halogen, methyl or lower alkoxy groups, or a benzyl group which can be nuclear substituted by halogen, methyl or lower alkoxy groups
  • X represents —O—, —S—, —SO—, or —SO2-
  • n represents an integer from 1-4
  • aryl represents a phenyl group which can be substituted by lower alkoxy or lower alkylmercapto groups.
  • —R—X—C n H 2n — can represent the following groups: methoxy-, ethoxy-, propoxy-, isopropoxy-, butoxy-, isobutoxy-, allyloxy-, crotyloxy-.
  • aryl can be, for example, the o- or p-methylmercaptophenyl group, the o- or p-ethyl mercaptophenyl group, the o-; m-, or p-methoxyphenyl group or the o-, m- or p-ethoxyphenyl group.
  • formula XI An example of the compound of formula X is set forth herein as formula XI.
  • the compound of formula X is sulfinapyrazone. Sulfinapyrazone is also known as Anturane.
  • Also provided herein is a method of treating or preventing an infection in a subject with or at risk of developing an infection, the method comprising administering to the subject a compound selected from the group consisting of:
  • R and R 6 are the same or different and are hydroxy, lower alkoxy, lower alkenoxy, dilower alkylamino lower alkoxy (dimethylaminoethoxy), acylamino lower alkoxy (acetylaminoethoxy), acyloxy lower alkoxy (pivaloyloxymethoxy), aryloxy, such as phenoxy, arloweralkoxy, such as benzyloxy, substituted aryloxy or substituted arloweralkoxy wherein the substitutent is methyl, halo or methoxy, amino, loweralkylamino, diloweralkylamino, hydroxyamino, arloweralkylamino such as benzylamino;
  • R 1 is hydrogen, alkyl of from 1 to 20 carbon atoms which include branched and cyclic and unsaturated (such as allyl) alkyl groups, substituted loweralkyl wherein the substituent can be halo, hydroxy, lower alk
  • R and R 6 are the same or different and are hydroxy, lower alkoxy, lower alkenoxy, dilower alkylamino lower alkoxy (dimethylaminoethoxy), acylamino lower alkoxy (acetylaminoethoxy), acyloxy lower alkoxy (pivaloyloxymethoxy), aryloxy, such as phenoxy, arloweralkoxy, such as benzyloxy, substituted aryloxy or substituted arloweralkoxy wherein the substitutent is methyl, halo or methoxy, amino, loweralkylamino, diloweralkylamino, hydroxyamino, arloweralkylamino such as benzylamino;
  • R 1 is hydrogen, alkyl of from 1 to 20 carbon atoms which include branched and cyclic and unsaturated (such as allyl) alkyl groups, substituted loweralkyl wherein the substituent can be halo, hydroxy, lower alkoxy, aryloxy such as phenoxy, amino, diloweralkylamino, acylamino, such as acetamido and benzamido, arylamino, guanidino, imidazolyl, indolyl, mercapto, loweralkylthio, arylthio such as phenylthio, carboxy or carboxamido, carboloweralkoxy, aryl such as phenyl or naphthyl, substituted aryl such as phenyl wherein the substituent is lower alkyl, lower alkoxy or halo, arloweralkyl, arloweralkenyl, heteroarlower alkyl or heteroarlower alkenyl
  • R 2 and R 7 are the same or different and are hydrogen or lower alkyl
  • R 3 is hydrogen, lower alkyl, phenyl lower alkyl, aminomethyl phenyl lower alkyl, hydroxy phenyl lower alkyl, hydroxy lower alkyl, acylamino lower alkyl (such as benzoylamino lower alkyl, acetylamino lower alkyl), amino lower alkyl, dimethylamino lower alkyl, halo lower alkyl, guanidino lower alkyl, imidazolyl lower alkyl, indolyllower alkyl, mercapto lower alkyl, lower alkyl thio lower alkyl;
  • R 4 is hydrogen or lower alkyl
  • R 5 is hydrogen, lower alkyl, phenyl, phenyl lower alkyl, hydroxy phenyl lower alkyl, hydroxy lower alkyl, amino lower alkyl, guanidino lower alkyl, imidazolyl lower alkyl, indolyl lower alkyl, mercapto lower alkyl or lower alkyl thio lower alkyl;
  • R 4 and R 5 may be connected together to form an alkylene bridge of from 2 to 4 carbon atoms, an alkylene bridge of from 2 to 3 carbon atoms and one sulfur atom, an alkylene bridge of from 3 to 4 carbon atoms containing a double bond or an alkylene bridge as above substituted with hydroxy, loweralkoxy, loweralkylor diloweralky.
  • the loweralkyl or lower alkenyl groups except where noted otherwise represented by any of the variables include straight and branched chain hydrocarbon radicals from one to six carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, hexyl or vinyl, allyl, butenyl and the like.
  • the aralkyl groups represented by any of the above variables have from one to four carbon atoms in the alkyl portion thereof and include for example, benzyl, p-methoxy benzyl and the like.
  • Halo means chloro, bromo, iodo or fluoro.
  • Aryl where it appears in any of the radicals except where noted represents phenyl or naphthyl.
  • Heteroaryl groups where they appear include for example pyridyl, thienyl, furyl, indolyl, benzthienyl, imidazoyl and thiazolyl.
  • the R 1 , R 3 and R 5 substituted lower alkyl moieties are exemplified by groups such as
  • R 4 and R 5 when joined through the carbon and nitrogen atoms to which they are attached form a 4 to 6 membered ring which may contain one sulfur atom or a double bond.
  • Preferred rings have the formulae:
  • Y is CH 2 , S, or CHOCH 3 .
  • R and R 6 can each independently be hydroxy, lower alkoxy, lower alkenoxy, arloweralkyloxy, amino, dilower alkylamino lower alkoxy, acylamino lower alkoxy, acyloxy lower alkoxy wherein the substituent is methyl, halo or methoxy;
  • R 2 and R 7 are hydrogen;
  • R 3 is lower alkyl, amino lower alkyl, imidazoyllower alkyl, halo lower alkyl;
  • R 4 and R 5 are joined to form the preferred rings as defined above where Y is CH 2 , S, or CH—OCH 3 ;
  • R 1 is as defined previously.
  • R 1 is alkyl having from 1 to 8 carbon atoms, substituted lower alkyl wherein the alkyl group has 1-5 carbon atoms and the substituent is amino, arylthio, aryloxy or arylamino, aralkyl or heteroaralkyl wherein the alkyl portion has 1 to 3 carbon atoms such as phenethyl or indolylethyl or substituted arloweralkyl 65 (phenyl lower alkyl or naphthyl lower alkyl) and substituted heteroarloweralkyl wherein the alkyl groups have 1-3 carbons and wherein the substituent(s) is halo, dihalo, amino, aminoalkyl, hydroxy, lower alkoxy or lower alkyl.
  • R 2 and R 7 are hydrogen
  • R 3 is methyl or amino lower alkyl
  • R 4 and R 5 are joined through the carbon and nitrogen atom to form proline, 4-thiaproline or 4-methoxy proline;
  • R 1 is alkyl having from 1 to 8 carbon atoms, substituted lower alkyl wherein the alkyl group has 1-5 carbon atoms and the substituent is amino, arylthio or aryloxy, aralkyl or heteroaralkyl wherein the alkyl portion has 1 to 3 carbon atoms such as phenethyl or indolylethyl or substituted aralkyl (phenyl lower alkyl or naphthyl lower alkyl) and substituted heteroaralkyl wherein the alkyl groups have 1-3 carbons and wherein the substituent(s) is halo, dihalo, amino, aminoalkyl, hydroxy, lower alkoxy or lower alkyl.
  • Also provided herein is a method of treating or preventing an infection in a subject with or at risk of developing an infection, the method comprising administering to the subject a compound selected from the group consisting of:
  • R 1 is H, alkyl, acyl or silyl(alkyl) 3 ;
  • R 2 is H and R 3 is OH, O-acyl, O-alkyl or O-silyl (alkyl) 3 or
  • R 3 is H and R 2 is OH.
  • R 1 might also represent a substituted alkyl such as e.g. methoxy ethoxy methyl; or a pharmaceutically acceptable salt thereof.
  • Also provided herein is a method of treating or preventing an infection in a subject with or at risk of developing an infection, the method comprising administering to the subject a compound selected from the group consisting of:
  • PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents
  • R is hydrogen, lower-alkyl or lower-hydroxyalkyl
  • Q is nitro, carbamyl, halo, amino, lower-alkylamino, di(lower-alkyl)amino, or NHAc where Ac is lower-alkanoyl or lower-carbalkoxy; or a pharmaceutically acceptable salt thereof.
  • PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents
  • R is hydrogen, lower-alkyl or lower-hydroxyalkyl
  • Q is nitro, carbamyl, halo, amino, lower-alkylamino, di(lower-alkyl)amino, or NHAc where Ac is lower-alkanoyl or lower-carbalkoxy, or pharmaceutically-acceptable acid-addition salt thereof.
  • Q is amino, lower-alkylamino, di-(lower-alkyl) amino, or NHAc are provided herein.
  • the compounds of formula XIII where Q is nitro or carbamyl are useful as intermediates for preparing the said compounds where Q is amino and those where Q is halo are useful as intermediates in the preparation of the compounds where Q is lower-alkylamino and di-(lower-alkyl)amino.
  • Other compounds of Formula XIII include compounds where Q is amino, R is hydrogen and PY is 4-pyridinyl or 3-pyridinyl, for example, 3-amino-5-(4-pyridinyl)-2(1H)-pyridinone (amrinone).
  • Formula XV is fluspirilen
  • Formula XVI is hexestrol
  • Formula XVII is dienestrol
  • Formula XVIII is napelline
  • Formula XIX is iopanoic acid
  • Formula XX is suloctodil.
  • a method of treating or preventing an infection in a subject with or at risk of developing an infection comprising administering to the subject a compound selected from the group consisting of: Didanosine, Norcyclobenzaprine, Niridazole, Ifosfamide, Cefalonium, Tamoxifen citrate, Butoconazole, Suloctidil, Clomiphene, Sulconazole, Miconazole, Mefloquine, Sulfinpyrazone, Terfenadine, Lisinopril, Econzaole, Clofazimine, Equilin, Felodipine, dacarbazine, Furazolidone, Perhexiline maleate, Oxethazaine, Pimozide, Trifluoperazine, Ellipticine, Fluspirilen, Hexestrol, Dienestrol, Zidovudine, Metoprolol, Napelline, Methimazole, Amrinone, Iopanoic acid,
  • a method of treating or preventing an infection in a subject with or at risk of developing an infection comprising administering to the subject a compound selected from the group consisting of: Didanosine, Norcyclobenzaprine, Niridazole, Ifosfamide, Cefalonium, Tamoxifen citrate, Butoconazole, Suloctidil, Clomiphene, Sulconazole, Miconazole, Mefloquine, Sulfinpyrazone, Terfenadine, Lisinopril, Econzaole, Clofazimine, Equilin, Felodipine, dacarbazine, Furazolidone, Perhexiline maleate, Oxethazaine, Pimozide, Trifluoperazine, Ellipticine, Fluspirilen, Hexestrol, Dienestrol, Zidovudine, Metoprolol, Napelline, Methimazole, Amrinone, Iopanoic acid,
  • a method of treating or preventing a bacterial infection in a subject with or at risk of developing a bacterial infection in a subject comprising administering to the subject a compound that inhibits bacterial DNA gyrase or topoisomerase IV.
  • the compound can be, for example, a compound of Formula I.
  • a compound of Formula I can be terfenadine or a derivative thereof.
  • an inhibitor of bacterial DNA gyrase or topoisomerase IV can be used to treat or prevent Staphylococcus aureus infection.
  • compositions or derivatives of the compounds set forth herein can be administered to treat or prevent infection.
  • combinations of the compounds set forth herein are also provided.
  • Pharmaceutically acceptable salts of all of the compounds set forth herein are also provided.
  • pharmaceutically acceptable salt as used herein refers to those salts of any of the compounds described herein or derivatives thereof that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of subjects without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds described herein.
  • salts refers to the relatively non-toxic, inorganic and organic acid addition salts of the compounds described herein. These salts can be prepared in situ during the isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed.
  • Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate mesylate, glucoheptonate, lactobionate, methane sulphonate, and laurylsulphonate salts, and the like.
  • alkali and alkaline earth metals such as sodium, lithium, potassium, calcium, magnesium, and the like
  • non-toxic ammonium, quaternary ammonium, and amine cations including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like.
  • the infection can be a viral infection, bacterial infection, fungal infection or a parasitic infection, to name a few. All strains and types of pathogenic infection are contemplated herein.
  • the infection can also be a respiratory infection, a gastrointestinal infection or a skin infection, to name a few.
  • the infection can be any infection, wherein the infection is not a bacterial infection. In any of the methods of treating or preventing infection set forth herein, the infection can be any infection, wherein the infection is not a viral infection. In any of the methods of treating or preventing infection set forth herein, the infection can be any infection, wherein the infection is not a parasitic infection. In any of the methods of treating or preventing infection set forth herein, the infection can be any infection, wherein the infection is not a fungal infection. In any of the methods of treating or preventing infection set forth herein, the infection can be any infection, wherein the infection is not a protozoal infection.
  • bacterial infections include, but are not limited to infections caused by the Gram negative or Gram positive bacteria.
  • the infection can be caused by Listeria (sp.), Franscicella tularensis, Enterobacter sp. Enterococcus faecium , other Enterococcus species, Klebsiella pneumonia, Acinetobacter baumannii, Mycobacterium tuberculosis, Rickettsia (all types), Ehrlichia or Chylamida .
  • Further examples of bacteria include M.
  • one or more compounds set forth herein can treat or prevent one or more bacterial infections selected from the group consisting of Enterobacterium faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinebacter baumannii, Pseudomonas aeruginosa and Enterobacter sp.
  • the bacteria can be a small colony variant strain, for example a small colony strain of Staphylococcus aureus .
  • the infection can be a bacterial infection, wherein the bacterial infection is not tuberculosis, for example, Mycobacterium tuberculosis .
  • compounds of Formula I and II can be used to treat or prevent infection in a subject with or at risk of developing an infection, wherein the infection is not tuberculosis.
  • parasitic infections include, but are not limited to infections caused by the following parasites: Cryptosporidium, Plasmodium (all species), American trypanosomes ( T. cruzi ), African trypanosomes, Acanthamoeba, Entaoeba histolytica, Angiostrongylus, Anisakis, Ascaris, Babesia, Balantidium, Baylisascaris , lice, ticks, mites, fleas, Capillaria, Clonorchis, Chilomastix mesnili, Cyclspora, Diphyllobothrium, Dipylidium caninum, Fasciola, Giardia, Gnathostoma, Hetetophyes, Hymenolepsis, Isospora, Loa loa, Microsporidia, Naegleria, Toxocara, Onchocerca, Opisthorchis, Paragonimus, Baylisascaris, Strongyloides, Ta
  • the infection can be a parasitic infection, wherein the parasitic infection is not malaria, for example, malaria caused by any species of Plasmodium including Plasmodium falciparum .
  • the compounds set forth herein including compounds of Formula I and II can be used to treat or prevent infection in a subject with or at risk of developing an infection, wherein the infection is not malaria.
  • protozoan and fungal species contemplated within the present methods include, but are not limited to, Plasmodium falciparum , other Plasmodium species, Toxoplasma gondii, Pneumocystis carinii, Trypanosoma cruzi , other trypanosomal species, Leishmania donovani , other Leishmania species, Theileria annulata , other Theileria species, Eimeria tenella , other Eimeria species, Histoplasma capsulatum, Cryptococcus neoformans, Blastomyces dermatitidis, Coccidioides immitis, Paracoccidioides brasibiensis, Penicillium marneffei , and Candida species.
  • the infection can be a protozoan infection, wherein the protozoan infection is not leishmaniasis, for example, leishmaniasis caused by a Leishmania species, for example, Leishmania major .
  • the protozoan infection is not leishmaniasis, for example, leishmaniasis caused by a Leishmania species, for example, Leishmania major .
  • any of the compounds set forth herein, including compounds of Formula I and III can be used to treat or prevent infection in a subject with or at risk of developing an infection, wherein the infection is not leishmaniasis.
  • viral infections include but are not limited to, infections caused by RNA viruses (including negative stranded RNA viruses, positive stranded RNA viruses, double stranded RNA viruses and retroviruses) and DNA viruses. All strains, types, subtypes of DNA and RNA viruses are contemplated herein.
  • RNA viruses include, but are not limited to picornaviruses, which include aphthoviruses (for example, foot and mouth disease virus O, A, C, Asia 1, SAT1, SAT2 and SAT3), cardioviruses (for example, encephalomycarditis virus and Theiller's murine encephalomyelitis virus), enteroviruses (for example polioviruses 1, 2 and 3, human enteroviruses A-D, bovine enteroviruses 1 and 2, human coxsackieviruses A1-A22 and A24, human coxsackieviruses B1-B5, human echoviruses 1-7, 9, 11-12, 24, 27, 29-33, human enteroviruses 68-71, porcine enteroviruses 8-10 and simian enteroviruses 1-18), erboviruses (for example, equine rhinitis virus), hepatovirus (for example human hepatitis A virus and simian
  • RNA viruses include caliciviruses, which include noroviruses (for example, Norwalk virus), sapoviruses (for example, Sapporo virus), lagoviruses (for example, rabbit hemorrhagic disease virus and European brown hare syndrome) and vesiviruses (for example vesicular exanthema of swine virus and feline calicivirus).
  • noroviruses for example, Norwalk virus
  • sapoviruses for example, Sapporo virus
  • lagoviruses for example, rabbit hemorrhagic disease virus and European brown hare syndrome
  • vesiviruses for example vesicular exanthema of swine virus and feline calicivirus.
  • RNA viruses include astroviruses, which include mastorviruses and avastroviruses. Togaviruses are also RNA viruses. Togaviruses include alphaviruses (for example, Chikungunya virus, Sindbis virus, Semliki Forest virus, Western equine encephalitis, Getah virus, Everglades virus, Venezuelan equine encephalitis virus and Aura virus) and rubella viruses.
  • alphaviruses for example, Chikungunya virus, Sindbis virus, Semliki Forest virus, Western equine encephalitis, Getah virus, Everglades virus, Venezuelan equine encephalitis virus and Aura virus
  • rubella viruses for example, Chikungunya virus, Sindbis virus, Semliki Forest virus, Western equine encephalitis, Getah virus, Everglades virus, Venezuelan equine encephalitis virus and Aura virus
  • RNA viruses include the flaviviruses (for example, tick-borne encephalitis virus, Tyuleniy virus, Aroa virus, Dengue virus (types 1 to 4), Kedougou virus, Japanese encephalitis virus (JEV), West Nile virus (WNV), Kokobera virus, Ntaya virus, Spondweni virus, Yellow fever virus, Entebbe bat virus, Modoc virus, Rio Bravo virus, Cell fusing agent virus, pestivirus, GB virus A, GBV-A like viruses, GB virus C, Hepatitis G virus, hepacivirus (hepatitis C virus (HCV)) all six genotypes), bovine viral diarrhea virus (BVDV) types 1 and 2, and GB virus B).
  • flaviviruses for example, tick-borne encephalitis virus, Tyuleniy virus, Aroa virus, Dengue virus (types 1 to 4), Kedougou virus, Japanese encephalitis virus (JEV), West Nile virus (WNV), Koko
  • RNA viruses are the coronaviruses, which include, human respiratory coronaviruses such as SARS-CoV, HCoV-229E, HCoV-NL63 and HCoV-OC43. Coronaviruses also include bat SARS-like CoV, turkey coronavirus, chicken coronavirus, feline coronavirus and canine coronavirus. Additional RNA viruses include arteriviruses (for example, equine arterivirus, porcine reproductive and respiratory syndrome virus, lactate dehyrogenase elevating virus of mice and simian hemorraghic fever virus).
  • arteriviruses for example, equine arterivirus, porcine reproductive and respiratory syndrome virus, lactate dehyrogenase elevating virus of mice and simian hemorraghic fever virus.
  • RNA viruses include the rhabdoviruses, which include lyssaviruses (for example, rabies, Lagos bat virus, Mokola virus, Duvenhage virus and European bat lyssavirus), vesiculoviruses (for example, VSV-Indiana, VSV-New Jersey, VSV-Alagoas, Piry virus, Cocal virus, Maraba virus, Isfahan virus and Chandipura virus), and ephemeroviruses (for example, bovine ephemeral fever virus, Sydney River virus and Berrimah virus).
  • RNA viruses include the filoviruses. These include the Marburg and Ebola viruses (for example, EBOV-Z, EBOV-S, EBOV-IC and EBOV-R.
  • the paramyxoviruses are also RNA viruses.
  • these viruses are the rubulaviruses (for example, mumps, parainfluenza virus 5, human parainfluenza virus type 2, Mapuera virus and porcine rubulavirus), avulaviruses (for example, Newcastle disease virus), respoviruses (for example, Sendai virus, human parainfluenza virus type 1 and type 3, bovine parainfluenza virus type 3), henipaviruses (for example, Hendra virus and Nipah virus), morbilloviruses (for example, measles, Cetacean morvilliirus, Canine distemper virus, Peste-des-petits-ruminants virus, Phocine distemper virus and Rinderpest virus), pneumoviruses (for example, human respiratory syncytial virus A2, B1 and S2, bovine respiratory syncytial virus and pneumonia virus of mice), metapneumoviruses (for example, human metapneumo
  • Additional paramyxoviruses include Fer-de-Lance virus, Tupaia paramyxovirus, Menangle virus, Tioman virus, Beilong virus, J virus, Mossman virus, Salem virus and Nariva virus.
  • Additional RNA viruses include the orthomyxoviruses.
  • influenza viruses include influenza viruses and strains (e.g., influenza A (H1N1 (including but not limited to A/WS/33 and A/California/04/2009 strains) H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3 and H10N7), B and C viruses, as well as avian influenza (for example, strains H5N1, H5N2, H7N1, H7N7 and H9N2) thogotoviruses and isaviruses.
  • influenza A H1N1 (including but not limited to A/WS/33 and A/California/04/2009 strains) H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3 and H10N7
  • B and C viruses as well as avian influenza (for example, strains H5N1, H5N2, H7N1, H7N7 and H9N2) th
  • Orthobunyaviruses for example, Akabane virus, California encephalitis, Cache Valley virus, Snowshoe hare virus,) nairoviruses (for example, Washington sheep virus, Crimean-Congo hemorrhagic fever virus Group and Hughes virus), phleboviruses (for example, Candiru, Punta Toro, Rift Valley Fever, Sandfly Fever, Naples, Toscana, Sicilian and Chagres), and hantaviruses (for example, Hantaan, Dobrava, Seoul, Puumala, Sin Nombre, Bayou, Black Creek Canal, Andes and Thottapalayam) are also RNA viruses.
  • phleboviruses for example, Candiru, Punta Toro, Rift Valley Fever, Sandfly Fever, Naples, Toscana, Sicilian and Chagres
  • hantaviruses for example, Hantaan, Dobrava, Seoul, Puumala, Sin Nombre,
  • Arenaviruses such as lymphocytic choriomeningitis virus, Lujo virus, Lassa fever virus, Argentine hemorrhagic fever virus, Venezuelan hemorrhagic fever virus, SABV and WWAV are also RNA viruses.
  • Borna disease virus is also an RNA virus.
  • Hepatitis D (Delta) virus and hepatitis E are also RNA viruses. Any of the compounds set forth herein, including, but not limited to the compounds of Formula I and II can be used to treat or prevent a viral infection, wherein the viral infection is not a Lassa fever virus infection.
  • RNA viruses include reoviruses, rotaviruses, birnaviruses, chrysoviruses, cystoviruses, hypoviruses partitiviruses and totoviruses.
  • Orbiviruses such as African horse sickness virus, Blue tongue virus, Changuinola virus, Chenuda virus, Chobar Gorge Corriparta virus, epizootic hemorraghic disease virus, equine encephalosis virus, Eubenangee virus, Ieri virus, Great Island virus, Lebombo virus, Orungo virus, Palyam virus, Peruvian Horse Sickness virus, St. Croix River virus, Umatilla virus, Wad Medani virus, Wallal virus, Warrego virus and Wongorr virus are also RNA viruses.
  • Retroviruses include alpharetroviruses (for example, Rous sarcoma virus and avian leukemia virus), betaretroviruses (for example, mouse mammary tumor virus, Mason-Pfizer monkey virus and Jaagsiekte sheep retrovirus), gammaretroviruses (for example, murine leukemia virus and feline leukemia virus, deltraretroviruses (for example, human T cell leukemia viruses (HTLV-1, HTLV-2), bovine leukemia virus, STLV-1 and STLV-2), epsilonretriviruses (for example, Walleye dermal sarcoma virus and Walleye epidermal hyperplasia virus 1), reticuloendotheliosis virus (for example, chicken syncytial virus, lentiviruses (for example, human immunodeficiency virus (HIV) type 1, human immunodeficiency virus (HIV) type 2, human immunodeficiency virus (HIV) type 3, simian immunodefic
  • DNA viruses examples include polyomaviruses (for example, simian virus 40, simian agent 12, BK virus, JC virus, Merkel Cell polyoma virus, bovine polyoma virus and lymphotrophic papovavirus), papillomaviruses (for example, human papillomavirus, bovine papillomavirus, adenoviruses (for example, adenoviruses A-F, canine adenovirus type I, canined adeovirus type 2), circoviruses (for example, porcine circovirus and beak and feather disease virus (BFDV)), parvoviruses (for example, canine parvovirus), erythroviruses (for example, adeno-associated virus types 1-8), betaparvoviruses, amdoviruses, densoviruses, iteraviruses, brevidensoviruses, pefudensoviruses, herpes viruses 1, 2, 3,
  • One or more of the compounds described herein can be contacted with a cell or populations of cells in vitro, ex vivo or in vivo.
  • the cell or population of cells can be in a subject, or in an in vitro culture.
  • one or more compounds set forth herein can be used to inhibit bacterial growth, fungal growth, parasitic growth, protozoal growth or viral replication, in vitro, ex vivo or in vivo. Any of the compounds set forth herein can be used alone or in combination with other therapeutic agents such as antiviral compounds, antibacterial agents (for example, antibiotics), antifungal agents, antiparasitic agents, anti-inflammatory agents, anti-cancer agents, etc.
  • the level of infection for example, in a cell, or a population of cells, or a cell culture, can be assessed by measuring an antigen or other product associated with a particular infection.
  • the level of infection can also be measured in a tissue sample or a culture of cells from a subject, either before or after administration of one or more compounds disclosed herein.
  • the level of viral infection can be measured by real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) assay (See for example, Payungporn et al. “Single step multiplex real-time RT-PCR for H5N1 influenza A virus detection.” J Virol Methods . Sep. 22, 2005; Landolt et la. “Use of real-time reverse transcriptase polymerase chain reaction assay and cell culture methods for detection of swine influenza A viruses” Am J Vet Res. 2005 January; 66(1):119-24).
  • RT-PCR real-time quantitative reverse transcription-polymerase chain reaction
  • subject an individual.
  • the subject is a mammal such as a primate, and, more preferably, a human.
  • Non-human primates are subjects as well.
  • subject includes domesticated animals, such as cats, dogs, etc., livestock (for example, cattle, horses, pigs, sheep, goats, etc.) and laboratory animals (for example, ferret, chinchilla, mouse, rabbit, rat, gerbil, guinea pig, etc.).
  • livestock for example, cattle, horses, pigs, sheep, goats, etc.
  • laboratory animals for example, ferret, chinchilla, mouse, rabbit, rat, gerbil, guinea pig, etc.
  • veterinary uses and medical formulations are contemplated herein.
  • a biological sample is a sample derived from a subject such as a mammal or human and includes, but is not limited to, any biological fluid, including a bodily fluid.
  • bodily fluids include, but are not limited to, whole blood, plasma, serum, urine, saliva, ocular fluid, ascites, a stool sample, spinal fluid, tissue infiltrate, pleural effusions, lung lavage fluid, and the like.
  • the biological fluid includes a cell culture medium or supernatant of cultured cells from the subject.
  • the methods and compounds as described herein are useful for therapeutic treatment. Use of one or more of the compounds set forth herein for the treatment or prevention of infection is also contemplated herein. One or more of the compounds set forth herein for use in a method of treating or preventing infection is also provided herein.
  • Therapeutic treatment involves administering to a subject a therapeutically effective amount of one or more of the agents described herein, optionally, after diagnosis of an infection or risk of infection in the subject. Therefore, all of the methods disclosed herein, can optionally comprise the step of diagnosing a subject with an infection or diagnosing a subject in need of prophylaxis or prevention of infection.
  • treatment refers to a method of reducing the effects of a disease or condition or symptom of the disease or condition.
  • treatment can refer to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the severity of an established disease or condition or symptom of the disease or condition.
  • a method for treating a disease is considered to be a treatment if there is a 10% reduction in one or more symptoms of the disease in a subject as compared to a control.
  • a control subject can be a subject that has not received a compound set forth herein.
  • the reduction can be a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any percent reduction in between 10% and 100% as compared to native or control levels. It is understood that treatment does not necessarily refer to a cure or complete ablation of the disease, condition, or symptoms of the disease or condition.
  • preventing infection is meant a method of precluding, delaying, averting, obviating, forestalling, stopping, or hindering the onset, incidence, severity, or recurrence of infection.
  • the disclosed method is considered to be a prevention if there is about a 10% reduction in onset, incidence, severity, or recurrence of infection, or symptoms of infection (e.g., inflammation, fever, lesions, weight loss, etc.) in a subject exposed to an infection when compared to control subjects exposed to an infection that did not receive a composition for decreasing infection.
  • the reduction in onset, incidence, severity, or recurrence of infection can be about a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to a control subject. For example, and not to be limiting, if about 10% of the subjects in a population do not become infected as compared to subjects that did not receive preventive treatment, this is considered prevention.
  • the compounds set forth herein can also be used to decrease infection in a cell.
  • a decrease or inhibition of infection can occur in a cell, in vitro, ex vivo or in vivo.
  • the term “infection” encompasses all phases of pathogenic life cycles including, but not limited to, attachment to cellular receptors, entry, internalization, disassembly, replication, genomic integration of pathogenic sequences, transcription of pathogen RNA, translation of pathogen RNA, transcription of host cell mRNA, translation of host cell mRNA, proteolytic cleavage of pathogenic proteins or cellular proteins, assembly of particles, endocytosis, cell lysis, budding, and egress of the pathogen from the cells.
  • the compounds described herein can be provided in a pharmaceutical composition.
  • the pharmaceutical composition can be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, or suspensions, preferably in unit dosage form suitable for single administration of a precise dosage.
  • the compositions will include a therapeutically effective amount of the compound described herein or derivatives thereof in combination with a pharmaceutically acceptable carrier and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, or diluents.
  • pharmaceutically acceptable is meant a material that is not biologically or otherwise undesirable, which can be administered to an individual along with the selected agent without causing unacceptable biological effects or interacting in a deleterious manner with the other components of the pharmaceutical composition in which it is contained.
  • the term carrier encompasses any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, lipid, stabilizer, or other material well known in the art for use in pharmaceutical formulations.
  • a carrier for use in a composition will depend upon the intended route of administration for the composition.
  • the preparation of pharmaceutically acceptable carriers and formulations containing these materials is described in, e.g., Remington's Pharmaceutical Sciences, 21st Edition, ed. University of the Sciences in Philadelphia, Lippincott, Williams & Wilkins, Philadelphia Pa., 2005.
  • physiologically acceptable carriers include buffers such as phosphate buffers, citrate buffer, and buffers with other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEEN® (ICI, Inc.; Bridgewater, N.J.), polyethylene glycol (PEG), and PLURONICSTM (BASF; Florham Park, N.J.).
  • buffers such as phosphate buffers, citrate buffer, and buffers with
  • compositions containing the compound(s) described herein suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
  • compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents.
  • adjuvants such as preserving, wetting, emulsifying, and dispensing agents.
  • Prevention of the action of microorganisms can be promoted by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like.
  • Isotonic agents for example, sugars, sodium chloride, and the like may also be included.
  • Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • Solid dosage forms for oral administration of the compounds described herein or derivatives thereof include capsules, tablets, pills, powders, and granules.
  • the compounds described herein or derivatives thereof is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or
  • fillers or extenders as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid
  • binders as for example, carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia
  • humectants as for example, glycerol
  • disintegrating agents as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate
  • solution retarders as for example, paraffin
  • absorption accelerators as for example, paraffin
  • compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethyleneglycols, and the like.
  • Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others known in the art. They may contain opacifying agents and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner.
  • embedding compositions examples include polymeric substances and waxes.
  • the active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.
  • Liquid dosage forms for oral administration of the compounds described herein or derivatives thereof include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, and fatty acid esters of sorbitan, or mixtures of these substances, and the like.
  • inert diluents commonly used in the art
  • composition can also include additional agents, such as wetting, emulsifying, suspending, sweetening, flavoring, or perfuming agents.
  • additional agents such as wetting, emulsifying, suspending, sweetening, flavoring, or perfuming agents.
  • Administration can be carried out using therapeutically effective amounts of the agents described herein for periods of time effective to treat or prevent infection in a subject.
  • the effective amount may be determined by one of ordinary skill in the art and includes exemplary dosage amounts for a mammal of from about 0.5 to about 200 mg/kg of body weight of active compound per day, which may be administered in a single dose or in the form of individual divided doses, such as from 1 to 4 times per day.
  • the dosage amount can be from about 0.5 to about 150 mg/kg of body weight of active compound per day, about 0.5 to 100 mg/kg of body weight of active compound per day, about 0.5 to about 75 mg/kg of body weight of active compound per day, about 0.5 to about 50 mg/kg of body weight of active compound per day, about 0.5 to about 25 mg/kg of body weight of active compound per day, about 1 to about 20 mg/kg of body weight of active compound per day, about 1 to about 10 mg/kg of body weight of active compound per day, about 20 mg/kg of body weight of active compound per day, about 10 mg/kg of body weight of active compound per day, or about 5 mg/kg of body weight of active compound per day.
  • the subject is administered an effective amount of the compound.
  • effective amount and effective dosage are used interchangeably.
  • effective amount is defined as any amount necessary to produce a desired physiologic response.
  • Effective amounts and schedules for administering the agent may be determined empirically, and making such determinations is within the skill in the art.
  • the dosage ranges for administration are those large enough to produce the desired effect in which one or more symptoms of the disease or disorder are affected (e.g., reduced or delayed). The dosage should not be so large as to cause substantial adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like.
  • the dosage will vary with the activity of the specific compound employed, the metabolic stability and length of action of that compound, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, drug combination, and severity of the particular condition and can be determined by one of skill in the art.
  • the dosage can be adjusted by the individual physician in the event of any contraindications. Dosages can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products.
  • compositions are administered via any of several routes of administration, including topically, orally, parenterally, intravenously, intra-articularly, intraperitoneally, intramuscularly, subcutaneously, intracavity, transdermally, intrahepatically, intracranially, nebulization/inhalation, or by installation via bronchoscopy.
  • the composition is administered by oral inhalation, nasal inhalation, or intranasal mucosal administration.
  • Administration of the compositions by inhalant can be through the nose or mouth via delivery by spraying or droplet mechanism, for example, in the form of an aerosol.
  • compositions can be delivered locally to the area in need of treatment, for example by topical application or local injection. Multiple administrations and/or dosages can also be used. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
  • the disclosure also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions.
  • a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions.
  • Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
  • Instructions for use of the composition can also be included.
  • Also provided is a method of removing biofilm from a surface comprising administering an effective amount of one or more of the compounds provided herein to a biofilm-containing surface, wherein the amount is effective to remove biofilm from the surface.
  • Removal of the biofilm from this surface does not have to be complete as this can range from a reduction to complete removal of the biofilm.
  • removal can refer to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the amount of biofilm on a surface.
  • a method for removing biofilm from a surface is considered to be removal if there is a 10% reduction in the amount of biofilm on the surface as compared to a control.
  • a control surface can be a biofilm containing surface that has not received a compound set forth herein.
  • the reduction can be a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any percent reduction in between 10% and 100% as compared to control.
  • a method of preventing biofilm formation on a surface comprising administering an effective amount of one or more of the compounds provided herein to the surface, wherein the amount is effective to prevent biofilm formation.
  • the surface can be susceptible to biofilm formation.
  • the biofilm can be produced by an organism selected from the group consisting of bacteria, algae, fungi and protozoa.
  • the compound can be, but is not limited to, a compound of Formula I
  • R represents hydrogen or hydroxyl and R 1 represents hydrogen, or R and R 1 taken together form a second bond between the carbon atoms bearing R and R 1 ;
  • R 2 represents hydrogen or phenyl;
  • n is zero or a positive whole integer of from 1 to 4;
  • X represents CH 2 , CHOH, NH, C ⁇ O, CHNR 3 R 4 , where R 3 and R 4 independently are hydrogen or lower alkyl;
  • Z represents thienyl, pyridinyl, substituted pyridinyl, phenyl or substituted phenyl wherein the substituents on the substituted pyridinyl or substituted phenyl are selected from phenyl, pyridinyl, nitro, a halogen atom, such as chlorine, fluorine, bromine, or iodine, a straight or branched lower alkyl chain of from 1 to 4 carbon atoms, a lower alkoxy group of from 1 to 4 carbon atoms, amino,
  • R 5 is hydrogen or lower alkyl
  • R 6 and R 7 independently are hydrogen or methyl or a pharmaceutically acceptable salt thereof.
  • biodegradable polymers include but are not limited to polylactic acid, polyglycolic acid and copolymers and mixtures thereof such as poly(L-lactide) (PLLA), poly(D,L-lactide) (PLA), polyglycolic acid [polyglycolide (PGA)], poly(L-lactide-co-D,L-lactide) (PLLA/PLA), poly(L-lactide-co-glycolide) (PLLA/PGA), poly(D,L-lactide-co-glycolide) (PLA/PGA), poly(glycolide-co-trimethylene carbonate) (PGA/PTMC), poly(D,L-lactide-co-caprolactone) (PLA/PCL) and poly(glycolide-co-cap
  • the surface can be a hard (for example, glass, metal, wood, chrome, plastic, vinyl or formica) or a soft surface (for example, cloth or upholstery).
  • the methods set forth herein can be used to remove or prevent biofilm formation in vitro, ex vivo or in vivo.
  • the methods set forth herein can also be used to remove or prevent biofilm formation on a medical device or a part thereof.
  • the methods set forth herein can be used to remove or prevent biofilm formation on an implantable medical device such as a cardiac rhythm management device (for example, a pacemaker, a defibrillator, an implantable cardioverter defibrillator (ICD) and a cardiac resynchronization therapy defibrillator (CRT device), a neurostimulator, a pulse generator, a drug pump, an infusion device, a physiological monitoring device (for example, a glucose sensor), contact lenses, a stent, a catheter, tubing or a breast implant.
  • a cardiac rhythm management device for example, a pacemaker, a defibrillator, an implantable cardioverter defibrillator (ICD) and a cardiac resynchronization therapy defibrillator (CRT device
  • a neurostimulator for example, a pacemaker, a defibrillator, an implantable cardioverter defibrillator (ICD) and a cardiac resynchronization therapy defi
  • organs can be treated with one or more of the compounds set forth herein prior to transplantation in a subject.
  • One or more of the compounds set forth herein can be used to inhibit biofilm formation by one or more of Staphylococcus aureus, Pseudomonas aeuroginosa, Staphylococcus epidermidis, Escherichia coli or Acinetobacter baummanii.
  • preventing biofilm formation is meant a method of precluding, delaying, averting, obviating, forestalling, stopping, or hindering the onset, incidence, severity, or recurrence of biofilm formation.
  • the disclosed method is considered to be prevention if there is about a 10% reduction in onset, incidence, severity, or recurrence of biofilm formation on a surface when compared to a control surface that did not receive a composition for preventing biofilm formation.
  • the reduction in onset, incidence, severity, or recurrence of biofilm can be about a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to a control surface.
  • a biofilm can also exist or form in a biological subject, for example, on the teeth or gums of a subject. Therefore, one or more of the compounds set forth herein can be in a toothpaste, mouth rinse, gel, foam, varnish, polish, floss, dental strip, or copolymer membrane in order to remove or prevent biofilm formation on a dental surface.
  • a method of identifying an antimicrobial agent comprising contacting a bacterial culture with a test agent and measuring adenylate kinase release in the supernatant of the bacterial culture, wherein an increase in adenylate kinase release as compared to a control indicates that the test compound is an antimicrobial agent.
  • the control can be a bacterial culture that was not contacted with the test compound.
  • the bacterial culture can be a culture of any bacterial strain, for example, a culture of any of the bacteria disclosed herein.
  • the bacterial culture can also be small colony variant bacterial culture or a biofilm associated bacterial culture. Examples of agents identified utilizing this method are provided in the Examples.
  • any subset or combination of these is also specifically contemplated and disclosed. This concept applies to all aspects of this disclosure including, but not limited to, steps in methods using the disclosed compositions. Thus, if there are a variety of additional steps that can be performed, it is understood that each of these additional steps can be performed with any specific method steps or combination of method steps of the disclosed methods, and that each such combination or subset of combinations is specifically contemplated and should be considered disclosed.
  • Adenylate kinase is a ubiquitous intracellular enzyme that is released into the extracellular space upon cell lysis. As shown herein, AK release serves as a useful reporter of bactericidal agent activity and can be exploited for antimicrobial screening purposes.
  • the AK assay exhibits improved sensitivity over that of growth-based assays and can detect agents that are active against bacteria in clinically relevant growth states that are difficult to screen using conventional approaches, such as small colony variants (SCV) and bacteria within established biofilms.
  • SCV small colony variants
  • the usefulness of the AK assay was validated by screening a library of off-patent drugs for agents that exhibit antimicrobial properties toward a variety of bacterial species, including Escherichia coli and all members of the “ESKAPE” pathogens ( Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa , and Enterobacter species).
  • the assay detected antibiotics within the library that were expected to be active against the organism screened.
  • 38 drugs elicited AK release. Examples include, the antihistamine, terfenadine, which was active against S.
  • the most successful and widely applied method to identify agents with antibacterial activity has been whole-cell, bacterial growth assays. In this approach, libraries of small molecules or natural products are screened for agents that limit bacterial growth.
  • growth-based assays have limitations. For example, the growth or no-growth readout has a limited dynamic range. This is likely to be problematic because growth assays lack the sensitivity required to detect antimicrobial molecules that are present in low concentrations within complex natural product extract libraries or compounds with limited antimicrobial activity. While the latter would obviously not represent a molecule that could be directly translated to clinical use, these low-activity hits could provide structurally novel scaffolds suitable for medicinal chemistry-based optimization.
  • traditional growth-based assays are not readily amenable to screening for agents that target bacteria within certain clinically relevant bacterial growth states, such as established biofilms and small-colony variants.
  • HTS high-throughput screen
  • the assay is based on the release of intracellular adenylate kinase (AK) into culture medium as a reporter of bacterial cell death.
  • AK intracellular adenylate kinase
  • the assay exhibits improved sensitivity over that of conventional whole-cell growth assays and displays specificity for bactericidal agents.
  • the assay can be used to screen for agents that kill small-colony-variant bacteria and bacteria within established biofilms.
  • the Prestwick library of off-patent drugs was screened against E. coli and each of the ESKAPE pathogens.
  • This library contains representative examples of nearly all classes of antibiotics, and the bactericidal agents within the library that were expected to be active against the organism screened were identified. Additionally, agents with no previously reported antibiotic activity were identified.
  • Traditional MIC testing confirmed the antimicrobial properties of many of these molecules, showing that they could be repurposed as antimicrobials or serve as lead molecules for antibiotic development. Consistent with that prediction, it was shown that one of these compounds, tamoxifen, is active against E. faecium in a Galleria mellonella model of infection.
  • terfenadine is active against planktonic, small-colony variant, and biofilm-associated S. aureus .
  • AK assay provides a general approach to screening for new antimicrobial agents active against a variety of pathogens during planktonic and other disease-associated growth states.
  • S. aureus strain UAMS-1112 (generous gift from M. Smeltzer, University of Arkansas Medical Center) is a stable small-colony variant of the common laboratory S. aureus strain 8325-4, which harbors a hemB deletion. Unless otherwise noted, bacteria were grown for 16 h in Mueller-Hinton (MH) (Becton, Dickinson, Franklin Lakes, N.J.) or brain heart infusion (BHI) (Becton. Dickinson) medium at 37° C. on a rotary shaker at 225 rotations per min (rpm) and then used to inoculate (1:100) fresh medium and processed, as described below.
  • MH Mueller-Hinton
  • BHI brain heart infusion
  • Prestwick Chemical Library of molecules with known biological activities was acquired from Prestwick Chemical (Illkirch, France). ToxiLight BioAssay kits were obtained from Lonza (Basel, Switzerland). Terfenadine, suloctidil, clomiphene citrate, ceftriaxone, sulfamethoxazole, erythromycin, kanamycin, ciprofloxacin, rifampin, ampicillin, minocycline, tamoxifen, and trimethoprim were purchased from Sigma-Aldrich (St. Louis, Mo.). Meropenem, linezolid, and vancomycin were purchased from Thermo Fisher (Waltham, Mass.). Colistin was purchased from APP Pharmaceuticals (Schaumburg, Ill.).
  • a stock solution of the indicated reference antibiotic or test compound (0 to 256 ⁇ g ml ⁇ 1 ) was added to each well.
  • the carrier solvent was either water or dimethyl sulfoxide (DMSO); final DMSO concentrations were less than or equal to 2%. Plates were incubated at 37° C. for 24 h, and the MIC was defined as the lowest concentration of antibiotic in which there was no visible cell pellet in the wells.
  • E. coli strain 8295 or S. aureus RN4220 were used to inoculate (1:100 dilution) 25 ml of fresh M H medium and grown at 37° C. on a rotary shaker at 225 rpm to exponential phase ( ⁇ 1 ⁇ 10 8 CFU ml ⁇ 1 ).
  • Cells were pelleted by centrifugation (2,000 ⁇ g) and resuspended in 2.5 ml of sterile water. One milliliter of the resulting suspension was boiled for 3 min and filter sterilized (0.45- ⁇ m filter) to remove cell debris.
  • the filtrate was serially diluted in sterile water, and 100 ⁇ l of each dilution was added to individual wells of a white-walled, 96-well plate (Corning, Inc., Corning, N.Y.).
  • 100 ⁇ l of ToxiLight AK reagent was added to each well, followed by incubation at room temperature for 30 min, and luminescence was measured using a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, Calif.).
  • Cells were serially diluted and plated to enumerate CFU (CFU ml ⁇ 1 ) before and after boiling to correlate cell lysis with viability.
  • Biofilms were grown as previously described (Beenken et al. Infect. Immun. 71: 4206-4211 (2003); Musken et al. Nat. Protoc. 5: 1460-1459 (2010); Tomaras et al. Microbiology 149: 3473-3483 (2003)). Briefly, P. aeruginosa and A. baumannii were cultured overnight in Luria-Bertani medium and then used to seed 96-well, flat-bottom plates. Plates were incubated at 37° C. in a humidified incubator for 48 h to allow the formation of static biofilms. Nonadherent cells were removed by aspiration and washing with sterile phosphate-buffered saline (PBS).
  • PBS sterile phosphate-buffered saline
  • Fresh LB medium supplemented with 0, 1 ⁇ , 10 ⁇ , or 100 ⁇ MIC of antibiotic was added to each well and incubated overnight at 37° C. Following treatment, 100 ⁇ l of each biofilm supernatant was transferred to 96-well, white-walled plates, 100 ⁇ l of ToxiLight AK reagent was added to each well, mixtures were incubated for 30 min at room temperature, and luminescence was measured using a SpectraMax M5 plate reader. Biofilm-associated bacteria were enumerated by resuspending each biofilm in fresh PBS and plating. For S. aureus UAMS-1 biofilms, 96-well, flat-bottom plates were first coated with 100 ⁇ l of 20% human plasma in carbonate buffer overnight at 4° C.
  • Well components were mixed by pipetting and incubated at 37° C. for 3 h. The plate was equilibrated to room temperature for 30 min. Next, 100 ⁇ l of ToxiLight AK reagent was added to each well, followed by incubation at room temperature for 30 min, and luminescence was measured using a SpectraMax M5 plate reader.
  • a Galleria mellonella model of infection was used to measure the putative antimicrobial properties of tamoxifen against E. faecium and terfenadine against S. aureus .
  • overnight cultures of E. faecium strain 824-05 or S. aureus strain USA300-0114 were used to inoculate (1:100 dilution) 25 ml of fresh MH medium and grown at 37° C. on a rotary shaker at 225 rpm to exponential phase ( ⁇ 1 ⁇ 10 8 CFU ml ⁇ 1 ).
  • mice were also treated with the test compound tamoxifen at 80, 160, or 320 mg kg ⁇ 1 , whereas groups were treated with the test compound terfenadine (80, 160, or 320 mg kg ⁇ 1 ) for S. aureus studies.
  • Treatments were administered in the same manner as infection, except that each injection was in the next left proleg moving toward the head of the worm.
  • Larvae were housed in petri dishes in the dark at 37° C. and monitored for viability at the conclusion of the study (48 h postinoculation); worms were considered dead if they did not respond to physical stimuli.
  • Adenylate kinase is a ubiquitous intracellular enzyme that catalyzes the conversion of 2 ADP ⁇ ATP+AMP and is released into the extracellular space upon cell lysis.
  • the premise of the assay is that agents which disrupt cellular integrity, either directly through damage of the membrane/cell wall or indirectly following the death of the cell, will induce release of AK into the culture medium.
  • Extracellular AK is subsequently detected by the addition of commercially available ToxiLight AK assay reporter cocktail (Lonza, Basel, Switzerland), which generates a luminescent signal by utilizing AK-generated ATP in the standard luciferase catalyzed reaction (see FIG. 1 ).
  • ToxiLight AK assay reporter cocktail Lid, Basel, Switzerland
  • the AK Assay Provides a Sensitive Measure of Bacterial Lysis—
  • the AK activity of the dilution series was measured and compared to the AK activity of mock-treated (viable) bacteria by Student's t test. In comparison to untreated cells, a statistically significant increase in AK activity was detected at dilutions containing 1.7 ⁇ 10 3 or more heat-killed E. coli supernatants, compared to results for live bacteria (see FIG. 2A ). AK activity increased ⁇ 433-fold and ⁇ 1,574-fold in cultures with 1 ⁇ 10 7 and 1 ⁇ 10 8 heat-killed E. coli supernatants, respectively, compared to results for mock-treated bacteria. A comparison of AK released from heat-killed S.
  • aureus to that of mock-treated cells revealed a statistically significant difference in AK activity was detected at dilutions containing 1.8 ⁇ 10 4 or more heat-killed S. aureus supernatants, with a maximum 122-fold increase in AK activity observed for 1 ⁇ 10 8 lysed cells.
  • these results indicate that the AK assay reproducibly detects AK release following bacterial cell lysis and that the assay is extremely sensitive, allowing the identification of agents that cause lysis in 0.0001% or 0.001% of the starting inoculum of E. coli or S. aureus cells, respectively.
  • the AK assay exhibited a dynamic range of nearly 3 orders of magnitude and an excellent signal-to-noise ratio.
  • the AK Assay Detects Bactericidal Molecules that are Active against the ESKAPE Pathogens—
  • AK assay ability of the AK assay to detect the activities of bactericidal antibiotics toward E. coli and each of the ESKAPE pathogens was examined. To do so, the MICs of six classes of bactericidal antibiotics (penicillin, cephalosporin, quinolone, glycopeptide, carbapenem, and polymyxin) were determined for each organism (see Table 2). An AK assay was then performed at 0, 0.125 ⁇ , 0.25 ⁇ , 0.5 ⁇ , 1 ⁇ , and 2 ⁇ MIC of each antibiotic. As discussed below, AK release was detected at antibiotic concentrations below the MIC for most antibiotics tested, showing that the AK assay is more sensitive than growth-based assays for detecting bactericidal agents. As a representative example, FIG.
  • 2B presents the AK assay measured polymyxin (colistin)-mediated killing of A. baumannii strain 98-37-09.
  • the MIC of colistin for this strain is 4 ⁇ g ml ⁇ 1 , whereas AK release was robustly detected at 0.25 ⁇ , 0.5 ⁇ , and 1 ⁇ MIC value.
  • the MIC measures for each ESKAPE pathogen and each organism's corresponding fold increase in AK signal following treatment with 0.5 ⁇ and 1.0 ⁇ the MIC are provided in Table 2 (bactericidal agents).
  • the AK assay proved to be superior to growth-based assays with respect to detecting the killing properties of bactericidal agents at sub-MIC values. More specifically, 100% of the organisms that were determined to be susceptible to the cell wall-active antibiotics ampicillin, meropenem, and colistin exhibited a significant increase in AK signal ( ⁇ 3-fold over that for vehicle-treated cells) at both 0.5 ⁇ and 1.0 ⁇ their MIC's.
  • AK release by each of the ESKAPE pathogens following exposure to five classes of bacteriostatic agents was also measured.
  • the MIC value of each bacteriostatic antibiotic/organism pair was measured by a conventional growth-based approach.
  • AK release by each bacterial species following treatment with 0.5 ⁇ or 1.0 ⁇ MIC of each bacteriostatic agent was subsequently measured. As shown in FIG. 3 , S.
  • aureus strain RN4220 was susceptible to all agents tested but bacteriostatic agents generated very low AK release, whereas bactericidal antibiotics generated robust AK detection. In most instances, a similar trend was observed for the other ESKAPE pathogens, indicating that the assay enriches for the identification of bactericidal agents, which are arguably the most valuable antibiotics because they can be used to treat patients with immunological defects or rapidly lethal infections (Table 2, bacteriostatic agents). Two exceptions were noted. Surprisingly, A. baumannii generated significant AK signal in response to all the bacteriostatic agents evaluated, showing that AK release may be a feature of a more general stress response in this organism. Additionally, the bacteriostatic agent minocycline generated signal by five of the eight (63%) organisms tested.
  • the AK assay provides a viable screening approach for identifying bactericidal agents at sub-MICs that could otherwise be missed by growth-based assays. Further, because the AK assay relies on bacterial killing as opposed to growth changes to generate its readout, it was hypothesized that it would provide a format to develop screens that are not readily available by conventional, growth-based approaches.
  • Established bacterial biofilms represent a particularly problematic disease state, in part because biofilm-associated bacteria are recalcitrant to conventional antibiotic therapy. Thus, they have been a focus of antibiotic development. As a result, a number of approaches to screening for molecules with activity toward bacterial biofilms have been developed recently (Benoit et al. Environ. Microb. 76: 4136-4142; Perez et al. Lett. Appl. Microb. 51:331-337 (2010)). Although each has its advantages, they also have a number of limitations, including reproducibility, reliance on specialized equipment, or low throughput. It was hypothesized that the AK assay would provide a solution to some of these problems because it is rapid, sensitive, and simple to perform and it detects bactericidal molecules, the type of antibiotics required to treat established biofilms.
  • biofilm-associated bacteria were enumerated by plating, and the corresponding supernatants were analyzed by the AK assay.
  • Plating verified that 10 ⁇ MIC antibiotic treatment resulted in a significant reduction in biofilm-associated P. aeruginosa (a 3.1-log decrease), S. aureus (a 0.7-log decrease), and A. baumannii (a 1.8-log decrease) compared to findings for untreated biofilms.
  • corresponding AK measures indicated that the assay robustly detects the mild effects of these antibiotics on each bacterial species tested, showing that it represents a promising approach to identify agents that exhibit bactericidal activity toward established bacterial biofilms.
  • AK assay can be particularly valuable in the identification of molecules that exhibit bactericidal activity toward bacterial small-colony variants (SCV).
  • SCV are slow-growing populations of bacterial species that have been hypothesized to cause latent or recurrent infections and are tolerant of standard antibiotic treatment regimens. Based on the aberrant SCV growth characteristics, typical growth-based HTS assays would be difficult to employ. Accordingly, the ability of the AK assay to identify agents that kill S. aureus SCV strain UAMS-1112 was tested. To do so, 1 ⁇ 10 6 UAMS-1112 cells were treated with 1 ⁇ or 10 ⁇ MIC ciprofloxacin, meropenem, or vancomycin for 3 h.
  • AK assay As a general tool in HTS-based antibacterial small-molecule discovery, optimized assay parameters, including inoculum, drug incubation time, and AK reaction time, for screening planktonic ESKAPE species as well as E. coli in a 384-well format were determined. Based on these experiments, a standardized assay, as described above, was developed. As part of this optimization process, control assays in a 384-well format were performed to measure the signal to noise and reproducibility of the assay in an I-ITS manner. For this, plates were seeded with E. coli or an ESKAPE pathogen.
  • E. coli and each of the ESKAPE pathogens was screened against the Prestwick library of FDA-approved drugs and biologically active molecules (1,120 compounds, total; 50 ⁇ M final drug concentration).
  • the Prestwick library contains representatives of nearly all classes of antibiotics currently in clinical use, making it an ideal library for testing the ability of the AK assay to detect bactericidal agents in a high-throughput screening format. Accordingly, the library was screened for antimicrobial agents that were active against planktonic E.
  • Antihypotensive and CNS stimulant 0.8 0.9 0.8 0.7 0.8 0.8 1.4 Fenoprofen calcium salt dihydrate Cyclooxygenase inhibitor Antiinflammatory 0.9 0.9 0.7 0.6 0.8 0.9 1.4 Hippeastrine hydrobromide — Hypotensor 12.6 0.9 0.4 2.3 3.3 8.7 1.3 Piperacillin sodium salt Bacterial transpeptidase Antibacterial inhibitor 0.9 0.9 0.8 0.7 0.8 0.7 1.4 Beta-Escin Peripheral vascular disorders 0.9 1.1 0.6 0.7 1.8 0.8 1.4 Diethylstilbestrol Estrogen 0.6 1.3 0.2 0.3 0.4 0.5 1.5 Gossypol Ca2+ uptake inhibitor Local contraceptive 0.9 1.0 0.8 0.8 0.8 0.8 1.4 Chlorotrianisene Nuclear receptor ligand Non-steroidal estrogen 0.8 0.9 0.9 0.8 0.8 0.7 1.3 Ricinine 0.9 0.9 0.8 0.7 0.8 0.8 1.2 Ribostamycin
  • Antihyperlipoproteinemic 1.3 0.9 1.3 1.0 1.3 1.1 1.3 Bromopride Dopamine antagonist Antiemetic 1.3 1.2 1.3 1.1 1.3 1.1 1.5 Bendroflumethiazide Na+ Cl ⁇ transport inhibitor Diuretic 5.1 7.4 ### 7.4 5.8 8.9 1.3 Methyl benzethonium chloride Detergent Antibacterial 1.1 1.3 1.3 1.1 1.3 1.2 1.5 Dicumarol Vitamin K antagonist Anticoagulant 1.3 1.0 1.2 1.1 1.5 1.1 1.6 Chlorcyclizine hydrochloride Histamine antagonist Antihistaminic 1.2 0.9 1.0 1.4 1.0 27.1 Methimazole Iodine oxidazing inhibitor Antihyperthyroid 1.3 1.1 1.2 1.0 1.3 1.1 1.4 Diphenylpyraline hydrochloride H1 antagonist Antihistaminic 0.5 0.6 0.2 0.4 0.7 0.4 1.4 Merbromin — Antibacterial 2.9 6.2 ### 5.7 5.4 5.8 1.3 Benzeth
  • AK screening enriches for the identification of bactericidal compounds (Table 3). More specifically, 100% of the antibiotics that were identified to be active against P. aeruginosa or K. pneumoniae represented bactericidal agents. Similarly, 96%, 94%, and 80% of the antibiotics that were active against E. coli, E. cloacae , and E. faecium , respectively, were bactericidal antibiotics. The assay identified 71% and 64% bactericidal antibiotics for A. baumannii and S. aureus.
  • ⁇ -lactam, cephalosporin, polymyxin, and fluoroquinolone antibiotics were active against Gram-negative pathogens ( E. coli and the ESKAPE pathogens A. baumannii, P. aeruginosa , and K. pneumoniae ), and penicillins, cephalosporins, quinolines, glycopeptides, and carbapenems were active toward S. aureus (see Table 4). It was also determined that clofazimine, which was initially developed as an antimycobacterial agent and was recently shown to exhibit bactericidal activity toward S. aureus , was indeed active against S. aureus .
  • Bacteriostatic compounds such as clindamycin, and macrolides, such as erythromycin, were not identified as being active toward any of the species tested.
  • many tetracyclines were identified as killing S. aureus strain USA300-0114 and A. baumannii strain 98-37-09.
  • the library contains membrane-active antiseptics, such as chlorhexidine, and with the exception of E. cloacae , these were also strong hits against all organisms tested. Screening results also revealed that the E. faecium strain tested proved to be resistant to most classes of antibiotics within the Prestwick library by MIC testing (Table 2), and this was also observed in the AK assay, indicating that the assay exhibits a low false-positive rate.
  • the assay also detected 38 drugs with no known antimicrobial properties (denoted as “other” in Table 3) that were active against each organism; see Table 4 for a complete list of these compounds.
  • Prestwick library screening results revealed that 4% to 56% (depending on the organism) of the members that generated significant AK signal were compounds with no previously reported antimicrobial activity (see Table 4).
  • nonantibiotic drugs that were commercially available were further evaluated by two secondary assays.
  • dose-response assays were performed to validate that they induced AK activity, and all were reconfirmed.
  • baumannii were susceptible to terfenadine (16- ⁇ g ml ⁇ 1 MIC and 64- ⁇ g ml ⁇ 1 MIC, respectively).
  • Suloctidil was also detected to be active against P. aeruginosa by both primary and confirmatory AK screens, but the drug did not elicit an antimicrobial response by MIC measures.
  • Terfenadine and tamoxifen which exhibited antimicrobial properties toward planktonic S. aureus and E. faecium cells, respectively, were characterized further.
  • Terfenadine was evaluated for activity against S. aureus biofilms and small-colony variants using the AK assays described above.
  • Treatment of 48-h S. aureus strain UAMS-1 biofilms with 10 ⁇ -MIC terfenadine elicited a modest 2.7-fold increase in AK release (see FIG.
  • plating-based viability assays determined that this correlated with a 1.1-log reduction in biofilm cell viability, which was comparable to the activity of ciprofloxacin under the same assay conditions (see FIG. 4A ).
  • treatment of S. aureus small-colony-variant UAMS-1112 cells with 10 ⁇ MIC terfenadine elicited a 3.3-fold increase in AK signal in comparison to that for mock-treated cells (see FIG. 6A ).
  • Conventional MIC testing subsequently verified that terfenadine is active against UAMS-1112 at 2 ⁇ g ml ⁇ 1 .
  • terfenadine and tamoxifen were evaluated using a Galleria mellonella model of S. aureus and E. faecium infection, respectively.
  • terfenadine is a nonsedating antihistamine based on a 4-substituted piperidine scaffold. Based on further studies, it was determined that terfenadine acts as a topoisomerase inhibitor and is structurally similar to certain topoisomerase inhibitors, including for example novel bacterial topoisomerase II inhibitor (NBTI).
  • NBTI novel bacterial topoisomerase II inhibitor
  • terfenadine Based on the structural similarity between terfenadine and these molecules, it is likely that terfenadine is acting as a DNA gyrase and topoisomerase inhibitor. More specifically, terfenadine and derivatives thereof act as topoisomerase 4 inhibitors. Furthermore, it was found that terfenadine has activity against S. aureus small-colony variants and biofilms, properties not previously reported for this scaffold.
  • a screen of E. faecium identified two structurally related nonsteroid estrogen receptor antagonists, tamoxifen and clomiphene. Tamoxifen is used to treat some forms of estrogen-receptor-positive breast cancer, while clomiphene is used in fertility treatment regimens. These two compounds are members of the triarylethylene class of estrogen receptors.
  • tamoxifen's in vivo activity was investigated using a Galleria model of enterococcus infection. Although it was not as active as vancomycin, tamoxifen did impart a survival benefit, indicating that it has in vivo antimicrobial activity. High-dose tamoxifen therapy has been used in experimental treatment of refractory human cancers, and dosing results in micromolar serum concentrations of tamoxifen corresponding to the levels of drug associated with antienterococcal activity observed in the studies provided herein.
  • an AK assay that is easily amenable to screening bacteria in disease states that cannot be readily screened via conventional approaches is provided herein.
  • the AK assay is capable of measuring the killing properties of bactericidal agents administered to biofilms formed by both Gram-negative and Gram-positive representatives of the ESKAPE pathogens.
  • the AK assay can detect the bactericidal properties of antibiotics toward a phenotypically stable S. aureus small-colony variant.
  • Method A diphenyl(piperidin-4-yl)methanol (0.544 g, 2.035 mmol), 1-(4-(tert-butyl)phenyl)-5-chloropentan-1-one (0.490 g, 1.938 mmol), sodium bicarbonate (0.195 g, 2.326 mmol) with water:2-butanone (18 mL, 1:5) to produce pure 1-(4-(tert-butyl)phenyl)-5-(4-(hydroxydiphenylmethyl)piperidin-1-yl)pentan-1-one (0.600 g, 1.240 mmol, 64.0% yield) as a colorless oil.
  • Method A diphenyl(piperidin-4-yl)methanol (0.543 g, 2.032 mmol), 1-(4-(tert-butyl)phenyl)-3-chloropropan-1-one (0.435 g, 1.936 mmol), sodium bicarbonate (0.195 g, 2.323 mmol) with water:2-butanone (18 mL, 1:5) to produce pure 1-(4-(tert-butyl)phenyl)-3-(4-(hydroxydiphenyl methyl)piperidin-1-yl)propan-1-one (0.838 g, 1.84 mmol, 95% yield) as a colorless oil.
  • Method A diphenyl(piperidin-4-yl)methanol (0.626 g, 2.341 mmol), 4-chloro-1-(4-chlorophenyl) butan-1-one (0.484 g, 2.229 mmol), sodium bicarbonate (0.225 g, 2.68 mmol) with water:2-butanone (18 mL, 1:5) to produce pure 1-(4-chlorophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (0.394 g, 0.879 mmol, 39.4% yield) as a colorless oil.
  • Method B 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(4-isopropylphenyl)butan-1-one (KSC-335-005) (0.154 g, 0.338 mmol) and MeOH (2 mL) sodium borohydride (0.026 g, 0.676 mmol) to produce pure 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(4-isopropylphenyl)butan-1-ol (0.146 g, 0.319 mmol, 94% yield) as on oil.
  • Method B 1-(4-(tert-butyl)phenyl)-5-(4-(hydroxydiphenylmethyl)piperidin-1-yl)pentan-1-one (KSC-335-006) (0.204 g, 0.422 mmol) and MeOH (2 mL) and sodium borohydride (0.032 g, 0.844 mmol) to produce pure 1-(4-(tert-butyl)phenyl)-5-(4-(hydroxydiphenylmethyl)piperidin-1-yl)pentan-1-ol (0.156 g, 0.321 mmol, 76% yield) as on oil.
  • Method B 1-(4-chlorophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (KSC-335-009) (0.156 g, 0.348 mmol) and MeOH (2 mL) sodium borohydride (0.026 g, 0.696 mmol) to produce pure 1-(4-chlorophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol (0.118 g, 0.262 mmol, 75% yield) as on oil.
  • Method B 1-(4-(tert-butyl)phenyl)-3-(4-(hydroxydiphenylmethyl)piperidin-1-yl)propan-1-one (KSC-335-008) (0.116 g, 0.255 mmol) and MeOH (2 mL) and sodium borohydride (0.019 g, 0.509 mmol) to produce pure 1-(4-(tert-butyl)phenyl)-3-(4-(hydroxydiphenylmethyl)piperidin-1-yl)propan-1-ol (0.106 g, 0.232 mmol, 91% yield) as on oil.
  • the DCM layer was collected and washed with water (1 ⁇ 5 mL), dried with MgSO 4 , filtered and adsorbed to silica and purified by Teledyne ISCO Combiflash chromatography (20 min, 0-40% EtOAc:Hex) and fractions 4 and 5 were collected to produce pure 1-(tert-butyl)-4-(4-chlorobutyl)benzene (0.155 g, 0.690 mmol, 61.9% yield) as an oil.
  • Method B 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-phenylbutan-1-one (KSC-335-018) (0.065 g, 0.157 mmol) and MeOH (2 mL) and sodium borohydride (0.012 g, 0.314 mmol) to produce pure 4-(4-(hydroxydiphenylmethyl) piperidin-1-yl)-1-phenylbutan-1-ol (0.048 g, 0.116 mmol, 73% yield) as on oil.
  • Method A diphenyl(piperidin-4-yl)methanol (0.490 g, 1.832 mmol), 4-chloro-1-(4-methoxyphenyl)butan-1-one (0.371 g, 1.744 mmol), sodium bicarbonate (0.176 g, 2.093 mmol) with water (3 mL) and 2-butanone (15 mL) to produce pure 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(4-methoxyphenyl)butan-1-one (0.282 g, 0.636 mmol, 36% yield) as a colorless oil.
  • Method A diphenyl(piperidin-4-yl)methanol (0.385 g, 1.439 mmol), 4-chloro-1-(4-fluorophenyl)butan-1-one (0.275 g, 1.371 mmol), sodium bicarbonate (0.138 g, 1.645 mmol) with water (3 mL) and 2-butanone (15 mL) to produce pure 1-(4-fluorophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (0.174 g, 0.403 mmol, 29% yield) as a colorless oil.
  • Method A diphenyl(piperidin-4-yl)methanol (0.439 g, 1.642 mmol), 1-(4-bromophenyl)-4-chlorobutan-1-one (0.409 g, 1.564 mmol), sodium bicarbonate (0.158 g, 1.877 mmol) with water (3 mL) and 2-butanone (15 mL) to produce pure 1-(4-bromophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (0.245 g, 0.498 mmol, 32% yield) as a colorless oil.
  • Method B 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(4-methoxyphenyl)butan-1-one (KSC-335-023) (0.113 g, 0.255 mmol) and MeOH (2 mL) and sodium borohydride (0.019 g, 0.509 mmol) to produce pure 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(4-methoxyphenyl)butan-1-ol (0.062 g, 0.139 mmol, 55% yield) as on oil.
  • Method B 1-(4-fluorophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (KSC-335-024) (0.064 g, 0.148 mmol) and MeOH (2 mL) and sodium borohydride (0.011 g, 0.297 mmol) to produce pure 1-(4-fluorophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol (0.059 g, 0.136 mmol, 92% yield) as on oil.
  • Method B 1-(4-bromophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (KSC-335-025) (0.083 g, 0.169 mmol) and MeOH (2 mL) and sodium borohydride (0.013 g, 0.337 mmol) to produce pure 1-(4-bromophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol (0.053 g, 0.107 mmol, 63.6% yield) as on oil.
  • Method B 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(p-tolyl)butan-1-one (0.073 g, 0.171 mmol) and MeOH (Volume: 2 mL) and SODIUM BOROHYDRIDE (0.013 g, 0.341 mmol) to produce pure 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(p-tolyl)butan-1-ol (0.070 g, 0.163 mmol, 95% yield) as on oil.
  • Method B methyl 2-(4-(4-(4-(4-(hydroxydiphenylmethyl) piperidin-1-yl)butanoyl)phenyl)-2-methylpropanoate (KSC-335-066)(0.148 g, 0.288 mmol) and MeOH (1 mL) and sodium borohydride (0.016 g, 0.432 mmol) to produce pure methyl 2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoate (0.108 g, 0.209 mmol, 73% yield).
  • Method A diphenyl(piperidin-4-yl)methanol (0.4 g, 1.496 mmol), 1-(4-(tert-butyl)phenyl)-2-chloroethanone (0.300 g, 1.425 mmol), sodium bicarbonate (0.144 g, 1.710 mmol) with water (3 mL) and 2-butanone (Volume: 15 mL) to produce pure 1-(4-(tert-butyl)phenyl)-2-(4-(hydroxydiphenylmethyl)piperidin-1-yl)ethanone (0.452 g, 1.024 mmol, 71.8% yield) as a colorless oil.
  • Method B 1-(4-(tert-butyl)phenyl)-2-(4-(hydroxydiphenylmethyl)piperidin-1-yl)ethanone (0.113 g, 0.256 mmol) and MeOH (1 mL) and SODIUM BOROHYDRIDE (0.019 g, 0.512 mmol) to produce pure 1-(4-(tert-butyl)phenyl)-2-(4-(hydroxydiphenylmethyl)piperidin-1-yl)ethanol (0.106 g, 0.239 mmol, 93% yield) as a solid.
  • Method B methyl 4-(4-chlorobutanoyl)benzoate (KSC-335-061) (0.042 g, 0.175 mmol) and MeOH with sodium borohydride (0.013 g, 0.349 mmol). to produce methyl 4-(4-chloro-1-hydroxybutyl)benzoate (0.037 g, 0.152 mmol, 87% yield).
  • the DCM layer was concentrated and purified by reverse-phase MPLC (10-100% MeCN:water) to produce pure 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)benzoic acid (0.009 g, 0.020 mmol, 47% yield).
  • reaction then purified by reverse-phase Teledyne ISCO Combiflash chromatography (10-100% MeCN:basic water) and fractions 5 and 6 were collected. These were then subjected to normal phase purification (0-10% MeOH (5% NH 3 OH):DCM) to produce pure (1-(4-amino-4-(4-(tert-butyl)phenyl)butyl)piperidin-4-yl)diphenylmethanol (0.010 g, 0.021 mmol, 5% yield).
  • Method B 1-([1,1′-biphenyl]-4-yl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (KSC-348-001) (0.035 g, 0.071 mmol) and MeOH (2 mL) and sodium borohydride (5.41 mg, 0.143 mmol) to produce pure 1-([1,1′-biphenyl]-4-yl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol (0.033 g, 0.067 mmol, 94% yield) as on oil.
  • EtOAc was collected, dried with MgSO 4 , filtered and adsorbed to silica and purified by MPLC (20 min, 0-30% EtOAc:Hex) to produce pure (4-(tert-butyl)phenyl)(4-(hydroxydiphenylmethyl)piperidin-1-yl)methanone (0.304 g, 0.711 mmol, 82% yield) as a white solid.
  • the product was purified by MPLC (20 min, 0-10% MeOH:DCM) to produce pure (1-(4methoxyphenethyl) piperidin-4-yl)diphenylmethanol (0.289 g, 0.720 mmol, 50% yield) as a sticky solid.
  • the EtOAc layer was dried with MgSO 4 , filtered and adsorbed to silica.
  • the product was purified by reverse-phase MPLC (20 min, 10-100% MeCN:water) to produce 4-(4-benzoylpiperidin-1-yl)-1-(4-(tert-butyl)phenyl)butan-1-one (0.026 g, 0.066 mmol, 26% yield).
  • Method B 4-(4-benzoylpiperidin-1-yl)-1-(4-(tert-butyl)phenyl)butan-1-one (KSC-352-055) (0.026 g, 0.066 mmol) and MeOH (2 mL) and sodium borohydride (10.05 mg, 0.266 mmol) to produce pure 1-(4-(tert-butyl)phenyl)-4-(4-(hydroxy(phenyl)methyl)piperidin-1-yl)butan-1-ol (0.019 g, 0.048 mmol, 72% yield) as a mixture of diastereomers.
  • reaction was diluted with DCM and washed with water and the DCM layer was dried with MgSO 4 , filtered and adsorbed to silica then purified by MPLC (0-15% MeOH:DCM) to produce pure (1-(4-aminophenethyl)piperidin-4-yl)diphenylmethanol (0.077 g, 0.199 mmol, 61% yield).
  • the product was purified by reverse-phase MPLC (10-100% MeCN:water) to produce (1-(4-(dimethylamino)phenethyl)piperidin-4-yl)diphenylmethanol (0.027 g, 0.065 mmol, 84% yield).
  • the EtOAc layer was collected and dried with MgSO 4 , filtered and adsorbed to silica then purified by MPLC (15 min, 0-10% MeOH:DCM) to produce pure diphenyl(1-(4-(trifluoromethyl)phenethyl)piperidin-4-yl)methanol (0.074 g, 0.168 mmol, 49% yield) as an oil.
  • the EtOAc layer was concentrated and purified by reverse-phase MPLC (10-100% MeCN:water) to provide 3-(4-(hydroxydiphenylmethyl)piperidin-1-yl)propan-1-ol (0.395 g, 1.214 mmol, 65% yield) as a white solid.
  • Method B 4-(4-benzylpiperidin-1-yl)-1-(4-(tert-butyl)phenyl)butan-1-one (KSC-367-032) (0.291 g, 0.771 mmol) and MeOH (5 mL) and sodium borohydride (0.117 g, 3.08 mmol) to produce pure 4-(4-benzylpiperidin-1-yl)-1-(4-(tert-butyl)phenyl)butan-1-ol (0.232 g, 0.611 mmol, 79% yield).
  • the DCM layer was concentrated and purified by reverse-phase MPLC (10-100% MeCN:water) to produce pure (1-(2-(6-(tert-butyl)pyridin-3-yl)ethyl)piperidin-4-yl)diphenylmethanol (0.308 g, 0.719 mmol, 92% yield).
  • the EtOAc layer was concentrated and purified by reverse-phase MPLC (10-100% MeCN:water) to produce pure 1-(4-(tert-butyl)phenyl)-4-(4-(diphenylmethylene)piperidin-1-yl)butan-1-one (0.019 g, 0.042 mmol, 32% yield).
  • the EtOAc layer was concentrated and purified by reverse-phase MPLC (10-100% MeCN:water) to produce pure (1-(4-chlorophenethyl)piperidin-4-yl)diphenylmethanol (0.224 g, 0.552 mmol, 73% yield).
  • Method B 1-(4-(tert-butyl)phenyl)-4-(4-(diphenylmethylene)piperidin-1-yl)butan-1-one (KSC-367-053) (0.019 g, 0.042 mmol) and sodium borohydride (6.37 mg, 0.168 mmol) to produce pure 1-(4-(tert-butyl)phenyl)-4-(4-(diphenylmethylene)piperidin-1-yl)butan-1-ol (0.010 g, 0.022 mmol, 52% yield).
  • the reaction stirred at reflux (100° C.) for 2 h.
  • the reaction was then removed from heat and diluted with water then extracted with DCM (3 ⁇ 5 mL).
  • the DCM layer was then washed again with water (3 ⁇ 10 mL).
  • the DCM layer was dried with MgSO 4 , filtered and concentrated.
  • the residue was diluted with hexanes and filtered through MgSO 4 to remove the residual Pd complex.
  • the hexanes layer was then concentrated to produce pure 2-(2-(tert-butyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.093 g, 0.357 mmol, 86% yield).
  • S. aureus strain UAMS-1 is an osteomyelitis clinical isolate (Gillaspy et al. “Role of the accessory gene regulator (agr) in pathogenesis of staphylococcal osteomyelitis. Infect. Immun.
  • ciprofloxacin-resistant strains CRC118 and CRC61 are spontaneous ciprofloxacin-resistant derivatives of UAMS-1 that were selected by growth on Mueller-Hinton agar (MHA) (Becton, Dickinson & Company, Franklin Lakes, N.J.) at 1.5 ⁇ MIC ciprofloxacin (0.75 ⁇ g/ml).
  • MHA Mueller-Hinton agar
  • MIC testing was performed to determine the minimum concentration of test compound that is necessary to inhibit visible growth of bacteria according to Clinical and Laboratory Standards (CLSI) guidelines (Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Ninth Edition. CLSI document M07-A9. 2012. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pa. 19087-1898 USA.) To do so, 10 5 colony forming units of an overnight bacterial culture were seeded into individual wells of 96-well round-bottom microtiter plates containing 88 ⁇ l of MHB medium.
  • test compound To the first column, 2 ⁇ l of the test compound's corresponding solvent was also added to each well (negative control). To the next ten columms, 2 ⁇ l of the test compound (dissolved in DMSO for terfenadine and its derivatives or sterile water for ciprofloxacin) was added in increasing 2-fold increments of 0.5 ⁇ g/ml to 256 ⁇ g/ml to each successive well. Each test compound was evaluated in duplicate. Plates were incubated at 37° C. incubator for 16 h at which point the minimum inhibitory concentration was determined to be the lowest concentration of test compound that inhibited bacterial growth, as judged by the unaided eye.
  • the gyrase supercoiling assays were performed to determine if test compounds interfered with S. aureus DNA gyrase activity, following the manufacturer's recommendations (TopoGEN). Reactions (20 ⁇ l) contained kit provided assay buffer, ATP, potassium glutamate, relaxed plasmid DNA (0.4 ⁇ g/ml), 2 Units of S. aureus DNA gyrase, and various amounts of test compound. Reactions were incubated at 37° C. for 30 min and then stopped by the addition of 10% SDS, filtered through 0.025 ⁇ m Millipore membrane filters in a 10 mM Tris-HCl buffer (pH 8), and electrophoresed in a 1% agarose TAE gel.
  • IC 50 values for each test compound was determined to be the compound concentration that inhibited S. aureus DNA gyrase activity by 50%.
  • a Topoisomerase IV assay was performed on test compounds to determine if they interfered with the ability of S. aureus topoisomerase IV to decatenate kDNA, according to the recommendations of the manufacturer (Inspiralis). To do so, 0.25 U S. aureus topoisomerase IV enzyme was mixed with 200 ng kDNA in kit provided reaction buffer, in the absence or presence of various concentrations of test compounds at 37° C. for 30 min. The reaction was stopped by the addition of STEB stop buffer and 30 ⁇ l of 24:1 chlorform:isoamyl alcohol (total volume 90 ⁇ l).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided herein are compositions and methods for treating or preventing infection.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application claims the benefit of U.S. Provisional Application No. 61/706,492, filed on Sep. 27, 2012, which is incorporated by reference herein in its entirety.
    • STATEMENT REGARDING FEDERALLY FUNDED RESEARCH
  • This invention was made with government funding under Grant Nos. 1R01AI1075033-03 and 5P50GM069663 from the National Institutes of Health. The government has certain rights in this invention.
    • BACKGROUND
  • Infectious diseases affect the health of people and animals around the world, causing serious illness and death. Thus, an urgent need exists for treatments for infections.
    • SUMMARY
  • Provided herein is a method of treating or preventing an infection in a subject with or at risk of developing an infection, the method comprising administering to the subject
  • a compound of Formula I
  • Figure US20150238473A1-20150827-C00001
  • wherein R represents hydrogen or hydroxyl and R1 represents hydrogen, or R and R1 taken together form a second bond between the carbon atoms bearing R and R1; R2 represents hydrogen or phenyl; n is zero or a positive whole integer of from 1 to 4; X represents CH2, CHOH, NH, C═O, CHNR3R4, where R3 and R4 independently are hydrogen or lower alkyl; and Z represents thienyl, pyridinyl, substituted pyridinyl, phenyl or substituted phenyl wherein the substituents on the substituted pyridinyl or substituted phenyl are selected from phenyl, pyridinyl, nitro, a halogen atom, such as chlorine, fluorine, bromine, or iodine, a straight or branched lower alkyl chain of from 1 to 4 carbon atoms, a lower alkoxy group of from 1 to 4 carbon atoms, amino, a mono or di(lower)alkylamino group, a saturated monocyclic heterocyclic group such as pyrrolidino, piperidino, morpholino, or N-(lower)alkylpiperazino, or a group having the structure —COOR5, —CR6R7COOR5, —CF3, CHF2, CH2F, or
  • Figure US20150238473A1-20150827-C00002
  • where R5 is hydrogen or lower alkyl, and R6 and R7 independently are hydrogen or methyl or a pharmaceutically acceptable salt thereof.
  • Further provided is a method of treating or preventing an infection in a subject with or at risk of developing an infection, the method comprising administering to the subject
  • a compound of Formula III
  • Figure US20150238473A1-20150827-C00003
  • or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently selected from ethyl or methyl, n 1 or 2, R3 and R4 are both phenyl or substituted phenyl, wherein the substituent can be halo (for example, fluoro-, chloro-, iodo- or bromo-), hydroxyl, a lower alkyl or a substituted lower alkyl wherein the substituent can be halo, hydroxy, or lower alkoxy, and R5 is hydrogen, a halogen, a lower alkyl from about 1 to 4 carbon atoms or a substituted alkyl wherein the substituent can be halo, hydroxy, or lower alkoxy.
  • Also provided is a method of treating or preventing infection in a subject with or at risk of developing an infection, the method comprising administering to the subject a compound selected from the group consisting of:
      • a compound of Formula V
  • Figure US20150238473A1-20150827-C00004
  • wherein R1 is a lower alkyl group having from 1 to 4 carbon atoms being substituted with one or several halogen atoms, Z is hydrogen or a lower alkyl group having from 1 to 4 carbon atoms, m is 2 or 3 and X2 is the ethylene imino group or the group having the formula:
  • Figure US20150238473A1-20150827-C00005
  • wherein R is hydrogen or a lower alkyl group having from 1 to 4 carbon atoms which can be substituted with a chlorine atom or a hydroxy group, and Z and m have the above-given meaning,
      • a compound of Formula X
  • Figure US20150238473A1-20150827-C00006
  • wherein R represents a lower alkyl or a lower alkenyl group, a phenyl group which can be substituted by halogen, methyl or lower alkoxy groups, or a benzyl group which can be nuclear substituted by halogen, methyl or lower alkoxy groups,
    X represents —O—, —S—, —SO—, or —SO2—,
    n represents an integer from 1-4, and
  • Aryl represents a phenyl group which can be substituted by lower alkoxy or lower alkylmercapto groups;
      • a compound of Formula XII
  • Figure US20150238473A1-20150827-C00007
  • wherein R and R6 are the same or different and are hydroxy, lower alkoxy, lower alkenoxy, dilower alkylamino lower alkoxy (dimethylaminoethoxy), acylamino lower alkoxy (acetylaminoethoxy), acyloxy lower alkoxy (pivaloyloxymethoxy), aryloxy, such as phenoxy, arloweralkoxy, such as benzyloxy, substituted aryloxy or substituted arloweralkoxy wherein the substitutent is methyl, halo or methoxy, amino, loweralkylamino, diloweralkylamino, hydroxyamino, arloweralkylamino such as benzylamino;
  • R1 is hydrogen, alkyl of from 1 to 20 carbon atoms which include branched and cyclic and unsaturated (such as allyl) alkyl groups, substituted loweralkyl wherein the substituent can be halo, hydroxy, lower alkoxy, aryloxy such as phenoxy, amino, diloweralkylamino, acylamino, such as acetamido and benzamido, arylamino, guanidino, imidazolyl, indolyl, mercapto, loweralkylthio, arylthio such as phenylthio, carboxy or carboxamido, carboloweralkoxy, aryl such as phenyl or naphthyl, substituted aryl such as phenyl wherein the substituent is lower alkyl, lower alkoxy or halo, arloweralkyl, arloweralkenyl, heteroarlower alkyl or heteroarlower alkenyl such as benzyl, styryl or indolyl ethyl, substituted arloweralkyl, substituted arloweralkenyl, substituted heteroarlower alkyl, or substituted heteroarlower alkenyl, wherein the substituent(s) is halo, dihalo, lower alkyl, hydroxy, lower alkoxy, amino, aminomethyl, acylamino (acetyl amino or benzoylamino) diloweralkylamino, loweralkylamino, carboxyl, haloloweralkyl, cyano or sulfonamido; arloweralkyl or heteroarloweralkyl substituted on the alkyl portion by amino or acylamino (acetylamino or benzoylamino);
  • R2 and R7 are the same or different and are hydrogen or lower alkyl;
  • R3 is hydrogen, lower alkyl, phenyl lower alkyl, aminomethyl phenyl lower alkyl, hydroxy phenyl lower alkyl, hydroxy lower alkyl, acylamino lower alkyl (such as benzoylamino lower alkyl, acetylamino lower alkyl), amino lower alkyl, dimethylamino lower alkyl, halo lower alkyl, guanidino lower alkyl, imidazolyl lower alkyl, indolyllower alkyl, mercapto lower alkyl, lower alkyl thio lower alkyl;
  • R4 is hydrogen or lower alkyl;
  • R5 is hydrogen, lower alkyl, phenyl, phenyl lower alkyl, hydroxy phenyl lower alkyl, hydroxy lower alkyl, amino lower alkyl, guanidino lower alkyl, imidazolyl lower alkyl, indolyl lower alkyl, mercapto lower alkyl or lower alkyl thio lower alkyl;
  • R4 and R5 can be connected together to form an alkylene bridge of from 2 to 4 carbon atoms, an alkylene bridge of from 2 to 3 carbon atoms and one sulfur atom, an alkylene bridge of from 3 to 4 carbon atoms containing a double bond or an alkylene bridge as above substituted with hydroxy, loweralkoxy, loweralkyl or diloweralky;
      • a compound of Formula XIII
  • Figure US20150238473A1-20150827-C00008
  • wherein R1 is H, alkyl, acyl or silyl(alkyl)3; R2 is H and R3 is OH, O-acyl, O-alkyl or O-silyl (alkyl)3 or R3 is H and R2 is OH. O-acyl, O-alkyl or O-silyl (alkyl)3; or R2 and R3 together represent O; or R2 and R3 together represent acetal or cyclic acetal. R1 might also represent a substituted alkyl such as e.g. methoxy ethoxy methyl;
      • a compound of Formula XIV
  • Figure US20150238473A1-20150827-C00009
  • wherein PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, R is hydrogen, lower-alkyl or lower-hydroxyalkyl, and Q is nitro, carbamyl, halo, amino, lower-alkylamino, di(lower-alkyl)amino, or NHAc where Ac is lower-alkanoyl or lower-carbalkoxy;
      • a compound of Formula XV
  • Figure US20150238473A1-20150827-C00010
      • a compound of Formula XVI
  • Figure US20150238473A1-20150827-C00011
      • a compound of Formula XVII
  • Figure US20150238473A1-20150827-C00012
      • a compound of Formula XVIII
  • Figure US20150238473A1-20150827-C00013
      • a compound of Formula XIX
  • Figure US20150238473A1-20150827-C00014
      • a compound of Formula (XX)
  • Figure US20150238473A1-20150827-C00015
  • or a pharmaceutically acceptable salt thereof.
  • Further provided is a method of treating or preventing an infection in a subject with or at risk of developing an infection, the method comprising administering to the subject a compound selected from the group consisting of: Didanosine, Norcyclobenzaprine, Niridazole, Ifosfamide, Cefalonium, Tamoxifen citrate, Butoconazole, Suloctidil, Clomiphene, Sulconazole, Miconazole, Mefloquine, Sulfinpyrazone, Terfenadine, Lisinopril, Econzaole, Clofazimine, Equilin, Felodipine, Dacarbazine, Furazolidone, Perhexiline maleate, Oxethazaine, Pimozide, Trifluoperazine, Ellipticine, Fluspirilen, Hexestrol, Dienestrol, Zidovudine, Metoprolol, Napelline, Methimazole, Amrinone, Iopanoic acid, R-Propanolol, Rimexolone and Pyrvinium pamoate, wherein the infection is a bacterial infection.
  • Also provided is a method of removing or preventing biofilm formation on a surface, the method comprising administering to a biofilm containing surface or a surface susceptible to biofilm formation an effective amount of a compound selected from the group consisting of:
  • a compound of Formula I
  • Figure US20150238473A1-20150827-C00016
  • wherein R represents hydrogen or hydroxyl and R1 represents hydrogen, or R and R1 taken together form a second bond between the carbon atoms bearing R and R1; R2 represents hydrogen or phenyl; n is zero or a positive whole integer of from 1 to 4; X represents CH2, CHOH, NH, C═O, CHNR3R4, where R3 and R4 independently are hydrogen or lower alkyl; and Z represents thienyl, pyridinyl, substituted pyridinyl, phenyl or substituted phenyl wherein the substituents on the substituted pyridinyl or substituted phenyl are selected from phenyl, pyridinyl, nitro, a halogen atom, such as chlorine, fluorine, bromine, or iodine, a straight or branched lower alkyl chain of from 1 to 4 carbon atoms, a lower alkoxy group of from 1 to 4 carbon atoms, amino, a mono or di(lower)alkylamino group, a saturated monocyclic heterocyclic group such as pyrrolidino, piperidino, morpholino, or N-(lower)alkylpiperazino, or a group having the structure —COOR5, —CR6R7COOR5, —CF3, CHF2, CH2F, or
  • Figure US20150238473A1-20150827-C00017
  • where R5 is hydrogen or lower alkyl, and R6 and R7 independently are hydrogen or methyl or a pharmaceutically acceptable salt thereof.
    • DESCRIPTION OF DRAWINGS
  • FIG. 1 depicts the adenylate kinase (AK) assay described in the Examples. Bactericidal agents compromise bacterial cell integrity, releasing cellular adenylate kinase. Extracellular AK is measured by the addition of a commercial ToxiLight AK cocktail containing ADP and luciferase, resulting in luminescence.
  • FIG. 2 shows AK assay development. (A) AK assay measures of E. coli lysed cell supernatants. E. coli DH5α cells (1×109) were heat inactivated by boiling and diluted, and the AK assay was used to measure adenylate kinase release. Background signal is also shown (mock-treated cells (right-hand column in FIG. 2A). “*” indicates a significant difference between results for boiled and mock treatment (Student's t test; P≦0.05). (B) AK assay results for colistin-treated A. baumannii strain 98-37-09. Cells were treated with the indicated concentration of colistin, and AK was measured; MIC (4 μg ml−1 is indicated. “*” indicates a significant increase in signal compared to that for mock treatment (0 μg ml−1; Student's t test, P≦0.05).
  • FIG. 3 shows AK assay measures of S. aureus strain RN4220 treatment with bacteriostatic and bactericidal antibiotics. Standard MIC testing determined the MIC of each antibiotic class (in parentheses). Graphed are the fold changes in AK signal of cells treated with 0.5× or 1.0× the MIC value (left hand column and right hand column, respectively) for each antibiotic, in comparison to untreated control cells; “*” indicates a significant change in signal as determined by Student's t test; P≦0.05 (compared to results for untreated cells).
  • FIG. 4 shows AK assay measures of antibiotic-treated biofilms and small-colony variants. (A) Graphed are AK signals generated by static biofilm-associated cells following mock or antibiotic treatment: colistin (P. aeruginosa) or ciprofloxacin (S. aureus and A. baumannii). (B) Fold change of AK measures of S. aureus SCV UAMS-1112 cells following treatment with 1× and 10× ciprofloxacin, meropenem, and vancomycin, compared to results for mock treated cells. “*” indicates a significant change in signal in comparison to results for mock-treated cells (Student's t test, P≦0.05).
  • FIG. 5 shows AK-based HTS development and screening. (A) Z′ factor assay results for Klebsiella pneumoniae. Three-hundred-eighty-four-well microtiter plates were seeded with K. pneumoniae, and alternating rows were mock treated (DMSO) or treated with 50 μM colistin. Following 3 h of incubation, AK release was measured and plotted. DMSO-treated well measures are shown at the bottom of FIG. 5A; colistin-treated wells are shown at the top of FIG. 5A. (B) Prestwick library Klebsiella pneumoniae screening results. In total, 26 compounds were determined to result in a 3-fold increase in AK signal, in comparison to results for DMSO-treated cells. Included among this list were polymyxin, cephalosporins, aminoglycosides, fluoroquinolones, and detergents; the complete Prestwick screening results for K. pneumoniae and all other organisms screened are provided in Table 4.
  • FIG. 6 shows antimicrobial properties of terfenadine and tamoxifen. (A) Fold changes in AK signal of terfenadine-treated (10×MIC) S. aureus strain UAMS-1 static biofilms and the SCV strain UAMS-1112, compared to those for mock (DMSO)-treated populations, are plotted. “*” indicates a significant increase in signal over that with mock-treated cells (Student's t test, P≦0.05). (B) Plotted are the percent survival of G. mellonella larvae at 48 h post-E. faecium inoculation. Groups of larvae (n=45) were treated at 2 h and 24 h with either PBS (mock), DMSO, 80 mg kg−1 tamoxifen, 160 mg kg−1 tamoxifen, or 20 mg kg−1 vancomycin.
    •  DETAILED DESCRIPTION
  • Provided herein is a method of treating or preventing an infection in a subject with or at risk of developing an infection, the method comprising administering to the subject a compound selected from the group consisting of:
      • a compound of Formula I
  • Figure US20150238473A1-20150827-C00018
  • wherein R represents hydrogen or hydroxyl and R1 represents hydrogen, or R and R1 taken together form a second bond between the carbon atoms bearing R and R1; R2 represents hydrogen or phenyl; n is zero or a positive whole integer of from 1 to 4; X represents CH2, CHOH, NH, C═O, CHNR3R4, where R3 and R4 independently are hydrogen or lower alkyl; and Z represents thienyl, pyridinyl, substituted pyridinyl, phenyl or substituted phenyl wherein the substituents on the substituted pyridinyl or substituted phenyl are selected from phenyl, pyridinyl, nitro, a halogen atom, such as chlorine, fluorine, bromine, or iodine, a straight or branched lower alkyl chain of from 1 to 4 carbon atoms, a lower alkoxy group of from 1 to 4 carbon atoms, amino, a mono or di(lower)alkylamino group, a saturated monocyclic heterocyclic group such as pyrrolidino, piperidino, morpholino, or N-(lower)alkylpiperazino, or a group having the structure —COOR5, —CR6R7COOR5, —CF3, CHF2, CH2F, or
  • Figure US20150238473A1-20150827-C00019
  • where R5 is hydrogen or lower alkyl, and R6 and R7 independently are hydrogen or methyl. The substituents on the substituted phenyl may be attached at the ortho, meta or para positions of the phenyl ring.
  • Compounds of Formula I include compounds of Formula II,
  • Figure US20150238473A1-20150827-C00020
  • wherein R represents hydrogen or hydroxyl and R1 represents hydrogen, or R and R1 taken together form a second bond between the carbon atoms bearing R and R1; n is zero or a positive whole integer of from 1 to 4; Z represents thienyl, pyridinyl, substituted pyridinyl, phenyl or substituted phenyl wherein the substituents on the substituted pyridinyl or substituted phenyl are selected from phenyl, pyridinyl, nitro, a halogen atom, such as chlorine, fluorine, bromine, or iodine, a straight or branched lower alkyl chain of from 1 to 4 carbon atoms, a lower alkoxy group of from 1 to 4 carbon atoms, amino, a mono or di(lower)alkylamino group, a saturated monocyclic heterocyclic group such as pyrrolidino, piperidino, morpholino, or N-(lower)alkylpiperazino, or a group having the structure —COOR5, —CR6R7COOR5, —CF3, CHF2, CH2F, or
  • Figure US20150238473A1-20150827-C00021
      • where R5 is hydrogen or lower alkyl, and R6 and R7 independently are hydrogen or methyl
      • or a pharmaceutically acceptable salt thereof.
  • Compounds of Formula I also include terfenadine and derivatives thereof, including, but not limited to the following compounds. The compounds are identified by structure, name and registry number. The registry number for each compound is also set forth in Table 6 as an additional identifier for each compound.
  • Compound
    Lot #
    Figure US20150238473A1-20150827-C00022
    Figure US20150238473A1-20150827-C00023
    Figure US20150238473A1-20150827-C00024
    Figure US20150238473A1-20150827-C00025
    Figure US20150238473A1-20150827-C00026
    Figure US20150238473A1-20150827-C00027
    Figure US20150238473A1-20150827-C00028
    Figure US20150238473A1-20150827-C00029
    Figure US20150238473A1-20150827-C00030
    Figure US20150238473A1-20150827-C00031
    Figure US20150238473A1-20150827-C00032
    Figure US20150238473A1-20150827-C00033
    Figure US20150238473A1-20150827-C00034
    Figure US20150238473A1-20150827-C00035
    Figure US20150238473A1-20150827-C00036
    Figure US20150238473A1-20150827-C00037
    Figure US20150238473A1-20150827-C00038
    Figure US20150238473A1-20150827-C00039
    Figure US20150238473A1-20150827-C00040
    Figure US20150238473A1-20150827-C00041
    Figure US20150238473A1-20150827-C00042
    Figure US20150238473A1-20150827-C00043
    Figure US20150238473A1-20150827-C00044
    Figure US20150238473A1-20150827-C00045
    Figure US20150238473A1-20150827-C00046
    Figure US20150238473A1-20150827-C00047
    Figure US20150238473A1-20150827-C00048
    Figure US20150238473A1-20150827-C00049
    Figure US20150238473A1-20150827-C00050
    Figure US20150238473A1-20150827-C00051
    Figure US20150238473A1-20150827-C00052
    Figure US20150238473A1-20150827-C00053
    Figure US20150238473A1-20150827-C00054
    Figure US20150238473A1-20150827-C00055
    Figure US20150238473A1-20150827-C00056
    Figure US20150238473A1-20150827-C00057
    Figure US20150238473A1-20150827-C00058
    Figure US20150238473A1-20150827-C00059
    Figure US20150238473A1-20150827-C00060
    Figure US20150238473A1-20150827-C00061
    Figure US20150238473A1-20150827-C00062
    Figure US20150238473A1-20150827-C00063
    Figure US20150238473A1-20150827-C00064
    Figure US20150238473A1-20150827-C00065
    Figure US20150238473A1-20150827-C00066
    Figure US20150238473A1-20150827-C00067
    Figure US20150238473A1-20150827-C00068
  • Also provided is a method of treating or preventing an infection in a subject with or at risk of developing an infection, the method comprising administering to the subject a compound selected from the group consisting of:
  • a compound of Formula III
  • Figure US20150238473A1-20150827-C00069
  • or a pharmaceutically acceptable salt thereof, wherein R1 and Rare independently selected from ethyl or methyl, n 1 or 2, R3 and R4 are both phenyl or substituted phenyl, wherein the substituent can be halo (for example, fluoro-, chloro-, iodo- or bromo-), hydroxyl, a lower alkyl or a substituted lower alkyl wherein the substituent can be halo, hydroxy, or lower alkoxy, and R5 is hydrogen, a halogen, a lower alkyl from about 1 to 4 carbon atoms or a substituted alkyl wherein the substituent can be halo, hydroxy, or lower alkoxy. Examples of the compounds of Formula III include, tamoxifen and derivatives
  • Figure US20150238473A1-20150827-C00070
  • thereof, including but not limited to tamoxifen (Formula IV), 4-hydroxy tamoxifen and clomiphene. In the methods provided herein, wherein a one or more compounds of Formula III are used to treat or prevent infection, the infection can be an infection, wherein the infection is not a fungal infection or a parasitic infection.
  • Further provided herein is a method of treating or preventing an infection in a subject with or at risk of developing an infection, the method comprising administering to the subject a compound selected from the group consisting of:
      • a compound of Formula V
  • Figure US20150238473A1-20150827-C00071
  • wherein R1 is a lower alkyl group having from 1 to 4 carbon atoms being substituted with one or several halogen atoms, Z is hydrogen or a lower alkyl group having from 1 to 4 carbon atoms, m is 2 or 3 and X2 is the ethylene imino group or the group having the formula:
  • Figure US20150238473A1-20150827-C00072
  • wherein R is hydrogen or a lower alkyl group having from 1 to 4 carbon atoms which may be substituted with a chlorine atom or a hydroxy group, and Z and m have the above-given meaning, or a pharmaceutically acceptable salt thereof.
  • As used throughout, the term “lower alkyl group containing from 1 to 4 carbon atoms” means methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tertiary butyl, and I-methylpropyl. The term “halogen” means chlorine, bromine, fluorine, and iodine. Included herein are compounds of formula IV that correspond to formula VI:
  • Figure US20150238473A1-20150827-C00073
  • wherein R1, X2 and m have the same meaning as in Formula IV. Additional compounds of formula IV, include the compounds of formula VII:
  • Figure US20150238473A1-20150827-C00074
  • wherein R2 is a β-chloroethyl or a γ-chloropropyl group, and R3 is hydrogen, a methyl group or an ethyl group, optionally substituted in the β-position with a chlorine atom or a hydroxy group. Among the compounds of formula VII, are the compounds of formula VIII and IX. The compound of formula VIII is 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide or ifosfamide. Ifosfamide is also known as IFEX.
  • Figure US20150238473A1-20150827-C00075
  • Further provided herein is a method of treating or preventing an infection in a subject with or at risk of developing an infection, the method comprising administering to the subject a compound selected from the group consisting of:
  • a compound of Formula X
  • Figure US20150238473A1-20150827-C00076
  • wherein R represents a lower alkyl or a lower alkenyl group, a phenyl group which can be substituted by halogen, methyl or lower alkoxy groups, or a benzyl group which can be nuclear substituted by halogen, methyl or lower alkoxy groups,
    X represents —O—, —S—, —SO—, or —SO2—,
    n represents an integer from 1-4, and
    Aryl represents a phenyl group which can be substituted by lower alkoxy or lower alkylmercapto groups;
    or a pharmaceutically acceptable salt thereof.
  • With respect to Formula X, R represents a lower alkyl or a lower alkenyl group, a phenyl group which can be substituted by halogen, methyl or lower alkoxy groups, or a benzyl group which can be nuclear substituted by halogen, methyl or lower alkoxy groups, X represents —O—, —S—, —SO—, or —SO2-, n represents an integer from 1-4, and aryl represents a phenyl group which can be substituted by lower alkoxy or lower alkylmercapto groups.
  • For example, —R—X—CnH2n— can represent the following groups: methoxy-, ethoxy-, propoxy-, isopropoxy-, butoxy-, isobutoxy-, allyloxy-, crotyloxy-. phenoxy-, o, -m- and p-methylphenoxy-, o,p-dimethylphenoxy-, m,p-dimethylphenoxy-, p-chlorophenoxy-, p-bromophenoxy-, -o, m and p-methoxyphenoxy-, p-ethoxyphenoxy-, benzyloxy-, o-, m-, and p-methylbenzyloxy-, p-chlorobenzyloxy-, p-bromobenzyloxy, o, m and p-methoxybenzyloxyand-, p-ethoxybenzyloxy-; methyl, -ethyl, -propyl, -isopropyl, and butyl radicals and •analogous radicals with SO or SO2 instead of O as divalent group X.
  • Besides the phenyl group, aryl can be, for example, the o- or p-methylmercaptophenyl group, the o- or p-ethyl mercaptophenyl group, the o-; m-, or p-methoxyphenyl group or the o-, m- or p-ethoxyphenyl group.
  • An example of the compound of formula X is set forth herein as formula XI. The compound of formula X is sulfinapyrazone. Sulfinapyrazone is also known as Anturane.
  • Figure US20150238473A1-20150827-C00077
  • Also provided herein is a method of treating or preventing an infection in a subject with or at risk of developing an infection, the method comprising administering to the subject a compound selected from the group consisting of:
  • a compound of Formula XII
  • Figure US20150238473A1-20150827-C00078
  • wherein R and R6 are the same or different and are hydroxy, lower alkoxy, lower alkenoxy, dilower alkylamino lower alkoxy (dimethylaminoethoxy), acylamino lower alkoxy (acetylaminoethoxy), acyloxy lower alkoxy (pivaloyloxymethoxy), aryloxy, such as phenoxy, arloweralkoxy, such as benzyloxy, substituted aryloxy or substituted arloweralkoxy wherein the substitutent is methyl, halo or methoxy, amino, loweralkylamino, diloweralkylamino, hydroxyamino, arloweralkylamino such as benzylamino;
    R1 is hydrogen, alkyl of from 1 to 20 carbon atoms which include branched and cyclic and unsaturated (such as allyl) alkyl groups, substituted loweralkyl wherein the substituent can be halo, hydroxy, lower alkoxy, aryloxy such as phenoxy, amino, diloweralkylamino, acylamino, such as acetamido and benzamido, arylamino, guanidino, imidazolyl, indolyl, mercapto, loweralkylthio, arylthio such as phenylthio, carboxy or carboxamido, carboloweralkoxy, aryl such as phenyl or naphthyl, substituted aryl such as phenyl wherein the substituent is lower alkyl, lower alkoxy or halo, arloweralkyl, arloweralkenyl, heteroarlower alkyl or heteroarlower alkenyl such as benzyl, styryl or indolyl ethyl, substituted arloweralkyl, substituted arloweralkenyl, substituted heteroarlower alkyl, or substituted heteroarlower alkenyl, wherein the substituent(s) is halo, dihalo, lower alkyl, hydroxy, lower alkoxy, amino, aminomethyl, acylamino (acetyl amino or benzoylamino) diloweralkylamino, loweralkylamino, carboxyl, haloloweralkyl, cyano or sulfonamido; arloweralkyl or heteroarloweralkyl substituted on the alkyl portion by amino or acylamino (acetylamino or benzoylamino);
    R2 and R7 are the same or different and are hydrogen or lower alkyl;
    R3 is hydrogen, lower alkyl, phenyl lower alkyl, aminomethyl phenyl lower alkyl, hydroxy phenyl lower alkyl, hydroxy lower alkyl, acylamino lower alkyl (such as benzoylamino lower alkyl, acetylamino lower alkyl), amino lower alkyl, dimethylamino lower alkyl, halo lower alkyl, guanidino lower alkyl, imidazolyl lower alkyl, indolyllower alkyl, mercapto lower alkyl, lower alkyl thio lower alkyl;
    R4 is hydrogen or lower alkyl;
    R5 is hydrogen, lower alkyl, phenyl, phenyl lower alkyl, hydroxy phenyl lower alkyl, hydroxy lower alkyl, amino lower alkyl, guanidino lower alkyl, imidazolyl lower alkyl, indolyl lower alkyl, mercapto lower alkyl or lower alkyl thio lower alkyl;
    R4 and R5 may be connected together to form an alkylene bridge of from 2 to 4 carbon atoms, an alkylene bridge of from 2 to 3 carbon atoms and one sulfur atom, an alkylene bridge of from 3 to 4 carbon atoms containing a double bond or an alkylene bridge as above substituted with hydroxy, loweralkoxy, loweralkylor diloweralky;
    or a pharmaceutically acceptable salt thereof.
  • With respect to Formula XII, R and R6 are the same or different and are hydroxy, lower alkoxy, lower alkenoxy, dilower alkylamino lower alkoxy (dimethylaminoethoxy), acylamino lower alkoxy (acetylaminoethoxy), acyloxy lower alkoxy (pivaloyloxymethoxy), aryloxy, such as phenoxy, arloweralkoxy, such as benzyloxy, substituted aryloxy or substituted arloweralkoxy wherein the substitutent is methyl, halo or methoxy, amino, loweralkylamino, diloweralkylamino, hydroxyamino, arloweralkylamino such as benzylamino;
  • R1 is hydrogen, alkyl of from 1 to 20 carbon atoms which include branched and cyclic and unsaturated (such as allyl) alkyl groups, substituted loweralkyl wherein the substituent can be halo, hydroxy, lower alkoxy, aryloxy such as phenoxy, amino, diloweralkylamino, acylamino, such as acetamido and benzamido, arylamino, guanidino, imidazolyl, indolyl, mercapto, loweralkylthio, arylthio such as phenylthio, carboxy or carboxamido, carboloweralkoxy, aryl such as phenyl or naphthyl, substituted aryl such as phenyl wherein the substituent is lower alkyl, lower alkoxy or halo, arloweralkyl, arloweralkenyl, heteroarlower alkyl or heteroarlower alkenyl such as benzyl, styryl or indolyl ethyl, substituted arloweralkyl, substituted arloweralkenyl, substituted heteroarlower alkyl, or substituted heteroarlower alkenyl, wherein the substituent(s) is halo, dihalo, lower alkyl, hydroxy, lower alkoxy, amino, aminomethyl, acylamino (acetyl amino or benzoylamino) diloweralkylamino, loweralkylamino, carboxyl, haloloweralkyl, cyano or sulfonamido; arloweralkyl or heteroarloweralkyl substituted on the alkyl portion by amino or acylamino (acetylamino or benzoylamino);
  • R2 and R7 are the same or different and are hydrogen or lower alkyl;
  • R3 is hydrogen, lower alkyl, phenyl lower alkyl, aminomethyl phenyl lower alkyl, hydroxy phenyl lower alkyl, hydroxy lower alkyl, acylamino lower alkyl (such as benzoylamino lower alkyl, acetylamino lower alkyl), amino lower alkyl, dimethylamino lower alkyl, halo lower alkyl, guanidino lower alkyl, imidazolyl lower alkyl, indolyllower alkyl, mercapto lower alkyl, lower alkyl thio lower alkyl;
  • R4 is hydrogen or lower alkyl;
  • R5 is hydrogen, lower alkyl, phenyl, phenyl lower alkyl, hydroxy phenyl lower alkyl, hydroxy lower alkyl, amino lower alkyl, guanidino lower alkyl, imidazolyl lower alkyl, indolyl lower alkyl, mercapto lower alkyl or lower alkyl thio lower alkyl;
  • R4 and R5 may be connected together to form an alkylene bridge of from 2 to 4 carbon atoms, an alkylene bridge of from 2 to 3 carbon atoms and one sulfur atom, an alkylene bridge of from 3 to 4 carbon atoms containing a double bond or an alkylene bridge as above substituted with hydroxy, loweralkoxy, loweralkylor diloweralky.
  • The loweralkyl or lower alkenyl groups except where noted otherwise represented by any of the variables include straight and branched chain hydrocarbon radicals from one to six carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, hexyl or vinyl, allyl, butenyl and the like. The aralkyl groups represented by any of the above variables have from one to four carbon atoms in the alkyl portion thereof and include for example, benzyl, p-methoxy benzyl and the like. Halo means chloro, bromo, iodo or fluoro. Aryl where it appears in any of the radicals except where noted represents phenyl or naphthyl. Heteroaryl groups where they appear include for example pyridyl, thienyl, furyl, indolyl, benzthienyl, imidazoyl and thiazolyl. The R1, R3 and R5 substituted lower alkyl moieties are exemplified by groups such as
  • Figure US20150238473A1-20150827-C00079
  • R4 and R5 when joined through the carbon and nitrogen atoms to which they are attached form a 4 to 6 membered ring which may contain one sulfur atom or a double bond. Preferred rings have the formulae:
  • Figure US20150238473A1-20150827-C00080
  • where Y is CH2, S, or CHOCH3.
  • Compounds of Formula XI include compounds wherein:
  • R and R6 can each independently be hydroxy, lower alkoxy, lower alkenoxy, arloweralkyloxy, amino, dilower alkylamino lower alkoxy, acylamino lower alkoxy, acyloxy lower alkoxy wherein the substituent is methyl, halo or methoxy;
  • R2 and R7 are hydrogen; R3 is lower alkyl, amino lower alkyl, imidazoyllower alkyl, halo lower alkyl;
  • R4 and R5 are joined to form the preferred rings as defined above where Y is CH2, S, or CH—OCH3;
  • R1 is as defined previously.
  • Other compounds include compounds of Formula XI wherein further R1 is alkyl having from 1 to 8 carbon atoms, substituted lower alkyl wherein the alkyl group has 1-5 carbon atoms and the substituent is amino, arylthio, aryloxy or arylamino, aralkyl or heteroaralkyl wherein the alkyl portion has 1 to 3 carbon atoms such as phenethyl or indolylethyl or substituted arloweralkyl 65 (phenyl lower alkyl or naphthyl lower alkyl) and substituted heteroarloweralkyl wherein the alkyl groups have 1-3 carbons and wherein the substituent(s) is halo, dihalo, amino, aminoalkyl, hydroxy, lower alkoxy or lower alkyl.
  • Other compounds of Formula XI include compounds wherein R and R6 are hydroxy, lower alkoxy, aralkyloxy;
  • R2 and R7 are hydrogen;
  • R3 is methyl or amino lower alkyl;
  • R4 and R5 are joined through the carbon and nitrogen atom to form proline, 4-thiaproline or 4-methoxy proline;
  • R1 is alkyl having from 1 to 8 carbon atoms, substituted lower alkyl wherein the alkyl group has 1-5 carbon atoms and the substituent is amino, arylthio or aryloxy, aralkyl or heteroaralkyl wherein the alkyl portion has 1 to 3 carbon atoms such as phenethyl or indolylethyl or substituted aralkyl (phenyl lower alkyl or naphthyl lower alkyl) and substituted heteroaralkyl wherein the alkyl groups have 1-3 carbons and wherein the substituent(s) is halo, dihalo, amino, aminoalkyl, hydroxy, lower alkoxy or lower alkyl.
  • Further examples of compounds of Formula XII include, but are not limited to:
    • N-(1(S)-carboxy-3-phenylpropyl)-L-alanyl-L-proline;
    • N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L-proline and its maleate salt;
    • N-(1(S)-ethoxycarbonyl-4-methylpentyl)-L-alanyl-L-proline;
    • N-(1-carboxy-5-aminopentyl)-L-alanyl-L-proline;
    • N-.alpha.-(1(S)-carboxy-3-phenylpropyl)-L-lysyl-L-proline (lisinopril);
    • N-.alpha.(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-lysyl-L-proline;
    • N-.alpha.[1(S)-carboxy-3-(3-indolyl)propyl]-L-lysyl-L-proline;
    • N-.alpha.-[1(S)-carboxy-3-(4-chlorophenyl)-propyl]-L-lysyl-L-proline;
    • N-.alpha.-[1(S)-carboxy-2-phenylthioethyl]-L-lysyl-L-proline;
    • N-.alpha.-[1(S)-carboxy-3-(4-chlorophenyl)-propyl]-L-lysyl-L-4.alpha.-methoxyproline;
    • N-.alpha.-[1(S)-carboxy-5-aminopentyl]-L-lysyl-L-proline;
    • Ethyl N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L-prolinate hydrochloride; and the like.
  • Also provided herein is a method of treating or preventing an infection in a subject with or at risk of developing an infection, the method comprising administering to the subject a compound selected from the group consisting of:
  • a compound of Formula XIII
  • Figure US20150238473A1-20150827-C00081
  • wherein R1 is H, alkyl, acyl or silyl(alkyl)3; R2 is H and R3 is OH, O-acyl, O-alkyl or O-silyl (alkyl)3 or R3 is H and R2 is OH. O-acyl, O-alkyl or O-silyl (alkyl)3; or R2 and R3 together represent O; or R2 and R3 together represent acetal or cyclic acetal. R1 might also represent a substituted alkyl such as e.g. methoxy ethoxy methyl; or a pharmaceutically acceptable salt thereof.
  • Also provided herein is a method of treating or preventing an infection in a subject with or at risk of developing an infection, the method comprising administering to the subject a compound selected from the group consisting of:
  • a compound of Formula XIV
  • Figure US20150238473A1-20150827-C00082
  • wherein PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, R is hydrogen, lower-alkyl or lower-hydroxyalkyl, and Q is nitro, carbamyl, halo, amino, lower-alkylamino, di(lower-alkyl)amino, or NHAc where Ac is lower-alkanoyl or lower-carbalkoxy;
    or a pharmaceutically acceptable salt thereof.
  • With respect to Formula XIII, PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, R is hydrogen, lower-alkyl or lower-hydroxyalkyl, and Q is nitro, carbamyl, halo, amino, lower-alkylamino, di(lower-alkyl)amino, or NHAc where Ac is lower-alkanoyl or lower-carbalkoxy, or pharmaceutically-acceptable acid-addition salt thereof. Compounds of formula XIII where Q is amino, lower-alkylamino, di-(lower-alkyl) amino, or NHAc are provided herein. The compounds of formula XIII where Q is nitro or carbamyl are useful as intermediates for preparing the said compounds where Q is amino and those where Q is halo are useful as intermediates in the preparation of the compounds where Q is lower-alkylamino and di-(lower-alkyl)amino. Other compounds of Formula XIII include compounds where Q is amino, R is hydrogen and PY is 4-pyridinyl or 3-pyridinyl, for example, 3-amino-5-(4-pyridinyl)-2(1H)-pyridinone (amrinone).
  • Further provided herein is a method of treating or preventing an infection in a subject with or at risk of developing an infection, the method comprising administering to the subject a compound selected from the group consisting of:
  • a compound of Formula XV
  • Figure US20150238473A1-20150827-C00083
  • a compound of Formula XVI
  • Figure US20150238473A1-20150827-C00084
  • a compound of Formula XVII
  • Figure US20150238473A1-20150827-C00085
  • a compound of Formula XVIII
  • Figure US20150238473A1-20150827-C00086
  • a compound of Formula XIX
  • Figure US20150238473A1-20150827-C00087
  • a compound of Formula (XX)
  • Figure US20150238473A1-20150827-C00088
  • or pharmaceutically acceptable salt thereof
  • Formula XV is fluspirilen, Formula XVI is hexestrol, Formula XVII is dienestrol, Formula XVIII is napelline, Formula XIX is iopanoic acid and Formula XX is suloctodil.
  • Further provided is a method of treating or preventing an infection in a subject with or at risk of developing an infection, the method comprising administering to the subject a compound selected from the group consisting of: Didanosine, Norcyclobenzaprine, Niridazole, Ifosfamide, Cefalonium, Tamoxifen citrate, Butoconazole, Suloctidil, Clomiphene, Sulconazole, Miconazole, Mefloquine, Sulfinpyrazone, Terfenadine, Lisinopril, Econzaole, Clofazimine, Equilin, Felodipine, Dacarbazine, Furazolidone, Perhexiline maleate, Oxethazaine, Pimozide, Trifluoperazine, Ellipticine, Fluspirilen, Hexestrol, Dienestrol, Zidovudine, Metoprolol, Napelline, Methimazole, Amrinone, Iopanoic acid, R-Propanolol, Rimexolone and Pyrvinium pamoate, or a pharmaceutically acceptable salt thereof.
  • Further provided is a method of treating or preventing an infection in a subject with or at risk of developing an infection, the method comprising administering to the subject a compound selected from the group consisting of: Didanosine, Norcyclobenzaprine, Niridazole, Ifosfamide, Cefalonium, Tamoxifen citrate, Butoconazole, Suloctidil, Clomiphene, Sulconazole, Miconazole, Mefloquine, Sulfinpyrazone, Terfenadine, Lisinopril, Econzaole, Clofazimine, Equilin, Felodipine, Dacarbazine, Furazolidone, Perhexiline maleate, Oxethazaine, Pimozide, Trifluoperazine, Ellipticine, Fluspirilen, Hexestrol, Dienestrol, Zidovudine, Metoprolol, Napelline, Methimazole, Amrinone, Iopanoic acid, R-Propanolol, Rimexolone and Pyrvinium pamoate, or a pharmaceutically acceptable salt thereof, wherein the infection is a bacterial infection selected from the group consisting of Enterobacterium faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinebacter baumannii, Pseudomonas aeruginosa and Enterobacter sp.
  • Further provided is a method of treating or preventing a bacterial infection in a subject with or at risk of developing a bacterial infection in a subject comprising administering to the subject a compound that inhibits bacterial DNA gyrase or topoisomerase IV. The compound can be, for example, a compound of Formula I. As set forth above, a compound of Formula I can be terfenadine or a derivative thereof. In the methods set forth herein an inhibitor of bacterial DNA gyrase or topoisomerase IV can be used to treat or prevent Staphylococcus aureus infection.
  • It is contemplated that one or more, for example, two, three, four, five, etc., of the compounds or derivatives of the compounds set forth herein can be administered to treat or prevent infection. Thus, combinations of the compounds set forth herein are also provided. Pharmaceutically acceptable salts of all of the compounds set forth herein are also provided. The term pharmaceutically acceptable salt as used herein refers to those salts of any of the compounds described herein or derivatives thereof that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of subjects without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds described herein. The term salts refers to the relatively non-toxic, inorganic and organic acid addition salts of the compounds described herein. These salts can be prepared in situ during the isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate mesylate, glucoheptonate, lactobionate, methane sulphonate, and laurylsulphonate salts, and the like. These may include cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like.
  • The infection can be a viral infection, bacterial infection, fungal infection or a parasitic infection, to name a few. All strains and types of pathogenic infection are contemplated herein. The infection can also be a respiratory infection, a gastrointestinal infection or a skin infection, to name a few.
  • In any of the methods of treating or preventing infection set forth herein, the infection can be any infection, wherein the infection is not a bacterial infection. In any of the methods of treating or preventing infection set forth herein, the infection can be any infection, wherein the infection is not a viral infection. In any of the methods of treating or preventing infection set forth herein, the infection can be any infection, wherein the infection is not a parasitic infection. In any of the methods of treating or preventing infection set forth herein, the infection can be any infection, wherein the infection is not a fungal infection. In any of the methods of treating or preventing infection set forth herein, the infection can be any infection, wherein the infection is not a protozoal infection.
  • Examples of bacterial infections include, but are not limited to infections caused by the Gram negative or Gram positive bacteria. For example, the infection can be caused by Listeria (sp.), Franscicella tularensis, Enterobacter sp. Enterococcus faecium, other Enterococcus species, Klebsiella pneumonia, Acinetobacter baumannii, Mycobacterium tuberculosis, Rickettsia (all types), Ehrlichia or Chylamida. Further examples of bacteria include M. tuberculosis, Legionella pneumophila, other Legionella species, Salmonella typhi, other Salmonella species, Shigella species, Yersinia pestis, Pasteurella haemolytica, Pasteurella multocida, other Pasteurella species, Actinobacillus pleuropneumoniae, Listeria monocytogenes, Listeria ivanovii, Brucella abortus, other Brucella species, Chlamydia pneumoniae, Chlamydia trachomatis, Chlamydia psittaci, Coxiella burnetti, other Rickettsial species, Ehrlichia species, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus agalactiae, Bacillus anthracis, Escherichia coli, Vibrio cholerae, Kingella kingae, Campylobacter species, Neiserria meningitidis, Neiserria gonorrhea, Pseudomonas aeruginosa, other Pseudomonas species, Haemophilus influenzae, Haemophilus ducreyi, other Hemophilus species, Clostridium tetani, other Clostridium species, Yersinia enterolitica, and other Yersinia species. In the methods provided herein, one or more compounds set forth herein can treat or prevent one or more bacterial infections selected from the group consisting of Enterobacterium faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinebacter baumannii, Pseudomonas aeruginosa and Enterobacter sp. In the methods set forth herein, the bacteria can be a small colony variant strain, for example a small colony strain of Staphylococcus aureus. In any of the methods set forth herein, the infection can be a bacterial infection, wherein the bacterial infection is not tuberculosis, for example, Mycobacterium tuberculosis. For example, and not to be limiting any of the compounds set forth herein, including compounds of Formula I and II can be used to treat or prevent infection in a subject with or at risk of developing an infection, wherein the infection is not tuberculosis.
  • Examples of parasitic infections include, but are not limited to infections caused by the following parasites: Cryptosporidium, Plasmodium (all species), American trypanosomes (T. cruzi), African trypanosomes, Acanthamoeba, Entaoeba histolytica, Angiostrongylus, Anisakis, Ascaris, Babesia, Balantidium, Baylisascaris, lice, ticks, mites, fleas, Capillaria, Clonorchis, Chilomastix mesnili, Cyclspora, Diphyllobothrium, Dipylidium caninum, Fasciola, Giardia, Gnathostoma, Hetetophyes, Hymenolepsis, Isospora, Loa loa, Microsporidia, Naegleria, Toxocara, Onchocerca, Opisthorchis, Paragonimus, Baylisascaris, Strongyloides, Taenia, Trichomonas and Trichuris. In any of the methods set forth herein, the infection can be a parasitic infection, wherein the parasitic infection is not malaria, for example, malaria caused by any species of Plasmodium including Plasmodium falciparum. For example, and not to be limiting any of the compounds set forth herein, including compounds of Formula I and II can be used to treat or prevent infection in a subject with or at risk of developing an infection, wherein the infection is not malaria.
  • Furthermore, examples of protozoan and fungal species contemplated within the present methods include, but are not limited to, Plasmodium falciparum, other Plasmodium species, Toxoplasma gondii, Pneumocystis carinii, Trypanosoma cruzi, other trypanosomal species, Leishmania donovani, other Leishmania species, Theileria annulata, other Theileria species, Eimeria tenella, other Eimeria species, Histoplasma capsulatum, Cryptococcus neoformans, Blastomyces dermatitidis, Coccidioides immitis, Paracoccidioides brasibiensis, Penicillium marneffei, and Candida species. In any of the methods set forth herein, the infection can be a protozoan infection, wherein the protozoan infection is not leishmaniasis, for example, leishmaniasis caused by a Leishmania species, for example, Leishmania major. For example, and not to be limiting any of the compounds set forth herein, including compounds of Formula I and III can be used to treat or prevent infection in a subject with or at risk of developing an infection, wherein the infection is not leishmaniasis.
  • Examples of viral infections include but are not limited to, infections caused by RNA viruses (including negative stranded RNA viruses, positive stranded RNA viruses, double stranded RNA viruses and retroviruses) and DNA viruses. All strains, types, subtypes of DNA and RNA viruses are contemplated herein.
  • Examples of RNA viruses include, but are not limited to picornaviruses, which include aphthoviruses (for example, foot and mouth disease virus O, A, C, Asia 1, SAT1, SAT2 and SAT3), cardioviruses (for example, encephalomycarditis virus and Theiller's murine encephalomyelitis virus), enteroviruses (for example polioviruses 1, 2 and 3, human enteroviruses A-D, bovine enteroviruses 1 and 2, human coxsackieviruses A1-A22 and A24, human coxsackieviruses B1-B5, human echoviruses 1-7, 9, 11-12, 24, 27, 29-33, human enteroviruses 68-71, porcine enteroviruses 8-10 and simian enteroviruses 1-18), erboviruses (for example, equine rhinitis virus), hepatovirus (for example human hepatitis A virus and simian hepatitis A virus), kobuviruses (for example, bovine kobuvirus and Aichi virus), parechoviruses (for example, human parechovirus 1 and human parechovirus 2), rhinovirus (for example, human rhinovirus 1-100 and bovine rhinoviruses 1-3) and teschoviruses (for example, porcine teschovirus).
  • Additional examples of RNA viruses include caliciviruses, which include noroviruses (for example, Norwalk virus), sapoviruses (for example, Sapporo virus), lagoviruses (for example, rabbit hemorrhagic disease virus and European brown hare syndrome) and vesiviruses (for example vesicular exanthema of swine virus and feline calicivirus).
  • Other RNA viruses include astroviruses, which include mamastorviruses and avastroviruses. Togaviruses are also RNA viruses. Togaviruses include alphaviruses (for example, Chikungunya virus, Sindbis virus, Semliki Forest virus, Western equine encephalitis, Getah virus, Everglades virus, Venezuelan equine encephalitis virus and Aura virus) and rubella viruses. Additional examples of RNA viruses include the the flaviviruses (for example, tick-borne encephalitis virus, Tyuleniy virus, Aroa virus, Dengue virus (types 1 to 4), Kedougou virus, Japanese encephalitis virus (JEV), West Nile virus (WNV), Kokobera virus, Ntaya virus, Spondweni virus, Yellow fever virus, Entebbe bat virus, Modoc virus, Rio Bravo virus, Cell fusing agent virus, pestivirus, GB virus A, GBV-A like viruses, GB virus C, Hepatitis G virus, hepacivirus (hepatitis C virus (HCV)) all six genotypes), bovine viral diarrhea virus (BVDV) types 1 and 2, and GB virus B).
  • Other examples of RNA viruses are the coronaviruses, which include, human respiratory coronaviruses such as SARS-CoV, HCoV-229E, HCoV-NL63 and HCoV-OC43. Coronaviruses also include bat SARS-like CoV, turkey coronavirus, chicken coronavirus, feline coronavirus and canine coronavirus. Additional RNA viruses include arteriviruses (for example, equine arterivirus, porcine reproductive and respiratory syndrome virus, lactate dehyrogenase elevating virus of mice and simian hemorraghic fever virus). Other RNA viruses include the rhabdoviruses, which include lyssaviruses (for example, rabies, Lagos bat virus, Mokola virus, Duvenhage virus and European bat lyssavirus), vesiculoviruses (for example, VSV-Indiana, VSV-New Jersey, VSV-Alagoas, Piry virus, Cocal virus, Maraba virus, Isfahan virus and Chandipura virus), and ephemeroviruses (for example, bovine ephemeral fever virus, Adelaide River virus and Berrimah virus). Additional examples of RNA viruses include the filoviruses. These include the Marburg and Ebola viruses (for example, EBOV-Z, EBOV-S, EBOV-IC and EBOV-R.
  • The paramyxoviruses are also RNA viruses. Examples of these viruses are the rubulaviruses (for example, mumps, parainfluenza virus 5, human parainfluenza virus type 2, Mapuera virus and porcine rubulavirus), avulaviruses (for example, Newcastle disease virus), respoviruses (for example, Sendai virus, human parainfluenza virus type 1 and type 3, bovine parainfluenza virus type 3), henipaviruses (for example, Hendra virus and Nipah virus), morbilloviruses (for example, measles, Cetacean morvilliirus, Canine distemper virus, Peste-des-petits-ruminants virus, Phocine distemper virus and Rinderpest virus), pneumoviruses (for example, human respiratory syncytial virus A2, B1 and S2, bovine respiratory syncytial virus and pneumonia virus of mice), metapneumoviruses (for example, human metapneumovirus and avian metapneumovirus). Additional paramyxoviruses include Fer-de-Lance virus, Tupaia paramyxovirus, Menangle virus, Tioman virus, Beilong virus, J virus, Mossman virus, Salem virus and Nariva virus. Additional RNA viruses include the orthomyxoviruses.
  • These viruses include influenza viruses and strains (e.g., influenza A (H1N1 (including but not limited to A/WS/33 and A/California/04/2009 strains) H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3 and H10N7), B and C viruses, as well as avian influenza (for example, strains H5N1, H5N2, H7N1, H7N7 and H9N2) thogotoviruses and isaviruses. Orthobunyaviruses (for example, Akabane virus, California encephalitis, Cache Valley virus, Snowshoe hare virus,) nairoviruses (for example, Nairobi sheep virus, Crimean-Congo hemorrhagic fever virus Group and Hughes virus), phleboviruses (for example, Candiru, Punta Toro, Rift Valley Fever, Sandfly Fever, Naples, Toscana, Sicilian and Chagres), and hantaviruses (for example, Hantaan, Dobrava, Seoul, Puumala, Sin Nombre, Bayou, Black Creek Canal, Andes and Thottapalayam) are also RNA viruses. Arenaviruses such as lymphocytic choriomeningitis virus, Lujo virus, Lassa fever virus, Argentine hemorrhagic fever virus, Bolivian hemorrhagic fever virus, Venezuelan hemorrhagic fever virus, SABV and WWAV are also RNA viruses. Borna disease virus is also an RNA virus. Hepatitis D (Delta) virus and hepatitis E are also RNA viruses. Any of the compounds set forth herein, including, but not limited to the compounds of Formula I and II can be used to treat or prevent a viral infection, wherein the viral infection is not a Lassa fever virus infection.
  • Additional RNA viruses include reoviruses, rotaviruses, birnaviruses, chrysoviruses, cystoviruses, hypoviruses partitiviruses and totoviruses. Orbiviruses such as African horse sickness virus, Blue tongue virus, Changuinola virus, Chenuda virus, Chobar Gorge Corriparta virus, epizootic hemorraghic disease virus, equine encephalosis virus, Eubenangee virus, Ieri virus, Great Island virus, Lebombo virus, Orungo virus, Palyam virus, Peruvian Horse Sickness virus, St. Croix River virus, Umatilla virus, Wad Medani virus, Wallal virus, Warrego virus and Wongorr virus are also RNA viruses.
  • Retroviruses include alpharetroviruses (for example, Rous sarcoma virus and avian leukemia virus), betaretroviruses (for example, mouse mammary tumor virus, Mason-Pfizer monkey virus and Jaagsiekte sheep retrovirus), gammaretroviruses (for example, murine leukemia virus and feline leukemia virus, deltraretroviruses (for example, human T cell leukemia viruses (HTLV-1, HTLV-2), bovine leukemia virus, STLV-1 and STLV-2), epsilonretriviruses (for example, Walleye dermal sarcoma virus and Walleye epidermal hyperplasia virus 1), reticuloendotheliosis virus (for example, chicken syncytial virus, lentiviruses (for example, human immunodeficiency virus (HIV) type 1, human immunodeficiency virus (HIV) type 2, human immunodeficiency virus (HIV) type 3, simian immunodeficiency virus, equine infectious anemia virus, feline immunodeficiency virus, caprine arthritis encephalitis virus and Visna maedi virus) and spumaviruses (for example, human foamy virus and feline syncytia-forming virus).
  • Examples of DNA viruses include polyomaviruses (for example, simian virus 40, simian agent 12, BK virus, JC virus, Merkel Cell polyoma virus, bovine polyoma virus and lymphotrophic papovavirus), papillomaviruses (for example, human papillomavirus, bovine papillomavirus, adenoviruses (for example, adenoviruses A-F, canine adenovirus type I, canined adeovirus type 2), circoviruses (for example, porcine circovirus and beak and feather disease virus (BFDV)), parvoviruses (for example, canine parvovirus), erythroviruses (for example, adeno-associated virus types 1-8), betaparvoviruses, amdoviruses, densoviruses, iteraviruses, brevidensoviruses, pefudensoviruses, herpes viruses 1, 2, 3, 4, 5, 6, 7 and 8 (for example, herpes simplex virus 1, herpes simplex virus 2, varicella-zoster virus, Epstein-Barr virus, cytomegalovirus, Kaposi's sarcoma associated herpes virus, human herpes virus-6 variant A, human herpes virus-6 variant B and cercophithecine herpes virus 1 (B virus)), poxviruses (for example, smallpox (variola), cowpox, monkeypox, vaccinia, Uasin Gishu, camelpox, psuedocowpox, pigeonpox, horsepox, fowlpox, turkeypox and swinepox), and hepadnaviruses (for example, hepatitis B and hepatitis B-like viruses).
  • One or more of the compounds described herein can be contacted with a cell or populations of cells in vitro, ex vivo or in vivo. For example, the cell or population of cells can be in a subject, or in an in vitro culture. In another example, one or more compounds set forth herein can be used to inhibit bacterial growth, fungal growth, parasitic growth, protozoal growth or viral replication, in vitro, ex vivo or in vivo. Any of the compounds set forth herein can be used alone or in combination with other therapeutic agents such as antiviral compounds, antibacterial agents (for example, antibiotics), antifungal agents, antiparasitic agents, anti-inflammatory agents, anti-cancer agents, etc.
  • In the methods described herein, the level of infection, for example, in a cell, or a population of cells, or a cell culture, can be assessed by measuring an antigen or other product associated with a particular infection. The level of infection can also be measured in a tissue sample or a culture of cells from a subject, either before or after administration of one or more compounds disclosed herein. For example, the level of viral infection can be measured by real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) assay (See for example, Payungporn et al. “Single step multiplex real-time RT-PCR for H5N1 influenza A virus detection.” J Virol Methods. Sep. 22, 2005; Landolt et la. “Use of real-time reverse transcriptase polymerase chain reaction assay and cell culture methods for detection of swine influenza A viruses” Am J Vet Res. 2005 January; 66(1):119-24).
  • Methods of measuring bacterial growth and inhibition of bacterial growth are provided in the Examples. Further, one of skill in the art would know how to determine the concentration of a compound that inhibits bacterial infection (see, for example, Andrews, et al. “Determination of minimum inhibitory concentrations”. Journal of Antimicrobial Chemotherapy 48 (suppl 1): 5-16 (2001)). Other methods for determining antifungal and antibacterial activity are known in the art. See, for example, Hayhoe et al. “Screening for Antibacterial, Antifungal and Anti quorum Sensing Activity,” Methods Mol. Biol. 1055: 219-225 (2013)); Doddanna et al. “Antimicrobial activity of plant extracts on Candida albicans: An in vitro study Indian J. Dent. Res. 24(4): 401-405 (2013), both of which are incorporated by this reference in their entireties.
  • As used throughout, by subject is meant an individual. Preferably, the subject is a mammal such as a primate, and, more preferably, a human. Non-human primates are subjects as well. The term subject includes domesticated animals, such as cats, dogs, etc., livestock (for example, cattle, horses, pigs, sheep, goats, etc.) and laboratory animals (for example, ferret, chinchilla, mouse, rabbit, rat, gerbil, guinea pig, etc.). Thus, veterinary uses and medical formulations are contemplated herein.
  • As used herein, a biological sample is a sample derived from a subject such as a mammal or human and includes, but is not limited to, any biological fluid, including a bodily fluid. Examples of bodily fluids include, but are not limited to, whole blood, plasma, serum, urine, saliva, ocular fluid, ascites, a stool sample, spinal fluid, tissue infiltrate, pleural effusions, lung lavage fluid, and the like. The biological fluid includes a cell culture medium or supernatant of cultured cells from the subject.
  • The methods and compounds as described herein are useful for therapeutic treatment. Use of one or more of the compounds set forth herein for the treatment or prevention of infection is also contemplated herein. One or more of the compounds set forth herein for use in a method of treating or preventing infection is also provided herein. Therapeutic treatment involves administering to a subject a therapeutically effective amount of one or more of the agents described herein, optionally, after diagnosis of an infection or risk of infection in the subject. Therefore, all of the methods disclosed herein, can optionally comprise the step of diagnosing a subject with an infection or diagnosing a subject in need of prophylaxis or prevention of infection.
  • As used herein, the terms treatment, treat, or treating refers to a method of reducing the effects of a disease or condition or symptom of the disease or condition. Thus, in the disclosed methods, treatment can refer to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the severity of an established disease or condition or symptom of the disease or condition. For example, a method for treating a disease is considered to be a treatment if there is a 10% reduction in one or more symptoms of the disease in a subject as compared to a control. A control subject can be a subject that has not received a compound set forth herein. Thus, the reduction can be a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any percent reduction in between 10% and 100% as compared to native or control levels. It is understood that treatment does not necessarily refer to a cure or complete ablation of the disease, condition, or symptoms of the disease or condition.
  • As utilized herein, by preventing infection is meant a method of precluding, delaying, averting, obviating, forestalling, stopping, or hindering the onset, incidence, severity, or recurrence of infection. For example, the disclosed method is considered to be a prevention if there is about a 10% reduction in onset, incidence, severity, or recurrence of infection, or symptoms of infection (e.g., inflammation, fever, lesions, weight loss, etc.) in a subject exposed to an infection when compared to control subjects exposed to an infection that did not receive a composition for decreasing infection. Thus, the reduction in onset, incidence, severity, or recurrence of infection can be about a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to a control subject. For example, and not to be limiting, if about 10% of the subjects in a population do not become infected as compared to subjects that did not receive preventive treatment, this is considered prevention.
  • The compounds set forth herein can also be used to decrease infection in a cell. A decrease or inhibition of infection can occur in a cell, in vitro, ex vivo or in vivo. As utilized throughout, the term “infection” encompasses all phases of pathogenic life cycles including, but not limited to, attachment to cellular receptors, entry, internalization, disassembly, replication, genomic integration of pathogenic sequences, transcription of pathogen RNA, translation of pathogen RNA, transcription of host cell mRNA, translation of host cell mRNA, proteolytic cleavage of pathogenic proteins or cellular proteins, assembly of particles, endocytosis, cell lysis, budding, and egress of the pathogen from the cells.
  • The compounds described herein can be provided in a pharmaceutical composition. Depending on the intended mode of administration, the pharmaceutical composition can be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, or suspensions, preferably in unit dosage form suitable for single administration of a precise dosage. The compositions will include a therapeutically effective amount of the compound described herein or derivatives thereof in combination with a pharmaceutically acceptable carrier and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, or diluents. By pharmaceutically acceptable is meant a material that is not biologically or otherwise undesirable, which can be administered to an individual along with the selected agent without causing unacceptable biological effects or interacting in a deleterious manner with the other components of the pharmaceutical composition in which it is contained.
  • As used herein, the term carrier encompasses any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, lipid, stabilizer, or other material well known in the art for use in pharmaceutical formulations. The choice of a carrier for use in a composition will depend upon the intended route of administration for the composition. The preparation of pharmaceutically acceptable carriers and formulations containing these materials is described in, e.g., Remington's Pharmaceutical Sciences, 21st Edition, ed. University of the Sciences in Philadelphia, Lippincott, Williams & Wilkins, Philadelphia Pa., 2005. Examples of physiologically acceptable carriers include buffers such as phosphate buffers, citrate buffer, and buffers with other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEEN® (ICI, Inc.; Bridgewater, N.J.), polyethylene glycol (PEG), and PLURONICS™ (BASF; Florham Park, N.J.).
  • Compositions containing the compound(s) described herein suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
  • These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be promoted by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. Isotonic agents, for example, sugars, sodium chloride, and the like may also be included. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • Solid dosage forms for oral administration of the compounds described herein or derivatives thereof include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compounds described herein or derivatives thereof is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders, as for example, carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate, (e) solution retarders, as for example, paraffin, (f) absorption accelerators, as for example, quaternary ammonium compounds, (g) wetting agents, as for example, cetyl alcohol, and glycerol monostearate, (h) adsorbents, as for example, kaolin and bentonite, and (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethyleneglycols, and the like.
  • Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others known in the art. They may contain opacifying agents and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner.
  • Examples of embedding compositions that can be used are polymeric substances and waxes. The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.
  • Liquid dosage forms for oral administration of the compounds described herein or derivatives thereof include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, and fatty acid esters of sorbitan, or mixtures of these substances, and the like.
  • Besides such inert diluents, the composition can also include additional agents, such as wetting, emulsifying, suspending, sweetening, flavoring, or perfuming agents.
  • Administration can be carried out using therapeutically effective amounts of the agents described herein for periods of time effective to treat or prevent infection in a subject. The effective amount may be determined by one of ordinary skill in the art and includes exemplary dosage amounts for a mammal of from about 0.5 to about 200 mg/kg of body weight of active compound per day, which may be administered in a single dose or in the form of individual divided doses, such as from 1 to 4 times per day. Alternatively, the dosage amount can be from about 0.5 to about 150 mg/kg of body weight of active compound per day, about 0.5 to 100 mg/kg of body weight of active compound per day, about 0.5 to about 75 mg/kg of body weight of active compound per day, about 0.5 to about 50 mg/kg of body weight of active compound per day, about 0.5 to about 25 mg/kg of body weight of active compound per day, about 1 to about 20 mg/kg of body weight of active compound per day, about 1 to about 10 mg/kg of body weight of active compound per day, about 20 mg/kg of body weight of active compound per day, about 10 mg/kg of body weight of active compound per day, or about 5 mg/kg of body weight of active compound per day.
  • According to the methods taught herein, the subject is administered an effective amount of the compound. The terms effective amount and effective dosage are used interchangeably. The term effective amount is defined as any amount necessary to produce a desired physiologic response. Effective amounts and schedules for administering the agent may be determined empirically, and making such determinations is within the skill in the art. The dosage ranges for administration are those large enough to produce the desired effect in which one or more symptoms of the disease or disorder are affected (e.g., reduced or delayed). The dosage should not be so large as to cause substantial adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like. Generally, the dosage will vary with the activity of the specific compound employed, the metabolic stability and length of action of that compound, the species, age, body weight, general health, sex and diet of the subject, the mode and time of administration, rate of excretion, drug combination, and severity of the particular condition and can be determined by one of skill in the art. The dosage can be adjusted by the individual physician in the event of any contraindications. Dosages can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products.
  • Any appropriate route of administration can be employed, depending on whether local or systemic treatment is desired, and on the area to be treated. The compositions are administered via any of several routes of administration, including topically, orally, parenterally, intravenously, intra-articularly, intraperitoneally, intramuscularly, subcutaneously, intracavity, transdermally, intrahepatically, intracranially, nebulization/inhalation, or by installation via bronchoscopy. Optionally, the composition is administered by oral inhalation, nasal inhalation, or intranasal mucosal administration. Administration of the compositions by inhalant can be through the nose or mouth via delivery by spraying or droplet mechanism, for example, in the form of an aerosol. Pharmaceutical compositions can be delivered locally to the area in need of treatment, for example by topical application or local injection. Multiple administrations and/or dosages can also be used. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
  • The disclosure also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. Instructions for use of the composition can also be included.
  • Also provided is a method of removing biofilm from a surface, comprising administering an effective amount of one or more of the compounds provided herein to a biofilm-containing surface, wherein the amount is effective to remove biofilm from the surface. Removal of the biofilm from this surface does not have to be complete as this can range from a reduction to complete removal of the biofilm. Thus, in the disclosed methods, removal can refer to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the amount of biofilm on a surface. For example, a method for removing biofilm from a surface is considered to be removal if there is a 10% reduction in the amount of biofilm on the surface as compared to a control. A control surface can be a biofilm containing surface that has not received a compound set forth herein. Thus, the reduction can be a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any percent reduction in between 10% and 100% as compared to control.
  • Further provided is a method of preventing biofilm formation on a surface comprising administering an effective amount of one or more of the compounds provided herein to the surface, wherein the amount is effective to prevent biofilm formation. The surface can be susceptible to biofilm formation. The biofilm can be produced by an organism selected from the group consisting of bacteria, algae, fungi and protozoa.
  • The compound can be, but is not limited to, a compound of Formula I
  • Figure US20150238473A1-20150827-C00089
  • wherein R represents hydrogen or hydroxyl and R1 represents hydrogen, or R and R1 taken together form a second bond between the carbon atoms bearing R and R1; R2 represents hydrogen or phenyl; n is zero or a positive whole integer of from 1 to 4; X represents CH2, CHOH, NH, C═O, CHNR3R4, where R3 and R4 independently are hydrogen or lower alkyl; and Z represents thienyl, pyridinyl, substituted pyridinyl, phenyl or substituted phenyl wherein the substituents on the substituted pyridinyl or substituted phenyl are selected from phenyl, pyridinyl, nitro, a halogen atom, such as chlorine, fluorine, bromine, or iodine, a straight or branched lower alkyl chain of from 1 to 4 carbon atoms, a lower alkoxy group of from 1 to 4 carbon atoms, amino, a mono or di(lower)alkylamino group, a saturated monocyclic heterocyclic group such as pyrrolidino, piperidino, morpholino, or N-(lower)alkylpiperazino, or a group having the structure —COOR5, —CR6R7COOR5, —CF3, CHF2, CH2F, or
  • Figure US20150238473A1-20150827-C00090
  • where R5 is hydrogen or lower alkyl, and R6 and R7 independently are hydrogen or methyl
    or a pharmaceutically acceptable salt thereof.
  • One or more of the compounds set forth herein can be combined with one or more biodegradable polymers to form a biodegradable antimicrobial composition. These compositions can be applied to a surface or used as a coating. The biodegradable polymers include but are not limited to polylactic acid, polyglycolic acid and copolymers and mixtures thereof such as poly(L-lactide) (PLLA), poly(D,L-lactide) (PLA), polyglycolic acid [polyglycolide (PGA)], poly(L-lactide-co-D,L-lactide) (PLLA/PLA), poly(L-lactide-co-glycolide) (PLLA/PGA), poly(D,L-lactide-co-glycolide) (PLA/PGA), poly(glycolide-co-trimethylene carbonate) (PGA/PTMC), poly(D,L-lactide-co-caprolactone) (PLA/PCL) and poly(glycolide-co-caprolactone) (PGA/PCL); polyethylene oxide (PEO), polydioxanone (PDS), polypropylene fumarate, poly(ethyl glutamate-co-glutamic acid), poly(tert-butyloxy-carbonylmethyl glutamate), polycaprolactone (PCL), polycaprolactone co-butylacrylate, polyhydroxybutyrate (PHBT) and copolymers of polyhydroxybutyrate, poly(phosphazene), polyphosphate ester), poly(amino acid), polydepsipeptides, maleic anhydride copolymers, polyiminocarbonates, poly[(97.5% dimethyl-trimethylene carbonate)-co-(2.5% trimethylene carbonate)], poly(orthoesters), tyrosine-derived polyarylates, tyrosine-derived polycarbonates, tyrosine-derived polyiminocarbonates, tyrosine-derived polyphosphonates, polyethylene oxide, polyethylene glycol, polyalkylene oxides, hydroxypropylmethylcellulose, polysaccharides such as hyaluronic acid, chitosan and regenerate cellulose, and proteins such as gelatin and collagen, and mixtures and copolymers thereof, among others as well as PEG derivatives or blends of any of the foregoing.
  • In the methods of removing or preventing biofilm formation, the surface can be a hard (for example, glass, metal, wood, chrome, plastic, vinyl or formica) or a soft surface (for example, cloth or upholstery). The methods set forth herein can be used to remove or prevent biofilm formation in vitro, ex vivo or in vivo. The methods set forth herein can also be used to remove or prevent biofilm formation on a medical device or a part thereof. For example, the methods set forth herein can be used to remove or prevent biofilm formation on an implantable medical device such as a cardiac rhythm management device (for example, a pacemaker, a defibrillator, an implantable cardioverter defibrillator (ICD) and a cardiac resynchronization therapy defibrillator (CRT device), a neurostimulator, a pulse generator, a drug pump, an infusion device, a physiological monitoring device (for example, a glucose sensor), contact lenses, a stent, a catheter, tubing or a breast implant. Mesh, bandages, and implantable devices, for example, can be coated with a compositions comprising one or more of the compounds set forth herein. Further, organs can be treated with one or more of the compounds set forth herein prior to transplantation in a subject. One or more of the compounds set forth herein can be used to inhibit biofilm formation by one or more of Staphylococcus aureus, Pseudomonas aeuroginosa, Staphylococcus epidermidis, Escherichia coli or Acinetobacter baummanii.
  • As utilized herein, by preventing biofilm formation is meant a method of precluding, delaying, averting, obviating, forestalling, stopping, or hindering the onset, incidence, severity, or recurrence of biofilm formation. For example, the disclosed method is considered to be prevention if there is about a 10% reduction in onset, incidence, severity, or recurrence of biofilm formation on a surface when compared to a control surface that did not receive a composition for preventing biofilm formation. Thus, the reduction in onset, incidence, severity, or recurrence of biofilm can be about a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to a control surface.
  • A biofilm can also exist or form in a biological subject, for example, on the teeth or gums of a subject. Therefore, one or more of the compounds set forth herein can be in a toothpaste, mouth rinse, gel, foam, varnish, polish, floss, dental strip, or copolymer membrane in order to remove or prevent biofilm formation on a dental surface.
  • Further provided herein is a method of identifying an antimicrobial agent comprising contacting a bacterial culture with a test agent and measuring adenylate kinase release in the supernatant of the bacterial culture, wherein an increase in adenylate kinase release as compared to a control indicates that the test compound is an antimicrobial agent. The control can be a bacterial culture that was not contacted with the test compound. The bacterial culture can be a culture of any bacterial strain, for example, a culture of any of the bacteria disclosed herein. The bacterial culture can also be small colony variant bacterial culture or a biofilm associated bacterial culture. Examples of agents identified utilizing this method are provided in the Examples.
  • Disclosed are materials, compositions, and components that can be used for, can be used in conjunction with, can be used in preparation for, or are products of the disclosed methods and compositions. These and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutations of these compounds may not be explicitly disclosed, each is specifically contemplated and described herein. For example, if a method is disclosed and discussed and a number of modifications that can be made to a number of molecules including in the method are discussed, each and every combination and permutation of the method, and the modifications that are possible are specifically contemplated unless specifically indicated to the contrary. Likewise, any subset or combination of these is also specifically contemplated and disclosed. This concept applies to all aspects of this disclosure including, but not limited to, steps in methods using the disclosed compositions. Thus, if there are a variety of additional steps that can be performed, it is understood that each of these additional steps can be performed with any specific method steps or combination of method steps of the disclosed methods, and that each such combination or subset of combinations is specifically contemplated and should be considered disclosed.
  • Publications cited herein and the material for which they are cited are hereby specifically incorporated by reference in their entireties.
  • The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compounds and/or methods claimed herein are made and evaluated, and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention except as and to the extent that they are included in the accompanying claims.
    • Example I Identification of Antimicrobial Compounds
  • Adenylate kinase (AK) is a ubiquitous intracellular enzyme that is released into the extracellular space upon cell lysis. As shown herein, AK release serves as a useful reporter of bactericidal agent activity and can be exploited for antimicrobial screening purposes. The AK assay exhibits improved sensitivity over that of growth-based assays and can detect agents that are active against bacteria in clinically relevant growth states that are difficult to screen using conventional approaches, such as small colony variants (SCV) and bacteria within established biofilms. The usefulness of the AK assay was validated by screening a library of off-patent drugs for agents that exhibit antimicrobial properties toward a variety of bacterial species, including Escherichia coli and all members of the “ESKAPE” pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species). The assay detected antibiotics within the library that were expected to be active against the organism screened. Moreover, 38 drugs elicited AK release. Examples include, the antihistamine, terfenadine, which was active against S. aureus planktonic, SCV population, and biofilm-associated cells, to name a few. Tamoxifen, an estrogen receptor antagonist, was active toward E. faecium in vitro and also reduced E. faecium pathogenesis in a Galleria mellonella infection model. These data demonstrate that the A K assay provides an attractive screening approach for identifying new antimicrobial agents. Further, drugs identified using this screening approach, for example, terfenadine and tamoxifen, provide novel antimicrobial drug development scaffolds.
  • The ESKAPE pathogens frequently cause health care-associated bacterial infections and can escape the effects of most currently available antibiotics. The most successful and widely applied method to identify agents with antibacterial activity has been whole-cell, bacterial growth assays. In this approach, libraries of small molecules or natural products are screened for agents that limit bacterial growth. However, growth-based assays have limitations. For example, the growth or no-growth readout has a limited dynamic range. This is likely to be problematic because growth assays lack the sensitivity required to detect antimicrobial molecules that are present in low concentrations within complex natural product extract libraries or compounds with limited antimicrobial activity. While the latter would obviously not represent a molecule that could be directly translated to clinical use, these low-activity hits could provide structurally novel scaffolds suitable for medicinal chemistry-based optimization. In addition, traditional growth-based assays are not readily amenable to screening for agents that target bacteria within certain clinically relevant bacterial growth states, such as established biofilms and small-colony variants.
  • To address these limitations, provided herein is a high-throughput screen (HTS)-compatible whole-cell assay to detect agents that directly kill bacteria. The assay is based on the release of intracellular adenylate kinase (AK) into culture medium as a reporter of bacterial cell death. As shown herein, the AK assay exhibits improved sensitivity over that of conventional whole-cell growth assays and displays specificity for bactericidal agents. Further, the assay can be used to screen for agents that kill small-colony-variant bacteria and bacteria within established biofilms.
  • To validate the A K assay as an HTS-compatible screening platform, the Prestwick library of off-patent drugs was screened against E. coli and each of the ESKAPE pathogens. This library contains representative examples of nearly all classes of antibiotics, and the bactericidal agents within the library that were expected to be active against the organism screened were identified. Additionally, agents with no previously reported antibiotic activity were identified. Traditional MIC testing confirmed the antimicrobial properties of many of these molecules, showing that they could be repurposed as antimicrobials or serve as lead molecules for antibiotic development. Consistent with that prediction, it was shown that one of these compounds, tamoxifen, is active against E. faecium in a Galleria mellonella model of infection. Further, it was shown that terfenadine is active against planktonic, small-colony variant, and biofilm-associated S. aureus. Taken together, these data demonstrate that the AK assay provides a general approach to screening for new antimicrobial agents active against a variety of pathogens during planktonic and other disease-associated growth states.
  • Bacterial Growth Conditions—
  • The bacterial species and strains used in these experiments are listed in Table 1. S. aureus strain UAMS-1112 (generous gift from M. Smeltzer, University of Arkansas Medical Center) is a stable small-colony variant of the common laboratory S. aureus strain 8325-4, which harbors a hemB deletion. Unless otherwise noted, bacteria were grown for 16 h in Mueller-Hinton (MH) (Becton, Dickinson, Franklin Lakes, N.J.) or brain heart infusion (BHI) (Becton. Dickinson) medium at 37° C. on a rotary shaker at 225 rotations per min (rpm) and then used to inoculate (1:100) fresh medium and processed, as described below.
  • TABLE 1
    Bacterial Strains
    Source or
    Species Strain Relevant resistancea referenceb
    Enterococcus 824-05 Amp, Cf, Cp, Cl, Mp, Clinical
    faecium Tmp, Sul, Erm, Kan isolate
    Staphylococcus USA300-0114 Amp, Cf, Cl, Sul, Kan 6
    aureus
    UAMS-1 ND 7
    UAMS-1112 Erm Univ. of
    Arkansas
    RN4220 Cl
    8
    Klebsiella cKP1 Amp, Cp, Sul, Erm, 9
    pneumoniae Van
    Acinetobacter 98-37-09 Amp, Lz 10 
    baumannii
    Pseudomonas PA01 Amp, Kan, Lz, Sul, 11 
    aeruginosa Van
    Enterobacter PMD1001 Amp, Erm, Lz, Sul, Clinical
    cloacae Van isolate
    Escherichia 8295 Erm, Lz, Sul Clinical
    coli isolate
    aAbbreviations: ampicillin. Amp; colistin, Cl; ceftriaxone, Cf; ciprofloxacin, Cp; erythromycin, Erm: kanamycin, Kan; linezolid, Lz: meropenem, Mp; minocycline, Min; Sulfamethoxazole, Sul; vancomycin, Van; not determined, ND; Univ., university.
    bClinical isolates were obtained from the University of Rochester School of Medicine and Dentistry.
  • Chemicals—
  • The Prestwick Chemical Library of molecules with known biological activities was acquired from Prestwick Chemical (Illkirch, France). ToxiLight BioAssay kits were obtained from Lonza (Basel, Switzerland). Terfenadine, suloctidil, clomiphene citrate, ceftriaxone, sulfamethoxazole, erythromycin, kanamycin, ciprofloxacin, rifampin, ampicillin, minocycline, tamoxifen, and trimethoprim were purchased from Sigma-Aldrich (St. Louis, Mo.). Meropenem, linezolid, and vancomycin were purchased from Thermo Fisher (Waltham, Mass.). Colistin was purchased from APP Pharmaceuticals (Schaumburg, Ill.).
  • MIC Testing—
  • MIC testing was performed to determine the antibiotic susceptibility profile of selected bacterial strains according to Clinical and Laboratory Standards (CLSI) protocols (Hindler et al. Antimicrobial susceptibility testing, section 5. Clinical microbiology procedures handbook, Vol. 1 America Society of Microbiology, Washington, DC (2010). Briefly, colonies of each bacterial species were collected from MH agar plates and suspended in individual tubes of MH medium to an optical density (600 nm) of 0.8. The resulting cultures were incubated at 37° C. in a rotary shaker at 225 rpm to exponential phase (˜1×108 CFU ml−1) and then diluted in fresh MH medium to a cell density of ˜3×107 CFU ml−1. Ten microliters of the diluted cultures was added to 88 μl of MH medium in individual wells of a 96-well, round-bottom plate (Corning, Inc.), and 2 μl of a stock solution of the indicated reference antibiotic or test compound (0 to 256 μg ml−1) was added to each well. The carrier solvent was either water or dimethyl sulfoxide (DMSO); final DMSO concentrations were less than or equal to 2%. Plates were incubated at 37° C. for 24 h, and the MIC was defined as the lowest concentration of antibiotic in which there was no visible cell pellet in the wells.
  • Heat-Killed Bacterial AK Release Assays—
  • Overnight cultures of E. coli strain 8295 or S. aureus RN4220 were used to inoculate (1:100 dilution) 25 ml of fresh M H medium and grown at 37° C. on a rotary shaker at 225 rpm to exponential phase (˜1×108 CFU ml−1). Cells were pelleted by centrifugation (2,000×g) and resuspended in 2.5 ml of sterile water. One milliliter of the resulting suspension was boiled for 3 min and filter sterilized (0.45-μm filter) to remove cell debris. The filtrate was serially diluted in sterile water, and 100 μl of each dilution was added to individual wells of a white-walled, 96-well plate (Corning, Inc., Corning, N.Y.). To measure the AK activity in the supernatants at each dilution, 100 μl of ToxiLight AK reagent was added to each well, followed by incubation at room temperature for 30 min, and luminescence was measured using a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, Calif.). Cells were serially diluted and plated to enumerate CFU (CFU ml−1) before and after boiling to correlate cell lysis with viability.
  • AK Assay 96-Well Format—
  • Overnight cultures of each bacterial species were used to inoculate (1:100 dilution) 25 ml of fresh MH medium and grown at 37° C. on a rotary shaker at 225 rpm to exponential phase (˜1×108 CFU ml−1). Ninety-eight microliters of MH medium. 2 μl of the indicated antibiotic, and 5×106 bacteria were added to individual wells of a white-walled, 96-well microtiter plate. Well components were mixed by pipetting and incubated at 37° C. for 3 h. The plate was equilibrated to room temperature for 30 min. Next, 100 μl of ToxiLight AK reagent was added to each well and incubated at room temperature for 30 min, and luminescence was measured using a SpectraMax M5 plate reader.
  • AK Assay 384-Well Format and High-Throughput Screening—
  • Overnight cultures of each bacterial species were used to inoculate (1:100 dilution) 25 ml of fresh medium and grown at 37° C. on a rotary shaker at 225 rpm to exponential phase (˜1×108 CFU ml−1). In a white-walled, 384-well plate, 24 μl of MH medium, 0.3 μl (50 μM) of antibiotic or compound, and 5×106 bacteria were added to individual wells and incubated at 37° C. for 3 h. The plates were equilibrated at room temperature for 1 h. Twenty-five microliters of ToxiLight AK reagent was then added to each well, followed by incubation at room temperature for 30 min, and luminescence was measured using a SpectraMax M5 plate reader.
  • AK Assay of Established Bloflims—
  • Biofilms were grown as previously described (Beenken et al. Infect. Immun. 71: 4206-4211 (2003); Musken et al. Nat. Protoc. 5: 1460-1459 (2010); Tomaras et al. Microbiology 149: 3473-3483 (2003)). Briefly, P. aeruginosa and A. baumannii were cultured overnight in Luria-Bertani medium and then used to seed 96-well, flat-bottom plates. Plates were incubated at 37° C. in a humidified incubator for 48 h to allow the formation of static biofilms. Nonadherent cells were removed by aspiration and washing with sterile phosphate-buffered saline (PBS). Fresh LB medium supplemented with 0, 1×, 10×, or 100×MIC of antibiotic was added to each well and incubated overnight at 37° C. Following treatment, 100 μl of each biofilm supernatant was transferred to 96-well, white-walled plates, 100 μl of ToxiLight AK reagent was added to each well, mixtures were incubated for 30 min at room temperature, and luminescence was measured using a SpectraMax M5 plate reader. Biofilm-associated bacteria were enumerated by resuspending each biofilm in fresh PBS and plating. For S. aureus UAMS-1 biofilms, 96-well, flat-bottom plates were first coated with 100 μl of 20% human plasma in carbonate buffer overnight at 4° C. Following coating, the plasma solution was removed and cells were inoculated in each well 1:200 in 100 μl of tryptic soy broth supplemented with 3% glucose and 0.5% NaCl. Biofilms were cultured for 48 h in a humidified incubator at 37° C. Established S. aureus biofilms were washed once with PBS and then treated with a 100 μl of ToxiLight lysis buffer for 3 h, after which the amount of AK released into supernatants was measured, as described above.
  • Small-Colony Variant AK Assays—
  • Thirty-six-hour cultures of S. aureus strain UAMS-1112 were used to inoculate (1:100 dilution) 100 ml of fresh MH medium and grown at 37° C. on a rotary shaker at 225 rpm to an optical density (600 nm) of 0.1 to 0.2, corresponding to ˜1×106 CFU ml−1. Cells were pelleted by centrifugation and resuspended in 2 ml of fresh MH medium. Ninety-eight microliters of MH medium containing 5×106 bacteria and 2 μl of the indicated antibiotic were added to individual wells of a white-walled, 96-well microtiter plate. Well components were mixed by pipetting and incubated at 37° C. for 3 h. The plate was equilibrated to room temperature for 30 min. Next, 100 μl of ToxiLight AK reagent was added to each well, followed by incubation at room temperature for 30 min, and luminescence was measured using a SpectraMax M5 plate reader.
  • Galleria mellonella Model of S. aureus Infection—
  • A Galleria mellonella model of infection was used to measure the putative antimicrobial properties of tamoxifen against E. faecium and terfenadine against S. aureus. To do so, overnight cultures of E. faecium strain 824-05 or S. aureus strain USA300-0114 were used to inoculate (1:100 dilution) 25 ml of fresh MH medium and grown at 37° C. on a rotary shaker at 225 rpm to exponential phase (˜1×108 CFU ml−1). Cultures were pelleted by centrifugation (2,000×g), washed with sterile PBS, and resuspended at ˜1×109 CFU ml−1 in fresh PBS. Galleria mellonella larvae (Vanderhorst Wholesale. Inc.; St. Marys, Ohio) weighing 200 to 300 mg were inoculated with 5 μl of E. faecium or S. aureus (5×106 CFU) into the last left proleg using a 10-μl Hamilton syringe. Worms were then mock treated with either DMSO (negative control), vancomycin (20 mg kg−1: positive control) at 2 h and 24 h postinoculation. For E. faecium studies, groups were also treated with the test compound tamoxifen at 80, 160, or 320 mg kg−1, whereas groups were treated with the test compound terfenadine (80, 160, or 320 mg kg−1) for S. aureus studies. Treatments were administered in the same manner as infection, except that each injection was in the next left proleg moving toward the head of the worm. Larvae were housed in petri dishes in the dark at 37° C. and monitored for viability at the conclusion of the study (48 h postinoculation); worms were considered dead if they did not respond to physical stimuli. In addition to mock or compound treatment of infected larvae, studies included two additional noninfected negative-control groups: one group that did not receive injections and one group that was injected with PBS to control for the impact of physical trauma. All experimental groups contained 15 worms, and each experiment was repeated three times.
  • Rationale for Adenylate Kinase as a Reporter of Bacterial Cell Lysis—
  • Adenylate kinase (AK) is a ubiquitous intracellular enzyme that catalyzes the conversion of 2 ADP⇄ATP+AMP and is released into the extracellular space upon cell lysis. The premise of the assay is that agents which disrupt cellular integrity, either directly through damage of the membrane/cell wall or indirectly following the death of the cell, will induce release of AK into the culture medium. Extracellular AK is subsequently detected by the addition of commercially available ToxiLight AK assay reporter cocktail (Lonza, Basel, Switzerland), which generates a luminescent signal by utilizing AK-generated ATP in the standard luciferase catalyzed reaction (see FIG. 1). As shown herein, an AK assay was developed as a high-throughput screening platform for antibacterial drug discovery.
  • The AK Assay Provides a Sensitive Measure of Bacterial Lysis—
  • As an initial test of AK release as a reporter of bacterial cell death for Gram-positive and Gram-negative organisms, the sensitivity with which the assay measures AK in the culture supernatants of heat-killed E. coli and S. aureus was determined. Each bacterial species was grown to exponential phase, harvested, and resuspended at 1×109 CFU per ml in Mueller-Hinton (MH) medium. Bacterial suspensions were heat killed, and a 10-fold dilution series of supernatants was prepared; an aliquot of each heat-killed sample was plated to ensure ≧99% bacterial death. The AK activity of the dilution series was measured and compared to the AK activity of mock-treated (viable) bacteria by Student's t test. In comparison to untreated cells, a statistically significant increase in AK activity was detected at dilutions containing 1.7×103 or more heat-killed E. coli supernatants, compared to results for live bacteria (see FIG. 2A). AK activity increased ˜433-fold and ˜1,574-fold in cultures with 1×107 and 1×108 heat-killed E. coli supernatants, respectively, compared to results for mock-treated bacteria. A comparison of AK released from heat-killed S. aureus to that of mock-treated cells revealed a statistically significant difference in AK activity was detected at dilutions containing 1.8×104 or more heat-killed S. aureus supernatants, with a maximum 122-fold increase in AK activity observed for 1×108 lysed cells. Taken together, these results indicate that the AK assay reproducibly detects AK release following bacterial cell lysis and that the assay is extremely sensitive, allowing the identification of agents that cause lysis in 0.0001% or 0.001% of the starting inoculum of E. coli or S. aureus cells, respectively. Furthermore, the AK assay exhibited a dynamic range of nearly 3 orders of magnitude and an excellent signal-to-noise ratio.
  • The AK Assay Detects Bactericidal Molecules that are Active Against the ESKAPE Pathogens—
  • Next, ability of the AK assay to detect the activities of bactericidal antibiotics toward E. coli and each of the ESKAPE pathogens was examined. To do so, the MICs of six classes of bactericidal antibiotics (penicillin, cephalosporin, quinolone, glycopeptide, carbapenem, and polymyxin) were determined for each organism (see Table 2). An AK assay was then performed at 0, 0.125×, 0.25×, 0.5×, 1×, and 2×MIC of each antibiotic. As discussed below, AK release was detected at antibiotic concentrations below the MIC for most antibiotics tested, showing that the AK assay is more sensitive than growth-based assays for detecting bactericidal agents. As a representative example, FIG. 2B presents the AK assay measured polymyxin (colistin)-mediated killing of A. baumannii strain 98-37-09. The MIC of colistin for this strain is 4 μg ml−1, whereas AK release was robustly detected at 0.25×, 0.5×, and 1×MIC value.
  • TABLE 2
    MIC and AK measures of bacterial species and antibiotic combinationsa
    Value for agent
    Bactericidal Bacteriostatic
    Strain and Treatment Ceftri- Cipro- Vanco- Sulfame- Mino- Erythro- Line-
    parameter (×MIC) Ampicillin axone floxacin mycin Meropenem Colistin thoxazole cycline mycin Kanamycin zolid
    Enterococcus
    faecium 824-05
    MIC >256 >256 256 2 >256 >256 >256 1 >256 >256 16
    Fold increase 0.5 ND ND ND 1 ND ND ND 3 ND ND 2
    in AK signal
    1.0 ND ND ND 2 ND ND ND 4 ND ND 2
    Staphylococcus
    aureus
    USA300-0114
    MIC >256 >256 2 1 4 >256 >256 1 64 >256 2
    Fold increase 0.5 ND ND 3 11 13 ND ND 1 1 ND 1
    in AK signal
    1.0 ND ND 5 3 17 ND ND 1 1 ND 1
    RN4220
    MIC 2 2 2 2 2 >256 2 8 2 16 2
    Fold increase 0.5 4 10 8 3 11 ND 2 1 1 1 1
    in AK signal
    1.0 3 12 10 6 11 ND 3 1 1 1 1
    Klebsiella
    pneumoniae
    cKP1
    MIC >256 2 >256 >256 2 8 >256 64 >256 2 >256
    Fold increase 0.5 ND 50 ND ND 128 34 ND 1 ND 1 ND
    in AK signal
    1.0 ND 55 ND ND 220 33 ND 1 ND 1 ND
    Acinetobacter
    baumannii
    98-37-09
    MIC 256 8 0.0625 64 2 4 8 1 16 2 256
    Fold increase 0.5 ND 5 2 2 79 17 6 23 3 3 ND
    in AK signal
    1.0 ND 21 2 4 134 49 5 14 12 14 ND
    Pseudomonas
    aeruginosa PA01
    MIC >256 4 2 >256 2 4 256 32 32 256 >256
    Fold increase 0.5 ND 2 27 ND 45 5 ND 1 3 ND ND
    in AK signal
    1.0 ND 14 182 ND 39 12 ND 6 1 ND ND
    Enterobacter
    cloacae
    PMD1001
    MIC >256 2 <1 >256 2 2 >256 4 256 2 >256
    Fold increase 0.5 ND 20 6 ND 99 10 ND 4 ND 1 ND
    in AK signal
    1.0 ND 17 7 ND 296 32 ND 9 ND 1 ND
    Escherichia coli
    8295
    MIC 128 2 0.125 16 2 8 >256 16 256 32 >256
    Fold increase in 0.5 50 51 17 1 60 15 ND 4 ND 55 ND
    AK signal
    1.0 74 76 39 2 85 22 ND 38 ND 70 ND
    % increase 0.5 100 83.3 83.3 40 100 100 50 50 50 40 0
    expected
    1.0 100 100 83.3 60 100 100 100 62.5 25 40 0
    aShading indicates significant increase in AK signal (greater than or equal to threefold over vehicle-treated cells).
  • The MIC measures for each ESKAPE pathogen and each organism's corresponding fold increase in AK signal following treatment with 0.5× and 1.0× the MIC are provided in Table 2 (bactericidal agents). For four of the six bactericidal antibiotics tested, the AK assay proved to be superior to growth-based assays with respect to detecting the killing properties of bactericidal agents at sub-MIC values. More specifically, 100% of the organisms that were determined to be susceptible to the cell wall-active antibiotics ampicillin, meropenem, and colistin exhibited a significant increase in AK signal (≧3-fold over that for vehicle-treated cells) at both 0.5× and 1.0× their MIC's. Eighty-three percent and 100% of ceftriaxone-susceptible species exhibited increased AK signal at 0.5× and 1× their MICs, respectively. Five of six (83%) ciprofloxacin-susceptible organisms exhibited AK signal at both 0.5× and 1.0×MIC. Interestingly, the cell wall-targeted glycopeptide, vancomycin, caused significant AK release at 0.5× and 1.0× their MICs in only 40% and 60% of susceptible species.
  • To evaluate the specificity of the assay for detecting bactericidal agents, measured AK release by each of the ESKAPE pathogens following exposure to five classes of bacteriostatic agents (sulfonamide, tetracycline, macrolide, aminoglycoside, and oxazolidine) was also measured. To do this, the MIC value of each bacteriostatic antibiotic/organism pair was measured by a conventional growth-based approach. AK release by each bacterial species following treatment with 0.5× or 1.0×MIC of each bacteriostatic agent was subsequently measured. As shown in FIG. 3, S. aureus strain RN4220 was susceptible to all agents tested but bacteriostatic agents generated very low AK release, whereas bactericidal antibiotics generated robust AK detection. In most instances, a similar trend was observed for the other ESKAPE pathogens, indicating that the assay enriches for the identification of bactericidal agents, which are arguably the most valuable antibiotics because they can be used to treat patients with immunological defects or rapidly lethal infections (Table 2, bacteriostatic agents). Two exceptions were noted. Surprisingly, A. baumannii generated significant AK signal in response to all the bacteriostatic agents evaluated, showing that AK release may be a feature of a more general stress response in this organism. Additionally, the bacteriostatic agent minocycline generated signal by five of the eight (63%) organisms tested.
  • Taken together, these results show that the AK assay provides a viable screening approach for identifying bactericidal agents at sub-MICs that could otherwise be missed by growth-based assays. Further, because the AK assay relies on bacterial killing as opposed to growth changes to generate its readout, it was hypothesized that it would provide a format to develop screens that are not readily available by conventional, growth-based approaches.
  • Use of the AK Assay to Identify Agents with Antimicrobial Activities Against Established Biofilms and Small Colony Variants—
  • Established bacterial biofilms represent a particularly problematic disease state, in part because biofilm-associated bacteria are recalcitrant to conventional antibiotic therapy. Thus, they have been a focus of antibiotic development. As a result, a number of approaches to screening for molecules with activity toward bacterial biofilms have been developed recently (Benoit et al. Environ. Microb. 76: 4136-4142; Perez et al. Lett. Appl. Microb. 51:331-337 (2010)). Although each has its advantages, they also have a number of limitations, including reproducibility, reliance on specialized equipment, or low throughput. It was hypothesized that the AK assay would provide a solution to some of these problems because it is rapid, sensitive, and simple to perform and it detects bactericidal molecules, the type of antibiotics required to treat established biofilms.
  • To determine whether the AK assay could detect agents with activity against established biofilms, S. aureus strain UAMS-1, A. baumannii strain 98-37-09, and P. aeruginosa strain PAO1 static biofilms were formed in 96-well flat-bottom plates. Forty-eight hours postinoculation, one well corresponding to each organism was stained with crystal violet to verify that biofilm formation had occurred, whereas the remaining wells were treated with 10× the MIC value with either colistin (A. baumannii biofilms) or ciprofloxacin (P. aeruginosa, and S. aureus biofilms). Following overnight antibiotic treatment, biofilm-associated bacteria were enumerated by plating, and the corresponding supernatants were analyzed by the AK assay. Plating verified that 10×MIC antibiotic treatment resulted in a significant reduction in biofilm-associated P. aeruginosa (a 3.1-log decrease), S. aureus (a 0.7-log decrease), and A. baumannii (a 1.8-log decrease) compared to findings for untreated biofilms. As shown in FIG. 4A, corresponding AK measures indicated that the assay robustly detects the mild effects of these antibiotics on each bacterial species tested, showing that it represents a promising approach to identify agents that exhibit bactericidal activity toward established bacterial biofilms.
  • Another context in which the AK assay can be particularly valuable is in the identification of molecules that exhibit bactericidal activity toward bacterial small-colony variants (SCV). SCV are slow-growing populations of bacterial species that have been hypothesized to cause latent or recurrent infections and are tolerant of standard antibiotic treatment regimens. Based on the aberrant SCV growth characteristics, typical growth-based HTS assays would be difficult to employ. Accordingly, the ability of the AK assay to identify agents that kill S. aureus SCV strain UAMS-1112 was tested. To do so, 1×106 UAMS-1112 cells were treated with 1× or 10×MIC ciprofloxacin, meropenem, or vancomycin for 3 h. Following treatment, suspensions were plated to measure the antimicrobial properties of each antibiotic, and the AK assay was performed to measure adenylate kinase release. Plating revealed that ciprofloxacin and vancomycin had no effect on SCV viability at any concentration tested and exhibited no change in AK release in comparison to results for mock-treated cells (FIG. 4B), supporting the observation that S. aureus small-colony variants are recalcitrant to antibiotic treatment. Meropenem treatment resulted in a 0.5-log decrease in SCV viability, which corresponded to a 2.5-fold increase in AK signal compared to that for mock-treated cells (FIG. 4B). Taken together, these results show that the AK assay provides the sensitivity needed to detect the slight antimicrobial effects of antibiotics, such as meropenem, toward S. aureus SCV.
  • Validation of AK as an HTS-Compatible Assay of Antibacterial Activity—
  • To test the viability of the AK assay as a general tool in HTS-based antibacterial small-molecule discovery, optimized assay parameters, including inoculum, drug incubation time, and AK reaction time, for screening planktonic ESKAPE species as well as E. coli in a 384-well format were determined. Based on these experiments, a standardized assay, as described above, was developed. As part of this optimization process, control assays in a 384-well format were performed to measure the signal to noise and reproducibility of the assay in an I-ITS manner. For this, plates were seeded with E. coli or an ESKAPE pathogen. Alternating columns of the plate were then mixed with either 2% DMSO (negative control) or a bactericidal antibiotic (positive control), and AK signal was detected; a representative result for DMSO- and colistin-treated K. pneumoniae is shown in FIG. 5A. Comparisons of the variance in signal between positive- and negative-control measures indicated that the AK assay provides Z′-factor scores between 0.59 and 0.82 (depending on the specific organism), indicating that the assay is sufficiently robust for HTS.
  • AK-Based Screening of Library of Off-Patent Drugs and Biologically Active Molecules—
  • To further validate the AK assay protocol, E. coli and each of the ESKAPE pathogens was screened against the Prestwick library of FDA-approved drugs and biologically active molecules (1,120 compounds, total; 50 μM final drug concentration). The Prestwick library contains representatives of nearly all classes of antibiotics currently in clinical use, making it an ideal library for testing the ability of the AK assay to detect bactericidal agents in a high-throughput screening format. Accordingly, the library was screened for antimicrobial agents that were active against planktonic E. coli and each of the ESKAPE pathogens using the AK assay; the cutoff for positive-scoring molecules was set at a 3-fold increase in extracellular AK activity, corresponding to the detection limit of statistically significant increases in AK activity for planktonic bacteria. The hit rates for the different organisms ranged from 1.4% to 4.8%; a representative example of raw screening data for Klebsiella pneumoniae is shown in FIG. 5B. Screening results for all ESKAPE pathogens are summarized in Table 3, whereas results for all compounds within the Prestwick library are provided in Table 4.
  • TABLE 3
    Preswick library screening results
    No. of active agents for species
    Compound E. coli E. faecium S. aureus a K. pneumoniae A. baumannii a P. aeruginosa E. cloacae
    Bactericidal 45 4 25 19 17 21 16
    Bacteriostatic 2 1 14 0 7 0 1
    Detergent 2 2 2 2 2 1 0
    Other 5 9 10 4 18 1 12
    Total 54 16 51 25 44 23 29
    aTetracyclines were identified.
  • TABLE 4
    AK-based Prestwick Library Screening Results.
    E. coli E. faecium S. aureus K. pneumoniae A. baumannii P. aeruginosa E. cloacae Chemical name Mechanism Therapeutic group
    0.4 0.8 0.6 0.3 0.3 0.3 0.3 Azaguanine-8 Purine antimetabolite Antineoplastic
    0.4 0.8 0.4 0.4 0.4 0.3 0.3 Metronidazole Bacterial DNA damage Antibacterial
    0.4 0.7 1.4 0.4 0.4 0.3 0.3 Allantoin Precipitate proteins Vulnerary
    0.5 0.8 0.4 0.4 0.3 0.3 0.3 Cotinine (−) Antidepressant
    0.4 0.9 0.4 0.4 0.4 0.3 0.3 Acetazolamide Carbonic anhydrase inhibitor Diuretic
    0.4 0.8 0.4 0.5 0.4 0.4 0.3 Edrophonium chloride Cholinergic Myasthenia Gravis test
    0.5 0.8 0.4 0.4 0.4 0.3 0.3 Metformin hydrochloride — Antidiabetic
    0.5 0.8 0.4 0.4 0.4 0.3 0.3 Moroxidine hydrochloride — Antiviral
    0.5 0.8 0.5 0.5 0.4 0.4 0.3 Atracurium besylate Neuromuscular blocking agent Curarizing agent
    0.5 0.8 0.4 0.6 0.4 0.3 0.3 Baclofen (R,S) GABAb agonist Antispasmodic
    0.5 0.9 0.4 0.5 0.4 0.4 0.4 Isoflupredone acetate Anti-inflammatory
    0.5 0.9 0.5 0.5 0.4 0.4 0.3 Acyclovir ADN polymerase inhibitor Antiviral
    0.5 0.8 0.4 0.4 0.4 0.3 0.4 Amiloride hydrochloride dihydrate Antialdosteron Diuretic
    0.5 0.9 0.5 0.4 0.4 0.4 0.4 Diazoxide Activator of ATP-dependent K+ channels Antihypertensor
    0.5 0.9 0.5 0.6 0.5 0.4 0.4 Amprolium hydrochloride Thiamine transport inhibitor Coccidiostatic
    0.5 0.9 0.4 0.5 0.4 0.4 0.4 Amidopyrine ACTH secretor Antipyretic
    0.5 1.1 0.5 0.6 0.5 0.5 0.4 Hydrochlorothiazide Na+ Cl− transport inhibitor Diuretic
    0.4 2.8 0.1 0.4 0.5 0.4 0.5 Ursolic acid — Diuretic
    0.5 1.0 0.5 0.6 0.5 0.5 0.4 Sulfaguanidine Inhibitor of folic acid synthesis Antibacterial
    0.5 1.0 0.5 0.6 0.5 0.4 0.4 Pindolol Beta adrenergic antagonist Antiarrhythmic
    0.6 1.0 0.7 0.6 0.6 0.6 0.6 Isoniazid — Antibacterial
    0.6 0.9 0.7 0.6 0.5 0.7 0.7 Mexiletine hydrochloride Na+ channel blocker Antiarrhythmic
    0.6 1.0 0.7 0.5 0.6 0.7 0.6 Pentylenetetrazole GABA antagonist CNS stimulant
    0.5 0.9 0.6 0.6 0.5 0.6 0.6 Flavoxate hydrochloride Phosphodiesterase inhibitor Antispasmodic
    0.6 0.9 0.5 0.5 0.6 0.6 0.6 Chlorzoxazone — Muscle relaxant
    0.5 0.9 0.4 0.5 0.5 0.5 0.6 Bufexamac — Antiinflammatory
    0.6 0.9 0.5 0.5 0.6 0.6 0.6 Ornidazole Bacterial DNA damage Antibacterial
    0.5 0.9 0.5 0.6 0.6 0.6 0.5 Glutethimide, para-amino Aromatase inhibitor Antineoplasic
    0.6 0.9 0.5 0.6 0.5 0.5 0.6 Ethosuximide Ca++ channel inhibitor Anticonvulsant
    voltage dependant
    0.7 0.9 0.5 0.5 0.5 0.5 0.5 Dropropizine (R,S) — Antitussive
    0.6 1.2 0.6 0.5 0.5 0.5 0.6 Mafenide hydrochloride Inhibitor of folic acid Antibacterial
    biosynthesis
    0.5 0.9 0.5 0.5 0.5 0.5 0.6 Pinacidil K+ channel Ca++ dependant Vasodilatator
    activator
    0.2 0.3 0.2 0.2 0.2 0.2 0.5 Riluzole hydrochloride Glutamate antagonist Neuroprotective
    0.3 0.5 0.2 0.3 0.3 0.3 0.4 Albendazole
    0.4 1.0 0.4 0.8 0.5 0.4 0.6 Nitrofurantoin Bacterial DNA damage Urinary antiseptic
    0.5 0.9 0.5 0.5 0.6 0.5 0.6 Clonidine hydrochloride Alpha2 agonist Antihypertensor
    0.0 0.3 0.2 0.0 0.1 0.0 0.3 Hydralazine hydrochloride Adrenergic antagonist Antihypertensor
    0.5 1.0 0.5 0.5 0.5 0.5 0.5 Bupropion hydrochloride — Antidepressant
    0.5 0.8 0.5 0.6 0.5 0.5 0.5 Phenelzine sulfate MAO inhibitor Antidepressant
    0.6 0.9 0.6 0.5 0.7 0.5 0.4 Alprenolol hydrochloride Beta1 antagonist Antihypertensor
    0.6 0.9 0.8 0.5 0.8 0.6 0.7 Meticrane Na+ channel blocker Antihypertensor
    0.6 0.9 0.7 0.6 0.7 0.7 0.7 Khellin — Phototherapeutic agent
    0.7 0.8 0.7 0.6 0.7 0.6 0.7 Benzonatate Antitussive
    0.7 0.9 0.8 0.5 0.7 0.6 0.8 Zimelidine dihydrochloride 5-HT uptake inhibitor Antidepressant
    monohydrate
    0.7 0.9 0.5 0.5 0.7 0.5 0.7 Hydroflumethiazide Na+ Cl− transport inhibitor Antihypertensor
    0.6 0.9 0.7 0.6 0.6 0.6 0.9 Azacyclonol H1 antagonist Anxiolytic
    0.6 0.9 0.7 0.5 2.2 0.5 0.7 Sulfacetamide sodic hydrate Antipsoriasic
    0.6 0.8 0.7 0.5 0.7 0.6 0.8 Azathioprine Antimetabolite Immunosuppressant
    0.8 0.9 0.7 0.5 0.6 0.5 0.7 Heptaminol hydrochloride — Antihypotensive
    0.7 0.9 0.5 0.6 1.4 0.6 0.7 Lynestrenol Antioestrogen Progestogen
    0.7 0.9 0.6 0.6 1.0 0.6 0.7 Sulfathiazole Inhibitor of folic acid Antibacterial
    synthesis
    0.7 1.0 0.5 0.4 0.8 0.6 0.7 Guanabenz acetate Alpha agonist Antihypertensor
    0.6 0.8 0.5 0.6 0.7 0.5 0.8 Levodopa Tyrosine aminotransferase Antiparkinsonian
    inhibitor
    0.9 1.0 1.1 0.6 1.0 0.6 0.7 Disulfiram Dopamine beta-hydroxylase Alcohol deterrent
    inhibitor
    0.7 1.0 0.7 0.6 0.7 0.6 0.8 Idoxuridine Nucleic acid synthesis Antiviral
    inhibitors
    0.6 1.0 0.7 0.6 0.7 0.6 0.8 Acetylsalicylsalicylic acid Cyclooxygenase inhibitor Antiinflammatory
    0.7 1.0 0.7 0.6 0.8 0.6 0.8 Captopril Angiotensive converting Antihypertensor
    enzyme inhibitor
    0.7 0.9 0.7 0.6 0.8 0.8 0.7 Mianserine hydrochloride 5-HT antagonist Antidepressant
    0.6 1.0 0.7 0.6 0.8 0.6 0.7 Minoxidil K+ channel activator Antihypertensor
    0.6 0.9 0.6 0.5 0.6 0.6 0.7 Nocodazole Microtubule poison Antineoplastic
    0.8 1.1 0.7 0.7 0.8 0.9 0.9 Tranexamic acid Plasminogen inhibitor Hemostatic
    0.9 1.0 0.8 0.7 0.9 0.9 0.9 Chlorothiazide Na+ Cl− transport inhibitor Antihypertensor
    0.8 1.0 0.8 0.6 0.8 0.7 0.9 Etofylline Phosphodiesterase inhibitor Cardiac analeptic
    0.8 1.0 0.7 0.7 0.7 0.8 0.8 Diphenidol hydrochloride — Antivertigo
    0.8 1.0 0.8 0.6 0.9 0.8 0.9 Tranylcypromine hydrochloride MAO inhibitor Antidepressant
    0.7 1.0 0.8 0.7 0.7 0.8 0.9 Norethindrone — Progestogen
    0.9 0.9 0.7 0.7 0.9 0.8 0.9 Alverine citrate salt Anticholinergic Spasmolytic
    0.9 0.9 1.0 0.7 0.9 0.8 0.9 Nortriptyline hydrochloride Norepinephrine uptake Antidepressant
    inhibitor
    0.7 1.0 0.7 0.6 0.7 0.8 0.8 Aceclofenac Cyclooxygenase inhibitor Antiinflammatory
    0.6 0.9 0.7 0.6 0.7 0.7 0.8 Niflumic acid Prostaglandine synthesis Analgesic
    inhibitor
    0.8 1.0 1.0 0.7 0.7 0.7 0.8 Iproniazide phosphate Monoamine oxydase Antidepressant
    inhibitor (non selective)
    0.7 1.0 0.6 0.6 0.7 0.8 0.9 Isotretinoin — Cystic acne
    0.7 1.0 0.7 0.6 1.3 0.7 0.7 Sulfamethoxazole
    0.7 1.0 0.8 0.6 0.8 0.7 0.9 Retinoic acid — Keratolytic
    0.7 1.0 0.8 0.7 0.8 0.6 0.8 Mephenesin — Muscle relaxant
    0.7 1.0 0.8 0.6 0.8 0.7 0.8 Antazoline hydrochloride H1 antagonist Antihistaminic
    0.8 1.0 0.7 0.6 0.8 0.7 0.8 Phenformin hydrochloride Neoglucogenese inhibitor Antidiabetic
    0.7 1.3 1.4 0.6 0.8 0.7 0.8 Ethacrynic acid Na+ Cl− uptake inhibitor Diuretic
    0.7 1.0 0.4 0.6 0.7 0.8 0.7 Flutamide Androgenic receptor Anticancer
    antagonist
    0.9 1.0 0.8 0.6 0.7 0.6 0.7 Praziquantel Modulates cell membrane Anthelmintic
    permeability
    0.8 0.8 0.8 0.7 1.4 0.8 0.8 Sulfaphenazole Inhibitor of folic acid Antibacterial
    synthesis
    0.8 0.8 0.9 0.8 0.8 0.6 0.9 R(−) Apomorphine hydrochloride D1 agonist Emetic
    hemihydrate
    0.9 0.8 0.6 0.7 0.8 0.7 1.0 Panthenol (D) — Vitamin
    1.0 0.9 0.7 0.8 0.8 0.9 0.9 Amoxapine Dopamine-reuptake Antidepressant
    inhibitor
    1.0 0.8 0.7 0.7 1.2 0.8 0.9 Sulfadiazine Inhibitor of folic acid Antibacterial
    synthesis
    0.9 0.9 0.6 0.6 0.9 0.9 0.9 Cyproheptadine hydrochloride 5-HT antagonist Antipruritic
    0.9 0.9 0.7 0.7 0.7 0.8 1.0 Norethynodrel — Progestogen
    0.9 0.8 0.5 0.8 0.8 0.8 1.0 Famotidine H2 histaminic antagonist Antiulcerative
    0.9 0.9 8.7 0.4 0.9 0.8 1.4 Thiamphenicol Ribosomal protein synthesis Antibacterial
    inhibitor
    0.7 0.9 0.6 0.6 0.9 0.8 0.9 Danazol Estrogen antagonist Antigonadotropin
    0.9 0.9 0.8 0.7 0.8 0.8 1.0 Cimetidine H2 antagonist Antiulcer
    0.9 0.9 0.6 0.8 0.8 0.7 0.9 Nicorandil Antihypertensor
    0.8 0.9 0.7 0.6 0.8 0.8 1.0 Doxylamine succinate H1 antagonist Antihistaminic
    0.9 1.0 0.8 0.7 1.0 0.8 1.1 Tomatine Antifungal
    0.9 0.9 0.6 0.7 0.8 0.7 1.1 Ethambutol dihydrochloride Chelating agent Antibacterial
    0.9 0.9 0.7 0.8 0.8 0.8 1.0 Nomifensine maleate Dopamine uptake inhibitor Antidepressant
    0.9 1.0 0.7 0.7 1.0 0.8 1.0 Antipyrine — Analgesic
    0.9 0.9 0.7 0.7 0.8 0.9 1.0 Dizocilpine maleate Probe for NMDA receptors —
    0.9 1.0 0.7 0.7 0.8 0.8 1.0 Antipyrine, 4-hydroxy — Antipyrine metabolite
    0.9 1.0 0.8 0.7 0.8 0.9 0.9 Acenocoumarol Vitamin K antagonist Anticoagulant
    0.9 1.0 0.8 0.7 0.9 1.0 1.0 Ampyrone — Analgesic
    1.0 0.9 0.8 0.8 0.9 1.0 1.1 Ethisterone — Progestogen
    1.0 1.0 0.9 0.7 1.1 1.0 1.0 Levamisole hydrochloride Alkaline phosphatase Immunomodulator
    inhibitor
    1.0 1.0 0.6 0.7 0.9 1.0 1.0 Triprolidine hydrochloride H1 antagonist Antihistaminic
    1.0 0.9 0.8 0.8 0.9 1.0 0.9 Pargyline hydrochloride Monoamine oxidase Antihypertensor
    inhibitor
    1.1 1.0 0.9 0.8 0.9 1.1 1.0 Doxepin hydrochloride Adrenaline uptake inhibitor Anticonvulsant
    0.9 0.9 0.8 0.6 0.9 0.9 1.0 Methocarbamol — Muscle relaxant
    1.0 1.0 0.9 0.7 0.9 1.0 1.1 Dyclonine hydrochloride Na+ channel blocker Local anesthesic
    15.9 1.0 0.6 2.6 5.4 9.1 18.4 Aztreonam Bacterial transpeptidase Antibacterial
    inhibitor
    1.0 1.0 0.8 0.7 0.8 1.0 1.2 Dimenhydrinate H1 antogonist Antihistaminic
    1.0 1.0 5.3 0.7 1.3 1.0 1.0 Cloxacillin sodium salt Bacterial transpeptidase Antibacterial
    inhibitor
    0.9 0.9 2.7 0.6 0.9 0.9 1.0 Disopyramide Na+ channel blocker Antiarrhythmic
    1.0 1.0 0.8 0.8 0.8 0.7 1.0 Catharanthine
    1.0 1.3 2.0 1.0 3.3 1.0 1.0 Clotrimazole Specific inhibitor of Ca2+ Antibacterial
    activated K+ channels
    0.8 0.9 0.7 0.7 1.0 1.0 1.1 Pentolinium bitartrate Glanglionic blocking agent Antihypertensor
    0.9 1.0 0.8 0.8 0.9 1.0 1.0 Vinpocetine Phosphodiesterase inhibitor Nootropic drug
    0.9 0.9 0.7 0.8 0.8 0.9 1.1 Aminopurine, 6-benzyl Inhibitor of respiratory
    kinase in plants
    1.1 1.1 0.8 0.7 1.0 0.9 1.0 Clomipramine hydrochloride Noradrenaline reuptake Antidepressant
    inhibitor
    0.8 1.0 0.7 0.8 0.9 0.9 1.0 Tolbutamide K+ channel ATP dependant Hypoglycemic
    inhibitor
    1.0 1.1 0.8 0.8 1.5 1.1 0.9 Fendiline hydrochloride Ca++ channel activator Antianginal
    0.7 0.8 9.7 0.2 1.0 0.8 1.5 Chloramphenicol Ribosomal Antibacterial
    peptidyltransferase inhibitor
    0.9 0.8 0.7 0.6 0.8 0.8 1.1 Naloxone hydrochloride Opiate antagonist Opioate antidote
    1.0 0.8 2.2 0.7 0.9 0.8 1.2 Epirizole Antiinflammatory
    0.8 0.8 0.7 0.6 0.8 0.7 1.0 Metolazone — Diuretic
    1.0 0.9 0.7 0.6 0.8 0.7 1.1 Diprophylline Phosphodiesterase inhibitor Cardiac analeptic
    33.6 1.2 1.5 0.8 2.2 29.7 4.7 Ciprofloxacin hydrochloride Anti-bacterial
    0.6 0.7 0.6 0.5 1.1 0.6 1.2 Triamterene Non competitive Diuretic
    aldosterone antagonist
    12.2 1.1 0.5 0.6 1.6 0.7 3.5 Ampicillin trihydrate Antibacterial
    0.8 0.9 0.6 0.7 1.3 0.8 1.1 Dapsone Folic acid antagonist Antiinflammatory
    0.9 0.9 0.8 0.6 1.0 0.9 1.1 Haloperidol Dopamine antagonist Antipsychotic
    0.9 1.0 6.5 0.6 0.8 0.7 1.1 Troleandomycin Ribosomal protein synthesis Antibacterial
    inhibitor
    0.9 1.0 0.7 0.6 0.9 0.8 1.3 Naltrexone hydrochloride Opioid antagonist Analgesic
    dihydrate
    1.4 1.0 0.7 0.7 2.5 0.9 1.3 Pyrimethamine Antimalarial
    1.0 0.9 0.8 0.7 0.9 0.8 1.1 Chlorpheniramine maleate H1 antagonist Antihistaminic
    0.9 0.9 0.7 0.7 0.9 0.8 1.2 Hexamethonium dibromide Ganglion blocking agent Antihypertensor
    dihydrate
    0.9 0.9 0.7 0.7 0.9 0.8 1.2 Nalbuphine hydrochloride Opioid ligand Analgesic
    0.7 0.9 0.6 0.6 0.7 0.6 1.2 Diflunisal Cyclooxygenase inhibitor Antiinflammatory
    0.9 0.9 0.7 0.8 0.9 0.8 1.2 Picotamide monohydrate Eicosenoid receptor Antithrombotic
    antagonist
    0.1 0.1 0.4 0.1 0.2 0.1 0.5 Niclosamide Helmintic DNA damage Anthelmintic
    1.0 1.0 0.8 0.7 0.9 0.7 1.2 Triamcinolone — Antiinflamatory
    1.0 1.0 0.9 0.7 0.9 0.9 1.0 Midodrine hydrochloride Alpha adrenergic Hypotensor
    0.9 0.9 0.7 0.7 0.9 1.0 1.2 Vincamine — Cerebral antianoxic
    1.0 1.0 1.0 0.8 0.9 0.9 1.1 Thalidomide — Immunosuppressant
    0.9 0.9 0.6 0.8 1.0 0.9 1.2 Indomethacin Cyclooxygenase inhibitor Antiinflammatory
    13.1 1.1 1.0 1.6 2.3 1.0 4.3 Oxolinic acid Topoisomerase II inhibitor Antibacterial
    0.9 0.9 0.8 0.8 1.0 1.0 1.2 Cortisone Antiinflammatory
    0.9 0.8 0.7 0.7 0.9 0.9 1.4 Nimesulide Cyclooxygenase 2 inhibitor Antiinflammatory
    1.0 1.0 0.8 0.7 1.0 1.0 1.3 Prednisolone — Glucocorticoid
    1.0 0.9 0.7 0.8 0.9 0.9 1.2 Hydrastinine hydrochloride Dopamine receptor blocker Cardiotonic
    0.8 0.8 0.8 0.6 0.7 0.8 1.2 Fenofibrate Lipoprotein lipase activator Hypolipidemiant
    0.8 0.9 0.8 0.7 0.9 0.8 1.1 Pentoxifylline Phosphodiesterase inhibitor Vasodilatator
    0.9 0.9 0.7 0.7 0.8 0.8 1.3 Bumetanide Vascular cyclooxygenase Diuretic
    activator
    1.0 1.0 0.7 0.8 0.9 0.8 1.3 Metaraminol bitartrate Adrenergic agonist Vasoconstrictor
    0.9 0.9 0.8 0.7 0.9 0.9 1.3 Labetalol hydrochloride
    0.9 1.0 0.8 0.7 0.9 0.8 1.4 Salbutamol Beta adrenergic agonist Bronchodilatator
    0.9 1.0 1.0 0.8 2.3 0.9 1.2 Cinnarizine H1 antagonist Antihistaminic
    0.9 0.9 0.8 0.7 0.9 0.9 1.3 Prilocaine hydrochloride Na+ channel blocker Local anesthesic
    0.8 1.0 0.8 0.7 0.9 0.9 1.3 Methylprednisolone, 6-alpha Glucocorticoid
    0.9 0.9 0.7 0.8 0.8 0.8 1.1 Camptothecine (S,+) Topoisomerase I inhibitor Antitumor agent
    1.0 1.0 0.9 0.8 0.9 0.9 1.1 Quinidine hydrochloride Heme polymerase inhibitor Antiarrhythmic
    monohydrate
    1.2 0.9 1.2 1.0 1.1 1.0 1.4 Procaine hydrochloride Na+ channel blocker Local anesthesic
    1.3 0.9 0.6 1.1 1.4 1.1 1.4 Bromocryptine mesylate Prolactin inhibitor Antiparkinsonian
    1.2 0.9 1.1 1.0 1.1 1.1 1.6 Moxisylyte hydrochoride Alpha antagonist Vasodilatator
    1.3 1.0 1.2 1.0 1.1 1.1 1.3 Metanephrine hydrochloride DL Isoprenaline uptake inhibitor
    extraneuronal
    1.3 1.0 1.2 0.9 1.2 1.0 1.4 Betazole hydrochloride Histamine analog Gastric secretion stimulant
    1.3 1.0 1.0 0.8 1.0 1.0 1.4 Dehydrocholic acid — Choleretic
    1.2 1.0 1.0 1.0 1.0 1.0 1.4 Isoxicam Cyclooxygenase inhibitor Antiinflammatory
    1.1 0.9 0.5 0.9 1.1 0.9 1.3 Hesperetin P450 inhibitor
    1.2 1.0 0.8 0.9 1.1 1.0 1.4 Naproxen Cyclooxygenase inhibitor Antiinflammatory
    1.5 1.2 0.9 1.3 1.6 1.1 1.4 Perphenazine Dopamine antagonist Antipsychotic
    1.3 1.1 1.0 0.8 1.1 1.0 1.5 Naphazoline hydrochloride Adrenergic ligand Vasoconstrictor
    1.3 1.0 3.2 1.3 2.6 1.1 1.2 Mefloquine hydrochloride Heme polymerase inhibitor Antimalarial
    1.3 1.0 0.8 1.0 1.1 1.1 2.0 Ticlopidine hydrochloride ADP antagonist Platelet antiaggregant
    1.8 1.8 5.2 1.4 5.6 1.3 1.7 Isoconazole Sterol 14-demethylase Antibacterial
    inhibitor
    1.2 1.1 1.0 0.9 1.3 1.2 1.5 Dicyclomine hydrochloride Anticholinergic Antispasmodic
    1.4 1.0 1.2 1.0 1.1 1.0 1.3 Spironolactone Aldosterone antagonist Diuretic
    1.4 1.1 1.1 0.8 1.1 0.9 1.2 Amyleine hydrochloride Na+ channel blocker Local Anesthesic
    1.4 1.1 1.0 1.0 1.1 1.0 1.4 Pirenzepine dihydrochloride M1 antagonist Antiulcerative
    1.3 1.2 1.1 1.1 1.1 1.1 1.3 Lidocaine hydrochloride Na+ channel blocker Local anesthesic
    1.4 1.2 1.2 1.1 1.1 1.0 1.2 Dexamethasone acetate Antiinflammatory
    1.4 1.1 1.2 0.9 1.1 1.3 1.5 Ranitidine hydrochloride H2 antagonist Antiulcerative
    1.3 1.1 1.0 1.0 1.2 1.2 1.4 Fludrocortisone acetate — Mineralocorticoid
    1.1 1.3 0.4 1.0 1.1 1.2 1.5 Tiratricol, 3,3′,5- — Hypocholesterolemic drug
    triiodothyroacetic acid
    1.3 1.1 1.0 0.9 1.3 1.1 1.4 Fenoterol hydrobromide Beta adrenergic agonist Bronchodilatator
    1.0 1.0 0.5 1.0 1.3 1.1 1.8 Flufenamic acid Cyclooxygenase inhibitor Analgesic
    1.5 1.2 1.0 1.1 1.2 1.2 1.8 Homochlorcyclizine H1 antagonist Antihistaminic
    dihydrochloride
    13.6 1.5 2.2 2.2 2.9 1.4 24.4 Flumequine Topoisomerase II inhibitor Antibacterial
    1.3 1.2 1.1 0.9 1.1 1.1 1.7 Diethylcarbamazine citrate Lipoxygenase inhibitor Antihelmintic
    1.0 1.1 0.5 0.8 1.4 1.2 1.6 Tolfenamic acid Cyclooxygenase inhibitor Antiinflammatory
    1.2 1.0 1.7 0.8 1.0 1.2 1.5 Chenodiol Detergent Anticholelithogenic
    1.1 1.2 0.6 1.0 1.2 1.2 1.4 Meclofenamic acid sodium salt Cyclooxygenase inhibitor Antiinflammatory
    monohydrate
    1.8 1.2 0.8 1.6 3.4 1.4 1.5 Perhexiline maleate Ca2+ blocking agent Vasodilatator
    1.1 1.1 1.0 1.0 1.2 1.0 1.4 Kawain Ca++ channel blocker Antiaggregant
    1.4 1.1 1.2 0.9 1.1 1.0 1.6 Oxybutynin chloride Anticholinergic Spasmolytic
    1.2 1.1 1.0 0.8 3.1 1.1 7.2 Trimethoprim Folic acid antagonist Antibacterial
    1.3 1.2 1.0 0.9 1.2 1.2 1.3 Spiperone D2 antagonist Antipsychotic
    1.3 1.2 0.9 0.9 1.2 1.1 1.6 Metoclopramide 5-HT3 antagonist Antiemetic
    monohydrochloride
    1.4 1.2 1.4 1.0 1.1 1.1 1.4 Pyrilamine maleate H1 antagonist Antihistaminic
    0.9 0.9 0.6 0.7 0.9 0.9 1.3 Fenbendazole Microtubule formation Antihelmintic
    inhibitor
    1.3 1.1 3.5 1.0 1.2 1.0 1.2 Sulfinpyrazone — Uricosuric
    1.2 0.8 1.1 1.1 0.9 1.0 1.5 Trichlorfon Cholinesterase inhibitor Antihelminthic
    1.2 0.9 1.2 0.8 1.0 1.0 1.3 Glipizide
    1.0 0.8 1.0 0.9 0.9 1.0 1.5 Carbamazepine Cholinergic antagonist Anticonvulsivant
    1.0 0.9 1.1 1.0 1.0 0.9 1.3 Loxapine succinate Dopamine antagonist Anxiolytic
    1.1 0.9 1.1 1.0 1.5 1.0 1.6 Triflupromazine hydrochloride Dopaminergic antagonist ? Antipsychotic
    1.0 0.9 0.9 0.8 1.0 1.0 1.6 Hydroxyzine dihydrochloride H1 antogonist Antihistaminic
    0.9 0.9 0.7 0.8 1.2 0.9 1.6 Mefenamic acid Cyclooxygenase inhibitor Antiinflammatory
    1.0 0.9 0.8 1.0 1.0 0.9 1.5 Diltiazem hydrochloride Ca2+ channel inhibitor (L- Antianginal
    Type)
    1.2 0.9 1.1 0.8 1.1 1.2 1.7 Acetohexamide Blocking of ATP-sensitive K+ Antidiabetic (type II,
    channel noninsulin-dependent)
    1.1 0.8 0.9 0.8 1.0 1.0 1.3 Methotrexate
    1.0 1.0 1.1 1.0 1.0 1.1 1.6 Sulpiride D2 antagonist Antipsychotic
    1.3 1.0 2.2 1.1 1.6 1.0 1.6 Astemizole H1 antagonist Antihistaminic
    1.3 0.9 1.0 1.0 1.1 0.9 1.4 Benoxinate hydrochloride Na+ channel blocker Local anesthesic
    0.8 1.2 8.4 0.5 1.0 1.1 1.7 Clindamycin hydrochloride Ribosomal protein synthesis Antibacterial
    inhibitor
    1.4 1.0 1.0 1.5 4.2 1.0 1.5 Oxethazaine Na+ channel blocker Local anesthesic
    1.7 1.5 ### 1.1 3.1 1.0 1.2 Terfenadine H1 antagonist Antihistaminic
    1.4 1.0 1.0 1.0 1.0 1.0 1.7 Pheniramine maleate H1 antagonist Antihistaminic
    21.9 1.0 2.9 5.5 2.2 10.0 22.0 Cefotaxime sodium salt Bacterial transpeptidase Antibacterial
    inhibitor
    1.4 1.0 1.2 1.0 1.3 1.1 1.5 Tolazoline hydrochloride Alpha antagonist Vasodilatator
    0.8 1.0 9.2 0.2 4.4 0.5 1.0 Tetracycline hydrochloride Ribosomal protein synthesis Antibacterial
    inhibitor
    1.2 1.1 1.4 1.0 1.0 1.2 1.4 Piroxicam Cyclooxygenase inhibitor Antiinflammatory
    1.0 1.0 1.1 0.9 1.1 1.2 1.5 Dantrolene sodium salt Blocker of Ca2+ release Skeletal muscle relaxant
    1.3 1.1 1.2 0.9 1.1 1.2 1.4 Pyrantel tartrate Neuromuscular depolarizing Anthelmintic
    agent
    0.9 1.0 0.9 1.0 1.0 1.2 1.3 Trazodone hydrochloride 5-HT uptake inhibitor Antidepressant
    1.3 1.0 1.1 1.0 1.2 1.1 1.6 Fenspiride hydrochloride Bradykinin antagonist Antiinflammatory
    1.2 1.1 1.1 1.0 1.1 1.2 1.5 Glafenine hydrochloride — Analgesic
    1.3 1.0 0.9 0.9 1.3 1.2 1.5 Gemfibrozil — Antihyperlipoproteinemic
    1.4 1.1 0.9 1.2 1.1 1.1 1.4 Pimethixene maleate Anticholinergic Antihistaminic
    1.2 1.0 0.9 0.9 1.0 1.1 1.3 Mefexamide hydrochloride — Psychoanaleptic
    1.3 1.0 1.0 0.8 1.3 1.0 1.4 Pergolide mesylate Dopaminergic agonist Antiparkinsonian
    1.4 1.1 1.0 0.9 1.1 1.2 1.5 Tiapride hydrochloride Dopamine antagonist Antidyskinetic
    1.2 1.0 1.1 0.9 1.1 1.1 1.3 Acemetacin Cyclooxygenase inhibitor Antiinflammatory
    0.8 0.9 0.9 0.8 0.7 0.8 1.2 Mebendazole
    1.3 1.1 1.1 1.0 1.0 1.2 1.2 Benzydamine hydrochloride 5-HT receptor antagonist Analgesic
    0.8 0.8 0.7 0.8 1.0 0.8 1.6 Fenbufen Cyclooxygenase inhibitor Antiinflammatory
    1.3 1.1 0.9 1.1 1.0 1.0 1.3 Fipexide hydrochloride Glutamatergic Nootropic
    1.1 0.9 1.0 1.1 1.0 1.0 1.5 Ketoprofen Cyclooxygenase inhibitor Antiinflammatory
    1.3 1.1 0.7 0.9 1.1 1.0 1.4 Mifepristone Progesterone receptor Abortifacient
    antagonist
    1.1 1.1 1.0 1.1 1.0 1.1 1.7 Indapamide Diuretic
    1.4 1.1 1.2 0.9 1.1 1.1 1.4 Diperodon hydrochloride — Local anesthesic
    1.4 0.8 1.2 0.9 1.1 1.2 1.3 Morantel tartrate Fumarate reductase Anthelmintic
    inhibitor
    1.3 0.9 1.2 0.9 1.5 1.2 1.2 Verapamyl hydrochloride Alpha1 antagonist Antyhypertensive
    1.4 0.8 1.1 0.9 1.3 1.1 1.4 Homatropine hydrobromide (R,S) Muscarinic antagonist Antispasmodic
    1.3 0.9 0.8 0.9 1.2 1.1 1.4 Dipyridamole
    1.4 0.9 0.5 0.9 1.5 1.0 1.4 Nifedipine L-type Ca2+ channels blocker Antihypertensor
    50.1 4.0 ### 18.8 12.3 23.8 1.8 Chlorhexidine Detergent Bacteriostatic
    1.4 1.0 1.4 1.1 1.5 1.1 1.4 Chlorpromazine hydrochloride Dopamine antagonist Antiemetic
    1.4 0.9 1.0 0.9 1.5 1.2 1.5 Loperamide hydrochloride Ca2+ channel antagonist Antidiarrhoeic
    1.3 0.9 1.1 1.0 1.3 1.0 1.4 Diphenhydramine hydrochloride H1 receptor antagonist Antihistaminic
    0.8 0.9 6.8 0.2 3.9 0.7 1.0 Chlortetracycline hydrochloride Ribosomal protein synthesis Antibacterial
    inhibitor
    1.3 0.8 1.0 0.9 1.3 1.1 1.3 Minaprine dihydrochloride Dopamine agonist Antidepressant
    1.9 4.0 2.1 2.1 6.6 1.4 1.3 Tamoxifen citrate Oestrogen receptor
    antagonist
    1.4 2.5 2.2 1.4 4.7 1.2 1.6 Miconazole Sterol 14-demethylase Antifungal
    inhibitor
    1.3 1.0 1.4 1.0 1.4 1.2 1.2 Nicergoline Alpha agonist Vasodilatator
    1.1 1.0 1.1 1.0 1.5 1.1 1.5 Isoxsuprine hydrochloride beta adrenergic agonist Vasodilatator
    1.4 1.0 1.1 0.9 1.5 1.3 1.2 Canrenoic acid potassium salt Detergent Antihypercholesterolemic
    1.3 1.1 1.1 0.9 1.3 1.1 1.2 Acebutolol hydrochloride Beta1 antagonist Antianginal
    1.5 1.0 1.0 1.1 1.7 1.1 1.3 Thioproperazine dimesylate Dopamine antagonist Antipsychotic
    1.1 1.0 1.3 0.9 1.5 1.0 1.2 Tolnaftate — Antifungal
    1.3 1.0 1.0 0.9 1.5 1.2 1.3 Dihydroergotamine tartrate Serotonine antagonist Antimigraine
    33.1 1.5 1.8 0.8 3.1 31.3 3.1 Norfloxacin Topoisomerase II inhibitor Antibacterial
    1.2 1.0 4.3 1.0 1.3 1.2 1.5 Lisinopril Converting enzyme inhibitor Antihypertensor
    1.3 1.1 1.0 1.0 1.4 1.1 1.3 Antimycin A Inhibitor of mitochondrial Antifungal
    electron transport
    0.9 1.3 7.9 0.9 1.2 1.2 1.3 Lincomycin hydrochloride Ribosomal protein synthesis Antibacterial
    inhibitor
    1.2 1.0 1.2 0.9 1.3 1.2 1.4 Xylometazoline hydrochloride Vasoconstrictor
    1.5 1.1 1.3 1.0 1.6 1.2 1.4 Telenzepine dihydrochloride M1 muscarinic antagonist Antiulcerative
    1.1 1.0 1.1 1.1 1.4 1.2 1.3 Oxymetazoline hydrochloride Partial alpha2A agonist Vasoconstrictor
    1.3 1.5 3.7 1.3 6.7 1.3 1.3 Econazole nitrate Ergosterol synthesis Antifungal
    inhibition
    1.2 1.0 1.3 1.0 1.6 1.2 1.2 Nifenazone Cyclooxygenase inhibitor Analgesic
    1.3 1.0 1.1 1.0 1.4 1.2 1.5 Bupivacaine hydrochloride Na+ channel blocker Local anesthesic
    1.3 1.1 1.4 0.9 1.4 1.3 1.3 Griseofulvin Enzymatic inductor Antifungal
    1.4 1.0 1.2 1.1 1.5 1.2 1.2 Clemastine fumarate H1 antagonist Antihistaminic
    1.2 1.2 1.6 1.0 1.6 1.2 1.4 Clemizole hydrochloride H1 antagonist Antihistaminic
    1.0 0.9 3.4 0.2 5.3 0.5 1.1 Oxytetracycline dihydrate Ribosomal protein synthesis Antibacterial
    inhibitor
    1.2 1.0 1.1 1.1 1.5 1.2 1.4 Tropicamide Muscarinic antagonist Mydriatic
    1.7 1.3 2.3 1.3 8.7 1.3 1.2 Pimozide Dopamine antagonist ? Antipsychotic
    1.2 1.0 1.1 0.9 1.4 1.2 1.4 Nefopam hydrochloride — Analgesic
    1.2 1.1 1.3 0.9 1.5 1.2 1.4 Amodiaquin dihydrochloride Heme polymerase inhibitor Antimalarial
    dihydrate
    1.4 1.0 1.1 1.1 1.4 1.2 1.2 Phentolamine hydrochloride Alpha adrenergic antagonist Antihypertensor
    1.3 1.0 1.1 1.0 1.4 1.1 1.3 Mebeverine hydrochloride Antispasmodic
    1.3 0.8 1.3 1.0 1.1 1.1 1.7 Todralazine hydrochloride — Antihypertensor
    1.0 1.0 8.2 1.0 1.5 0.7 1.6 Erythromycin Ribosomal protein synthesis Antibacterial
    inhibitor
    1.2 0.9 1.2 1.0 1.3 1.1 1.7 Imipramine hydrochloride 5-HT transport inhibitor Antidepressant
    1.1 1.0 3.6 1.0 1.1 1.0 1.6 Oleandomycin phosphate Ribosomal protein synthesis Antibacterial
    inhibitor
    1.1 0.9 0.8 1.0 1.1 0.8 1.5 Sulindac Cyclooxygenase inhibitor Antiinflammatory
    4.7 0.9 1.2 0.9 1.5 1.0 4.2 Didanosine Transrcriptase inverse Antiviral
    inhibitor
    1.2 1.0 1.4 1.1 1.3 1.0 1.8 Amitryptiline hydrochloride Alpha 1 antogonist Antidiabetic
    1.3 1.0 8.4 1.0 1.1 0.9 1.4 Josamycin Ribosomal protein synthesis Antibacterial
    inhibitor
    1.2 1.0 1.3 1.0 1.3 0.9 1.5 Adiphenine hydrochloride Anticholinergic Local anesthesic
    1.1 1.0 1.0 1.0 1.3 1.0 1.6 Paclitaxel Tubuline inhibitor Antineoplastic
    1.3 0.9 1.3 1.1 1.3 1.1 1.7 Dibucaine Na+ channel blocker Local anesthesic
    1.3 1.2 2.1 1.0 1.5 1.0 1.6 Ivermectin GABA ligand Anthelmintic
    1.2 0.9 1.1 0.9 1.2 0.9 1.4 Prednisone — Glucocorticoid
    1.3 1.0 1.1 1.1 1.2 1.0 1.5 Gallamine triethiodide M2 antagonist allosteric Muscle relaxant
    1.6 1.0 1.3 1.3 2.9 1.1 1.5 Thioridazine hydrochloride Ca2+ channel antagonist Neuroleptic
    1.2 1.0 1.1 1.0 1.4 0.9 1.3 Neomycin sulfate Ribosomal protein synthesis Antibacterial
    inhibitor
    1.2 1.1 1.5 1.1 1.3 1.0 1.6 Diphemanil methylsulfate Anticholinergic Bronchodilatator
    1.2 1.0 1.2 0.7 1.2 0.9 1.3 Dihydrostreptomycin sulfate Ribosomal protein synthesis Antibacterial
    inhibitor
    1.2 1.1 1.2 1.1 1.2 1.0 1.3 Trimethobenzamide D2 antagonist Antiemetic
    hydrochloride
    1.3 1.0 1.1 1.0 1.5 0.9 1.4 Gentamicine sulfate Ribosomal protein synthesis Antibacterial
    inhibitor
    1.2 1.1 1.0 1.3 1.4 1.5 1.2 Etodolac Cyclooxygenase inhibitor Antiinflammatory
    1.2 1.0 1.1 1.3 1.4 1.2 1.3 Ifenprodil tartrate Adrenergic antagonist Vasodilatator
    1.2 1.1 1.4 1.2 1.4 1.3 1.5 Scopolamin-N-oxide Anticholinergic Antiparkinsonian
    hydrobromide
    1.7 1.3 1.1 1.4 2.6 1.3 1.6 Flunarizine dihydrochloride Na+ channel blocker Vasodilatator
    1.3 1.0 1.2 1.2 1.4 1.2 1.5 Hyoscyamine (L) Cholinergic Antispasmodic
    1.7 1.1 1.2 1.5 3.4 1.4 1.3 Trifluoperazine dihydrochloride Dopamine antagonist Psycholeptic
    1.2 0.9 1.0 1.1 1.3 1.1 1.4 Chlorphensin carbamate — Muscle relaxant
    1.2 1.1 1.3 1.2 1.3 1.2 1.3 Enalapril maleate Converting enzyme inhibitor Antihypertensor
    16.8 1.6 1.3 1.0 1.1 1.3 4.3 Metampicillin sodium salt Bacterial transpeptidase Antibacterial
    inhibitor
    2.3 1.1 6.9 0.6 3.9 0.7 0.9 Minocycline hydrochloride Ribosomal protein synthesis Antibacterial
    inhibitor
    1.5 1.1 1.2 1.4 1.4 1.3 1.1 Dilazep dihydrochloride Adenosine uptake inhibitor Vasodilatator
    1.2 1.0 0.9 1.1 1.3 1.2 1.4 Glibenclamide ATP-dependent K+ channel Antidiabetic
    inhibitor
    15.7 1.4 2.8 1.0 3.7 20.0 4.1 Ofloxacin Topoisomerase II inhibitor Antibacterial
    1.4 1.1 1.1 1.1 1.3 1.4 1.4 Guanethidine sulfate Catecholamine depletor Antihypertensor
    26.8 1.5 3.4 1.0 3.8 30.2 3.5 Lomefloxacin hydrochloride Topoisomerase II inhibitor Antibacterial
    1.2 1.0 1.2 1.0 1.3 0.9 1.4 Quinacrine dihydrochloride Monoamine oxydase Antimalarial
    dihydrate inhibitor
    1.3 1.0 1.0 1.2 1.3 1.1 1.2 Orphenadrine hydrochloride H1 antogonist Antihistaminic
    1.5 1.4 1.2 1.5 1.6 1.3 1.2 Clofilium tosylate K+ channel blocker Antiarrhythmic
    1.3 1.0 1.1 1.2 1.3 1.1 1.5 Proglumide Gastrin inhibitor Antiulcerative
    1.3 1.1 1.0 1.5 1.6 1.1 1.6 Fluphenazine dihydrochloride Dopamine antagonist Antipsychotic
    0.5 0.9 0.4 0.3 0.4 0.4 0.3 Streptomycin sulfate Ribosomal protein synthesis Antibacterial
    inhibitor
    0.5 0.9 0.3 0.4 0.5 0.4 0.3 Testosterone propionate — Androgen
    0.5 0.9 0.3 0.4 0.4 0.4 0.4 Alfuzosin hydrochloride Alpha 1-adrenergic Antihypertensor
    antagonist
    0.4 0.9 0.4 0.4 0.4 0.4 0.3 Arecoline hydrobromide Cholinergic Anthelmintic
    0.4 0.9 0.4 0.4 0.3 0.3 0.3 Chlorpropamide Glucagon secretogen, Antidiabetic
    somatostatin secretogen
    0.5 1.0 0.2 0.4 0.4 0.4 0.3 Thyroxine (L) Thyroid hormone Hypocholesterolemic drug
    0.5 0.8 0.3 0.5 0.4 0.4 0.4 Phenylpropanolamine Alpha adrenergic agonist Decongestant
    hydrochloride
    0.6 0.9 0.4 0.4 0.4 0.4 0.4 Tocopherol (R,S) — Anti-oxidant
    0.5 0.9 0.4 0.5 0.4 0.3 0.4 Ascorbic acid — Vitamin
    0.5 0.8 0.4 0.5 0.4 0.4 0.4 Pepstatin A Aspartic proteases Antiviral
    irreversible inhibitor
    0.6 0.9 0.4 0.6 0.5 0.4 0.5 Methyldopa (L,−) L-aromatic aminoacid Antihypertensor
    decarboxylase inhibitor
    0.5 0.8 0.4 0.5 0.5 0.4 0.4 SR-95639A M1 agonist receptor
    16.5 0.9 0.7 2.1 0.7 5.2 12.0 Cefoperazone dihydrate Bacterial transpeptidase Antibacterial
    inhibitor
    0.5 0.9 0.4 0.5 0.5 0.4 0.4 Adamantamine fumarate Inhibition of viral uncoating Antiviral
    and viral assembly,
    alteration of dopamine
    release and reuptake
    0.7 0.8 0.4 0.6 0.4 0.4 0.4 Zoxazolamine Uric acid uptake inhibitor Muscle relaxant
    0.7 3.3 0.6 0.7 2.0 0.5 0.5 Butoconazole nitrate Ergosterol inhibitor Antifungal
    0.5 0.9 0.5 0.4 0.5 0.5 0.4 Tacrine hydrochloride hydrate Cholinesterase inhibitor Cognition enhancer
    0.7 1.7 0.7 0.6 2.2 0.5 0.5 Amiodarone hydrochloride Na+ channel blocker, K+ Antiarrhythmic
    channel blocker, non-
    competitive beta-adrenergic
    blocker
    0.5 0.9 0.6 0.5 0.5 0.5 0.6 Bisoprolol fumarate Beta1 antagonist Antihypertensor
    0.5 0.9 0.5 0.7 0.5 0.4 0.5 Amphotericin B Ergosterol ligand Antibacterial
    0.8 0.9 0.6 0.6 0.6 0.6 0.6 Serotonin hydrochloride 5-HT agonist Neurotransmitter
    0.7 0.9 0.5 0.6 0.7 0.6 0.6 Tubocurarine chloride Curarising Muscle relaxant
    pentahydrate (+)
    23.9 0.9 2.3 7.8 0.9 0.6 15.6 Cefotiam hydrochloride Antibacterial
    0.7 0.9 0.5 0.6 0.7 0.6 0.6 Dihydroergocristine mesylate 5-HT antagonist, partial Vasodilatator
    adrenergic agonist, partial
    dopaminergic agonist
    0.6 0.9 0.4 0.5 0.5 0.6 0.6 Azathymine, 6 Antimetabolite Anticancer
    0.6 0.9 0.5 0.5 0.6 0.5 0.6 Noscapine Inhibitor of carbachol- Antitussive
    stimulated phosphoinositide
    turnover
    0.6 1.0 0.5 0.5 0.5 0.6 0.6 Benperidol Dopamine antagonist, 5-HT Antipsychotic
    antagonist
    0.6 0.9 0.3 0.5 0.6 0.5 0.6 Syrosingopine Catecholamine depletor —
    10.7 0.9 0.5 2.5 1.5 0.5 0.7 Cefaclor Bacterial transpeptidase Antibacterial
    inhibitor
    0.6 0.8 0.5 0.5 0.5 0.5 0.5 Atropine sulfate monohydrate Muscarinic antagonist Anticholinergic
    42.2 1.0 0.6 24.1 10.0 23.6 0.7 Colistin sulfate Performs membrane Antibacterial
    ionophores
    0.7 0.9 0.4 0.5 0.5 0.6 0.7 Eserine sulfate, physostigmine Cholinesterase inhibitor Ophtalmic agent
    sulfate
    0.9 2.3 2.1 0.5 0.6 0.5 0.6 Daunorubicin hydrochloride DNA intercaling Antineoplastic
    0.6 0.9 0.5 0.5 0.6 0.5 0.6 Aconitine Open TTX-Na+ channel Analgesic
    0.6 0.9 0.5 0.5 0.5 0.5 0.5 Dosulepin hydrochloride — Antidepressant
    0.7 1.0 0.3 0.6 1.1 0.4 0.6 Rescinnamin Catecholamine depletor Antihypertensor
    11.5 0.9 0.4 3.2 0.5 7.8 12.9 Ceftazidime pentahydrate Antibacterial
    0.6 0.8 0.4 0.5 0.5 0.4 0.6 Dihydroergotoxine mesylate High affinity GABA A Anticonvulsant
    receptor Cl− channel,
    prolactin inhibitor
    0.5 0.9 0.5 0.5 0.5 0.4 0.6 Iobenguane sulfate — Antineoplastic if radiolabeled
    0.5 0.9 0.5 0.6 0.5 0.5 0.5 Emetine dihydrochloride Protein synthesis inhibitor, Antiamebic
    5-HT ligand
    0.7 1.0 0.5 0.6 0.7 0.6 0.7 Tremorine dihydrochloride Cholinergic Convulsant
    0.6 1.0 0.5 0.5 0.7 0.6 0.7 Androsterone — Antihypertensor
    0.7 0.9 0.6 0.5 0.7 0.6 0.8 Practolol Beta antagonist Antihypertensor
    0.7 1.0 0.7 0.5 0.7 0.7 0.7 Anisomycin Acetylcholine esterase Antiprotozoal
    inhibitor
    2.1 0.9 0.6 1.2 1.8 0.6 4.2 Zidovudine, AZT Transcriptase reverse Antiviral
    inhibitor
    0.6 1.0 0.6 0.5 0.6 0.6 0.7 Carbarsone Antiamebic
    0.7 0.9 0.5 0.5 1.0 0.6 0.7 Sulfisoxazole Inhibitor of folic acid Antibacterial
    biosynthesis, Eta endothelin
    receptor antagonist
    0.2 0.3 0.0 0.2 0.2 0.2 0.5 Apigenin MAP kinase inhibitor Antiproliferative
    0.7 1.0 0.6 0.5 0.6 0.7 0.8 Zaprinast cGMP phosphodiesterase Erectogen
    inhibitor, phosphodiesterase
    5 inhibitor
    0.6 0.9 0.5 0.5 0.6 0.6 0.7 Aspartic acid, N-acetyl (R,S) — —
    0.7 1.0 0.7 0.6 0.7 0.6 0.7 Chlormezanone — Skeletal muscle relaxant
    11.9 1.1 0.5 0.6 1.3 0.6 0.6 Bacampicillin hydrochloride Bacterial transpeptidase Antibacterial
    inhibitor
    0.6 1.0 0.6 0.6 0.7 0.6 0.9 Procainamide hydrochloride Alpha antagonist, Antiarrhythmic
    antinuclear antibodies,
    anticholinergic
    0.6 0.9 0.1 0.5 0.6 0.6 0.7 Betulinic acid Apoptosis inducer, PLA2 Antimalarial
    inhibitor
    0.6 0.9 0.5 0.5 0.6 0.6 0.7 N6-methyladenosine Antimetabolite Anticancer
    0.6 0.9 1.4 0.6 0.8 0.7 0.8 Biotin — Vitamin H
    0.8 1.1 0.6 0.5 0.7 0.7 0.9 Guanfacine hydrochloride Alpha 2A agonist Antihypertensor
    0.6 1.0 0.5 0.6 0.8 0.6 0.9 Bisacodyl Na+ uptake inhibitor Cathartic
    0.6 0.9 0.8 0.6 0.7 0.6 0.8 Domperidone Dopamine Antagonists Antiemetic
    0.8 0.9 0.5 0.7 0.7 0.7 0.7 Calciferol Stimulator of calcium and Vitamin D
    phosphate absorption
    0.9 1.0 0.7 0.8 1.0 0.8 0.8 Metixene hydrochloride Anticholinergic Antiparkinsonian
    0.9 0.9 0.6 0.6 0.8 0.8 0.9 Tetracaine hydrochloride Local anesthesic
    0.7 1.0 0.5 0.2 1.0 0.8 0.8 Nitrofural Bacterial DNA damage Antibacterial
    0.9 1.0 0.4 0.7 0.9 0.6 0.9 Mometasone furoate — Antiinflammatory
    0.7 0.8 0.2 0.6 0.8 0.6 0.8 Omeprazole Non competitive ATPase H+ Antiulcerative
    pump inhibitor
    0.7 1.2 0.5 0.6 0.7 0.7 1.0 Tomatidine Cholinesterase activity Antifungal
    0.7 1.0 0.7 0.6 0.8 0.7 1.1 Propylthiouracil Antimetabolite Antihyperthyroid
    2.0 1.1 0.7 3.8 1.6 0.9 0.8 Dacarbazine Alkylating agent Antineoplastic
    0.9 1.0 0.6 0.7 0.8 0.8 0.9 Terconazole Sterol 14-demethylase Antifungal
    inhibitor
    0.6 0.9 0.7 0.6 0.6 0.8 0.8 Ipratropium bromide Antimuscarinic agent Bronchodilatator
    0.6 0.8 0.5 0.5 0.7 0.6 0.8 Tiaprofenic acid Cyclooxygenase inhibitor Antiinflammatory
    0.8 1.0 0.8 0.6 0.8 0.7 0.8 Acetopromazine maleate salt Dopaminergic antagonist ? Tranquilizer
    1.2 1.5 ### 0.8 1.1 0.9 0.9 Vancomycin hydrochloride Bacterial mucopeptide Antibacterial
    biosynthesis inhibitor
    0.7 1.0 0.7 0.6 0.8 0.6 0.8 Rauwolscine hydrochloride Alpha2 antagonist Antidepressant
    0.5 0.9 0.5 0.6 0.7 0.6 0.7 Artemisinin Oxidant Antimalarial
    0.7 1.0 0.7 0.6 0.6 0.7 0.8 Corynanthine hydrochloride Alpha1-adrenoreceptor Anti-leishmania drug
    antagonist
    1.0 1.0 0.7 0.6 0.7 0.7 0.8 Propafenone hydrochloride Beta adrenergic antagonist Antiarrhythmic
    0.7 1.0 0.8 0.5 0.7 0.7 0.9 Palmatine chloride Anticholinestrase activity Uterine contractant
    0.6 1.0 0.6 0.6 0.9 0.6 0.9 Ethamivan — Respiratory analeptic
    0.8 1.2 0.6 0.7 1.0 0.7 0.8 Trimethylcolchicinic acid Tubuline inhibitor ? Anticancer agent
    1.0 0.9 0.7 0.7 0.8 0.9 0.8 Furosemide Na+ Cl− uptake inhibitor, Diuretic
    carbonic anhydrase inhibitor
    1.9 5.4 2.0 2.5 4.1 6.8 0.9 Suloctidil — Vasodilatator
    0.9 1.0 0.5 0.6 0.9 0.9 0.8 Methapyrilene hydrochloride Histamine H1 antagonist Antihistaminic
    0.8 0.9 0.7 0.6 0.8 0.8 0.8 Carcinine — Anti-oxidant
    0.9 0.8 0.7 0.7 0.7 0.9 0.8 Desipramine hydrochloride Adrenergic transport Antidepressant
    inhibitor, 5-HT transport
    inhibitor
    0.9 0.9 0.7 0.6 0.8 0.9 0.8 Carisoprodol — Muscle relaxant
    0.7 0.7 0.5 0.5 0.6 0.7 0.8 Clorgyline hydrochloride Monoamine oxidase A Antidepressant
    inhibitor
    0.9 0.9 0.6 0.7 0.8 0.8 0.8 Cephalosporanic acid, 7-amino Bacterial transpeptidase Antibacterial
    inhibitor
    0.8 0.9 0.7 0.7 0.8 0.8 0.9 Clenbuterol hydrochloride Beta adrenergic agonist Bronchodilatator
    0.5 0.5 0.0 0.3 0.4 0.4 0.9 Chicago sky blue 6B Competitive glutamate —
    uptake inhibitor
    0.8 0.8 1.1 0.6 0.8 0.9 0.9 Maprotiline hydrochloride Noradrenaline uptake Antidepressant
    inhibitor, 5-HT uptake
    inhibitor
    0.8 0.8 0.6 0.6 0.7 0.8 0.9 Buflomedil hydrochloride — Vasodilatator
    0.8 0.9 0.5 0.7 0.9 0.8 0.9 Thioguanosine Antimetabolite Anticancer
    0.8 0.9 0.5 0.7 0.8 0.7 0.8 Chlorogenic acid Glucose-6-phosphate Antiinflammatory
    translocase inhibitor
    1.0 1.0 0.6 0.8 1.2 0.9 1.0 Chlorprothixene hydrochloride D2 dopamine receptor Neuroleptic
    antagonist, GABAA receptors
    antagonist
    0.8 1.0 0.6 0.7 0.8 0.7 0.9 Roxatidine Acetate HCl Antiulcerative
    0.8 0.9 0.5 0.7 0.8 0.9 0.9 Ritodrine hydrochloride Beta2 agonist Tocolytic
    1.0 0.9 0.7 0.7 0.8 0.9 1.0 Cholecalciferol — Vitamin
    0.9 0.9 0.7 0.8 0.9 1.0 1.0 Clozapine 5-HT antagonist, dopamine Antipsychotic
    antagonist, GABA ligand
    0.9 0.9 0.6 0.7 1.1 0.9 0.9 Cisapride 5-HT antagonist Peristaltic stimulant
    1.0 0.9 0.7 0.8 1.1 0.9 0.8 Vigabatrin GABA transaminase inhibitor Anticonvulsant
    0.9 1.0 0.6 0.8 1.0 0.9 0.9 Hydrastine hydrochloride GABAa antagonist Hypotensor
    1.0 0.9 0.6 0.8 0.8 0.8 0.9 Biperiden hydrochloride Anticholinergic Antiparkinsonian
    1.0 0.9 0.6 0.8 1.0 1.0 1.0 Lobelanidine hydrochloride Nicotinic ligand —
    0.9 0.9 0.7 0.7 1.1 0.9 0.9 Cetirizine dihydrochloride H1 antagonist Antihistaminic
    0.9 1.0 0.6 0.8 0.8 1.0 0.9 Papaverine hydrochloride Phosphodiesterase inhibitor Vasodilator
    1.1 0.9 0.5 0.8 0.9 0.9 1.0 Etifenin Chelating agent Diagnostic agent
    0.8 0.9 0.6 0.8 0.8 0.9 1.0 Yohimbine hydrochloride Alpha antagonist Mydriatic
    1.0 0.9 0.6 0.7 0.9 0.9 1.0 Metaproterenol sulfate, Beta-adrenergic agonist Bronchodilatator
    orciprenaline sulfate
    1.0 0.9 0.8 0.7 0.8 0.9 1.0 Lobeline alpha (−) hydrochoride Nicotinic receptor ligand Respiratory stimulant
    0.8 0.9 0.6 0.6 0.9 0.9 1.0 Sisomicin sulfate Ribosomal protein synthesis Antibacterial
    inhibitor
    1.0 1.0 0.7 0.7 0.9 0.9 1.1 Berberine chloride Anti-HIV reverse Antibacterial
    transcriptase, cholinesterase
    inhibitor
    0.7 0.8 0.1 0.6 0.4 0.6 0.9 Quercetine dihydrate Lipoxygenase inhibitor Antimalarial
    0.9 0.9 0.8 0.7 0.9 0.9 0.9 Cilostazol Antithrombotic
    0.0 0.0 0.0 0.0 0.0 0.0 0.1 Resveratrol Antiinflammatory
    0.9 0.9 0.8 0.8 0.8 0.8 1.0 Galanthamine hydrobromide Cholinesterase inhibitor, Alzheimer treatment
    nicotinic receptor agonist
    0.8 0.9 0.7 0.7 1.0 1.1 1.1 Bromperidol Dopamine antagonist Antipsychotic
    0.8 0.9 0.6 0.8 0.8 0.9 0.9 Bicuculline (+) GABAa receptor antagonist Convulsant
    0.9 1.0 0.9 0.8 1.0 0.9 0.9 Cyclizine hydrochloride H1 antagonist Antiemetic
    0.9 0.9 0.7 0.7 0.8 0.9 0.9 Yohimbinic acid monohydrate — —
    0.9 0.9 0.7 0.6 0.8 0.8 1.0 Chlorthalidone Na+ uptake inhibitor, Diuretic
    carbonic anhydrase inhibitor
    0.9 0.9 0.4 0.6 0.8 0.8 1.1 Coralyne chloride hydrate Topoisomerase I inhibitor Anti-leukemic
    0.8 0.8 0.1 0.8 0.7 0.6 1.1 Dobutamine hydrochloride Beta1, Beta2 agonist Bronchodilatator
    0.9 0.9 0.6 0.7 0.9 0.8 1.2 Corticosterone — Glucocorticoid
    0.9 0.9 0.6 0.6 0.7 0.8 1.2 Moclobemide Mono amine oxidase Antidepressant
    inhibitor (Type A)
    0.8 0.8 0.5 0.6 0.8 0.7 1.2 Cyanocobalamin — Vitamin
    0.8 0.9 0.7 0.7 0.8 0.8 1.0 Clopamide Gonad stimuling agent Antihypertensor
    0.9 0.8 0.5 0.8 0.9 0.8 1.2 Cefadroxil Bacterial transpeptidase Antibacterial
    inhibitor
    0.9 1.2 0.8 0.7 0.8 0.8 1.1 Hycanthone DNA intercaling agent Anthelmintic
    0.9 0.9 0.6 0.7 0.9 0.8 1.4 Cyclosporin A IL 2 synthesis inhibitor, Immunosuppressant
    calcineurine phosphatase
    inhibitor
    0.8 0.8 0.6 0.6 0.7 0.8 1.2 Adenosine 5′-monophosphate Ca++ channel block, Nutrient
    monohydrate adenosine receptor
    activation, activation of
    outward K+ current
    0.9 0.9 0.6 0.7 0.8 0.8 1.2 Digitoxigenin Na+ K+ ATPase inhibitor Cardiotonic
    10.6 1.4 0.4 0.7 1.7 0.7 1.0 Amoxicillin Bacterial transpeptidase Antibacterial
    inhibitor
    0.8 0.9 0.8 0.7 0.9 0.8 1.2 Digoxin Na+ K+ ATPase inhibitor Cardiotonic
    0.8 0.9 0.7 0.7 0.9 0.8 1.4 Cephalexin monohydrate Bacterial transpeptidase Antibacterial
    inhibitor
    1.0 1.7 0.9 0.7 1.0 0.6 1.2 Doxorubicin hydrochloride DNA intercalant Antibacterial
    0.8 0.9 0.7 0.7 0.8 0.8 1.1 Dextromethorphan hydrobromide Opioid ligand Antitussive
    monohydrate
    0.8 0.9 0.6 0.7 0.8 0.7 1.2 Carbimazole Iodine oxidazing inhibitor Antityroidic hormone
    0.9 1.0 0.9 0.7 1.0 0.7 1.2 Droperidol Alpha adrenergic antagonist, Antipsychotic
    5-HT antagonist, dopamine
    antagonist
    0.9 1.0 0.6 0.7 0.8 0.8 1.1 Epiandrosterone — Anabolic steroid
    1.0 0.9 1.1 0.8 1.0 0.9 1.1 Fluoxetine hydrochloride 5-HT uptake inhibitor Antidepressant
    1.0 0.9 0.7 0.7 0.9 0.9 1.3 Laudanosine (R,S) — Convulsant
    1.0 0.9 0.7 0.7 0.9 0.8 1.1 Iohexol — Diagnostic aid
    0.9 0.9 0.5 0.7 0.9 0.9 1.2 Ajmalicine hydrochloride Alpha antagonist Antihypertensor
    6.3 0.8 0.6 0.9 1.1 1.0 1.3 Norcyclobenzaprine — Antiulcerative
    0.9 0.9 0.8 0.7 0.9 0.8 1.2 Trigonelline Antihyperglycaemic agent
    0.9 0.8 0.7 0.8 0.9 0.8 1.2 Pyrazinamide — Antibacterial
    0.9 0.9 0.8 0.7 0.8 0.9 1.2 Diclofenac sodium Cyclooxygenase inhibitor Antiinflammatory
    1.0 0.9 0.7 0.7 0.9 0.8 1.4 Trimethadione Ca++ channel blocker Anticonvulsant
    voltage dependant ?
    0.9 0.8 0.6 0.7 0.8 0.8 1.2 Calycanthine Calcium channel blocker
    1.0 1.0 0.3 0.8 1.0 0.8 1.2 Lovastatin HMG CoA reductase Antihypercholesterolemic
    inhibitor
    1.1 0.9 0.6 0.7 1.0 0.8 1.3 Convolamine hydrochloride Cholinergic ligand Vasodilatator
    1.0 0.8 0.7 0.8 0.9 0.8 1.4 Nystatins Performs membrane Antifungal
    ionophores
    0.9 0.9 0.7 0.7 0.9 0.8 1.3 Isocorydine (+) Ganglioblocker Hypotensor
    0.9 0.9 0.6 0.7 0.9 0.9 1.4 Budesonide — Antiinflammatory
    0.8 0.9 0.8 0.7 0.9 0.9 1.4 Xylazine Alpha-2 adrenergic agonist Antinociceptive
    12.1 0.9 2.5 1.7 1.2 1.0 2.4 Imipenem Bacterial transpeptidase Antibacterial
    inhibitor
    0.9 0.9 0.8 0.7 0.8 0.8 1.2 Seneciphylline — Antitumor activity
    0.8 0.9 0.8 0.7 1.1 0.8 1.1 Sulfasalazine 15-hydroxydehydrogenase Treatment of ulcerative colitis
    inhibitor
    0.9 0.9 0.8 0.7 0.8 0.9 1.2 Boldine Smooth muscle relaxant Choleretic
    1.3 1.1 1.2 0.9 1.0 1.2 1.2 Bambuterol hydrochloride Beta2 adrenergic receptor Bronchodilatator
    agonist
    1.1 0.9 0.8 0.8 0.8 1.0 1.3 Estradiol-17 beta — Estrogen
    1.1 1.1 1.1 0.9 0.9 1.1 1.3 Betamethasone — Glucocorticoid
    0.8 1.1 0.9 0.9 0.9 1.1 1.2 Fusaric acid Dopamine beta hydroxylase Antibacterial
    inhibitor
    1.2 1.0 1.0 0.9 1.0 1.0 1.1 Colchicine Tubulin polymerisation Antiinflammatory
    inhibitor
    1.0 1.1 1.1 0.8 1.1 1.0 1.3 Gabazine Antagonist GABA
    1.2 1.0 1.1 1.0 1.3 1.1 1.3 Metergoline 5-HT1 antagonist, D2 Antiprolactin
    agonist, 5-HT2 antagonist
    1.3 1.0 1.1 1.0 1.0 1.1 1.2 Ginkgolide A Cholinergic antagonist Alzheimer treatment
    1.1 1.4 1.0 0.9 1.1 1.1 1.5 Brinzolamide Carbonic anhydrase inhibitor Antiglaucoma drug
    1.3 1.0 1.0 0.9 1.2 1.1 1.2 Cyclobenzaprine hydrochloride — Muscle relaxant
    1.0 1.0 1.0 1.0 1.2 1.2 1.5 Ambroxol hydrochloride — Expectorant
    1.2 1.0 1.1 0.8 1.0 1.1 1.1 Carteolol hydrochloride Antihypertensor
    1.4 0.9 1.2 1.1 1.0 1.1 1.4 Benfluorex hydrochloride Increase of glucose Hypolipedimic
    penetration and use by cells,
    decrease of triglyceride
    intestinal absorption
    1.1 1.0 1.3 0.9 1.3 1.1 1.4 Hydrocortisone base — Glucocorticoid
    1.3 1.1 1.6 1.0 1.5 1.2 1.4 Bepridil hydrochloride Ca++ channel blocker Antianginal
    1.3 1.0 3.0 1.0 1.0 1.0 1.3 Hydroxytacrine maleate (R,S) Acetylcholine esterase
    inhibitor
    1.0 0.9 2.0 0.8 0.9 0.9 1.2 Meloxicam Cyclooxygenase inhibitor Anti-inflammatory
    1.0 1.1 1.3 0.9 1.0 1.0 1.5 Pilocarpine nitrate Cholinergic Antiglaucoma drug
    1.1 1.2 0.4 0.9 1.4 1.5 1.4 Benzbromarone Uric acid transport inhibitor Coronarodilatator
    1.2 1.0 7.1 0.9 1.5 1.4 1.2 Dicloxacillin sodium salt Bacterial transpeptidase Antibacterial
    inhibitor
    1.1 1.1 1.2 1.0 1.1 1.1 1.4 Glycocholic acid Detergent Anticholelithogenic
    1.2 1.0 1.0 1.0 1.3 1.1 1.6 Scoulerine Dopamine antagonist, Antiemetic
    alpha1 antagonist
    1.3 1.0 0.4 1.0 1.1 0.9 1.4 Thiostrepton Antibacterial
    1.2 1.1 1.0 0.9 1.1 1.1 1.6 Ajmaline Inhibitor of glucose uptake Antihypertensor
    by heart tissue
    1.3 1.0 1.1 0.9 1.0 1.2 1.5 Methionine sulfoximine (L) Glutamine synthetase —
    inhibitor
    1.3 1.1 1.0 1.0 1.2 1.2 1.3 Monocrotaline — For inducing pulmonary
    diseases in rats
    0.6 0.5 0.6 0.4 0.5 0.6 1.3 Tiabendazole Microtubule inhibitor Anthelmintic
    1.2 1.0 1.0 1.0 1.0 1.1 1.6 Piperlongumine — Antifungal
    1.3 0.8 0.8 0.7 3.0 0.6 1.4 Rifampicin RNA polymerase inhibitor Antibacterial
    1.2 1.0 1.0 0.9 1.3 1.2 1.4 Hydrocotarnine hydrobromide — Hemostatic
    1.1 1.0 1.3 1.0 1.2 1.1 1.4 Ethionamide Antibacterial
    1.3 1.0 0.9 0.8 1.1 1.1 1.6 (−)-Cinchonidine Antimalarial
    1.3 1.0 1.2 0.9 1.0 1.1 1.6 Tenoxicam Cyclooxygenase inhibitor Antiinflammatory
    1.2 1.1 1.0 1.0 1.1 1.3 1.4 Eburnamonine (−) — Cerebral vasodilatator
    1.2 1.0 1.4 0.9 1.0 1.2 1.3 Triflusal Cyclooxygenase inhibitor Antithrombotic
    1.2 1.1 1.6 1.0 1.1 1.1 1.5 Cinchonine Heme polymerase inhibitor Antimalarial
    1.1 1.1 1.3 1.0 1.0 1.2 1.3 Mesoridazine besylate D antagonist Antipsychotic
    1.2 1.1 1.6 0.9 1.1 1.1 1.4 Canavanine sulfate monohydrate Nitric oxide inductible Anticancer agent
    (L,+) synthetase inhibitor
    1.1 1.1 1.6 1.1 1.1 1.1 1.6 Trolox — Vitamin E analog
    1.1 1.0 1.4 0.9 1.0 1.0 1.3 Harmaline hydrochloride Monoamine oxydase Antihelminthic
    dihydrate inhibitor
    1.3 1.0 1.1 0.9 1.1 1.1 1.7 Ketotifen fumarate H1 antagonist Antihistaminic
    1.0 1.0 1.0 0.9 1.1 1.1 1.4 Alizapride HCl Antiemetic
    1.2 1.0 0.9 0.8 0.9 1.0 1.7 Debrisoquin sulfate Catecholamine depletor Antihypertensor
    1.0 1.0 0.8 0.9 1.1 1.0 1.2 Lactobionic acid — Antithrombonic
    1.1 0.9 1.0 0.8 0.9 1.1 1.3 Amethopterin (R,S) Dehydrofolate reductase Antineoplastic
    inhibitor
    1.1 1.0 0.9 1.0 1.2 1.1 1.4 Lumicolchicine gamma Microtubule —
    depolymerizating agent
    1.0 0.9 0.8 1.0 0.9 0.9 1.6 Methylergometrine maleate 5-HT antagonist, alpha Oxytocic
    adrenergic agonist
    1.1 0.9 0.9 0.8 1.0 1.1 1.6 Lysergol 5-HT antagonist Antipsychotic
    1.4 1.0 1.3 1.3 1.5 1.1 1.8 Methiothepin maleate 5-HT autoreceptor —
    antagonist, 5-HT1c
    antagonist, 5-HT release
    inhibitor electrical or K+
    induced
    1.1 1.0 0.9 0.8 0.9 1.1 1.5 Mebhydroline 1,5- H1 antagonist Antihistaminic
    naphtalenedisulfonate
    1.2 1.0 4.6 1.1 5.0 1.0 1.8 Clofazimine — Antileprosy
    0.8 1.0 4.3 0.3 3.2 0.5 2.1 Meclocycline sulfosalicylate Ribosomal protein synthesis Antibacterial
    inhibitor
    1.0 1.0 0.9 1.0 1.0 1.1 1.4 Nafronyl oxalate Phosphodiesterase inhibitor Vasodilatator
    ?, 5-HT antagonist,
    bradykinine antagonist
    1.2 1.2 2.1 0.9 1.9 1.2 1.4 Meclozine dihydrochloride Histamine antagonist Antiemetic
    0.9 0.8 1.1 0.7 0.8 1.0 1.5 Bezafibrate Lipoprotein lipase activator Antihyperlipoproteinemic
    0.9 1.0 1.3 0.8 1.2 1.1 1.4 Melatonin Melatonin receptor ligand Immunostimulant
    1.0 1.0 1.4 0.9 0.9 1.1 1.5 Mimosine Cell cycle blocker, apoptosis Anticancer agent
    inducer
    1.0 1.1 1.4 1.0 1.0 1.2 1.5 Menadione — Vitamin K3
    1.0 1.1 1.2 1.0 1.0 0.9 1.6 Clebopride maleate — Spasmolytic
    1.0 1.0 1.4 1.0 1.2 1.0 1.1 Dinoprost trometamol Protaglandin agonist Smooth muscle activator
    1.1 1.1 1.1 1.0 1.2 1.2 1.5 Pirenperone 5-HT2 antagonist
    1.2 1.0 0.8 0.8 1.1 1.2 1.6 Harmalol hydrochloride dihydrate — Vasorelaxant
    1.3 0.9 1.0 1.0 1.0 1.2 1.5 Isoquinoline, 6,7-dimethoxy-1- — —
    methyl-1,2,3,4-tetrahydro,
    hydrochloride
    1.4 1.0 0.9 0.9 1.1 1.1 1.6 Harmol hydrochloride Liver conjugation probe Anxiolytic
    monohydrate
    1.2 0.9 0.8 0.9 1.1 0.9 1.4 Phenacetin Cyclooxygenase inhibitor Analgesic
    1.1 1.1 0.9 0.7 1.0 1.2 1.5 Harmine hydrochloride Topoisomerase II inhibitor Antibacterial
    1.1 1.0 1.2 0.8 1.2 1.0 1.4 Atovaquone Antipneumocystic
    1.3 1.3 0.8 1.0 4.1 1.2 1.8 Ellipticine Intercaling agent Anticancer
    1.1 1.0 0.9 1.0 1.0 1.2 1.4 Methoxamine hydrochloride Alpha adrenergic agonist Antihypotensive
    1.1 0.9 0.1 0.8 0.8 1.0 1.4 Chrysene-1,4-quinone — —
    1.2 1.0 1.2 0.9 1.1 1.1 1.7 (S)-(−)-Atenolol Blokage of the action of Antihypertensor
    adrenergic mediators on
    beta receptors
    1.4 1.0 0.8 1.0 1.1 1.3 2.0 Demecarium bromide Cholinergic (ophtalmic)
    1.1 0.9 1.0 1.0 0.9 1.1 1.4 Piracetam — Nootropic drug
    1.1 1.0 1.0 0.8 1.0 1.2 1.3 Quipazine dimaleate salt 5-HT agonist, 5-HT3 ligand
    1.2 0.9 1.1 1.1 1.1 0.9 1.3 Phenindione Antivitamin K Anticoagulant
    1.3 1.0 1.1 1.0 1.0 1.0 1.7 Sparteine (−) Ganglioplegic Antiarrhythmic
    1.0 1.1 1.2 0.8 0.9 1.0 1.7 Thiocolchicoside GABA agonist ? Muscle relaxant
    1.1 1.1 1.1 1.0 0.9 1.0 1.4 Diflorasone Diacetate Anti-inflammatory (topical)
    1.0 1.4 1.5 1.0 1.0 1.1 1.7 Clorsulon Anthelmintic
    1.1 1.0 1.3 0.6 1.0 0.9 1.4 Harmane hydrochloride Imidazoline receptors ligand Vasorelaxant
    1.4 1.0 1.4 1.1 2.9 1.3 1.4 Lidoflazine Ca++ channel activator Coronary vasodilatator
    1.1 1.0 0.9 0.8 1.3 1.1 1.3 Tropisetron HCl 5 HT3 antagonist Antiemetic
    1.2 0.9 0.9 1.0 1.4 1.1 1.6 Betaxolol hydrochloride Beta adrenergic antagonist Antihypertensor
    18.6 1.1 1.2 4.6 1.8 11.7 21.9 Cefixime Antibacterial
    1.2 1.1 0.6 1.0 1.3 1.1 1.4 Nicardipine hydrochloride Ca2+ channel antagonist Antihypertensor
    1.2 1.0 1.2 1.0 1.3 1.2 1.3 Metrizamide — Contrasting product
    1.1 0.9 0.6 0.9 1.4 1.1 1.3 Probucol — Antihyperlipoproteinemic
    1.1 1.0 1.0 1.0 1.5 1.1 1.4 Muramic acid, N-acetyl Constituent of bacterial
    peptidoglycan
    1.5 0.8 0.7 1.0 1.5 0.9 1.2 Mitoxantrone dihydrochloride DNA topoisomerase II Antineoplastic
    inhibitor
    0.9 0.8 0.5 0.9 0.8 0.9 1.2 Myricetin Neutral endopeptidase —
    inhibitor
    1.4 1.3 1.5 1.0 2.2 1.2 1.5 GBR 12909 dihydrochloride Dopamine reuptake inhibitor Antidepressant
    1.1 0.9 0.5 0.9 1.2 1.0 1.5 Naringenine Antiestrogenic
    1.4 1.0 1.1 1.0 1.4 1.2 1.4 Carbetapentane citrate Sigma1 receptor ligand Antitussive
    1.3 1.0 1.2 0.9 1.2 1.3 1.2 Naringin hydrate — Anti-oxidant
    3.0 1.1 1.2 1.6 3.2 2.3 1.8 Dequalinium dichloride Blocker of the apamin- Antibacterial
    sensitive small conductance
    Ca2+ activated K+ channel,
    detergent
    1.3 1.0 1.2 1.0 1.3 1.1 1.2 Neostigmine bromide Cholinesterase inhibitor Spinal analgesic
    1.3 0.9 1.2 1.2 1.5 1.1 1.5 Ketoconazole Cytochrome P450c17 Antifungal
    inhibitor, sterol 14-
    demethylase inhibitor
    13.2 1.0 1.8 6.0 1.4 1.2 6.1 Niridazole Helminthic DNA damage Anthelmintic
    1.1 1.1 4.2 1.1 1.3 1.1 1.4 Fusidic acid sodium salt Protein synthesis inhibitor Antibacterial
    GTPase coupled
    12.2 1.0 1.8 3.1 1.8 1.2 1.9 Ceforanide Antibacterial
    1.1 1.6 0.7 0.9 1.2 1.0 1.2 Ciclopirox ethanolamine Cell membrane proteins Antifungal
    synthesis inhibitor
    1.4 1.0 0.8 1.0 1.3 1.2 1.4 Methoxy-6-harmalan Benzodiazepine receptor Psoriasis treatment
    ligand
    1.4 1.0 1.0 1.1 1.3 1.2 1.4 Probenecid Uric acid uptake inhibitor Uricosuric
    1.4 1.0 1.0 1.1 1.4 1.2 1.5 Stachydrine hydrochloride Potent inhibitor of
    tyrosinase
    1.4 0.9 0.9 1.1 1.2 1.1 1.3 Betahistine mesylate H1 agonist, H3 antagonist Vasodilatator
    1.4 1.0 1.3 1.1 1.4 1.2 1.7 Pyridoxine hydrochloride — Vitamin
    7.5 0.9 1.1 2.0 5.7 17.1 1.5 Tobramycin Ribosomal protein synthesis Antibacterial
    inhibitor
    1.3 1.0 1.0 1.2 1.4 1.2 1.5 Cytisine (−) Partial nicotinic receptor Antiinflammatory
    antagonist
    1.3 1.0 1.1 1.1 1.4 1.2 1.4 Tetramisole hydrochloride Alkaline phosphatase Antihelminthic
    inhibitor
    1.4 0.9 1.0 1.2 1.2 1.1 1.5 Pseudopelletierine hydrochloride — —
    1.4 1.1 1.1 1.1 1.3 1.1 1.5 Pregnenolone Estrogen
    1.2 1.0 1.9 1.1 1.3 1.2 1.5 Racecadotril Enkephalinase inhibitor Antidiarrhoeic
    1.4 0.9 0.9 1.0 1.2 1.1 1.5 Molsidomine NO° production ? Vasodilatator
    1.3 1.1 1.0 1.0 1.3 1.1 1.3 Folic acid — Vitamin Bc or M
    1.2 0.9 1.1 1.1 1.3 1.1 1.6 Chloroquine diphosphate Heme polymerase inhibitor Antipaludic
    1.2 1.0 1.1 1.2 1.2 1.1 1.5 Salsolinol hydrobromide Dopamine analog —
    1.4 1.0 1.2 1.1 1.2 1.1 1.7 Trimetazidine dihydrochloride — Antianoxic
    1.2 1.0 1.3 1.0 1.3 1.1 1.5 Gramine Cholinesterase inhibitor Antibacterial
    1.5 1.0 1.3 1.1 1.3 1.2 1.4 Parthenolide MAP kinase inhibitor Antiinflammatory
    1.3 1.0 1.3 1.2 1.5 1.2 1.5 Dimethisoquin hydrochloride Local anesthesic
    1.2 1.0 1.1 1.3 1.1 1.1 1.4 Terbutaline hemisulfate Beta-2 adrenergic agonist Bronchodilatator
    1.2 1.0 1.1 0.9 1.2 1.1 1.7 Strophantine octahydrate Na+ K+ ion dependant Cardiotonic
    ATPase inhibitor
    1.3 1.0 1.0 1.0 1.2 1.0 1.4 Ketanserin tartrate hydrate 5-HT1, 5-HT2, 5-HT2A Antihypertensor
    antagonist
    1.1 1.1 1.1 1.0 1.1 1.0 1.4 Pantothenic acid calcium salt — Nutritional factor
    monohydrate
    1.1 0.9 1.0 1.0 1.2 0.9 2.0 Hemicholinium bromide Acetylcholine stores —
    depleter, acetylcholine
    uptake inhibitor
    22.1 1.2 2.5 8.4 2.0 1.2 25.3 Cefotetan Antibacterial
    1.2 0.9 2.5 1.0 1.1 1.0 1.9 Kanamycin A sulfate Ribosomal protein synthesis Antibacterial
    inhibitor
    0.4 0.3 0.2 0.3 0.4 0.4 1.6 Piperine Enzyme inhibitor Antidiarrhoeic
    22.1 1.0 1.3 6.2 7.6 14.2 4.9 Amikacin hydrate Ribosomal protein synthesis Antibacterial
    inhibitor
    1.4 1.0 1.1 1.1 1.2 1.1 2.0 Brompheniramine maleate H1 Antagonist, Antihistaminic
    anticholinergic
    1.2 1.1 1.4 1.0 1.2 1.0 1.4 Etoposide Topoisomerase II inhibitor, Antineoplastic
    kinase inhibitor
    1.2 0.9 2.1 1.0 1.1 1.0 1.4 Primaquine diphosphate Heme polymerase inhibitor Antimalarial
    1.8 4.4 2.0 1.6 5.4 1.4 1.9 Clomiphene citrate (Z,E) Antioestrogen, gonad- Ovulation inductor
    stimulating agent
    1.0 1.1 1.1 1.1 1.1 1.0 1.7 Progesterone — Progestogen
    1.1 1.0 1.3 1.0 1.1 1.0 1.8 Oxantel pamoate Fumarate reductase Anthelmintic
    inhibitor, neuromuscular
    depolarizing agent
    1.2 1.3 2.5 1.0 3.0 1.0 1.7 Felodipine L-type Ca2+ channels blocker Antihypertensor
    1.2 1.1 1.1 1.2 1.6 1.2 2.0 Prochlorperazine dimaleate Dopamine antagonist Antiemetic
    1.1 1.1 1.0 0.9 1.0 1.0 1.5 Methoxy-8-psoralen Apoptosis inducer with UV Psoriasis treatment
    1.1 1.1 1.3 1.0 1.2 1.0 1.4 Hesperidin — Anticancer
    1.1 1.1 1.1 1.1 1.6 1.0 1.4 Puromycin dihydrochloride Antimetabolite Antiprotozoal
    1.5 1.1 1.2 1.4 3.0 1.1 1.6 Hexetidine Detergent Antifungal
    1.4 1.0 1.1 1.4 1.3 1.3 1.3 Thiamine hydrochloride — Vitamin
    1.3 1.0 1.1 1.2 1.1 1.2 1.6 Selegiline hydrochloride Monoamine B oxydase Antiparkinsonian
    inhibitor
    1.4 1.0 1.2 1.3 1.4 1.3 1.6 Dipivefrin hydrochloride Antiglaucoma drug
    1.4 1.4 1.9 1.2 1.2 1.2 1.4 Pentamidine isethionate — Antiparasitic
    1.2 1.0 1.3 1.3 1.2 1.2 1.5 Thiorphan Neutral endopeptidase Antinociceptive
    inhibitor
    1.5 1.0 1.0 1.4 1.2 1.4 1.6 Tolazamide ATP-sensitive K+ ion Antidiabetic
    channels blocker
    1.1 1.0 0.9 1.6 1.2 1.2 1.5 Riboflavine — Vitamin
    1.2 1.0 0.7 1.8 1.1 1.2 1.5 Nifuroxazide Bacterial DNA damage Antibacterial
    1.2 1.1 1.0 1.3 1.2 1.2 1.6 Hydroquinine hydrobromide — Preventor of muscular cramp
    hydrate
    1.2 1.1 1.1 1.5 1.2 1.2 1.3 Mycophenolic acid Inosine monophosphate Antineoplastic
    dehydrogenase inhibitor
    1.3 1.0 1.0 1.2 1.2 1.2 1.6 Epivincamine Antiaggregant
    1.1 1.2 2.1 1.2 1.8 0.9 1.5 Dirithromycin Ribosomal protein synthesis Antibacterial
    inhibitor
    1.3 1.0 1.2 1.2 1.2 1.2 1.5 Retrorsine — Antineoplastic
    1.2 1.0 1.0 1.2 1.3 1.2 1.8 Gliclazide K+ channel voltage Antidiabetic
    dependant inhibitor
    1.5 1.1 1.2 1.2 1.4 1.2 1.6 Conessine Antiamebic
    1.4 1.0 1.1 1.3 1.2 1.3 1.7 DO 897/99 D3 antagonist —
    1.1 1.0 1.2 1.2 1.2 1.1 1.3 Protoveratrine A Acetylcholinesterase release Antihypertensor
    stimulant
    1.6 1.2 1.6 1.3 1.9 1.3 1.6 Prenylamine lactate Ca++ channel activator Vasodilatator
    1.2 1.0 1.2 1.2 1.3 1.2 1.7 Solanine alpha Butyrylcholinesterase Antifungal
    inhibitor
    0.3 0.9 0.4 0.5 0.3 0.3 0.3 Sulmazole Phosphodiesterase III Cardiotonic
    inhibitor
    0.4 1.0 0.4 0.4 0.4 0.4 0.3 Althiazide Na+ Cl− transport inhibitor Diuretic
    0.4 0.9 0.3 0.4 0.3 0.3 0.3 Epicatechin-(−) — Antidiarrhoeic
    0.4 0.8 0.4 0.4 0.3 0.4 0.3 Isopyrin hydrochloride Cyclooxygenase inhibitor Antipyretic
    0.5 0.9 0.4 0.5 0.4 0.3 0.3 Flunisolide — Glucocorticoid
    0.5 1.0 0.6 0.5 0.8 0.4 0.3 Phenethicillin potassium salt Bacterial transpeptidase Antibacterial
    inhibitor
    0.5 0.8 0.4 0.4 0.4 0.3 0.7 N-Acetyl-DL-homocysteine Disulfure bridge breaker Expectorant
    Thiolactone
    0.5 0.9 0.4 0.5 0.7 0.3 0.3 Sulfamethoxypyridazine Inhibitor of folic acid Antibacterial
    synthesis
    0.5 0.8 0.4 0.5 0.5 0.4 0.3 Flurandrenolide Glucocorticoid
    0.4 0.9 0.4 0.5 0.4 0.4 0.4 Deferoxamine mesylate Iron chelating agent
    0.5 0.9 0.4 0.5 0.4 0.4 0.4 Helveticoside Inhibitor of membrane ATP Cardiotonic
    0.5 0.8 0.4 0.5 0.4 0.4 0.4 Mephentermine hemisulfate Alpha-adrenergic receptor Antihypotensive
    agonist
    0.5 0.9 0.4 0.5 0.5 0.4 0.4 Myosmine Cholinergic —
    0.4 0.7 0.2 0.5 0.5 0.4 0.4 Ergocryptine-alpha Vasoconstrictor
    0.4 0.9 0.4 0.6 0.4 0.4 0.4 Betonicine — —
    0.6 0.9 0.5 0.5 0.9 0.4 0.4 Sulfadimethoxine Inhibitor of folic acid Antibacterial
    biosynthesis
    0.5 0.8 0.4 0.5 0.5 0.4 0.4 Etanidazole DNA damage Antineoplastic adjunct
    (radiosensitizer)
    0.5 0.9 0.4 0.6 1.5 0.5 0.4 Sulfanilamide Inhibitor of folic acid Antibacterial
    biosynthesis
    0.5 0.8 0.5 0.5 0.5 0.5 0.4 Butirosin disulfate salt Ribosomal protein synthesis Antibacterial
    inhibitor
    0.5 0.9 0.4 0.7 0.5 0.5 0.4 Balsalazide Sodium Anti-inflammatory
    0.7 0.8 0.6 0.6 0.7 0.6 0.7 Carbinoxamine maleate salt Histamine antagonist Antihistaminic
    0.7 0.9 0.6 0.5 0.6 0.6 0.7 Niacin Antihyperlipoproteine-mic
    0.5 1.5 0.6 0.5 0.5 0.6 0.7 Methazolamide Anhydrase carbonic inhibitor Diuretic
    0.6 0.9 0.7 0.6 0.7 0.6 0.6 Bemegride Respiratory stimulant
    0.7 0.8 0.6 0.6 0.5 0.6 0.7 Pyrithyldione — Sedative
    0.7 0.8 0.6 0.6 0.6 0.5 0.7 Digoxigenin Mainly used as a non- Diagnosis
    isotopic label for DNA
    0.6 1.0 0.6 0.2 0.5 0.5 0.6 Spectinomycin dihydrochloride Ribosomal protein synthesis Antibacterial
    inhibitor
    0.5 0.8 0.5 0.7 0.5 0.5 0.6 Meglumine Expectorant
    0.6 0.9 0.7 0.6 0.5 0.5 0.6 Piromidic acid Topoisomerase II inhibitor Antibacterial
    0.6 0.8 0.5 0.6 0.5 0.5 0.6 Cantharidin Aphrodisiac
    0.6 0.9 0.5 0.6 0.6 0.6 0.6 Trimipramine maleate salt noradrednaline and 5-HT
    uptake inhibitor, alpha
    antagonist, anticholinergic,
    Dopamine and Histamine
    antagonist
    0.5 0.9 0.2 0.6 1.1 0.4 0.5 Clioquinol Anti-infective
    0.7 0.9 0.5 0.6 0.6 0.5 0.6 Chloropyramine hydrochloride H1 antagonist Antihistaminic
    0.5 0.7 0.4 0.4 0.4 0.5 0.6 Oxybenzone Ultraviolet screen
    0.8 0.9 0.8 3.2 0.4 0.6 0.6 Furazolidone Monoamine oxidase Antiinfective
    inhibitor and protozoal DNA
    damage
    0.6 0.8 0.5 0.5 0.6 0.6 0.5 Promethazine hydrochloride Antihistaminic
    0.6 1.1 0.5 0.5 0.5 0.5 0.5 Dichlorphenamide Carbonic anhydrase inhibitor
    0.2 0.3 0.2 0.2 0.2 0.1 0.6 Chrysin 5-lipoxygenase inhibitor Antifungal
    0.8 3.5 0.7 0.9 2.6 0.5 0.6 Sulconazole nitrate Ergosterol synthesis Antifungal
    inhibition
    0.5 0.9 0.5 0.5 0.6 0.5 0.5 Proxyphylline Vasodilator
    0.5 1.4 0.5 0.7 0.7 0.7 0.9 Glimepiride Antidiabetic
    0.6 0.9 0.7 0.6 1.0 0.6 0.8 Sulfaquinoxaline sodium salt Inhibitor of folic acid Antibacterial
    synthesis
    0.6 1.0 0.6 0.6 0.7 0.6 0.7 Picrotoxinin GABA channel blocker Analeptic
    0.7 2.6 1.2 1.4 0.7 0.7 0.7 Streptozotocin Antineoplastic
    0.6 1.0 0.6 0.6 0.7 0.6 0.7 Mepenzolate bromide Anticholinergic and
    muscarinic antagonist
    0.6 0.9 0.6 0.5 0.7 0.7 7.0 Metoprolol-(+,−) (+)-tartrate salt Beta adrenergic antagonist
    0.7 0.9 0.5 0.6 0.7 0.6 0.8 Benfotiamine Vitamin
    0.6 0.9 0.6 0.6 0.7 0.7 0.8 Flumethasone Antiinflammatory
    0.6 0.9 0.6 0.5 0.7 0.7 0.8 Halcinonide Antiinflammatory
    0.6 0.9 0.7 0.6 0.8 0.6 0.7 Flecainide acetate Antiarrhythmic
    0.6 0.9 0.7 0.6 0.8 0.6 1.0 Lanatoside C Na+ K+ ATPase inhibitor Cardiotonic
    16.5 0.9 3.1 3.6 0.5 0.7 0.9 Cefazolin sodium salt Bacterial transpeptidase Antibacterial
    inhibitor
    0.6 1.1 0.7 0.6 0.6 0.6 0.7 Benzamil hydrochloride Na+ channel blocker and
    blocker of Na+/Ca++
    exchanger
    0.7 0.9 0.7 0.6 0.8 0.6 0.8 Atractyloside potassium salt Nucleotide transport Anticancer
    inhibitor
    0.6 0.9 0.6 0.6 0.8 0.6 0.8 Suxibuzone — Antiinflammatory
    0.7 1.0 0.7 0.6 0.7 0.6 0.7 Folinic acid calcium salt — Antianemic
    0.7 0.9 0.6 0.5 0.7 0.7 0.9 6-Furfurylaminopurine — Plant growth accelerator
    0.7 1.0 0.6 0.8 0.8 0.7 0.7 Levonordefrin Adrenergic receptor agonist Vasoconstrictor
    0.8 1.2 1.7 0.6 0.8 0.6 0.9 Avermectin B1 Ligand GABA receptors Antihelmetic
    0.6 0.9 0.5 0.6 0.7 0.6 0.7 Ebselen Cyclooxygenase inhibitor Antiinflammatory
    0.7 0.9 0.9 0.8 0.9 0.8 1.1 Bergenin monohydrate — Antiarrhythmic
    0.7 0.9 0.6 0.6 0.8 0.8 1.1 3-Acetylcoumarin
    0.7 0.9 0.7 0.7 0.9 0.8 1.0 Cromolyn disodium salt — Antiasthmatic
    0.7 0.9 0.7 0.6 0.8 0.8 0.9 Esculin Hydrate Skin protectant
    0.7 0.9 0.7 0.6 0.8 0.8 0.9 Bucladesine sodium salt Adenylate cyclase modulator Cardiotonic
    0.7 0.9 0.6 0.6 0.8 0.7 1.0 Felbinac Analgesic
    0.9 0.9 1.0 0.7 1.1 8.6 0.9 Cefsulodin sodium salt Bacterial transpeptidase Antibacterial
    inhibitor
    0.5 0.5 0.7 0.4 0.6 0.6 1.0 Butylparaben Antifungal
    0.7 0.9 0.7 0.6 0.8 0.7 0.8 Fosfosal Cyclooxygenase inhibitor Analgesic
    0.7 0.9 0.6 0.6 0.7 0.7 0.8 Aminohippuric acid Diagnostic aid (renal function)
    0.7 0.9 0.6 0.7 0.8 0.7 0.9 Suprofen Cyclooxygenase inhibitor Analgesic
    0.7 0.9 0.7 0.6 0.7 0.7 0.9 N-Acetyl-L-leucine Vertigo
    0.7 0.9 0.7 0.6 0.7 0.6 1.0 Catechin-(+,−) hydrate Antidiarrhoeic
    14.7 1.1 0.7 1.7 0.9 0.9 1.0 Pipemidic acid Antibacterial
    0.8 0.9 0.7 0.6 0.7 0.6 0.8 Nadolol Adrenergic beta antagonist Antihypertensor
    0.8 0.8 0.5 0.7 0.6 0.7 1.0 Dioxybenzone Ultraviolet screen
    18.1 1.3 4.4 3.9 0.6 0.6 0.8 Moxalactam disodium salt Bacterial transpeptidase Antibacterial
    inhibitor
    0.7 0.9 0.6 0.6 0.8 0.6 1.2 Adrenosterone Androgenic activity
    0.6 0.9 0.6 0.6 0.7 0.8 0.8 Aminophylline Mastocytes degranulation Vasodilatator
    inhibitor and
    benzodiazepines antagonist
    0.7 1.0 0.6 0.6 0.7 0.7 0.8 Methylatropine nitrate Mydriatic
    0.8 1.0 0.7 0.8 0.7 0.8 0.8 Vitexin Antiviral
    0.9 0.9 0.6 0.7 0.8 0.8 0.9 Nadide Coenzyme nicotinamide —
    adenine dinucleotide
    0.9 0.9 0.7 0.7 0.7 0.9 0.9 Gelsemine Tumour inhibitor
    1.0 0.9 0.7 0.7 1.4 0.8 0.9 Sulfamethizole Inhibitor of folic acid Antibacterial
    synthesis
    1.0 0.9 0.6 0.7 0.7 1.0 0.9 Solasodine Cytotoxic
    0.7 1.0 0.6 0.7 0.7 0.8 1.0 Medrysone — Glucocorticoid
    0.8 0.9 0.7 0.7 0.9 0.9 1.2 Delcorine Nicotinic ligand Antiarrhythmic
    0.6 0.6 0.5 0.5 0.5 0.6 1.0 Flunixin meglumine Analgesic
    0.7 0.8 0.6 0.7 0.7 0.8 1.1 Evoxine Glycine receptor antagonist Sedative
    0.9 1.0 6.6 0.8 0.9 0.7 1.2 Spiramycin Ribosomal protein synthesis Antibacterial
    inhibitor
    0.9 0.9 0.4 0.7 1.4 0.8 1.0 Nisoldipine Antihypertensive
    0.9 0.9 0.7 0.8 0.8 0.9 1.1 Glycopyrrolate Antispasmodic
    0.9 0.9 0.7 0.8 0.8 0.8 1.0 Foliosidine — Anticonvulsant
    10.5 0.9 1.3 2.3 0.6 0.7 0.9 Cefamandole sodium salt Bacterial transpeptidase Antibacterial
    inhibitor
    0.6 0.6 0.6 0.5 0.5 0.6 1.1 Skimmianine 5-HT ligand Sedative
    0.9 1.1 0.7 0.6 0.7 0.9 1.1 Monensin sodium salt Performs membrane Antibacterial
    ionophores
    1.0 0.9 0.6 0.8 0.8 0.9 1.0 Anabasine Insecticide
    0.9 0.9 0.6 1.4 0.8 0.6 0.9 Isoetharine mesylate salt Beta adrenergic agonist Bronchodilator
    0.9 1.0 0.9 0.9 0.9 0.9 1.1 Tetrandrine Analgesic
    1.0 1.0 0.9 0.8 0.9 0.8 0.9 Mevalonic-D, L acid lactone HMG CoA substrate —
    12.3 0.9 0.4 0.7 2.1 9.7 1.0 Azlocillin sodium salt Bacterial transpeptidase Antibacterial
    inhibitor
    0.9 1.0 1.0 0.7 0.8 1.0 1.1 Hymecromone Antispasmodic
    1.0 0.9 0.9 0.8 1.1 1.1 1.3 Clidinium bromide Anticholinergic Spasmolytic
    1.0 0.9 0.8 0.8 0.8 0.9 1.0 Caffeic acid Antineoplastic
    0.9 0.9 0.7 0.8 1.6 1.0 1.1 Sulfamonomethoxine Inhibitor of folic acid Antiseptic
    synthesis
    1.0 0.8 0.7 0.7 0.9 1.0 1.2 Diloxanide furoate Antiamebic
    0.9 1.4 0.8 0.8 0.9 0.9 1.1 Benzthiazide Na+ Cl− transport inhibitor Diuretic
    0.9 0.8 0.8 0.7 1.0 1.0 1.2 Metyrapone Diagnostic aid (pituitary
    function)
    0.8 1.4 1.3 0.8 1.0 0.8 1.2 Trichlormethiazide Na+ Cl− transport inhibitor Diuretic
    1.0 0.9 0.9 0.7 1.0 1.0 1.1 Urapidil hydrochloride Antihypertensor
    0.9 0.8 0.8 0.7 0.8 0.9 1.2 Oxalamine citrate salt — Antiinflammatory
    1.3 1.3 1.4 1.1 6.6 0.8 1.0 Fluspirilen Antipsychotic
    0.9 0.8 0.8 0.8 1.0 0.9 1.3 Propantheline bromide Muscarinic antagonist Antiulcerative
    0.9 0.9 0.8 0.7 0.8 0.9 1.3 S-(+)-ibuprofen Analgesic
    1.0 0.9 3.7 0.7 2.6 0.7 1.0 Lasalocid sodium salt Membrane ionophores Antibacterial
    producer
    0.8 0.9 0.5 0.7 0.9 0.9 1.1 Ethynodiol diacetate Progestogen
    0.9 0.9 0.7 0.8 0.8 0.8 1.0 Dimethadione — Anticonvulsant
    0.5 0.4 0.4 0.5 0.4 0.6 1.0 Nabumetone Analgesic
    0.9 1.0 0.5 0.7 0.9 0.9 1.0 Ethaverine hydrochloride Antispasmodic
    0.9 1.0 0.7 0.7 0.8 0.9 0.9 Nisoxetine hydrochloride Inhibitor of noradrenaline
    0.9 1.0 0.7 0.8 0.8 0.9 1.2 Dydrogesterone Progestogen
    0.8 0.8 0.8 0.7 0.7 0.6 1.2 Terazosin hydrochloride Alpha adrenergic antagonist Treatment of benign prostatic
    hyperplasia
    0.8 0.9 0.7 0.7 0.9 0.8 1.3 (d,l)-Tetrahydroberberine — Sedative
    0.1 0.1 0.3 0.1 0.1 0.1 1.4 Phenazopyridine hydrochloride — Analgesic
    0.9 0.9 0.8 0.7 0.8 0.8 1.1 Deltaline Nicotinic receptor ligand Antiarrhythmic
    0.5 0.9 7.1 0.2 3.4 0.4 1.3 Demeclocycline hydrochloride Ribosomal protein synthesis Antibacterial
    inhibitor
    0.8 0.8 0.7 0.6 0.8 0.8 1.2 Graveoline topoisomerase II inhibitor? Antihypotensive
    and CNS stimulant
    0.8 0.9 0.8 0.7 0.8 0.8 1.4 Fenoprofen calcium salt dihydrate Cyclooxygenase inhibitor Antiinflammatory
    0.9 0.9 0.7 0.6 0.8 0.9 1.4 Hippeastrine hydrobromide — Hypotensor
    12.6 0.9 0.4 2.3 3.3 8.7 1.3 Piperacillin sodium salt Bacterial transpeptidase Antibacterial
    inhibitor
    0.9 0.9 0.8 0.7 0.8 0.7 1.4 Beta-Escin Peripheral vascular disorders
    0.9 1.1 0.6 0.7 1.8 0.8 1.4 Diethylstilbestrol Estrogen
    0.6 1.3 0.2 0.3 0.4 0.5 1.5 Gossypol Ca2+ uptake inhibitor Local contraceptive
    0.9 1.0 0.8 0.8 0.8 0.8 1.4 Chlorotrianisene Nuclear receptor ligand Non-steroidal estrogen
    0.8 0.9 0.9 0.8 0.8 0.7 1.3 Ricinine
    0.9 0.9 0.8 0.7 0.8 0.8 1.2 Ribostamycin sulfate salt Ribosomal protein synthesis Antibacterial
    inhibitor
    0.9 0.9 0.8 0.7 0.9 0.8 1.3 Delsoline Nicotinic receptor antagonist
    and Ganglioblocker
    0.9 0.9 0.7 0.7 0.8 0.9 1.3 Methacholine chloride Cholinergic agonist
    0.9 0.9 0.8 0.7 0.9 0.8 1.4 Fluorocurarine chloride Muscle relaxant
    0.9 0.9 0.8 0.7 0.7 0.8 0.9 Pipenzolate bromide Nicotinic receptor antagonist Spasmolytic
    0.9 0.9 0.8 0.8 0.9 1.0 1.4 Butacaine Na+ channel blocker Local anesthesic
    0.9 0.9 0.8 1.0 0.8 0.8 1.4 (+)-Isoproterenol (+)-bitartrate Sympathomimetic (VET)
    salt
    20.1 1.0 3.4 3.2 1.3 0.8 1.2 Cefoxitin sodium salt Bacterial transpeptidase Antibacterial
    inhibitor
    0.7 0.6 0.6 0.5 0.5 0.7 1.4 Monobenzone Depigmentor
    9.0 0.8 0.8 0.7 0.8 0.9 1.4 Ifosfamide Antineoplastic
    1.1 0.9 0.8 0.7 0.9 0.9 1.4 2-Aminobenzenesulfonamide Ligand and potent inhibitor
    of carbonic anhydrase B
    3.2 1.5 4.5 0.7 1.1 1.0 1.6 Novobiocin sodium salt DNA topoisomerase IV Antibacterial
    inhibitor
    0.8 0.8 0.7 0.7 0.8 0.8 1.4 Estrone Estrogen
    0.9 0.9 0.8 0.8 1.1 0.9 1.3 Tetrahydroxy-1,4-quinone — Keratolytic
    monohydrate
    0.9 1.0 0.3 0.7 0.8 0.9 1.3 Lorglumide sodium salt CCKa ligand
    0.2 0.1 0.2 0.1 0.2 0.2 1.5 Indoprofen Cyclooxygenase inhibitor Analgesic
    0.8 0.9 0.4 0.8 0.9 0.9 1.4 Nitrendipine Antihypertensor
    0.8 0.9 1.6 0.7 1.1 0.9 1.4 Carbenoxolone disodium salt Mucus stimulating synthesis Antiulcerative
    0.8 0.9 0.6 0.7 0.9 0.8 1.6 Flurbiprofen Anti-inflammatory
    0.9 0.9 0.8 0.8 0.8 0.9 1.4 locetamic acid Diagnostic aid (radiopaque
    medium)
    0.9 1.0 0.7 0.7 1.0 0.9 1.4 Nimodipine Vasodilator
    0.9 0.9 0.9 0.7 0.8 0.9 1.4 Ganciclovir Antimetabolite Antiviral
    1.0 1.3 0.4 0.8 1.1 0.8 1.2 Bacitracin Antibacterial
    0.9 0.9 0.7 0.8 1.0 1.0 1.3 Ethopropazine hydrochloride Anticholinergic Antiparkinsonian
    0.8 0.9 0.8 0.7 0.8 0.8 1.2 L(−)-vesamicol hydrochloride Potent inhibitor of vesicular
    acetylcholine storage
    1.2 1.1 1.2 1.0 1.0 1.1 1.3 Austricine hydrate Antiatherosclerotic
    0.8 0.8 1.1 0.6 0.7 0.9 1.7 Butamben Na+ channel blocker Anesthetic
    1.2 1.0 1.3 0.9 1.0 1.2 1.3 beta-Belladonnine Muscarinic receptor and
    dichloroethylate nicotinic receptor lignad
    1.2 1.0 1.4 0.9 2.2 1.1 1.6 Sulfapyridine Antibacterial
    1.1 1.0 1.1 1.0 1.1 1.1 1.5 Pempidine tartrate Nicotinic acetylcholine Antihypertensor
    receptor antagonist
    1.2 1.0 1.2 1.0 1.0 1.1 1.4 Meclofenoxate hydrochloride Acetylcholine precursor Cerebral stimulant
    1.2 1.0 1.4 1.0 1.0 1.0 1.7 Heliotrine Model for hepatitis and
    cirrhosis in liver
    0.9 1.1 0.7 2.6 1.0 1.1 1.7 Furaltadone hydrochloride Bacterial DNA damage Antibacterial
    1.2 1.0 1.3 1.1 1.0 1.1 1.4 Nitrarine dihydrochloride — Hypotensor
    1.1 0.9 1.1 0.9 0.9 1.1 1.4 Ethoxyquin — Antifungal
    1.0 1.0 1.4 0.8 1.0 1.1 1.5 Lycorine hydrochloride Inhibitor of protein Antitumoral
    translation
    1.2 0.9 1.2 0.8 1.0 1.1 1.5 Tinidazole Protozoal and bacterial DNA Antiprotozoal
    damage
    1.0 1.0 1.2 0.9 1.0 1.1 1.3 Karakoline Inhibitor of ACE Hypotensor
    1.3 1.0 1.2 0.7 1.0 1.1 1.4 Guanadrel sulfate Antihypertensor
    1.1 1.0 1.1 1.0 1.0 1.1 1.3 Estropipate Menopause
    1.1 1.1 1.5 0.7 1.0 1.0 1.8 Vidarabine Adenosine antimetabolite Antiviral
    1.3 1.0 1.2 1.0 1.1 1.1 1.4 Ungerine nitrate Enhancer of analgesics Sedative
    1.3 1.0 1.2 1.0 2.3 1.1 1.2 Sulfameter Inhibitor of folic acid Antibacterial
    synthesis
    1.3 1.0 1.4 1.0 1.0 1.1 3.6 Napelline Anticholinergic agent Antiarrhythmic
    1.3 1.1 1.2 1.1 1.0 1.2 1.5 Isopropamide iodide Anticholinergic
    1.3 1.0 1.1 0.8 1.1 1.2 1.6 Securinine — CNS stimulant
    1.3 1.0 1.2 0.9 1.0 1.2 1.7 Nizatidine H2 antagonist Antiulcerative
    1.2 1.0 1.1 0.9 1.1 1.2 1.5 Trimeprazine tartrate Histamine antagonist Antipruritic
    1.2 1.0 1.1 1.0 1.0 1.3 1.6 Thioperamide maleate H3 antagonist Antiemetic
    1.2 1.0 6.5 1.0 1.5 1.3 1.4 Nafcillin sodium salt Bacterial transpeptidase Antibacterial
    monohydrate inhibitor
    1.3 1.0 1.1 0.8 1.0 1.2 1.8 Xamoterol hemifumarate beta1-Adrenoceptor Cardiotonic
    selective partial agonist
    1.4 1.1 1.2 0.9 1.1 1.2 1.8 Procyclidine hydrochloride Muscarinic antagonist Antiparkinsonian
    1.1 1.0 1.3 1.0 1.2 1.2 1.7 Rolipram Nootropic drug
    1.3 1.1 1.3 0.9 1.2 1.1 1.5 Amiprilose hydrochloride — Immunomodulator
    3.2 7.5 ### 4.7 5.6 1.5 1.8 Thonzonium bromide Detergent
    1.2 0.9 0.8 0.8 1.1 1.1 1.5 Ethynylestradiol 3-methyl ether — Estrogen
    1.1 1.0 1.1 1.0 1.1 1.2 1.5 Idazoxan hydrochloride Alpha2 agonist Antiparkinsonian
    1.3 1.0 1.0 1.0 1.0 1.2 1.9 (−)-Levobunolol hydrochloride Adrenergic beta antagonist Antiglaucoma drug
    1.2 1.1 1.2 1.0 1.2 1.2 1.6 Quinapril HCl Angiotensin
    1.3 1.1 1.3 1.0 1.0 1.2 1.5 Iodixanol Diagnostic aid (radiopaque
    medium)
    1.2 1.0 1.3 1.0 1.2 1.2 1.4 Nilutamide Antineoplastic
    1.1 1.0 1.1 1.0 1.2 1.1 1.7 Rolitetracycline Ribosomal protein synthesis Antibacterial
    inhibitor
    1.3 1.0 1.1 1.0 1.0 1.0 1.4 Ketorolac tromethamine Analgesic
    1.3 1.0 3.9 0.9 1.0 1.1 1.4 Equilin — Estrogen
    1.2 1.0 2.8 1.1 1.1 1.2 1.4 Protriptyline hydrochloride Antidepressant
    1.2 1.0 1.0 0.8 0.9 1.2 1.8 Fillalbin — —
    1.1 1.0 1.1 1.1 0.9 1.0 1.2 Alclometasone dipropionate Corticoide Anti-inflammatory
    1.0 1.0 1.0 0.9 0.9 1.2 1.5 Citalopram Hydrobromide 5HT uptake inhibitor
    0.8 0.7 0.6 0.6 0.8 0.8 1.5 Leflunomide Inhibitor of T and B cell Immunosuppressive
    proliferation
    1.2 1.0 1.4 0.8 0.9 1.1 1.7 Promazine hydrochloride Dopamine receptor Antipsychotic
    antagonist
    1.0 1.0 1.1 1.1 1.1 1.1 1.7 Norgestrel-(−)-D Progestogen Oral contraceptive
    1.1 1.0 0.9 1.0 2.1 1.0 1.9 Sulfamerazine Inhibitor of folic acid Antibacterial
    synthesis
    1.0 1.0 1.1 0.9 0.9 1.2 1.7 Fluocinonide Antiinflammatory
    0.7 0.5 0.7 0.6 0.3 0.6 1.6 Acacetin Inhibitor of glutathione Antitumor agent
    reductase and of
    topoisomerase I
    1.0 1.0 1.4 1.0 1.6 1.1 1.4 Sulfamethazine sodium salt Inhibitor of folic acid Antibacterial
    synthesis
    1.2 1.0 1.2 1.0 1.1 0.9 1.6 Ethotoin Anticonvulsant
    1.1 1.0 1.2 0.8 1.0 1.1 1.6 Guaifenesin — Expectorant
    1.2 1.0 1.0 0.9 0.9 1.1 1.9 3-alpha-Hydroxy-5-beta-
    androstan-17-one
    43.3 7.4 ### 23.4 12.3 19.2 1.5 Alexidine dihydrochloride Detergent Antibacterial
    1.4 1.0 1.1 0.9 1.0 1.0 1.4 Tetrahydrozoline hydrochloride Adrenergic Vasoconstrictor
    1.2 1.1 0.8 0.8 1.1 1.1 1.7 Proadifen hydrochloride Cytochrome P450 mono- Local anesthesic
    oxygenases inhibitor, Na+
    channel blocker
    1.4 1.2 0.7 0.7 3.0 1.1 1.6 Hexestrol Nuclear receptor ligand Estrogen antineoplastic
    1.1 1.1 0.9 1.0 1.1 0.9 1.6 Zomepirac sodium salt Cyclooxygenase inhibitor
    20.0 1.4 5.0 4.6 1.4 1.0 1.6 Cefmetazole sodium salt Bacterial transpeptidase Antibacterial
    inhibitor
    10.3 1.1 1.3 2.1 1.3 1.2 1.4 Cinoxacin Topoisomerase II inhibitor Antibacterial
    1.4 0.9 1.4 1.2 1.3 1.3 1.6 Paroxetine Hydrochloride 5-HT uptake inhibitor
    1.3 1.0 1.2 1.1 1.0 1.0 1.7 Propofol Anesthetic (intravenous)
    2.0 1.1 9.4 0.3 3.4 0.7 1.5 Doxycycline hyclate Ribosomal protein synthesis Antibacterial
    inhibitor
    0.9 1.0 1.6 1.1 1.0 1.3 1.8 S(−)Eticlopride hydrochloride
    1.2 1.1 1.0 0.9 1.1 1.1 1.6 Liothyronine Thyroid hormone Thyroidic drug
    1.0 0.9 1.3 0.9 1.2 1.2 1.8 Primidone Anticonvulsant
    0.9 1.4 2.8 1.1 1.0 0.9 1.5 Roxithromycin Ribosomal protein synthesis Antibacterial
    inhibitor
    1.1 0.9 1.1 0.8 1.2 1.1 1.8 Flucytosine Antifungal
    1.1 1.0 0.5 0.9 1.0 1.0 1.5 Beclomethasone dipropionate — Antiinflammatory
    1.2 1.0 1.1 1.0 1.1 1.3 1.9 (−)-MK 801 hydrogen maleate NMDA antagonist Anticonvulsant
    0.9 0.8 0.9 0.6 0.8 1.0 2.0 Tolmetin sodium salt dihydrate Cyclooxygenase inhibitor Antiinflammatory
    1.2 1.0 1.2 1.0 0.9 1.0 2.0 Bephenium hydroxynaphthoate Antihelmintic
    1.2 0.9 1.3 0.9 0.9 1.2 1.5 (+)-Levobunolol hydrochloride Beta adrenergic antagonist Antiglaucoma drug
    1.0 1.1 0.8 0.9 1.1 1.1 1.7 Dehydroisoandosterone 3-acetate Menopausal syndrome
    1.4 1.1 1.2 0.9 1.3 1.1 1.5 Doxazosin mesylate Alpha 1 adrenergic Antihypertensor
    antagonist
    1.3 0.9 1.4 1.2 1.0 1.1 1.8 Benserazide hydrochloride Inhibitor of L-aromatic In combination with levodopa
    amino acid decarboxylase as antiparkinsonian
    1.3 1.0 1.0 0.9 0.9 1.0 1.7 Fluvastatin sodium salt HMG CoA reductase Anti-hyperlipoproteinemic
    inhibitor
    1.2 1.0 1.0 1.0 1.2 1.1 1.6 Iodipamide Diagnostic aid (radiopaque
    medium-cholecystographic)
    1.4 1.1 1.3 1.0 1.0 1.1 2.0 Methylhydantoin-5-(L) — —
    1.4 1.0 1.1 1.2 1.1 0.9 1.4 Esculetin Antifungal
    1.2 1.1 1.4 1.1 1.4 1.3 1.5 Trihexyphenidyl-D,L Anticholinergic Antiparkinsonian
    Hydrochloride
    1.2 1.0 0.9 1.0 1.3 1.1 1.3 Clobetasol propionate — Glucocorticoid
    1.4 1.0 1.3 1.1 1.3 1.1 1.4 Succinylsulfathiazole Inhibitor of folic acid Antibacterial
    synthesis
    1.2 0.9 1.0 1.2 1.2 1.1 1.3 Podophyllotoxin Antiviral
    1.2 1.0 0.8 1.1 1.1 1.2 1.5 Famprofazone Antipyretic
    1.2 1.1 1.4 1.1 1.3 1.2 1.5 Clofibric acid Lipoproteine lipase activator ? Antihyperlipoproteinemic
    1.3 0.9 1.3 1.0 1.3 1.1 1.3 Bromopride Dopamine antagonist Antiemetic
    1.3 1.2 1.3 1.1 1.3 1.1 1.5 Bendroflumethiazide Na+ Cl− transport inhibitor Diuretic
    5.1 7.4 ### 7.4 5.8 8.9 1.3 Methyl benzethonium chloride Detergent Antibacterial
    1.1 1.3 1.3 1.1 1.3 1.2 1.5 Dicumarol Vitamin K antagonist Anticoagulant
    1.3 1.0 1.2 1.1 1.5 1.1 1.6 Chlorcyclizine hydrochloride Histamine antagonist Antihistaminic
    1.2 0.9 1.0 1.0 1.4 1.0 27.1 Methimazole Iodine oxidazing inhibitor Antihyperthyroid
    1.3 1.1 1.2 1.0 1.3 1.1 1.4 Diphenylpyraline hydrochloride H1 antagonist Antihistaminic
    0.5 0.6 0.2 0.4 0.7 0.4 1.4 Merbromin — Antibacterial
    2.9 6.2 ### 5.7 5.4 5.8 1.3 Benzethonium chloride Detergent Antibacterial
    1.2 1.0 1.3 1.0 1.3 1.1 1.4 Hexylcaine hydrochloride Local anesthesic
    1.2 0.9 0.9 1.0 1.2 1.0 1.3 Trioxsalen — Pigmentation agent
    (photosensitizer)
    1.5 1.0 1.5 1.2 1.3 1.2 1.5 Drofenine hydrochloride — Spasmolytic
    1.4 1.0 1.3 1.1 1.3 1.1 1.3 Strophanthidin ATPase inhibitor Cardiotonic
    1.3 1.0 1.1 1.0 1.2 1.1 0.9 Cycloheximide — Antibacterial
    1.4 1.0 1.5 1.1 1.4 1.3 1.6 Gabapentin GABA receptor ligand Anticonvulsant
    1.3 1.0 1.4 1.1 1.3 1.2 1.5 Pentetic acid Chelating agent (iron)
    1.5 0.9 1.2 1.1 1.5 1.2 1.3 Raloxifene hydrochloride
    1.3 1.0 1.3 1.1 1.3 1.2 1.6 Bretylium tosylate Antiadrenergic
    1.3 1.0 1.2 1.0 1.2 1.1 1.4 Etidronic acid, disodium salt — Calcium regulator
    1.3 1.0 1.3 1.0 1.4 1.2 1.5 Pralidoxime chloride
    1.2 1.0 1.2 1.1 1.3 1.2 1.5 Methylhydantoin-5-(D) — —
    1.4 0.9 1.1 1.2 1.3 1.1 1.4 Phenoxybenzamine hydrochloride Nonselective alpha- Antihypertensor
    adrenergic blockade
    1.6 1.0 0.4 1.2 2.5 1.1 1.5 Simvastatin HMG-CoA reductase Antihyperlipidemic
    inhibitor
    1.4 1.0 1.9 1.1 1.5 1.2 1.5 Salmeterol beta 2 adrenergic Bronchodilator
    agonist
    2.2 1.0 1.2 0.9 1.4 1.2 1.5 Azacytidine-5 Antimetabolite Antineoplastic
    1.3 1.0 1.1 1.0 1.3 1.2 1.4 Altretamine
    1.4 0.9 1.3 1.0 1.5 1.0 1.4 Paromomycin sulfate Ribosomal protein synthesis Antiamebic
    inhibitor
    1.2 1.1 1.4 0.9 1.4 1.1 1.5 Prazosin hydrochloride Antihypertensor
    1.4 1.0 1.6 1.2 1.5 1.1 1.6 Acetaminophen Cyclooxygenase inhibitor Antipyretic
    1.3 1.0 1.3 1.1 1.5 1.1 1.4 Timolol maleate salt Antiglaucoma drug
    1.4 1.0 1.4 1.0 1.4 1.0 1.2 Phthalylsulfathiazole Inhibitor of folic acid Antibacterial
    synthesis
    1.3 1.0 1.3 1.1 1.3 1.0 1.4 (+,−)-Octopamine hydrochloride beta-3 Adrenergic receptor Adrenergic
    agonist
    0.4 0.5 0.2 0.5 0.3 0.5 1.6 Luteolin — Expectorant
    1.4 1.0 1.3 1.2 1.3 1.0 1.3 (±)-Nipecotic acid Activates GABA-like ion
    channels
    1.1 1.1 1.2 1.1 2.8 1.1 1.6 Sulfabenzamide Inhibitor of folic acid Antibacterial
    synthesis
    1.1 1.0 1.0 1.0 1.1 1.0 1.7 (R)-Naproxen sodium salt Cyclooxygenase inhibitor Antiinflammatory
    1.1 1.0 1.2 0.9 1.2 1.1 1.6 Benzocaine Na+ channel blocker Anesthetic
    1.3 0.8 1.4 0.8 1.1 1.0 1.6 Propidium iodide Detergent Antibacterial
    1.1 1.0 1.4 1.1 1.1 1.1 1.4 Dipyrone Cyclooxygenase inhibitor Antipyretic
    1.2 1.1 1.3 1.2 1.4 1.2 2.0 Cloperastine hydrochloride Histamine antagonist Antitussive
    1.1 1.0 1.2 1.0 1.1 1.0 1.8 Isosorbide dinitrate Nitric oxide (NO) donor Antianginal
    1.2 1.1 1.3 0.9 1.1 1.1 1.6 Eucatropine hydrochloride Anticholinergic
    1.0 1.0 1.1 1.1 2.1 1.0 1.5 Sulfachloropyridazine Inhibitor of folic acid Antibacterial
    synthesis
    1.1 1.0 1.5 1.1 1.1 1.1 1.5 Isocarboxazid Antidepressant
    1.1 1.0 1.3 1.1 1.1 1.2 1.5 Pramoxine hydrochloride Local anesthesic
    0.8 1.2 1.1 0.8 1.0 1.0 1.7 Lithocholic acid Anticholelithogenic, Cholagogue
    gastrointestinal agent
    1.1 1.1 1.0 0.9 1.2 1.1 1.8 Finasteride Antialopecia agent
    1.3 1.0 1.2 1.0 1.1 1.1 1.8 Methotrimeprazine maleat salt — Analgesic
    1.1 1.0 1.2 1.0 1.3 1.1 1.7 Fluorometholone — Glucocorticoid
    1.1 1.3 0.4 0.9 3.2 1.1 21.9 Dienestrol Nuclear receptor ligand Non-steroidal estrogen
    11.8 1.0 5.3 3.2 1.1 1.1 2.0 Cephalothin sodium salt Bacterial transpeptidase Antibacterial
    inhibitor
    1.1 1.1 1.2 0.9 1.1 1.1 1.6 Pridinol methanesulfonate salt Anticholinergic Antiparkinsonian
    12.1 1.0 3.4 2.4 1.4 1.6 1.6 Cefuroxime sodium salt Bacterial transpeptidase Antibacterial
    inhibitor
    1.3 1.0 1.1 1.1 1.2 1.0 44.0 Amrinone TNF production inhibitor
    1.2 1.0 1.3 1.2 1.2 1.2 1.4 Iopamidol Diagnostic aid (radiopaque
    medium)
    1.5 1.1 1.3 1.1 1.3 1.3 1.3 Crotamiton Scabicide
    1.2 1.0 1.3 1.1 1.1 1.2 1.4 Iopromide Contrast molecule
    1.2 1.1 1.4 1.1 1.2 1.2 1.4 Propranolol hydrochloride Beta blocking agent Antiarrhythmic
    1.2 1.0 1.3 1.1 1.2 1.2 1.3 Theophylline monohydrate Mastocyte degranulation Bronchodilatator
    inhibitor in vitro
    1.3 1.0 1.2 1.2 1.3 1.2 1.3 (R)-(+)-Atenolol
    1.2 1.1 1.3 1.2 1.1 1.2 1.4 Theobromine Adenosine receptor Cardiotonic
    antagonist
    1.4 1.0 1.4 1.5 1.3 1.2 1.2 Tyloxapol Mucolytic
    1.3 1.1 1.3 1.2 1.5 1.4 1.5 Reserpine
    1.2 1.0 ### 0.3 1.2 1.4 1.4 Florfenicol Antibacterial
    0.7 0.6 0.9 0.7 0.8 0.8 1.2 Arcaine sulfate Lowers blood sugar
    1.1 1.2 0.9 1.0 1.2 1.2 1.6 Megestrol acetate Progestogen
    1.2 1.0 1.2 1.1 1.2 1.1 1.5 Scopolamine hydrochloride Non-selective muscarinic Antiemetic
    antagonist
    1.2 1.2 1.6 1.2 1.3 1.3 1.3 Deoxycorticosterone Corticoide Antiinflammatory
    1.2 1.0 1.2 1.2 1.3 1.2 1.4 Ioversol Diagnostic aid (radiopaque
    medium)
    1.2 1.0 1.2 1.0 1.3 1.2 1.4 Urosiol Anticholelithogenic
    1.3 1.1 1.2 1.0 1.2 1.1 1.5 Capsaicin Vanilloid receptor ligand Topical analgesic
    1.3 1.0 1.2 1.1 1.4 1.1 1.2 Proparacaine hydrochloride Local anesthesic (VET)
    1.2 1.1 1.4 1.2 1.3 1.2 1.2 Carbachol Cholinergic agonist, Myotic
    Cholinesterase inhibitor ?
    1.2 1.1 1.2 1.2 1.3 1.1 1.6 Aminocaproic acid Antiallergic
    0.5 0.9 0.4 0.4 0.3 0.4 0.4 Denatonium benzoate Bittering agent to prevent
    poisoning
    0.5 0.9 0.3 0.4 0.3 0.4 0.3 Etomidate Hypnotic
    0.4 0.9 0.3 0.4 0.4 0.4 0.3 Scopoletin Eicosanoid release inhibitor Antispasmodic
    0.4 0.8 0.4 0.4 0.4 0.4 0.3 Tridihexethyl chloride Antispasmodic
    0.5 1.1 0.4 0.5 0.4 0.4 0.4 Enilconazole Antifungal
    0.5 0.8 0.4 0.5 0.4 0.5 0.4 Penbutolol sulfate Antiarrhythmic
    3.2 0.9 1.9 0.2 4.2 0.2 0.4 Methacycline hydrochloride Antibacterial
    0.4 0.9 0.4 0.5 0.4 0.4 0.3 Prednicarbate Glucocorticoid (topical)
    0.5 0.8 0.4 0.5 0.4 0.4 0.4 Gibberellic acid Plant growth regulator
    0.7 2.8 0.7 0.7 2.4 0.5 0.4 Sertaconazole nitrate Antibacterial
    0.4 0.8 0.4 0.5 0.5 0.4 0.4 Sotalol hydrochloride Beta-blocker
    0.4 0.9 0.3 0.4 0.4 0.4 0.4 Repaglinide Antidiabetic
    0.5 0.9 0.4 0.5 0.5 0.4 0.4 6-Hydroxytropinone
    0.5 0.8 0.4 0.5 0.4 0.4 0.4 Piretanide Antihypertensor
    0.5 0.9 0.4 0.5 0.5 0.4 0.5 Decamethonium bromide Muscle relaxant (skeletal)
    0.5 0.9 0.5 0.5 0.6 0.5 0.4 Piperacetazine Antipsychotic
    0.5 0.8 0.4 0.4 0.4 0.4 0.4 3-Acetamidocoumarin Antiinflammatory
    0.5 0.9 0.4 0.5 0.5 0.5 0.5 Oxyphenbutazone Inhibition of cyclo-oxygenase Anti-inflammatory
    0.4 0.8 0.6 0.4 0.5 0.5 0.5 Roxarsone Control of enteric infections.
    To improve growth and feed
    efficiency (VET)
    0.6 0.9 0.4 0.6 0.5 0.5 0.4 Quinethazone Diuretic
    0.7 0.9 0.6 0.6 0.7 0.7 0.8 Remoxipride Hydrochloride Dopaminergic antagonist Antipsychotic
    0.6 1.0 0.6 0.6 0.6 0.6 0.7 Moricizine hydrochloride Antiarrhythmic
    0.6 1.0 0.6 0.6 0.6 0.6 0.8 THIP Hydrochloride GABAergic Agonist
    0.6 0.9 0.4 0.6 0.6 0.6 9.6 Iopanoic acid Contrast molecule
    0.7 0.9 0.6 0.6 0.7 0.7 0.7 Pirlindole mesylate Highly selective reversible Anti depressant
    inhibitor of monoamine Seizures
    oxidase type A
    7.7 0.9 0.6 0.5 1.1 0.6 0.8 Pivmecillinam hydrochloride Antibacterial
    0.7 0.9 0.6 0.6 0.6 0.6 0.9 Pronethalol hydrochloride Antihypertensor
    0.6 1.0 0.6 0.6 0.7 0.7 0.7 Levopropoxyphene napsylate Antitussive
    0.9 0.8 0.5 0.6 0.7 0.7 0.9 Naftopidil dihydrochloride Alpha1 agonist Antihypertensor
    0.7 1.0 0.6 0.6 0.6 0.7 0.7 Piperidolate hydrochloride Antispasmodic
    0.5 1.1 0.5 0.6 0.8 0.6 0.7 Tracazolate hydrochloride GABA receptor ligand
    0.9 0.9 0.7 1.1 1.1 0.6 0.7 Trifluridine Antiviral (ophthalmic)
    0.6 1.0 0.6 0.7 0.7 0.7 0.9 Zardaverine Phosphodiesterase III & IV
    inhibitor
    0.7 0.9 0.6 0.6 0.6 0.6 0.9 Oxprenolol hydrochloride Blocking beta-adrenergic Antiarrhythmic
    receptors
    0.6 0.9 0.6 0.5 0.7 0.6 0.7 Memantine Hydrochloride NMDA receptor antagonist Altzheimer disease
    0.7 1.1 0.6 0.6 0.7 0.7 0.8 Ondansetron Hydrochloride Antagonist of 5- Antiemetic
    hydroxytryptamine
    (serotonin) subtype 3 (5-HT
    3) receptors
    0.6 0.9 0.5 0.5 0.7 0.6 0.9 Ozagrel hydrochloride Thromboxane synthase Antianginal
    inhibitor
    0.6 1.0 0.7 0.6 0.8 0.7 0.8 Propoxycaine hydrochloride Local anesthesic
    0.6 0.9 0.6 0.5 0.7 0.6 1.0 Piribedil hydrochloride Dopaminergic agonist Vasodilator (peripheral)
    0.6 1.1 0.5 0.6 0.7 0.7 0.9 Oxaprozin Analgesic
    0.9 0.9 0.6 0.7 0.7 0.8 1.2 Nitrocaramiphen hydrochloride Muscarinic antagonist
    1.0 0.9 0.7 0.8 0.8 0.7 1.1 Phensuximide Anticonvulsant
    0.9 1.0 0.7 0.7 0.8 0.9 1.0 Nandrolone Anabolic
    0.9 0.9 0.6 0.8 0.8 0.8 1.1 loxaglic acid Low-osmolar, ionic contrast Diagnostic aid (radiopaque
    medium medium)
    0.8 0.9 0.7 0.7 0.8 0.8 1.0 Dimaprit dihydrochloride Histamine H2 receptor
    agonist
    1.0 1.0 0.8 0.7 1.1 0.8 1.0 Naftifine hydrochloride Antifungal
    0.9 0.9 0.6 0.7 0.8 0.8 1.0 Reserpinic acid hydrochloride
    0.9 0.9 0.6 0.7 0.8 0.9 0.8 Meprylcaine hydrochloride Local anesthesic
    0.8 0.9 0.7 0.8 0.8 0.8 1.1 Beta-sistosterol Anticholesteremic
    0.8 0.9 0.7 0.8 0.8 0.9 0.9 Milrinone Cardiotonic
    0.9 0.8 0.6 0.7 0.8 0.9 0.9 Proscillaridin A Glucoside cardiotonic
    0.9 0.9 0.7 0.8 0.8 0.9 1.1 Methantheline bromide Antispasmodic
    0.8 0.9 0.7 0.8 0.8 0.7 1.2 Ciprofibrate Antihyperlipoproteine-mic
    0.8 0.9 0.7 0.7 0.8 0.8 1.5 Fluticasone propionate Anti-inflammatory
    0.9 0.9 0.7 0.8 0.8 0.8 1.2 Tropine
    1.2 1.0 0.7 1.0 1.9 0.9 1.3 Zuclopenthixol hydrochloride Blocking of D1 and D2 Schizophrenia
    dopaminergic receptors
    11.3 1.7 0.8 0.6 2.9 0.7 1.2 Benzylpenicillin sodium Antibacterial
    0.9 0.8 0.9 0.7 0.9 0.8 1.1 Proguanil hydrochloride Inhibition of dihydrofolate
    reductase
    0.9 0.9 0.8 0.7 0.9 0.8 1.2 Chlorambucil Antineoplastic
    0.8 1.0 0.7 0.7 0.8 0.7 1.2 Lymecycline Antibiotic
    0.4 0.5 1.3 0.4 0.5 0.5 1.3 Methiazole
    1.2 1.1 1.0 0.9 1.0 1.0 1.4 Alfadolone acetate In combination with alfaxalone
    as anesthesic (intravenous)
    1.2 1.1 1.0 1.0 1.0 1.1 1.6 (S)-propranolol hydrochloride Beta-adrenergic blocking Antihypertensor
    agent
    1.2 1.1 1.2 1.0 1.0 1.2 1.7 Alfaxalone In combination with alfadolone
    acetate as anesthetic
    (intravenous)
    1.0 1.1 0.9 0.9 0.9 0.8 1.4 (−)-Eseroline fumarate salt Anti-acetylcholinesterase Potent analgesic
    activity & opiate agonist
    activity
    1.1 1.0 0.8 0.9 0.9 1.0 1.5 Azapropazone Cyclooxygenase inhibitor Analgesic
    1.1 1.1 1.1 1.0 1.1 1.0 1.2 Condelphine
    1.3 1.1 0.9 0.9 1.1 1.1 1.4 Meptazinol hydrochloride Analgesic (narcotic)
    1.3 1.1 0.9 1.0 1.0 1.1 1.6 Leucomisine
    1.2 1.0 0.9 0.8 1.0 1.1 1.4 Apramycin Antibacterial
    1.4 1.0 2.4 0.9 1.1 1.0 1.3 Dubinidine
    1.2 1.0 0.9 0.9 1.1 1.1 1.3 Epitiostanol Antineoplastic
    1.4 1.2 1.4 1.1 1.0 1.2 1.2 D-cycloserine Competitive inhibition of
    alanin racenase and D-alanin
    synthase (bacterial cell wall)
    1.4 1.1 1.0 1.0 1.3 1.1 1.2 Fursultiamine Hydrochloride Altzheimer's disease
    1.0 1.1 1.1 0.9 1.2 1.0 1.4 2-Chloropyrazine Cardiotonic
    1.1 1.1 1.3 0.9 1.1 1.1 1.4 Gabexate mesilate Anticoagulant
    1.3 1.1 1.0 1.0 1.1 1.1 1.3 (+,−)-Synephrine Hypertensive
    1.5 1.1 0.4 0.9 1.8 0.9 1.2 Pivampicillin Antibacterial
    1.3 1.1 1.1 1.0 1.1 1.1 1.6 (S)-(−)-Cycloserine Tuberculosis
    15.2 1.4 1.2 0.8 0.8 1.1 1.6 Talampicillin hydrochloride Antibacterial
    1.3 1.1 1.2 1.1 1.8 1.1 1.5 Homosalate Tool for uv screen
    1.3 1.0 6.1 1.1 1.5 1.2 1.3 Flucloxacillin sodium Antibacterial
    1.4 1.1 1.0 0.9 0.9 1.1 1.6 Spaglumic acid NMDA receptor ligands
    1.3 1.1 0.9 0.9 1.0 1.0 1.5 Trapidil Vasodilator (coronary)
    1.2 0.9 1.0 0.9 1.2 1.0 1.4 Ranolazine Antianginal
    1.5 1.1 1.1 0.9 1.3 1.0 1.6 Deptropine citrate Chronic bronchitis
    1.1 1.0 1.2 1.0 1.0 0.9 1.7 (−)-Quinpirole hydrochloride D2-dopamine
    receptor agonist, some
    selectivity for D3 sites
    1.6 1.1 1.6 1.4 2.9 1.2 1.5 Sertraline 5-HT uptake inhibitor
    1.0 1.0 0.9 1.0 2.9 1.0 1.3 Sulfadoxine Inhibition of Antibacterial
    dihydropteroate synthase
    1.2 0.9 1.0 1.1 1.2 1.0 0.8 Ethamsylate Retinopathy
    1.2 1.0 1.1 1.0 1.0 1.1 1.3 Cyclopentolate hydrochloride Mydriatic
    1.1 0.9 1.0 1.1 1.1 1.1 1.8 Moxonidine Imidazoline receptor ligand Antihypertensor
    1.1 1.1 1.2 0.8 1.2 1.0 1.4 Estriol Estrogen
    1.0 1.0 1.1 0.8 1.4 1.1 1.5 Etilefrine hydrochloride Adrenergic agonist Antihypotensive
    1.2 0.9 0.9 1.2 0.9 1.1 2.3 (−)-Isoproterenol hydrochloride Beta Adrenergic Agonist Cardiovascular drug (Sick Sinus
    Syndrome)
    1.3 1.0 1.1 1.1 1.0 1.1 1.4 Alprostadil Vasodilator
    0.5 1.0 0.2 0.6 0.5 0.6 1.6 Kaempferol Topoisomerase I inhibitor, Anti-inflammatory
    tyrosin kinase, xanthin
    oxidase
    0.9 1.1 0.6 0.9 1.7 1.1 1.5 Tribenoside Antihaemorrhoidic drug
    1.2 1.1 1.2 0.9 1.0 1.2 1.4 Nialamide Antidepressant
    0.9 0.9 1.1 0.8 0.9 1.0 4.9 Rimexolone Corticoid Anti-inflammatory (local)
    0.9 1.0 1.8 0.8 1.1 1.1 1.6 Vitamin K2 Dietary factor for controlling
    blood pressure
    1.1 1.1 0.7 1.1 1.2 1.1 1.4 Isradipine Antianginal
    1.2 1.0 1.1 1.1 1.4 1.2 1.3 Perindopril Antihypertensive
    1.2 1.0 1.1 1.1 1.6 1.1 1.4 Tiletamine hydrochloride Anesthetic
    1.2 1.0 1.1 1.1 1.3 1.0 1.3 Fexofenadine HCl Antihistaminic
    1.2 1.0 1.2 1.1 1.5 1.1 1.2 Isometheptene mutate Adrenergic Sympathomimetic (VET)
    1.2 1.0 1.2 1.3 1.4 1.1 1.2 Quinic acid
    1.1 1.0 0.8 1.2 1.5 1.1 1.3 Nifurtimox Antiprotozoal (Trypanosoma)
    1.0 0.9 1.2 1.1 1.4 1.0 1.5 Clonixin Lysinate Analgesic
    1.2 1.0 1.2 1.1 1.3 1.0 1.4 Letrozole Antineoplastic
    0.7 1.2 0.5 0.8 0.9 0.8 1.6 Verteporfin Treatment of age-related
    macular degeneration
    1.2 0.9 1.1 1.2 1.5 1.1 1.4 Arbutin Tyrosinase inhibitor and Antibacterial
    Melanin biosynthesis
    inhibitor
    13.4 1.0 3.9 3.6 1.5 14.8 1.2 Meropenem Antibacterial
    1.2 1.0 1.1 1.1 1.6 1.1 1.4 Tocainide hydrochloride Antiarrhythmic
    1.1 1.0 1.2 1.0 1.3 1.2 1.1 Ramipril Converting enzyme inhibitor Antihypertensor
    15.6 1.6 1.0 1.0 5.9 1.1 1.6 Benzathine benzylpenicillin Antibacterial
    1.1 1.0 1.1 1.0 1.3 1.0 1.3 Mephenytoin Anticonvulsant
    1.1 1.0 1.3 1.1 1.5 1.1 1.3 Risperidone 5-HT2 antagonist Antipsychotic
    1.3 1.2 0.7 1.3 3.3 0.6 1.6 Rifabutin Inhibition of RNA- Antibacterial
    polymerase DNA-dependent
    1.1 1.0 1.5 1.3 1.6 1.1 1.4 Torsemide Diuretic
    0.7 0.6 0.7 0.7 0.8 0.7 1.2 Parbendazole Anthelmintic (VET)
    1.0 1.0 1.2 1.1 1.3 1.1 1.3 Halofantrine hydrochloride Antimalarial
    1.4 1.1 1.4 1.0 1.2 1.1 1.6 Mecamylamine hydrochloride Antihypertensor
    1.1 1.2 1.1 1.1 1.2 1.0 1.6 Articaine hydrochloride Local Anesthesic
    1.0 1.0 1.1 1.1 1.1 0.9 1.7 Procarbazine hydrochloride DNA depolymerization
    1.1 1.2 1.0 1.1 1.1 1.1 1.5 Nomegestrol acetate Progestin
    1.0 1.0 1.3 0.9 1.1 0.9 1.6 Viomycin sulfate Antibacterial
    1.1 1.0 1.1 1.0 1.1 0.9 1.6 Pancuronium bromide Competitive antagonist of Neuromuscular blocking agent
    autonomic cholinergic
    receptors
    1.3 1.2 0.9 1.1 1.5 1.0 1.8 Saquinavir mesylate Protease inhibitor
    1.1 1.0 1.1 1.0 1.1 0.9 1.7 Molindone hydrochloride Antipsychotic
    1.1 1.1 1.3 1.7 1.6 1.0 1.6 Ronidazole Antimicrobial
    1.4 1.0 1.2 1.0 1.4 1.0 2.2 Alcuronium chloride Neuromuscular blocking agent
    1.1 2.3 1.0 1.1 1.2 0.9 1.3 Dorzolamide hydrochloride Antiglaucoma drug
    1.3 1.1 1.1 1.1 1.2 1.0 1.8 Zalcitabine Reverse transcriptase Antiviral (HIV)
    inhibitor
    1.1 1.0 1.2 1.0 1.2 1.0 1.9 Azaperone Tranquilizer
    1.2 1.1 1.2 1.2 1.4 1.1 1.8 Methyldopate hydrochloride Antihypertensor
    19.3 1.0 3.1 4.9 3.4 15.6 1.9 Cefepime hydrochloride Antibacterial
    1.1 1.0 1.1 1.1 1.2 1.0 1.6 Levocabastine hydrochloride Antihistaminic
    1.0 1.1 1.1 1.0 1.2 1.0 1.6 Clocortolone pivalate Glucocorticoid
    0.8 1.5 1.4 0.8 0.9 0.7 13.2 Pyrvinium pamoate Anthelmintic (Nematodes,
    enterobiasis)
    13.4 2.8 4.3 5.2 2.9 17.7 1.7 Nadifloxacin Antibacterial
  • Consistent with expectations, a detailed assessment of the hits revealed that AK screening enriches for the identification of bactericidal compounds (Table 3). More specifically, 100% of the antibiotics that were identified to be active against P. aeruginosa or K. pneumoniae represented bactericidal agents. Similarly, 96%, 94%, and 80% of the antibiotics that were active against E. coli, E. cloacae, and E. faecium, respectively, were bactericidal antibiotics. The assay identified 71% and 64% bactericidal antibiotics for A. baumannii and S. aureus.
  • Among the bactericidal antibiotics detected, β-lactam, cephalosporin, polymyxin, and fluoroquinolone antibiotics were active against Gram-negative pathogens (E. coli and the ESKAPE pathogens A. baumannii, P. aeruginosa, and K. pneumoniae), and penicillins, cephalosporins, quinolines, glycopeptides, and carbapenems were active toward S. aureus (see Table 4). It was also determined that clofazimine, which was initially developed as an antimycobacterial agent and was recently shown to exhibit bactericidal activity toward S. aureus, was indeed active against S. aureus. Bacteriostatic compounds, such as clindamycin, and macrolides, such as erythromycin, were not identified as being active toward any of the species tested. Interestingly, many tetracyclines were identified as killing S. aureus strain USA300-0114 and A. baumannii strain 98-37-09. In addition, the library contains membrane-active antiseptics, such as chlorhexidine, and with the exception of E. cloacae, these were also strong hits against all organisms tested. Screening results also revealed that the E. faecium strain tested proved to be resistant to most classes of antibiotics within the Prestwick library by MIC testing (Table 2), and this was also observed in the AK assay, indicating that the assay exhibits a low false-positive rate. Interestingly, the assay also detected 38 drugs with no known antimicrobial properties (denoted as “other” in Table 3) that were active against each organism; see Table 4 for a complete list of these compounds.
  • Antimicrobial Activities of Nonantibiotic Drugs that Induce AK Release—
  • Recently, the exploration of the so-called “off-target” activities of previously developed drugs has emerged as an approach to identify chemical scaffolds that could be exploited for new therapeutic indications. In that regard, Prestwick library screening results revealed that 4% to 56% (depending on the organism) of the members that generated significant AK signal were compounds with no previously reported antimicrobial activity (see Table 4).
  • To determine whether the 38 nonantibiotics identified in the screen have potential for repurposing as anti-infectives, 4 nonantibiotic drugs that were commercially available were further evaluated by two secondary assays. First, dose-response assays were performed to validate that they induced AK activity, and all were reconfirmed. Second, the in vitro antimicrobial activity for each drug was measured by standard MIC testing. With the exception of one drug/organism pair, all drugs exhibited in vitro activity toward each organism. More specifically, tamoxifen, suloctidil, and clomiphene exhibited MICs of 8 μg ml−1 against E. faecium. S. aureus and A. baumannii were susceptible to terfenadine (16-μg ml−1 MIC and 64-μg ml−1 MIC, respectively). Suloctidil was also detected to be active against P. aeruginosa by both primary and confirmatory AK screens, but the drug did not elicit an antimicrobial response by MIC measures. Some strains of P. aeruginosa secrete AK at high cell density, and it is possible that suloctidil may trigger a similar response.
  • Terfenadine and tamoxifen, which exhibited antimicrobial properties toward planktonic S. aureus and E. faecium cells, respectively, were characterized further. Terfenadine was evaluated for activity against S. aureus biofilms and small-colony variants using the AK assays described above. Treatment of 48-h S. aureus strain UAMS-1 biofilms with 10×-MIC terfenadine elicited a modest 2.7-fold increase in AK release (see FIG. 6A); plating-based viability assays determined that this correlated with a 1.1-log reduction in biofilm cell viability, which was comparable to the activity of ciprofloxacin under the same assay conditions (see FIG. 4A). Similarly, treatment of S. aureus small-colony-variant UAMS-1112 cells with 10×MIC terfenadine elicited a 3.3-fold increase in AK signal in comparison to that for mock-treated cells (see FIG. 6A). Conventional MIC testing subsequently verified that terfenadine is active against UAMS-1112 at 2 μg ml−1.
  • Next, the in vivo antimicrobial properties of terfenadine and tamoxifen were evaluated using a Galleria mellonella model of S. aureus and E. faecium infection, respectively. For terfenadine, groups of larvae (n=45) were infected with 1.0×106 S. aureus USA300-1114 cells. Worms were then treated at 2 h and 24 h with a range of terfenadine concentrations (20 to 160 mg kg−1), vehicle (DMSO; negative control), or 20 mg kg−1 vancomycin (positive control), and larval survival was assessed 48 h postinoculation. For tamoxifen studies, experiments were performed exactly as described above except that larvae were inoculated with 1.4×106 E. faecium strain 824-05 cells and larvae were treated with either 80 or 160 mg kg−1 kg tamoxifen. Terfenadine-treated larvae did not reproducibly exhibit increased survival relative to vehicle-treated larvae. However, tamoxifen treatment of E. faecium-infected larvae resulted in a dose-dependent increase in survival. As shown in FIG. 6B, treatment with 80 or 160 mg kg−1 resulted in a 4.2-fold- or 7-fold-higher survival, respectively, than was found with vehicle-treated controls. Taken together, these results indicate that terfenadine exhibits in vitro activity toward S. aureus planktonic, SCV, and biofilm populations and that tamoxifen is active toward planktonic E. faecium and against the organism in a simple animal model of infection. As discussed below, these data show that tamoxifen and terfenadine represent attractive new chemical scaffolds for antibacterial optimization.
  • As set forth herein, Prestwick library screening revealed that each bacterial species studied was susceptible to members of the library with no previously reported antimicrobial activity. The antimicrobial properties of two of these drugs was studied in more detail: terfenadine and tamoxifen. Terfenadine is a nonsedating antihistamine based on a 4-substituted piperidine scaffold. Based on further studies, it was determined that terfenadine acts as a topoisomerase inhibitor and is structurally similar to certain topoisomerase inhibitors, including for example novel bacterial topoisomerase II inhibitor (NBTI). Based on the structural similarity between terfenadine and these molecules, it is likely that terfenadine is acting as a DNA gyrase and topoisomerase inhibitor. More specifically, terfenadine and derivatives thereof act as topoisomerase 4 inhibitors. Furthermore, it was found that terfenadine has activity against S. aureus small-colony variants and biofilms, properties not previously reported for this scaffold.
  • A screen of E. faecium identified two structurally related nonsteroid estrogen receptor antagonists, tamoxifen and clomiphene. Tamoxifen is used to treat some forms of estrogen-receptor-positive breast cancer, while clomiphene is used in fertility treatment regimens. These two compounds are members of the triarylethylene class of estrogen receptors.
  • Since the number of agents with activity toward enterococcus is quite limited, tamoxifen's in vivo activity was investigated using a Galleria model of enterococcus infection. Although it was not as active as vancomycin, tamoxifen did impart a survival benefit, indicating that it has in vivo antimicrobial activity. High-dose tamoxifen therapy has been used in experimental treatment of refractory human cancers, and dosing results in micromolar serum concentrations of tamoxifen corresponding to the levels of drug associated with antienterococcal activity observed in the studies provided herein.
  • In addition to providing a powerful new HTS approach to identify antimicrobial agents active against planktonic bacteria, an AK assay that is easily amenable to screening bacteria in disease states that cannot be readily screened via conventional approaches is provided herein. In that regard, the AK assay is capable of measuring the killing properties of bactericidal agents administered to biofilms formed by both Gram-negative and Gram-positive representatives of the ESKAPE pathogens. Similarly, the AK assay can detect the bactericidal properties of antibiotics toward a phenotypically stable S. aureus small-colony variant. These features can be exploited to develop corresponding high-throughput screening assays for the identification of agents that kill established biofilms and small-colony variants or provide powerful secondary assays aimed at characterizing the potential antimicrobial properties of molecules of interest.
    • Example II Antimicrobial Properties of Terfenadine and Terfenadine Derivatives
  • Terfenadine derivatives were synthesized as described below.
  • Figure US20150238473A1-20150827-C00091
    • General Method A KSC-335-007 1-(4-(tert-butyl)phenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one
  • To a vial was added the diphenyl(piperidin-4-yl)methanol (1.190 g, 4.45 mmol), 1-(4-(tert-butyl)phenyl)-4-chlorobutan-1-one (1.012 g, 4.24 mmol), sodium bicarbonate (0.427 g, 5.09 mmol) with water:2-butanone (18 mL, 1:5). The reaction stirred at 85° C. for 16 h and was then cooled to rt and water (50 mL) was added. The reaction was extracted with EtOAc (3×50 mL). The EtOAc layer was dried with MgSO4, filtered, concentrated and purified by MPLC (20 min, 0-10% MeOH:DCM) to produce pure 1-(4-(tert-butyl)phenyl)-4-(4-(hydroxydiphenylmethyl) piperidin-1-yl)butan-1-one (1.37 g, 2.92 mmol, 69% yield) as a colorless oil. 1H NMR (500 MHz, CDCl3): δ 7.90 (d, J=8.4 Hz, 2H), 7.49-7.45 (m, 6H), 7.31-7.25 (m, 4H), 7.20-7.14 (m, 2H), 2.97-2.92 (m, 4H), 2.45-2.36 (m, 3H), 2.09 (br s, 1H), 2.00-1.87 (m, 4H), 1.49-1.32 (m, 4H), 1.34 (s, 9H). 13C NMR (125 MHz, CDCl3): δ 199.7, 156.5, 146.0, 134.5, 128.1, 128.0, 126.4, 125.7, 125.4, 79.4, 57.9, 43.9, 43.4, 44.1, 36.2, 35.0, 31.0, 26.2, 21.9. LCMS Retention time: 4.207 min. LCMS purity 99.5%. HRMS (ESI): m/z calcd for C32H39NO2 [M+H]+ 470.2981. found 470.3054.
  • Figure US20150238473A1-20150827-C00092
    • KSC-335-005 4-(4-(Hydroxydiphenylmethyl)piperidin-1-yl)-1-(4-isopropylphenyl)butan-1-one
  • Method A: diphenyl(piperidin-4-yl)methanol (0.620 g, 2.317 mmol), 4-chloro-1-(4-isopropylphenyl)butan-1-one (0.496 g, 2.207 mmol), sodium bicarbonate (0.222 g, 2.65
  • Figure US20150238473A1-20150827-C00093
  • mmol) with water (3 mL) and 2-butanone (15 mL, Ratio: 5). to produce pure 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(4-isopropylphenyl)butan-1-one (0.481 g, 1.056 mmol, 48% yield) as a colorless oil. 1H NMR (500 MHz, CDCl3): δ 7.89 (d, J=8.4 Hz, 2H), 7.49-7.45 (m, 4H), 7.31-7.26 (m, 6H), 7.20-7.14 (m, 2H), 2.98-2.91 (m, 4H), 2.45-2.35 (m, 1H), 2.38 (t, J=6.8 Hz, 2H), 2.08 (br s, 1H), 1.99-1.89 (m, 4H), 1.61 (br s, 1H), 1.48-1.33 (m, 4H), 1.27 (d, J=6.8 Hz, 6H).
    • KSC-335-006 1-(4-(tert-butyl)phenyl)-5-(4-(hydroxydiphenylmethyl)piperidin-1-yl)pentan-1-one
  • Method A: diphenyl(piperidin-4-yl)methanol (0.544 g, 2.035 mmol), 1-(4-(tert-butyl)phenyl)-5-chloropentan-1-one (0.490 g, 1.938 mmol), sodium bicarbonate (0.195 g, 2.326 mmol) with water:2-butanone (18 mL, 1:5) to produce pure 1-(4-(tert-butyl)phenyl)-5-(4-(hydroxydiphenylmethyl)piperidin-1-yl)pentan-1-one (0.600 g, 1.240 mmol, 64.0% yield) as a colorless oil. 1H NMR (500 MHz, CDCl3): δ 7.89 (d, J=8.4 Hz, 2H), 7.49-7.45 (m, 6H), 7.32-7.26 (m, 4H), 7.20-7.14 (m, 2H), 2.98-2.92 (m, 4H), 2.48-2.32 (m, 3H), 2.14 (br s, 1H), 1.99-1.89 (m, 2H), 1.77-1.62 (m, 2H), 1.60-1.42 (m, 6H), 1.34 (s, 9H).
  • Figure US20150238473A1-20150827-C00094
    • KSC-335-008 1-(4-(tert-butyl)phenyl)-3-(4-(hydroxydiphenylmethyl)piperidin-1-yl)propan-1-one
  • Method A: diphenyl(piperidin-4-yl)methanol (0.543 g, 2.032 mmol), 1-(4-(tert-butyl)phenyl)-3-chloropropan-1-one (0.435 g, 1.936 mmol), sodium bicarbonate (0.195 g, 2.323 mmol) with water:2-butanone (18 mL, 1:5) to produce pure 1-(4-(tert-butyl)phenyl)-3-(4-(hydroxydiphenyl methyl)piperidin-1-yl)propan-1-one (0.838 g, 1.84 mmol, 95% yield) as a colorless oil. 1H NMR (500 MHz, CDCl3): δ 7.89 (d, J=8.4 Hz, 2H), 7.50-7.45 (m, 6H), 7.32-7.25 (m, 4H), 7.21-7.14 (m, 2H), 3.15 (t, J=7.1 Hz, 2H), 3.01-2.96 (m, 2H), 2.81 (t, J=7.1 Hz, 2H), 2.49-2.42 (m, 1H), 2.15-2.04 (m, 3H), 1.56-1.46 (m, 4H), 1.33 (s, 9H). 13C NMR (125 MHz, CDCl3): δ 198.9, 171.1, 156.8, 145.8, 134.3, 128.2, 128.0, 126.5, 125.8, 125.5, 79.4, 60.4, 54.2, 53.4, 44.0, 36.3, 35.1, 31.1, 26.4, 21.1, 14.2. LCMS Retention time: 3.968 min. LCMS purity 98.1%. HRMS (ESI): m/z calcd for C31H37NO2 [M+H]+ 456.2824. found 456.2897.
  • Figure US20150238473A1-20150827-C00095
    • KSC-335-009 1-(4-chlorophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one
  • Method A: diphenyl(piperidin-4-yl)methanol (0.626 g, 2.341 mmol), 4-chloro-1-(4-chlorophenyl) butan-1-one (0.484 g, 2.229 mmol), sodium bicarbonate (0.225 g, 2.68 mmol) with water:2-butanone (18 mL, 1:5) to produce pure 1-(4-chlorophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (0.394 g, 0.879 mmol, 39.4% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3): δ 7.90 (d, J=8.4 Hz, 2H), 7.48-7.44 (m, 4H), 7.42 (d, J=8.6 Hz, 2H), 7.31-7.26 (m, 4H), 7.20-7.15 (m, 2H), 3.96-2.89 (m, 4H), 2.45-2.34 (m, 3H), 2.08 (br s, 1H), 1.99-1.87 (m, 4H), 1.50-1.30 (m, 4H).
  • Figure US20150238473A1-20150827-C00096
    • General Method B KSC-335-014, Terfenadine 1-(4-(tert-butyl)phenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol
  • To a vial was added the 1-(4-(tert-butyl)phenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (KSC-335-007 (0.198 g, 0.422 mmol) and MeOH (2 mL). The sodium borohydride (0.032 g, 0.844 mmol) was then added and the reaction stirred at rt for 3 h. The reaction was concentrated to dryness, water (5 mL) was added and a white precipitate formed. The precipitate was filtered out and then dissolved in DCM (10 mL), dried with MgSO4, filtered and concentrated to produce pure 1-(4-(tert-butyl)phenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol (0.151 g, 0.320 mmol, 76% yield) as on oil. 1H NMR (400 MHz, CDCl3): δ 7.52-7.46 (m, 4H), 7.33-7.25 (m, 8H), 7.21-7.15 (m, 2H), 4.61-4.56 (m, 1H), 3.16-3.11 (br m, 1H), 3.00-2.94 (m, 1H), 2.51-2.34 (m, 4H), 2.10-1.88 (m, 4H), 1.83-1.75 (m, 1H), 1.70-1.45 (m, 6H), 1.30 (s, 9H). 13C NMR (125 MHz, CDCl3): δ 149.4, 146.1, 146.0, 142.7, 128.2, 128.1, 126.4, 126.3, 125.7, 125.6, 125.3, 125.0, 79.2, 73.4, 58.9, 54.7, 53.3, 44.2, 39.7, 34.4, 31.4, 26.0, 25.9, 24.1. LCMS Retention time: 4.137 min. LCMS purity 97.5%. HRMS (ESI): m/z calcd for C32H41NO2 [M+H]+ 472.3144. found 472.3219.
  • Figure US20150238473A1-20150827-C00097
    • KSC-335-012 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(4-isopropylphenyl)butan-1-ol
  • Method B: 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(4-isopropylphenyl)butan-1-one (KSC-335-005) (0.154 g, 0.338 mmol) and MeOH (2 mL) sodium borohydride (0.026 g, 0.676 mmol) to produce pure 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(4-isopropylphenyl)butan-1-ol (0.146 g, 0.319 mmol, 94% yield) as on oil. 1H NMR (400 MHz, CDCl3): δ 7.52-7.46 (m, 4H), 7.32-7.23 (m, 6H), 7.20-7.14 (m, 4H), 4.61-4.58 (m, 1H), 3.18-3.11 (br m, 1H), 3.00-2.94 (br m, 1H), 2.87 (septet, J=6.9 Hz, 1H), 2.50-2.33 (m, 3H), 2.29 (br s, 1H), 2.10-1.89 (m, 3H), 1.82-1.44 (m, 8H), 1.22 (d, J=6.9 Hz, 6H). 13C NMR (125 MHz, CDCl3): δ 147.2, 146.1, 146.0, 128.2, 128.1, 126.5, 126.4, 126.1, 125.7, 125.7, 79.2, 73.5, 58.9, 54.7, 53.3, 44.2, 39.9, 33.7, 26.0, 25.9, 24.2, 24.1, 24.0. LCMS Retention time: 4.056 min. LCMS purity 98.6%. HRMS (ESI): m/z calcd for C31H39NO2 [M+H]+ 458.2986. found 458.3062.
  • Figure US20150238473A1-20150827-C00098
    • KSC-335-013 1-(4-(tert-butyl)phenyl)-5-(4-(hydroxydiphenylmethyl)piperidin-1-yl)pentan-1-ol
  • Method B: 1-(4-(tert-butyl)phenyl)-5-(4-(hydroxydiphenylmethyl)piperidin-1-yl)pentan-1-one (KSC-335-006) (0.204 g, 0.422 mmol) and MeOH (2 mL) and sodium borohydride (0.032 g, 0.844 mmol) to produce pure 1-(4-(tert-butyl)phenyl)-5-(4-(hydroxydiphenylmethyl)piperidin-1-yl)pentan-1-ol (0.156 g, 0.321 mmol, 76% yield) as on oil. 1H NMR (400 MHz, CDCl3): δ 7.50-7.45 (m, 4H), 7.36 (d, J=8.4 Hz, 2H), 7.31-7.24 (m, 6H), 7.19-7.14 (m, 2H), 4.65-4.60 (m, 1H), 2.98-2.90 (br m, 1H), 2.48-2.38 (m, 1H), 2.30 (t, J=7.2 Hz, 2H), 2.23 (br s, 1H), 1.97-1.87 (m, 2H), 1.84-1.60 (m, 4H), 1.55-1.35 (m, 8H), 1.31 (s, 9H). 13C NMR (125 MHz, CDCl3): δ 150.3, 146.0, 142.0, 128.1, 126.4, 125.8, 125.5, 125.3, 79.4, 74.1, 58.4, 54.1, 54.0, 44.2, 38.5, 34.5, 31.4, 31.3, 26.5, 26.3, 26.2, 23.7. LCMS Retention time: 4.254 min. LCMS purity 96.4%. HRMS (ESI): m/z calcd for C33H43NO2 [M+H]+ 486.3294. found 486.3370.
  • Figure US20150238473A1-20150827-C00099
    • KSC-335-015 1-(4-chlorophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol
  • Method B: 1-(4-chlorophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (KSC-335-009) (0.156 g, 0.348 mmol) and MeOH (2 mL) sodium borohydride (0.026 g, 0.696 mmol) to produce pure 1-(4-chlorophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol (0.118 g, 0.262 mmol, 75% yield) as on oil. 1H NMR (400 MHz, CDCl3): δ 7.51-7.46 (m, 4H), 7.32-7.24 (m, 8H), 7.20-7.15 (m, 2H), 4.61-4.56 (m, 1H), 3.16-3.10 (br m, 1H), 2.97-2.91 (m, 1H), 2.51-2.33 (m, 4H), 2.12-1.88 (m, 3H), 1.83-1.75 (m, 1H), 1.78-1.46 (m, 8H). 13C NMR (125 MHz, CDCl3): δ 146.0, 145.9, 144.5, 139.1, 128.19, 128.18, 128.1, 127.1, 126.49, 126.45, 125.62, 125.57, 79.2, 72.9, 58.8, 54.7, 53.2, 44.2, 40.2, 26.0, 25.9, 24.1. LCMS Retention time: 3.845 min. LCMS purity 98.4%. HRMS (ESI): m/z calcd for C28H32ClNO2 [M+H]+ 450.2122. found 450.2194.
  • Figure US20150238473A1-20150827-C00100
    • KSC-335-016 1-(4-(tert-butyl)phenyl)-3-(4-(hydroxydiphenylmethyl)piperidin-1-yl)propan-1-ol
  • Method B: 1-(4-(tert-butyl)phenyl)-3-(4-(hydroxydiphenylmethyl)piperidin-1-yl)propan-1-one (KSC-335-008) (0.116 g, 0.255 mmol) and MeOH (2 mL) and sodium borohydride (0.019 g, 0.509 mmol) to produce pure 1-(4-(tert-butyl)phenyl)-3-(4-(hydroxydiphenylmethyl)piperidin-1-yl)propan-1-ol (0.106 g, 0.232 mmol, 91% yield) as on oil. 1H NMR (400 MHz, CDCl3): δ 7.49-7.44 (m, 4H), 7.36-7.25 (m, 8H), 7.22-7.16 (m, 2H), 6.72 (br s, 1H), 4.90-4.85 (m, 1H), 3.21-3.15 (br m, 1H), 3.11-3.05 (br m, 1H), 2.70-2.62 (m, 1H), 2.57-2.40 (m, 2H), 2.14-2.06 (m, 2H), 1.91-1.79 (m, 3H), 1.57-1.45 (m, 4H), 1.31 (s, 9H). 13C NMR (125 MHz, CDCl3): δ 149.6, 145.8, 145.7, 141.9, 128.2, 128.1, 126.6, 126.5, 125.8, 125.7, 125.2, 125.0, 79.4, 75.3, 57.3, 55.2, 53.2, 44.1, 34.4, 33.7, 31.4, 26.7, 26.4. LCMS Retention time: 4.006 min. LCMS purity 97.7%. HRMS (ESI): m/z calcd for C31H39NO2 [M+H]+ 458.2991. found 458.3066.
  • Figure US20150238473A1-20150827-C00101
  • KSC-335-018
    • 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-phenylbutan-1-one
  • Method A: diphenyl(piperidin-4-yl)methanol (0.524 g, 1.961 mmol), 4-chloro-1-phenylbutan-1-one (0.300 ml, 1.868 mmol), sodium bicarbonate (0.188 g, 2.241 mmol) with water:2-butanone (18 mL, 1:5) to produce pure 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-phenylbutan-1-one (0.177 g, 0.428 mmol, 23% yield) as a colorless oil. 1H NMR (500 MHz, CDCl3): δ 7.98-7.94 (m, 2H), 7.57-7.52 (m, 1H), 7.49-7.42 (m, 6H), 7.32-7.26 (m, 4H), 7.20-7.15 (m, 2H), 3.00-2.90 (m, 4H), 2.46-2.35 (m, 3H), 2.09 (br s, 1H), 2.00-1.87 (m, 4H), 1.50-1.33 (m, 4H).
  • Figure US20150238473A1-20150827-C00102
    • KSC-335-020 1-(tert-butyl)-4-(4-chlorobutyl)benzene
  • To a vial was added the 1-(4-(tert-butyl)phenyl)-4-chlorobutan-1-one (0.266 g, 1.114 mmol) and triethylsilane (0.518 g, 0.712 ml, 4.46 mmol) with TFA (4 mL). The reaction stirred at 75° C. for 18 h, was cooled to rt and concentrated in vacuo. The residue was then dissolved in DCM (5 mL) and washed with water (4 mL). The DCM layer was collected and washed with water (1×5 mL), dried with MgSO4, filtered and adsorbed to silica and purified by Teledyne ISCO Combiflash chromatography (20 min, 0-40% EtOAc:Hex) and fractions 4 and 5 were collected to produce pure 1-(tert-butyl)-4-(4-chlorobutyl)benzene (0.155 g, 0.690 mmol, 61.9% yield) as an oil. 1H NMR (400 MHz, CDCl3): δ 7.32 (d, J=7.6 Hz, 2H), 7.12 (d, J=7.6 Hz, 2H), 3.56 (t, J=6.5 Hz, 2H), 2.62 (t, J=7.5 Hz, 2H), 1.87-1.74 (m, 4H), 1.32 (s, 9H).
  • Figure US20150238473A1-20150827-C00103
    • KSC-335-021 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-phenylbutan-1-ol
  • Method B: 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-phenylbutan-1-one (KSC-335-018) (0.065 g, 0.157 mmol) and MeOH (2 mL) and sodium borohydride (0.012 g, 0.314 mmol) to produce pure 4-(4-(hydroxydiphenylmethyl) piperidin-1-yl)-1-phenylbutan-1-ol (0.048 g, 0.116 mmol, 73% yield) as on oil. 1H NMR (400 MHz, CDCl3): δ 7.51-7.46 (m, 4H), 7.37-7.33 (m, 2H), 7.32-7.26 (m, 5H), 7.23-7.14 (m, 3H), 4.65-4.61 (m, 1H), 3.15 (d, J=11.7 Hz, 1H), 2.96 (d, J=11.7 Hz, 1H), 2.52-2.31 (m, 4H), 2.11-1.90 (m, 3H), 1.84-1.74 (m, 2H), 1.70-1.44 (m, 7H). 13C NMR (125 MHz, CDCl3): δ 146.0, 145.9, 145.8, 128.2, 128.1, 128.0, 126.6, 126.5, 126.4, 125.6, 125.6, 79.2, 73.6, 58.9, 54.7, 53.3, 44.2, 40.1, 26.0, 25.9, 24.1. LCMS Retention time: 3.711 min. LCMS purity 99.8%. HRMS (ESI): m/z calcd for C28H33NO2 [M+H]+ 416.2517. found 416.2592.
  • Figure US20150238473A1-20150827-C00104
    • KSC-335-022 Methyl 2-methyl-2-(4-(4-((methylsulfonyl)oxy)but-1-yn-1-yl)phenyl)propanoate
  • To a vial was added the methyl 2-(4-(4-hydroxybut-1-yn-1-yl)phenyl)-2-methylpropanoate (0.051 g, 0.207 mmol) and dry DCM (2 mL). The methanesulfonyl chloride (0.047 g, 0.032 mL, 0.414 mmol) and pyridine (0.147 g, 0.151 mL, 1.864 mmol) were each added and the reaction and stirred at rt for 16 h. The reaction was then diluted with DCM (5 mL) and washed with 1% w/v sulfuric acid in water (3×7 mL), saturated NaHCO3 (7 mL) and brine (7 mL). The organic layer was dried with MgSO4, filtered and concentrated to produce methyl 2-methyl-2-(4-(4-((methylsulfonyl) oxy)but-1-yn-1-yl)phenyl)propanoate (0.063 g, 0.194 mmol, 94% yield). 1H NMR (400 MHz, CDCl3): δ 7.35 (d, J=8.6 Hz, 2H), 7.26 (d, J=8.6 Hz, 2H), 4.38 (t, J=6.8 Hz, 2H), 3.64 (s, 3H), 3.06 (s, 3H), 2.87 (t, J=6.8 Hz, 2H), 1.56 (s, 6H).
  • Figure US20150238473A1-20150827-C00105
    • KSC-335-023 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(4-methoxyphenyl)butan-1-one
  • Method A: diphenyl(piperidin-4-yl)methanol (0.490 g, 1.832 mmol), 4-chloro-1-(4-methoxyphenyl)butan-1-one (0.371 g, 1.744 mmol), sodium bicarbonate (0.176 g, 2.093 mmol) with water (3 mL) and 2-butanone (15 mL) to produce pure 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(4-methoxyphenyl)butan-1-one (0.282 g, 0.636 mmol, 36% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3): δ 7.94 (d, J=9.0 Hz, 2H), 7.49-7.45 (m, 4H), 7.31-7.26 (m, 4H), 7.17 (tt, J1=7.3 Hz, J2=1.3 Hz, 2H), 6.92 (d, J=8.9 Hz, 2H), 3.87 (s, 3H), 2.97 (br s, 1H), 2.93 (t, J=7.3 Hz, 2H), 2.48-2.35 (m, 3H), 2.02-1.88 (m, 4H), 1.63-1.40 (m, 4H).
  • Figure US20150238473A1-20150827-C00106
    • KSC-335-024 1-(4-Fluorophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one
  • Method A: diphenyl(piperidin-4-yl)methanol (0.385 g, 1.439 mmol), 4-chloro-1-(4-fluorophenyl)butan-1-one (0.275 g, 1.371 mmol), sodium bicarbonate (0.138 g, 1.645 mmol) with water (3 mL) and 2-butanone (15 mL) to produce pure 1-(4-fluorophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (0.174 g, 0.403 mmol, 29% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3): δ 8.00-7.96 (m, 2H), 7.48-7.44 (m, 4H), 7.31-7.26 (m, 4H), 7.20-7.15 (m, 2H), 7.14-7.08 (m, 2H), 2.97-2.94 (m, 4H), 2.46-2.36 (m, 3H), 2.15 (br s, 1H), 2.01-1.88 (m, 4H), 1.52-1.35 (m, 4H).
  • Figure US20150238473A1-20150827-C00107
    • KSC-335-025 1-(4-Bromophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one
  • Method A: diphenyl(piperidin-4-yl)methanol (0.439 g, 1.642 mmol), 1-(4-bromophenyl)-4-chlorobutan-1-one (0.409 g, 1.564 mmol), sodium bicarbonate (0.158 g, 1.877 mmol) with water (3 mL) and 2-butanone (15 mL) to produce pure 1-(4-bromophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (0.245 g, 0.498 mmol, 32% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3): δ 7.83-7.79 (m, 2H), 7.60-7.56 (m, 2H), 7.48-7.45 (m, 4H), 7.31-7.26 (m, 4H), 7.20-7.15 (m, 2H), 2.95-2.90 (m, 4H), 2.45-2.35 (m, 3H), 2.17 (br s, 1H), 2.00-1.88 (m, 4H), 1.51-1.33 (m, 4H).
  • Figure US20150238473A1-20150827-C00108
    • KSC-335-030 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(4-methoxyphenyl)butan-1-ol
  • Method B: 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(4-methoxyphenyl)butan-1-one (KSC-335-023) (0.113 g, 0.255 mmol) and MeOH (2 mL) and sodium borohydride (0.019 g, 0.509 mmol) to produce pure 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(4-methoxyphenyl)butan-1-ol (0.062 g, 0.139 mmol, 55% yield) as on oil. 1H NMR (400 MHz, CDCl3): δ 7.51-7.46 (m, 4H), 7.32-7.24 (m, 6H), 7.20-7.15 (m, 2H), 6.84 (d, J=7.0 Hz, 2H), 4.60-4.56 (m, 1H), 3.78 (s, 3H), 3.14 (d, J=11.7 Hz, 1H), 2.95 (d, J=11.7 Hz, 1H), 2.50-2.35 (m, 4H), 2.10-2.02 (m, 1H), 1.99-1.86 (m, 2H), 1.80-1.73 (m, 1H), 1.69-1.45 (m, 7H). 13C NMR (125 MHz, CDCl3): δ 158.3, 146.1, 146.0, 138.1, 128.1, 128.1, 126.7, 126.4, 126.4, 125.7, 125.6, 113.5, 79.2, 73.2, 58.9, 55.2, 54.7, 53.2, 44.2, 40.0, 26.0, 25.9, 24.1. LCMS Retention time: 3.620 min. LCMS purity 98.3%. HRMS (ESI): m/z calcd for C29H35NO3 [M+H]+ 446.2652. found 446.2728.
  • Figure US20150238473A1-20150827-C00109
    • KSC-335-031 1-(4-fluorophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol
  • Method B: 1-(4-fluorophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (KSC-335-024) (0.064 g, 0.148 mmol) and MeOH (2 mL) and sodium borohydride (0.011 g, 0.297 mmol) to produce pure 1-(4-fluorophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol (0.059 g, 0.136 mmol, 92% yield) as on oil. 1H NMR (400 MHz, CDCl3): δ 7.51-7.46 (m, 4H), 7.33-7.25 (m, 6H), 7.20-7.14 (m, 2H), 6.96 (t, J=8.8 Hz, 2H), 4.61-4.57 (m, 1H), 3.14 (d, J=11.7 Hz, 1H), 2.94 (d, J=11.7 Hz, 1H), 2.51-2.35 (m, 4H), 2.13-2.02 (m, 1H), 2.02-1.86 (m, 2H), 1.78-1.45 (m, 7H). 13C NMR (125 MHz, CDCl3): δ 162.6, 160.7, 146.0, 145.9, 141.7, 141.6, 128.2, 128.1, 127.2, 127.1, 126.5, 126.4, 125.6, 125.5, 114.9, 114.7, 79.2, 73.0, 58.8, 54.8, 53.1, 44.2, 40.3, 30.9, 26.0, 25.9, 24.1. LCMS Retention time: 3.691 min. LCMS purity 98.5%. HRMS (ESI): m/z calcd for C28H32FNO2 [M+H]+ 434.2406. found 434.2482.
  • Figure US20150238473A1-20150827-C00110
    • KSC-335-032 1-(4-bromophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol
  • Method B: 1-(4-bromophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (KSC-335-025) (0.083 g, 0.169 mmol) and MeOH (2 mL) and sodium borohydride (0.013 g, 0.337 mmol) to produce pure 1-(4-bromophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol (0.053 g, 0.107 mmol, 63.6% yield) as on oil. 1H NMR (400 MHz, CDCl3): δ 7.51-7.46 (m, 4H), 7.41 (d, J=6.8 Hz, 2H), 7.32-7.26 (m, 4H), 7.22 (d, J=6.6 Hz, 2H), 7.20-7.15 (m, 2H), 4.60-4.56 (m, 1H), 3.14 (d, J=11.7 Hz, 1H), 2.93 (d, J=11.7 Hz, 1H), 2.50-2.42 (m, 1H), 2.41-2.34 (m, 2H), 2.11-2.05 (m, 1H), 2.01-1.95 (m, 1H), 1.94-1.86 (m, 1H), 1.78-1.45 (m, 8H). 13C NMR (125 MHz, CDCl3): δ 146.0, 145.9, 145.1, 131.1, 128.2, 128.1, 127.5, 126.5, 126.4, 125.6, 125.6, 120.2, 79.2, 72.9, 58.8, 54.7, 53.2, 44.1, 40.1, 26.0, 25.9, 24.1. LCMS Retention time: 3.902 min. LCMS purity 99.1%. HRMS (ESI): m/z calcd for C28H32BrNO2 [M+H]+ 494.1614. found 494.1673.
  • Figure US20150238473A1-20150827-C00111
    • KSC-335-041 (1-(4-(4-(tert-butyl)phenyl)butyl)piperidin-4-yl)diphenylmethanol
  • To a vial was added the diphenyl(piperidin-4-yl)methanol (0.153 g, 0.571 mmol), 1-(tert-butyl)-4-(4-chlorobutyl)benzene (KSC-335-020) (0.154 g, 0.685 mmol) and potassium carbonate (0.473 g, 3.43 mmol) in acetonitrile. The reaction stirred overnight at 85° C. and for 18 h and was then cooled to rt and filtered. The filtrate was then diluted with brine and extracted with diethyl ether (3×15 mL). The ether layers were combined, dried with MgSO4, filtered and purified by reverse-phase MPLC (20 min, 10-100% MeCN:H2O) to produce pure (1-(4-(4-(tert-butyl)phenyl)butyl)piperidin-4-yl)diphenylmethanol (0.180 g, 0.395 mmol, 69% yield) as an oil. 1H NMR (400 MHz, CDCl3): δ 7.38-7.34 (m, 4H), 7.19-7.14 (m, 6H), 7.07-7.02 (m, 2H), 6.99-6.95 (m, 2H), 2.86-2.80 (m, 2H), 2.45 (t, J=7.3 Hz, 2H), 2.35-2.26 (m, 1H), 2.22-2.17 (m, 2H), 1.84-1.76 (m, 3H), 1.52-1.30 (m, 8H), 1.18 (s, 9H). 13C NMR (125 MHz, CDCl3): δ 171.1, 148.4, 146.0, 139.4, 128.1, 128.0, 126.4, 125.8, 125.1, 79.5, 60.4, 58.8, 54.1, 44.2, 35.2, 34.3, 31.4, 29.5, 26.8, 26.4, 21.0, 14.2. LCMS Retention time: 3.928 min. LCMS purity 97.8%. HRMS (ESI): m/z calcd for C32H41NO [M+H]+ 456.3188. found 456.3261.
  • Figure US20150238473A1-20150827-C00112
    • KSC-335-053 Methyl 4-(1,3-dithian-2-yl)benzoate
  • A flame dried vial was evaporated 3 times with argon and methyl 4-formylbenzoate (0.50 g, 3.05 mmol) was added with anhydrous DCM (8.70 mL) followed by 1,3-propanedithiol (0.339 mL, 3.35 mmol). The reaction began to stir at rt for 1.5 h. The reaction was then cooled to 0° C. and the BF3.OEt2 (0.425 ml, 3.35 mmol) was added dropwise. The reaction was then warmed slowly to rt and stirred overnight. The reaction was then diluted with DCM (15 mL) and quenched with saturated NaHCO3 (15 mL) and the DCM layer was dried with MgSO4, filtered and adsorbed to silica and purified by MPLC (20 min, 0-35% EtOAc:Hex) to produce methyl 4-(1,3-dithian-2-yl)benzoate (0.669 g, 2.63 mmol, 86% yield). 1H NMR (400 MHz, CDCl3): δ 8.01 (d, J=8.4 Hz, 2H), 7.54 (d, J=8.3 Hz, 2H), 3.91 (s, 3H), 3.12-3.03 (m, 2H), 2.96-2.90 (m, 2H), 2.23-2.16 (m, 1H), 2.01-1.89 (m, 1H), 1.55 (s, 2H).
  • Figure US20150238473A1-20150827-C00113
    • KSC-335-054 Methyl 2-(4-(4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)but-1-yn-1-yl)phenyl)-2-methylpropanoate
  • To a vial was added the diphenyl(piperidin-4-yl)methanol (0.528 g, 1.974 mmol), methyl 2-methyl-2-(4-(4-((methylsulfonyl)oxy)but-1-yn-1-yl)phenyl)propanoate (KSC-335-022) (0.582 g, 1.794 mmol) and potassium carbonate (0.744 g, 5.38 mmol) with acetonitrile (10 mL). The reaction stirred at 70° C. for 18 h and cooled to rt and filtered to remove the potassium carbonate. The filtrate was adsorbed to silica gel and purified by reverse-phase MPLC (20 min, 10-100% MeCN:H2O) to produce pure methyl 2-(4-(4-(4-(hydroxydiphenylmethyl) piperidin-1-yl)but-1-yn-1-yl)phenyl)-2-methylpropanoate (0.434 g, 0.876 mmol, 49% yield). 1H NMR (400 MHz, CDCl3): δ 7.49-7.46 (m, 4H), 7.34-7.27 (m, 6H), 7.25-7.15 (m, 4H), 3.64 (s, 3H), 3.03-2.97 (m, 2H), 2.68-2.63 (m, 2H), 2.59-2.54 (m, 2H), 2.48-2.40 (m, 1H), 2.14-2.06 (m, 2H), 1.63 (br s, 1H), 1.55 (s, 6H), 1.55-1.45 (m, 4H).
  • Figure US20150238473A1-20150827-C00114
    • KSC-335-056 Methyl 4-(2-(3-chloropropyl)-1,3-dithian-2-yl)benzoate
  • To a dry vial was added the methyl 4-(1,3-dithian-2-yl)benzoate (KSC-335-053) (0.256 g, 1.01 mmol) and this was evacuated with argon 3 times. The dry THF (7 mL) was added and the reaction was cooled to −78° C. at and the NaHMDS (1.258 mL, 1.258 mmol) was added. After 30 minutes the 1-chloro-3-iodopropane (0.531 mL, 5.03 mmol) was added. The reaction was then allowed to warm to rt overnight. The mixture was quenched with the addition of saturated NH4Cl (10 mL) at and diluted with EtOAc (15 mL) and shaken. The EtOAc layer was collected, dried with MgSO4, filtered and adsorbed to silica and purified by MPLC (20 min, −25% EtOAc:Hex) to produce pure methyl 4-(2-(3-chloropropyl)-1,3-dithian-2-yl)benzoate (0.102 g, 0.308 mmol, 31% yield).). 1H NMR (400 MHz, CDCl3): δ 8.07-8.03 (m, 2H), 8.01-7.98 (m, 2H), 3.93 (s, 3H), 3.41 (t, J=6.4 Hz, 2H), 2.74-2.62 (m, 4H), 2.19-2.13 (m, 2H), 1.99-1.92 (m, 2H), 1.78-1.70 (m, 2H).
  • Figure US20150238473A1-20150827-C00115
    • KSC-335-059 (S)-1-(4-(tert-butyl)phenyl)-4-chlorobutan-1-ol
  • To a flame-dried vial was added dry THF (2 mL) and then cooled to 0° C. The 1.0 M R-5,5-Diphenyl-2-methyl-3,4-propano-1,3,2-oxazaborlidine (0.105 mL, 0.105 mmol) in THF was added followed by the 2.0 M borane-methyl sulfide complex (0.654 mL, 1.309 mmol) in THF. The reaction began to stir at 0° C. for 30 minutes. To another flame-dried vial was added the 1-(4-(tert-butyl)phenyl)-4-chlorobutan-1-one (0.250 g, 1.047 mmol) and this was evacuated with argon 3 times then dissolved in dry THF (5 mL) and the oxazaborlidine solution was added dropwise at 0° C. and the reaction was allowed to warm to rt stirred for 2 h. The reaction was quenched with MeOH (10 mL) extracted with EtOAc (20 mL) then was washed with 1.0 M HCl (3×25 mL). The EtOAc layer was dried with MgSO4, filtered and concentrated to produce pure (S)-1-(4-(tert-butyl)phenyl)-4-chlorobutan-1-ol (0.248 g, 1.030 mmol, 98% yield). [alpha]25 589=−24.0° (c=10 in CHCl3). 1H NMR (400 MHz, CDCl3): δ 7.38 (d, J=8.4 Hz, 2H), 7.28 (d, J=8.4, 2H), 4.71-4.67 (m, 1H), 3.61-3.53 (m, 2H), 1.98-1.79 (m, 4H), 1.32 (s, 9H).
  • Figure US20150238473A1-20150827-C00116
    • KSC-335-060 (R)-1-(4-(tert-butyl)phenyl)-4-chlorobutan-1-ol
  • Prepared the same as KSC-335-059 with 1.0 M (S)-5,5-diphenyl-2-methyl-3,4-propano-1,3,2-oxazaborlidine (0.105 ml, 0.105 mmol), 2.0 M Borane-methyl sulfide complex (0.654 ml, 1.309 mmol) and 1-(4-(tert-butyl)phenyl)-4-chlorobutan-1-one (0.250 g, 1.047 mmol) to produce pure (R)-1-(4-(tert-butyl)phenyl)-4-chlorobutan-1-ol (0.216 g, 0.897 mmol, 86% yield). [alpha]25 589=+23.1° (c=10 in CHCl3). 1H NMR (400 MHz, CDCl3): δ 7.38 (d, J=8.4 Hz, 2H), 7.28 (d, J=8.4, 2H), 4.71-4.67 (m, 1H), 3.61-3.53 (m, 2H), 1.98-1.79 (m, 4H), 1.32 (s, 9H).
  • Figure US20150238473A1-20150827-C00117
    • KSC-335-061 Methyl 4-(4-chlorobutanoyl)benzoate
  • To a vial was added the methyl 4-(2-(3-chloropropyl)-1,3-dithian-2-yl)benzoate (KSC-335-056) (0.102 g, 0.308 mmol) and acetonitrile (1.5 mL) with water (0.2 mL). The (bis(trifluoroacetoxy)iodo)benzene (0.199 g, 0.462 mmol) was then added and the reaction stirred at rt for 1 h. The reaction was quenched with saturated NaHCO3 (7 mL) then diluted with EtOAc (10 mL) and extracted. The EtOAc was collected and washed with water (2×8 mL) and then dried with MgSO4, filtered and adsorbed to silica and purified by MPLC (20 min, 0-25% EtOAc:hex to produce pure methyl 4-(4-chlorobutanoyl)benzoate (0.0512 g, 0.213 mmol, 69% yield). 1H NMR (400 MHz, CDCl3): δ 8.11 (d, J=8.00 Hz, 2H), 8.00 (d, J=8.6 Hz, 2H), 3.93 (s, 3H), 3.67 (t, J=6.1 Hz, 2H), 3.19 (t, J=6.1 Hz, 2H), 2.22 (quintet, J=6.3 Hz, 2H).
  • Figure US20150238473A1-20150827-C00118
    • KSC-335-062 (S)-1-(4-(tert-butyl)phenyl)-4-chlorobutyl acetate
  • To a vial was added the (S)-1-(4-(tert-butyl)phenyl)-4-chlorobutan-1-ol (KSC-335-059) (0.248 g, 1.030 mmol) and diethyl ether (5.15 ml). The TEA (0.215 mL, 1.545 mmol) was added followed by the acetyl chloride (0.073 mL, 1.030 mmol) and the reaction began to stir at rt for 2 h. A white precipitate formed immediately. Water (5 mL) was added the reaction after 2 h and the ether layer was extracted. The aqueous was extracted again with more ether and the combined organics were dried with MgSO4, filtered and concentrated to produce pure (S)-1-(4-(tert-butyl)phenyl)-4-chlorobutyl acetate (0.250 g, 0.884 mmol, 86% yield). [alpha]25 589=−42.11, (c=10, CH2Cl2). 1H NMR (400 MHz, CDCl3): δ 7.36 (d, J=8.4 Hz, 2H), 7.25 (d, J=8.4 Hz, 2H), 5.78-5.73 (m, 1H), 3.53 (t, J=6.4 Hz, 2H), 2.06 (s, 3H), 2.02-1.68 (m, 4H), 1.31 (s, 9H).
  • Figure US20150238473A1-20150827-C00119
    • KSC-336-063 (R)-1-(4-(tert-butyl)phenyl)-4-chlorobutyl acetate
  • Prepared the same as KSC-335-062 with (R)-1-(4-(tert-butyl)phenyl)-4-chlorobutan-1-ol (KSC-335-060) (0.216 g, 0.897 mmol) and diethyl ether (4.5 mL), TEA (0.188 ml, 1.346 mmol) and acetyl chloride (0.064 ml, 0.897 mmol) to produce pure (R)-1-(4-(tert-butyl)phenyl)-4-chlorobutyl acetate (0.249 g, 0.880 mmol, 98% yield). [alpha]25 589=+54.57, (c=10, CH2Cl2). 1H NMR (400 MHz, CDCl3): δ 7.36 (d, J=8.4 Hz, 2H), 7.25 (d, J=8.4 Hz, 2H), 5.78-5.73 (m, 1H), 3.53 (t, J=6.4 Hz, 2H), 2.06 (s, 3H), 2.02-1.68 (m, 4H), 1.31 (s, 9H).
  • Figure US20150238473A1-20150827-C00120
    • KSC-335-064 (S)-1-(4-(tert-butyl)phenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl acetate
  • To a vial was added the diphenyl(piperidin-4-yl)methanol (0.154 g, 0.578 mmol), (S)-1-(4-(tert-butyl)phenyl)-4-chlorobutyl acetate (0.196 g, 0.693 mmol) (KSC-335-062) and potassium carbonate (0.319 g, 2.310 mmol) in acetonitrile (10 mL). The reaction stirred overnight at 70° C. for 18 h and was then cooled to rt and filtered. The filtrate was then diluted with DCM and washed with water (10 mL) and brine (10 mL). The DCM layers were combined, dried with MgSO4, filtered and purified by reverse-phase MPLC (20 min, 10-100% MeCN:water) to produce pure (S)-1-(4-(tert-butyl)phenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl acetate (0.135 g, 0.263 mmol, 46% yield) as a brown oil. 1H NMR (400 MHz, CDCl3): δ 7.48-7.45 (m, 4H), 7.35-7.14 (m, 10H), 5.73-5.68 (m, 1H), 2.93-2.87 (m, 2H), 2.46-2.37 (m, 1H), 2.87 (t, J=7.7 Hz, 2H), 2.11 (br s, 1H), 2.04 (s, 3H), 1.95-1.84 (m, 3H), 1.80-1.72 (m, 1H), 1.53-1.38 (m, 6H), 1.29 (s, 9H).
  • Figure US20150238473A1-20150827-C00121
    • KSC-335-065 (R)-1-(4-(tert-butyl)phenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl acetate
  • Prepared the same way as KSC-335-064 with diphenyl(piperidin-4-yl)methanol (0.196 g, 0.734 mmol), (R)-1-(4-(tert-butyl)phenyl)-4-chlorobutyl acetate (KSC-335-063) (0.249 g, 0.880 mmol) and potassium carbonate (0.406 g, 2.93 mmol) in acetonitrile to produce pure (R)-1-(4-(tert-butyl)phenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl acetate (0.237 g, 0.461 mmol, 63% yield) as a brown oil. 1H NMR (400 MHz, CDCl3): δ 7.48-7.45 (m, 4H), 7.35-7.14 (m, 10H), 5.73-5.68 (m, 1H), 2.93-2.87 (m, 2H), 2.46-2.37 (m, 1H), 2.87 (t, J=7.7 Hz, 2H), 2.11 (br s, 1H), 2.04 (s, 3H), 1.95-1.84 (m, 3H), 1.80-1.72 (m, 1H), 1.53-1.38 (m, 6H), 1.29 (s, 9H).
  • Figure US20150238473A1-20150827-C00122
    • KSC-335-066 Methyl 2-(4-(4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butanoyl)phenyl)-2-methylpropanoate
  • To a vial was added the methyl 2-(4-(4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)but-1-yn-1-yl)phenyl)-2-methylpropanoate (KSC-335-054) (0.074 g, 0.149 mmol). The mercuric oxide (1.493 ml, 0.045 mmol) was made into a 0.03 M solution in 4% w/v sulfuric acid and added to the starting material then heated to 55° C. and stirred for 3.5 h. The reaction turned a milky white color upon addition of the mercuric oxide solution. The reaction was removed from heat and diluted with saturated NaHCO3 (10 mL) and extracted with DCM (3×10 mL). The DCM layers were combined and dried with MgSO4, filtered and concentrated then purified by reverse-phase MPLC (10-100% MeCN:water) to produce methyl 2-(4-(4-(4-(hydroxydiphenylmethyl) piperidin-1-yl)butanoyl)phenyl)-2-methylpropanoate (0.0217 g, 0.042 mmol, 28.3% yield). 1H NMR (400 MHz, CDCl3): δ 7.93-7.91 (m, 2H), 7.48-7.45 (m, 4H), 7.42-7.39 (m, 2H), 7.30-7.26 (m, 4H), 7.19-7.14 (m, 2H), 3.63 (s, 3H), 2.96-2.88 (m, 4H), 2.44-2.34 (m, 3H), 2.08 (br s, 1H), 1.60 (s, 6H), 1.62-1.56 (m, 4H), 1.46-1.30 (m, 4H).
  • Figure US20150238473A1-20150827-C00123
    • KSC-335-069 (S)-1-(4-(tert-butyl)phenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol
  • To a vial was added the (S)-1-(4-(tert-butyl)phenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl acetate (0.135 g, 0.263 mmol) and this vial was evacuated with nitrogen 3 times. The dry THF (9 mL) was then added. The 1.0 M lithium aluminum hydride (0.263 mL, 0.263 mmol) in THF was added dropwise at rt and the reaction stirred for 5 h. The reaction was quenched slowly with water (10 mL) and then extracted with diethyl ether (2×10 mL). The ether layer was dried with MgSO4, filtered, concentrated and purified by reverse-phase MPLC (20 min, 10-100%, MeCN:H2O) to produce pure (S)-1-(4-(tert-butyl)phenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol (0.100 g, 0.212 mmol, 81% yield). [alpha]25 589=−38.8°. 1H NMR (400 MHz, CDCl3): δ 7.51-7.46 (m, 4H), 7.33-7.24 (m, 8H), 7.20-7.14 (m, 2H), 4.59 (dd, J=8.2 Hz, 2.8 Hz, 1H), 3.13 (br d, J=11.2 Hz, 1H), 2.97 (br d, J=11.2 Hz, 1H), 2.50-2.34 (m, 3H), 2.10-1.88 (m, 4H), 1.84-1.74 (m, 1H), 1.68-1.44 (m, 6H), 1.30 (s, 9H). 13C NMR (125 MHz, CDCl3): δ 149.4, 146.1, 146.0, 142.7, 128.2, 128.1, 126.45, 126.43, 125.7, 125.6, 125.4, 125.0, 79.3, 73.4, 58.9, 54.7, 53.3, 44.2, 39.7, 34.4, 31.4, 26.1, 26.0, 24.1. LCMS Retention time: 4.159 min. LCMS purity 99.7%. HRMS (ESI): m/z calcd for C32H41NO2 [M+H]+ 472.3137. found 472.3210.
  • Figure US20150238473A1-20150827-C00124
    • KSC-335-070 (R)-1-(4-(tert-butyl)phenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol
  • To a vial was added the (R)-1-(4-(tert-butyl)phenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl acetate (0.237 g, 0.461 mmol) and this vial was evacuated with nitrogen 3 times. The dry THF (Volume: 4.61 ml) was added and then the 1.0 M lithium aluminum hydride (0.461 mL, 0.461 mmol) in THF was added portionwise at rt for 5 h. The reaction was quenched slowly with water (10 mL) and then extracted with diethyl ether (2×10 mL). The ether layer was dried with MgSO4, filtered, concentrated and purified by reverse-phase MPLC (20 min, 10-100%, MeCN:H2O) to produce pure (R)-1-(4-(tert-butyl)phenyl)-4-(4-(hydroxydiphenylmethyl) piperidin-1-yl)butan-1-ol (0.116 g, 0.246 mmol, 53% yield). [alpha]25 589=+38.6 °. 1H NMR (400 MHz, CDCl3): δ 7.51-7.46 (m, 4H), 7.33-7.24 (m, 8H), 7.20-7.14 (m, 2H), 4.59 (dd, J=8.2 Hz, 2.8 Hz, 1H), 3.13 (br d, J=11.2 Hz, 1H), 2.97 (br d, J=11.2 Hz, 1H), 2.50-2.34 (m, 3H), 2.10-1.88 (m, 4H), 1.84-1.74 (m, 1H), 1.68-1.44 (m, 6H), 1.30 (s, 9H). 13C NMR (125 MHz, CDCl3): δ 149.4, 146.1, 146.0, 142.7, 128.2, 128.1, 126.45, 126.43, 125.7, 125.6, 125.4, 125.0, 79.3, 73.4, 58.9, 54.7, 53.3, 44.2, 39.7, 34.4, 31.4, 26.1, 26.0, 24.1. LCMS Retention time: 4.156 min. LCMS purity 97.8%. HRMS (ESI): m/z calcd for C32H41NO2 [M+H]+ 472.3137. found 472.3210.
  • Figure US20150238473A1-20150827-C00125
    • KSC-335-077 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(p-tolyl)butan-1-ol
  • Method B: 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(p-tolyl)butan-1-one (0.073 g, 0.171 mmol) and MeOH (Volume: 2 mL) and SODIUM BOROHYDRIDE (0.013 g, 0.341 mmol) to produce pure 4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(p-tolyl)butan-1-ol (0.070 g, 0.163 mmol, 95% yield) as on oil. 1H NMR (400 MHz, CDCl3): δ 7.51-7.46 (m, 4H), 7.32-7.09 (m, 10H), 4.59 (dd, J=8.0, 2.8 Hz, 1H), 3.15-3.09 (m, 1H), 2.99-2.92 (m, 1H), 2.52-2.32 (m, 6H), 2.32 (s, 3H), 2.09-1.87 (m, 3H), 1.82-1.73 (m, 1H), 1.68-1.44 (m, 6H). 13C NMR (125 MHz, CDCl3): δ 146.1, 146.0, 142.9, 136.0, 128.7, 128.11, 128.10, 128.06, 126.39, 126.37, 125.7, 125.6, 125.5, 79.2, 73.3, 58.9, 54.6, 53.4, 53.3, 44.2, 39.9, 30.9, 26.0, 25.9, 26.0, 21.0. LCMS Retention time: 3.809 min. LCMS purity 94.1%. HRMS (ESI): m/z calcd for C29H35NO2 [M+H]+ 430.2668. found 430.2741.
  • Figure US20150238473A1-20150827-C00126
    • KSC-335-080 Methyl 2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoate
  • Method B: methyl 2-(4-(4-(4-(hydroxydiphenylmethyl) piperidin-1-yl)butanoyl)phenyl)-2-methylpropanoate (KSC-335-066)(0.148 g, 0.288 mmol) and MeOH (1 mL) and sodium borohydride (0.016 g, 0.432 mmol) to produce pure methyl 2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoate (0.108 g, 0.209 mmol, 73% yield). 1H NMR (400 MHz, CDCl3): δ 7.54-7.49 (m, 4H), 7.35-7.27 (m, 8H), 7.23-7.17 (m, 2H), 4.62 (dd, J=8.0, 2.8 Hz, 1H), 3.65 (s, 3H), 3.16 (d, J=11.7 Hz, 1H), 2.98 (d, J=11.7 Hz, 1H), 2.53-2.40 (m, 3H), 2.29 (br s, 1H), 2.14-2.06 (m, 1H), 2.01-1.93 (m, 2H), 1.84-1.50 (m, 14H). LCMS Retention time: 3.786 min. LCMS purity 98.2%. HRMS (ESI): m/z calcd for C33H41NO4 [M+H]+ 516.3036. found 516.3108.
  • Figure US20150238473A1-20150827-C00127
    • KSC-335-081 2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid
  • To a vial was added the methyl 2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoate (KSC-335-080) (0.094 g, 0.182 mmol) and THF (Volume: 3 mL,). The LiOH (0.022 g, 0.911 mmol) was dissolved in water (3.00 mL) and then added to the reaction stirred at 80° C. for 18 h. The reaction was removed from heat and cooled to rt and 1.0 M HCl in water was added to adjust to pH to 4 and a gummy off-white solid formed. DCM (5 mL) was added to the mixture and it was sonicated to break up the solid. The DCM layer was removed and the aqueous was extracted with DCM (2×5 mL). The DCM layer was concentrated and the residue was purified by reverse-phase MPLC (20 min, 10-100% MeCN:water) to produce the product with impurities. This was submitted to the purification core. The pure sample was recovered to produce 2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (0.0378 g, 0.075 mmol, 41% yield). 1H NMR (400 MHz, DMSO-d6): δ 8.22 (s, 1H), 7.52-7.49 (m, 4H), 7.29-7.26 (m, 8H), 7.15-7.10 (m, 2H), 4.47 (t, J=5.9 Hz, 1H), 2.94-2.86 (m, 3H), 2.35-2.30 (m, 2H), 2.05-1.95 (m, 2H), 1.60-1.35 (m, 12H), 1.28-1.22 (m, 2H). 13C NMR (125 MHz, CDCl3): δ 177.7, 163.7, 147.2, 144.4, 143.4, 127.8, 125.8, 125.7, 125.6, 125.1, 78.4, 71.8, 57.7, 53.4, 53.2, 45.5, 43.1, 37.3, 26.5, 25.6, 22.6. LCMS Retention time: 2.612 min. LCMS purity 100%. HRMS (ESI): m/z calcd for C32H39NO4 [M+H]+ 502.2879. found 502.2952.
  • Figure US20150238473A1-20150827-C00128
    • KSC-342-006 1-(4-(tert-butyl)phenyl)-2-(4-(hydroxydiphenylmethyl)piperidin-1-yl)ethanone
  • Method A: diphenyl(piperidin-4-yl)methanol (0.4 g, 1.496 mmol), 1-(4-(tert-butyl)phenyl)-2-chloroethanone (0.300 g, 1.425 mmol), sodium bicarbonate (0.144 g, 1.710 mmol) with water (3 mL) and 2-butanone (Volume: 15 mL) to produce pure 1-(4-(tert-butyl)phenyl)-2-(4-(hydroxydiphenylmethyl)piperidin-1-yl)ethanone (0.452 g, 1.024 mmol, 71.8% yield) as a colorless oil. 1H NMR (500 MHz, CDCl3): δ 7.93 (d, J=8.6 Hz, 2H), 7.50-7.43 (m, 6H), 7.32-7.26 (m, 4H), 7.20-7.15 (m, 2H), 3.78 (s, 2H), 3.07-3.01 (m, 2H), 2.47 (tt, J=11.8 Hz, 3.5 Hz, 1H), 2.26-2.18 (m, 2H), 1.66-1.45 (m, 5H), 1.33 (s, 9H).). 13C NMR (125 MHz, CDCl3): δ 196.1, 157.0, 145.8, 133.5, 129.8, 128.2, 128.0, 126.5, 125.8, 125.5, 125.1, 79.5, 64.2, 54.2, 43.8, 35.1, 31.2, 31.0, 26.2. LCMS Retention time: 3.987 min. LCMS purity 98.8%. HRMS (ESI): m/z calcd for C30H35NO2 [M+H]+ 442.2668. found 442.2741.
  • Figure US20150238473A1-20150827-C00129
    • KSC-342-010 1-(4-(tert-butyl)phenyl)-2-(4-(hydroxydiphenylmethyl)piperidin-1-yl)ethanol
  • Method B: 1-(4-(tert-butyl)phenyl)-2-(4-(hydroxydiphenylmethyl)piperidin-1-yl)ethanone (0.113 g, 0.256 mmol) and MeOH (1 mL) and SODIUM BOROHYDRIDE (0.019 g, 0.512 mmol) to produce pure 1-(4-(tert-butyl)phenyl)-2-(4-(hydroxydiphenylmethyl)piperidin-1-yl)ethanol (0.106 g, 0.239 mmol, 93% yield) as a solid. 1H NMR (400 MHz, CDCl3): δ 7.50-7.46 (m, 4H), 7.37-7.26 (m, 8H), 7.22-7.17 (M, 2H), 4.67 (m, 1H), 4.01 (br s, 1H), 3.20 (m, 1H), 2.86 (m, 1H), 2.50-2.45 (m, 3H), 2.37-2.30 (m, 1H), 2.10-2.02 (m, 1H), 1.60-1.45 (m, 5H), 1.31 (s, 9H). 13C NMR (125 MHz, CDCl3): δ 150.3, 145.82, 145.78, 139.1, 128.20, 128.19, 126.59, 126.57, 125.7, 125.6, 125.2, 79.5, 68.6, 66.3, 55.8, 53.4, 52.2, 44.1, 34.5, 31.3, 26.8, 26.5. LCMS Retention time: 4.083 min. LCMS purity 94.2%. HRMS (ESI): m/z calcd for C30H37NO2 [M+H]+ 444.2824. found 444.2897.
  • Figure US20150238473A1-20150827-C00130
    • KSC-342-014 Methyl 4-(4-chloro-1-hydroxybutyl)benzoate
  • Method B: methyl 4-(4-chlorobutanoyl)benzoate (KSC-335-061) (0.042 g, 0.175 mmol) and MeOH with sodium borohydride (0.013 g, 0.349 mmol). to produce methyl 4-(4-chloro-1-hydroxybutyl)benzoate (0.037 g, 0.152 mmol, 87% yield). 1H NMR (400 MHz, CDCl3): δ 8.00 (d, J=8.4 Hz, 2H), 7.40 (d, J=8.2 Hz, 2H), 4.8-4.6 (m, 1H), 3.90 (s, 3H), 3.58-3.52 (m, 2H), 2.19 (br s, 1H), 1.96-1.78 (m, 4H)
  • Figure US20150238473A1-20150827-C00131
    • KSC-342-017 Methyl 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)benzoate
  • To a vial was added the methyl 4-(4-chloro-1-hydroxybutyl)benzoate (KSC-342-014) (0.037 g, 0.152 mmol), diphenyl(piperidin-4-yl)methanol (0.122 g, 0.457 mmol), SODIUM BICARBONATE (0.026 g, 0.305 mmol), SODIUM IODIDE (1.143 mg, 7.62 μmol) and the vial was evacuated with argon 3 times. Dry acetonitrile (2 ml) was added and the reaction stirred overnight at reflux and was then cooled to rt after 18 h and the solvent was concentrated. The residue was dissolved in DCM (5 mL) and washed with 0.1 N HCl (5 mL), water (5 mL) and brine (5 mL). The product was purified by MPLC (0-10% MeOH:DCM) to produce pure methyl 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)benzoate (0.0268 g, 0.057 mmol, 37% yield). 1H NMR (400 MHz, CDCl3): δ 7.97 (d, J=8.4 Hz, 2H), 7.52-7.47 (m, 4H), 7.42 (d, J=7.9 Hz, 2H), 7.32-7.29 (m, 4H), 7.20-7.14 (m, 2H), 4.66 (m, 1H), 3.90 (s, 3H), 3.14 (m, 1H), 2.94 (m, 1H), 2.78 (br s, 1H), 2.52-2.43 (m, 1H), 2.39 (t, J=4.8 Hz, 2H), 2.13-2.06 (m, 1H), 2.04-1.92 (m, 2H), 1.77-1.47 (m, 8H). 13C NMR (125 MHz, CDCl3): δ 167.2, 151.4, 146.0, 145.9, 129.5, 128.4, 128.2, 128.2, 126.51, 126.48, 125.64, 125.59, 79.2, 73.2, 58.8, 54.7, 51.9, 44.2, 40.0, 26.0, 25.9, 24.0. LCMS Retention time: 3.652 min. LCMS purity 100%. HRMS (ESI): m/z calcd for C30H35NO4 [M+H]+ 474.2566. found 474.2639.
  • Figure US20150238473A1-20150827-C00132
    • KSC-342-021 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)benzoic acid
  • To a vial was added the methyl 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)benzoate (0.0195 g, 0.041 mmol) and THF (1 mL). The LiOH (6.90 mg, 0.288 mmol) was dissolved in water (1 mL) and added to the reaction. The reaction stirred at overnight and was then acidified with 1.0 M HCl to pH 2-3 then extracted with DCM (3×5 mL). The DCM layer was concentrated and purified by reverse-phase MPLC (10-100% MeCN:water) to produce pure 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)benzoic acid (0.009 g, 0.020 mmol, 47% yield). 1H NMR (400 MHz, CD3OD): δ 7.85 (d, J=8.2 Hz, 2H), 7.53-7.49 (m, 4H), 7.34-7.26 (m, 6H), 7.19-7.14 (m, 2H), 4.70 (m, 1H), 3.46 (m, 1H), 3.35 (s, 2H), 3.01-2.96 (m, 2H), 2.92-2.77 (m, 3H), 1.84-1.64 (m, 8H). 13C NMR (125 MHz, CD3OD): δ 174.7, 148.2, 147.2, 137.6, 130.4, 129.1, 127.6, 127.0, 126.4, 79.9, 74.0, 53.9, 49.8, 36.9, 25.5, 21.8. LCMS Retention time: 2.490 min. LCMS purity 100%. HRMS (ESI): m/z calcd for C29H33NO4 [M+H]+ 460.2410. found 460.2482.
  • Figure US20150238473A1-20150827-C00133
    • KSC-342-074 1-(Tert-butyl)-4-(2-chloroethyl)benzene
  • To a vial was added the 1-(4-(tert-butyl)phenyl)-2-chloroethanone (0.171 g, 0.812 mmol) and triethylsilane (0.519 mL, 3.25 mmol) with TFA (4 mL). The reaction stirred at 75° C. for 17 h and was then concentrated in vacuo. The residue was dissolved in DCM (5 mL) and washed with water (4 mL). The DCM layer was collected and washed with water (1×5 mL), dried with MgSO4, filtered and adsorbed to silica and purified by MPLC (20 min, 0-40% EtOAc:hex) to produce pure 1-(tert-butyl)-4-(2-chloroethyl)benzene (0.114 g, 0.580 mmol, 71% yield). 1H NMR (400 MHz, CDCl3): δ 7.34 (d, J=8.3 Hz, 2H), 7.16 (d, J=8.3 Hz, 2H), 3.71 (t, J=7.5 Hz, 2H), 3.05 (t, J=7.6 Hz, 2H), 1.32 (s, 9H).
  • Figure US20150238473A1-20150827-C00134
    • KSC-342-080 (1-(3-(4-(Tert-butyl)phenyl)propyl)piperidin-4-yl)diphenylmethanol
  • To a vial was added the diphenyl(piperidin-4-yl)methanol (0.142 g, 0.530 mmol), 1-(tert-butyl)-4-(3-chloropropyl)benzene (0.134 g, 0.636 mmol) and POTASSIUM CARBONATE (0.439 g, 3.18 mmol) in acetonitrile. The reaction stirred overnight at 85° C. for 18 h and then filtered. The filtrate was then diluted with brine and extracted with diethyl ether (3×15 mL). The ether layers were combined, dried with MgSO4, filtered and purified by reverse-phase MPLC (20 min, 10-100% MeCN:water) to produce pure (1-(3-(4-(tert-butyl)phenyl)propyl)piperidin-4-yl)diphenylmethanol (0.152 g, 0.344 mmol, 65% yield) as an oil. 1H NMR (400 MHz, CDCl3): δ 7.49-7.45 (m, 4H), 7.31-7.24 (m, 6H), 7.19-7.14 (m, 2H), 7.11-7.08 (m, 2H), 2.96 (m, 2H), 2.57 (t, J=7.7 Hz, 2H), 2.48-2.32 (m, 3H), 2.22 (br s, 1H), 1.97-1.90 (m, 2H), 1.83-1.75 (m, 2H), 1.53-1.45 (m, 4H), 1.29 (s, 9H). LCMS Retention time: 2.965 min. LCMS purity 97.2%. HRMS (ESI): m/z calcd for C31H39NO [M+H]+ 442.3032. found 442.3104.
  • Figure US20150238473A1-20150827-C00135
    • KSC-342-081 (1-(4-(Tert-butyl)phenethyl)piperidin-4-yl)diphenylmethanol
  • To a vial was added the diphenyl(piperidin-4-yl)methanol (0.150 g, 0.561 mmol), 1-(tert-butyl)-4-(2-chloroethyl)benzene (KSC-342-074) (0.110 g, 0.561 mmol) and potassium carbonate (0.465 g, 3.37 mmol) in acetonitrile. The reaction stirred overnight at 85° C. for 18 h and then filtered. The filtrate was then diluted with brine and extracted with diethyl ether (3×15 mL). The ether layers were combined, dried with MgSO4, filtered and purified by reverse-phase MPLC (20 min, 10-100% MeCN:water) to produce pure (1-(4-(tert-butyl)phenethyl)piperidin-4-yl)diphenylmethanol (0.180 g, 0.421 mmol, 75% yield) as an oil. 1H NMR (400 MHz, CDCl3): δ 7.51-7.47 (m, 4H), 7.33-7.27 (m, 6H), 7.21-7.16 (m, 2H), 7.14-7.11 (m, 2H), 3.09-3.03 (m, 2H), 2.80-2.74 (m, 2H), 2.60-2.55 (m, 2H), 2.51-2.42 (m, 1H), 2.28 (br s, 1H), 2.08-2.00 (m, 2H), 1.57-1.50 (m, 4H), 1.30 (s, 9H). 13C NMR (125 MHz, CDCl3): δ 148.8, 145.9, 137.3, 128.3, 128.1, 126.5, 125.8, 125.2, 79.5, 60.8, 54.0, 44.2, 40.9, 34.3, 33.1, 31.4, 26.4. LCMS Retention time: 4.384 min. LCMS purity 99.7%. HRMS (ESI): m/z calcd for C30H37NO [M+H]+ 428.2875. found 428.2948.
  • Figure US20150238473A1-20150827-C00136
    • KSC-342-088 (1-(4-amino-4-(4-(tert-butyl)phenyl)butyl)piperidin-4-yl)diphenylmethanol
  • To a vial was added the 1-(4-(tert-butyl)phenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (0.200 g, 0.426 mmol), Ammonium acetate (0.328 g, 4.26 mmol) and Sodium cyanoborohydride (0.040 g, 0.639 mmol) with MeOH (Volume: 4 ml). The reaction stirred at rt at 2:56:22 PM. The reaction was stirred overnight and then concentrated and diluted with dilute aqueous ammonium hydroxide and extracted with DCM. The DCM layer was concentrated and the crude NMR showed product and starting material. The reaction then purified by reverse-phase Teledyne ISCO Combiflash chromatography (10-100% MeCN:basic water) and fractions 5 and 6 were collected. These were then subjected to normal phase purification (0-10% MeOH (5% NH3OH):DCM) to produce pure (1-(4-amino-4-(4-(tert-butyl)phenyl)butyl)piperidin-4-yl)diphenylmethanol (0.010 g, 0.021 mmol, 5% yield). 1H NMR (400 MHz, CDCl3): δ 7.48-7.44 (m, 4H), 7.34-7.26 (m, 6H), 7.22-7.14 (m, 4H), 3.84 (t, J=6.7 Hz, 1H), 2.95-2.87 (m, 2H), 2.46-2.37 (m, 1H), 2.28 (t, J=7.6 Hz, 2H), 1.95-1.85 (m, 2H), 1.70-1.60 (m, 5H), 1.55-1.40 (m, 6H), 1.30 (s, 9H). 13C NMR (125 MHz, CDCl3): δ 149.7, 146.0, 143.3, 128.1, 126.5, 125.9, 125.8, 125.3, 79.5, 58.7, 55.8, 54.2, 54.0, 44.2, 37.5, 34.4, 31.4, 26.4, 24.2. LCMS Retention time: 2.397 min. LCMS purity 100%. HRMS (ESI): m/z calcd for C32H42N2O [M+H]+ 471.3297. found 471.3370.
  • Figure US20150238473A1-20150827-C00137
    • KSC-348-001 1-([1,1′-Biphenyl]-4-yl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one
  • To a vial was added the 1-(4-bromophenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (0.098 g, 0.199 mmol), 1,1′-bis(di-t-butylphosphino)ferrocene palladium dichloride, (2.71 mg, 3.98 μmol) and phenylboronic acid (0.029 g, 0.239 mmol) followed by acetonitrile (1.5 mL). The potassium carbonate (0.041 g, 0.299 mmol) was dissolved in water (1.5 mL) and added the reaction. The reaction stirred at 60° C. for 18 h. The reaction was stopped and the organic layer was diluted with EtOAc and extracted then washed with brine. The EtOAc layer was collected, dried with MgSO4, filtered and purified by reverse-phase MPLC (10-100% MeCN:water) to produce the desired 1-([1,1′-biphenyl]-4-yl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (0.035 g, 0.071 mmol, 36% yield). 1H NMR (400 MHz, CDCl3): δ 8.03 (d, J=8.6 Hz, 2H), 7.67 (d, J=8.4 Hz, 2H), 7.64-7.61 (m, 2H), 7.50-7.45 (m, 6H), 7.42-7.38 (m, 1H), 7.31-7.26 (m, 4H), 7.19-7.14 (m, 2H), 3.02-2.91 (m, 4H), 2.46-2.37 (m, 3H), 2.10 (br s, 1H), 1.97-1.92 (m, 4H), 1.50-1.35 (m, 4H).
  • Figure US20150238473A1-20150827-C00138
    • KSC-348-002 1-([1,1′-biphenyl]-4-yl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol
  • Method B: 1-([1,1′-biphenyl]-4-yl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (KSC-348-001) (0.035 g, 0.071 mmol) and MeOH (2 mL) and sodium borohydride (5.41 mg, 0.143 mmol) to produce pure 1-([1,1′-biphenyl]-4-yl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol (0.033 g, 0.067 mmol, 94% yield) as on oil. 1H NMR (400 MHz, CDCl3): δ 7.59-7.55 (m, 2H), 7.53-7.46 (m, 6H), 7.43-7.38 (m, 4H), 7.34-7.25 (m, 5H), 7.19-7.13 (m, 2H), 4.65 (dd, J=8.2 Hz, 2.7 Hz, 1H), 3.16-3.10 (m, 1H), 2.99-2.93 (m, 1H), 2.56 (br s, 1H), 2.50-2.34 (m, 3H), 2.10-1.92 (m, 3H), 1.86-1.76 (m, 1H), 1.70-1.45 (m, 6H).). 13C NMR (125 MHz, CDCl3): δ 146.1, 146.0, 145.0, 141.1, 139.4, 128.6, 128.2, 128.1, 127.01, 126.96, 126.8, 126.44, 126.41, 126.1, 125.7, 125.6, 79.2, 73.3, 58.9, 54.7, 53.3, 44.2, 40.0, 26.0, 25.9, 24.1. LCMS Retention time: 4.049 min. LCMS purity 97.6%. HRMS (ESI): m/z calcd for C34H37NO2 [M+H]+ 492.2824. found 492.2897.
  • Figure US20150238473A1-20150827-C00139
    • KSC-348-049 (4-(tert-butyl)phenyl)(4-(hydroxydiphenylmethyl)piperidin-1-yl)methanone
  • To a vial was added the diphenyl(piperidin-4-yl)methanol (0.232 g, 0.868 mmol), acetonitrile (3 mL) and TEA (0.181 ml, 1.30 mmol). The 4-(tert-butyl)benzoyl chloride (0.173 mL, 0.954 mmol) was added and the reaction stirred at 70° C. for 6 h and was diluted with EtOAc (15 mL) and washed with saturated NaHCO3 (15 mL). The EtOAc was collected, dried with MgSO4, filtered and adsorbed to silica and purified by MPLC (20 min, 0-30% EtOAc:Hex) to produce pure (4-(tert-butyl)phenyl)(4-(hydroxydiphenylmethyl)piperidin-1-yl)methanone (0.304 g, 0.711 mmol, 82% yield) as a white solid. 1H NMR (400 MHz, CDCl3): δ 7.50-7.44 (m, 4H), 7.38-7.14 (m, 10H), 4.77 (br s, 1H), 3.84 (br s, 1H), 3.05-2.63 (m, 3H), 2.25-2.17 (m, 1H), 1.75-1.35 (m, 4H), 1.29 (s, 9H). 13C NMR (125 MHz, CDCl3): δ 170.4, 152.7, 145.4, 133.2, 128.3, 126.7, 125.7, 125.2, 79.5, 44.5, 34.7, 31.2. LCMS Retention time: 3.774 min. LCMS purity 100%. HRMS (ESI): m/z calcd for C29H33NO2 [M+H]+ 428.2511. found 428.2584.
  • Figure US20150238473A1-20150827-C00140
    • KSC-348-050 (1-(4-(tert-butyl)benzyl)piperidin-4-yl)diphenylmethanol
  • To a vial was added the diphenyl(piperidin-4-yl)methanol (0.085 ml, 0.393 mmol), acetonitrile (2 mL) and TEA (0.082 ml, 0.589 mmol). The p-tert-butylbenzyl bromide (0.098 g, 0.432 mmol) was then added and the reaction stirred at 70° C. and stirred for 5 h then diluted with EtOAc (15 mL) and washed with saturated NaHCO3 (15 mL). The EtOAc was collected, dried with MgSO4, filtered and adsorbed to silica and purified by reverse phase MPLC (20 min, 10-100% MeCN:water) to produce pure (1-(4-(tert-butyl)benzyl)piperidin-4-yl)diphenylmethanol (0.131 g, 0.317 mmol, 81% yield) as a brown oil. 1H NMR (400 MHz, CDCl3): δ 7.48-7.45 (m, 4H), 7.32-7.25 (m, 6H), 7.22-7.14 (m, 4H), 3.47 (s, 2H), 2.96-2.90 (m, 2H), 2.46-2.38 (m, 1H), 2.02-1.95 (m, 1H), 1.51-1.44 (m, 4H), 1.30 (s, 9H). 13C NMR (125 MHz, CDCl3): δ 149.8, 146.0, 135.1, 128.9, 128.1, 126.4, 125.8, 125.0, 79.5, 62.8, 53.9, 44.2, 34.4, 31.4, 26.5, 21.0. LCMS Retention time: 4.186 min. LCMS purity 99.7%. HRMS (ESI): m/z calcd for C29H35NO [M+H]+ 414.2719. found 414.2791.
  • Figure US20150238473A1-20150827-C00141
    • KSC-348-058 (1-(4-methoxyphenethyl)piperidin-4-yl)diphenylmethanol
  • To a vial was added the diphenyl(piperidin-4-yl)methanol (0.381 g, 1.425 mmol), acetonitrile (5 mL) and TEA (0.298 ml, 2.138 mmol). The 1-(2-bromoethyl)-4-methoxybenzene (0.245 ml, 1.568 mmol) was then added and the reaction stirred at 75° C. and the stirred for 16 h then was quenched with saturated NaHCO3, extracted with EtOAc, dried with MgSO4, filtered and adsorbed to silica. The product was purified by MPLC (20 min, 0-10% MeOH:DCM) to produce pure (1-(4methoxyphenethyl) piperidin-4-yl)diphenylmethanol (0.289 g, 0.720 mmol, 50% yield) as a sticky solid. 1H NMR (400 MHz, CDCl3): δ 7.49-7.46 (m, 4H), 7.32-7.28 (m, 4H), 7.19 (tt, J=7.3 Hz, 1.9 Hz, 2H), 7.12 (d, J=8.6 Hz, 2H), 6.82 (d, J=8.5 Hz, 2H), 3.77 (s, 3H), 3.29-3.24 (m, 2H), 2.95-2.90 (m, 2H), 2.80-2.75 (m, 2H), 2.58-2.50 (m, 1H), 2.42-2.30 (m, 3H), 1.90-1.77 (m, 2H), 1.65-1.57 (m, 2H). 13C NMR (125 MHz, CDCl3): δ 158.3, 145.5, 129.6, 128.3, 126.7, 125.6, 114.0, 79.3, 55.3, 53.6, 53.4, 43.4, 31.5, 25.1. LCMS Retention time: 3.695 min. LCMS purity 100%. HRMS (ESI): m/z calcd for C27H31NO2 [M+H]+ 402.2355. found 402.2353.
  • Figure US20150238473A1-20150827-C00142
    • KSC-352-055 4-(4-Benzoylpiperidin-1-yl)-1-(4-(tert-butyl)phenyl)butan-1-one
  • To a vial was added the 1-(4-(tert-butyl)phenyl)-4-chlorobutan-1-one (0.060 g, 0.252 mmol) and potassium iodide (0.063 g, 0.377 mmol) with acetonitrile (2 mL). The reaction stirred at 85° C. for 1 h then the phenyl(piperidin-4-yl)methanone (0.050 g, 0.264 mmol) along with potassium carbonate (0.052 g, 0.377 mmol) was added. The reaction was then heated back to 85° C. for 48 h. The reaction was cooled to rt and diluted with water then extracted with EtOAc (3×15 mL). The EtOAc layer was dried with MgSO4, filtered and adsorbed to silica. The product was purified by reverse-phase MPLC (20 min, 10-100% MeCN:water) to produce 4-(4-benzoylpiperidin-1-yl)-1-(4-(tert-butyl)phenyl)butan-1-one (0.026 g, 0.066 mmol, 26% yield). 1H NMR (400 MHz, CDCl3): δ 7.95-7.90 (m, 4H), 7.57-7.53 (m, 1H), 7.49-7.44 (m, 4H), 3.27-3.18 (m, 1H), 3.03-2.96 (m, 4H), 2.44 (t, J=7.04 Hz, 2H), 2.13-2.06 (m, 2H), 1.98-1.91 (m,
  • Figure US20150238473A1-20150827-C00143
    • 2H), 1.85-1.76 (m, 4H), 1.34 (s, 9H). KSC-352-060 (1-(4-nitrophenethyl)piperidin-4-yl)diphenylmethanol
  • To a vial was added the diphenyl(piperidin-4-yl)methanol (0.513 g, 1.919 mmol), 1-(2-bromoethyl)-4-nitrobenzene (0.401 g, 1.744 mmol) and acetonitrile (10 mL). The TEA (0.365 ml, 2.62 mmol) was then added and the reaction stirred at 85° C. for 18 h then cooled to rt. The reaction was diluted with water and extracted with EtOAc (3×15 mL). The EtOAc layer was collected and dried with MgSO4, filtered and adsorbed to silica then purified by MPLC (15 min, 0-10% MeOH:DCM). to produce pure (1-(4-nitrophenethyl)piperidin-4-yl)diphenylmethanol (0.145 g, 0.348 mmol, 20% yield). 1H NMR (400 MHz, CDCl3): δ 8.13 (d, J=8.7 Hz, 2H), 7.49-7.46 (m, 4H), 7.35 (d, J=8.7 Hz, 2H), 7.32-7.27 (m, 4H), 7.21-7.16 (m, 2H), 3.11-3.05 (m, 2H), 2.97-2.91 (m, 2H), 2.69-2.63 (m, 2H), 2.52-2.43 (m, 1H), 2.25 (br s, 1H), 2.20-2.10 (m, 2H), 1.63-1.53 (m, 4H). 13C NMR (125 MHz, CDCl3): δ 147.9, 146.5, 145.7, 129.5, 128.2, 126.6, 125.7, 123.7, 79.4, 59.4, 53.9, 43.9, 33.2, 26.1, 21.1. LCMS Retention time: 3.654 min. LCMS purity 98.8%. HRMS (ESI): m/z calcd for C26H28N2O3 [M+H]+ 417.2162. found 417.2173.
  • Figure US20150238473A1-20150827-C00144
    • KSC-352-061 (1-(4-bromophenethyl)piperidin-4-yl)diphenylmethanol
  • To a vial was added the diphenyl(piperidin-4-yl)methanol (0.496 g, 1.855 mmol), 1-bromo-4-(2-bromoethyl)benzene (0.258 ml, 1.69 mmol) and acetonitrile (10 mL). The TEA (0.353 mL, 2.53 mmol) was then added and the reaction stirred at 85° C. for 18 h then cooled to rt. The reaction was diluted with water and extracted with EtOAc (3×15 mL). The EtOAc layer was collected and dried with MgSO4, filtered and adsorbed to silica then purified by MPLC (15 min, 0-10% MeOH:DCM). to produce pure (1-(4-bromophenethyl)piperidin-4-yl)diphenylmethanol (0.488 g, 1.083 mmol, 64% yield). 1H NMR (400 MHz, CDCl3): δ 7.50-7.46 (m, 4H), 7.38 (d, J=8.3 Hz, 2H), 7.34-7.27 (m, 4H), 7.18 (tt, J=7.3 Hz, 1.8 Hz, 2H), 7.06 (d, J=8.4 Hz, 2H), 3.06-3.00 (m, 2H), 2.77-2.72 (m, 2H), 2.58-2.52 (m, 2H), 2.50-2.41 (m, 1H), 2.15-2.00 (m, 3H), 1.56-1.49 (m, 4H). 13C NMR (125 MHz, CDCl3): δ 145.8, 139.3, 131.4, 130.4, 128.2, 126.6, 125.8, 119.8, 79.5, 60.4, 54.0, 44.1, 33.1, 26.4, 21.1 LCMS Retention time: 3.969 min. LCMS purity 99.8%. HRMS (ESI): m/z calcd for C26H28BrNO [M+H]+ 450.1354. found 450.1427.
  • Figure US20150238473A1-20150827-C00145
    • KSC-352-063 (1-(2-([1,1′-biphenyl]-4-yl)ethyl)piperidin-4-yl)diphenylmethanol
  • To a vial was added the phenylboronic acid (0.019 g, 0.152 mmol), 1,1′-bis(di-tert-butylphosphino)ferrocene palladium dichloride (4.12 mg, 6.33 μmol), (1-(4-bromophenethyl)piperidin-4-yl)diphenylmethanol (KSC-352-061) (0.057 g, 0.127 mmol) and potassium carbonate (0.035 g, 0.253 mmol). The vial was then evacuated with argon 3 times and acetonitrile (1 mL) was added followed by water (1 mL). The reaction then stirred at 60° C. for 18 h then was diluted with EtOAc (5 mL) and saturated NaHCO3 (5 mL). The EtOAc layer was collected and the aqueous layer was extracted with more EtOAc (2×5 mL). The EtOAc layers were combined and dried with MgSO4, filtered and concentrated. The reaction was purified by MPLC (10-100% MeCN:water) to produce pure (1-(2-([1,1′-biphenyl]-4-yl)ethyl)piperidin-4-yl)diphenylmethanol (0.045 g, 0.101 mmol, 79% yield) as a clear oil. 1H NMR (400 MHz, CDCl3): δ 7.59-7.45 (m, 2H), 7.53-7.48 (m, 6H), 7.45-7.40 (m, 2H), 7.35-7.25 (m, 7H), 7.22-7.16 (m, 2H), 3.11-3.05 (m, 2H), 2.87-2.81 (m, 2H), 2.65-2.59 (m, 2H), 2.53-2.44 (m, 1H), 2.22 (br s, 1H), 2.12-2.04 (m, 2H), 1.59-1.52 (m, 4H). 13C NMR (125 MHz, CDCl3): δ 145.9, 141.0, 139.5, 139.0, 129.1, 128.7, 128.2, 127.1, 127.03, 126.96, 126.5, 125.8, 79.5, 60.7, 54.0, 50.8, 44.2, 33.3, 26.4. LCMS Retention time: 4.086 min. LCMS purity 99%. HRMS (ESI): m/z calcd for C32H33NO [M+H]+ 448.2562. found 448.2635.
  • Figure US20150238473A1-20150827-C00146
    • KSC-352-064 Diphenyl(1-(4-(pyridin-4-yl)phenethyl)piperidin-4-yl)methanol
  • To a vial was added the (1-(4-bromophenethyl)piperidin-4-yl)diphenylmethanol (KSC-352-061) (0.050 g, 0.111 mmol), pyridin-4-ylboronic acid (0.018 g, 0.133 mmol), 1,1′-bis(di-tert-butylphosphino)ferrocene palladium dichloride (3.62 mg, 5.55 μmol) and potassium carbonate (0.031 g, 0.222 mmol). The vial was evacuated 3 times with argon and then acetonitrile (1 mL) followed by water (1 mL) was added. The reaction stirred at 60° C. for 18 h and was then cooled to rt and diluted with EtOAc (5 mL) and saturated NaHCO3 (5 mL). The EtOAc layer was collected and the aqueous layer was extracted with more EtOAc (2×5 mL). The EtOAc layers were combined and dried with MgSO4, filtered and concentrated. The reaction was purified by reverse-phase MPLC (10-100% MeCN:water) to produce pure diphenyl(1-(4-(pyridin-4-yl)phenethyl)piperidin-4-yl)methanol (0.015 g, 0.033 mmol, 30% yield) as an oil. 1H NMR (400 MHz, CDCl3): δ 8.64-8.62 (m, 2H), 7.60 (d, J=8.2 Hz, 2H), 7.51-7.46 (m, 6H), 7.32-7.28 (m, 6H), 7.18 (tt, J=7.3 Hz, 1.8 Hz, 2H), 3.10-3.04 (m, 2H), 2.88-2.82 (m, 2H), 2.65-2.58 (m, 2H), 2.51-2.43 (m, 1H), 2.19 (br s, 1H), 2.12-2.03 (m, 2H), 1.58-1.51 (m, 4H). 13C NMR (125 MHz, CDCl3): δ 150.2, 148.1, 145.9, 141.7, 135.8, 129.5, 128.2, 127.0, 126.5, 125.8, 121.4, 79.5, 60.5, 54.1, 44.1, 41.0, 33.4, 26.4. LCMS Retention time: 3.585 min. LCMS purity 93.3%. HRMS (ESI): m/z calcd for C31H32N2O [M+H]+ 449.2515. found 449.2587.
  • Figure US20150238473A1-20150827-C00147
    • KSC-352-065 Diphenyl(1-(4-(pyridin-3-yl)phenethyl)piperidin-4-yl)methanol
  • To a vial was added the (1-(4-bromophenethyl)piperidin-4-yl)diphenylmethanol (0.057 g, 0.127 mmol), pyridin-3-ylboronic acid (0.019 g, 0.152 mmol), 1,1′-Bis(di-tert-butylphosphino)ferrocene palladium dichloride (4.12 mg, 6.33 μmol) and potassium carbonate (0.035 g, 0.253 mmol). The vial was evacuated with argon 3 times and then acetonitrile (1 mL) followed by water (1 mL) was added. The reaction stirred at 60° C. for 18 h and then cooled to rt and diluted with EtOAc (5 mL) and saturated NaHCO3 (5 mL). The EtOAc layer was collected and the aqueous layer was extracted with more EtOAc (2×5 mL). The EtOAc layers were combined and dried with MgSO4, filtered and concentrated. The reaction was purified by RP MPLC (10-100% MeCN:water) to produce pure diphenyl(1-(4-(pyridin-3-yl)phenethyl)piperidin-4-yl)methanol (0.05 g, 0.111 mmol, 88% yield) as an oil. 1H NMR (400 MHz, CDCl3): δ 8.79 (dd, J=2.4 Hz, 0.9 Hz, 1H), 8.53 (dd, J=4.8 Hz, 1.6 Hz, 1H), 7.86-7.83 (m, 1H), 7.51-7.47 (m, 6H), 7.36-7.27 (m, 7H), 7.20-7.15 (m, 2H), 3.10-3.03 (m, 2H), 2.87-2.81 (m, 2H), 2.71 (br s, 1H), 2.63-2.58 (m, 2H), 2.51-2.43 (m, 1H), 2.11-2.03 (m, 2H), 1.58-1.52 (m, 4H).). 13C NMR (125 MHz, CDCl3): δ 148.04, 147.97, 146.0, 140.5, 136.5, 135.5, 134.3, 129.4, 128.1, 127.1, 126.4, 125.8, 123.5, 79.4, 60.5, 54.1, 44.1, 33.2, 26.2. LCMS Retention time: 3.582 min. LCMS purity 98.8%. HRMS (ESI): m/z calcd for C31H32N2O [M+H]+ 449.2515. found 449.2587.
  • Figure US20150238473A1-20150827-C00148
    • KSC-352-066 1-(4-(tert-butyl)phenyl)-4-(4-(hydroxy(phenyl)methyl)piperidin-1-yl)butan-1-ol
  • Method B: 4-(4-benzoylpiperidin-1-yl)-1-(4-(tert-butyl)phenyl)butan-1-one (KSC-352-055) (0.026 g, 0.066 mmol) and MeOH (2 mL) and sodium borohydride (10.05 mg, 0.266 mmol) to produce pure 1-(4-(tert-butyl)phenyl)-4-(4-(hydroxy(phenyl)methyl)piperidin-1-yl)butan-1-ol (0.019 g, 0.048 mmol, 72% yield) as a mixture of diastereomers. 1H NMR (400 MHz, CDCl3): δ 7.36-7.24 (m, 9H), 4.63-4.57 (m, 1H), 4.33 (d, J=7.6 Hz, 1H), 3.23-2.83 (m, 2H), 2.42-2.35 (m, 2H), 2.13-1.89 (m, 3H), 1.86-1.52 (m, 6H), 1.46-1.16 (m, 4H), 1.31 (s, 9H). 13C NMR (125 MHz, CDCl3): δ 149.4, 143.4, 142.8, 128.3, 127.63, 127.61, 126.6, 125.4, 125.0, 78.74, 78.67, 73.4, 58.9, 54.30, 54.26, 52.8, 52.7, 43.21, 43.2, 39.9, 34.4, 31.4, 28.4, 28.3, 28.2, 24.2, 24.1. LCMS Retention time: 3.707 min. LCMS purity 97.1%. HRMS (ESI): m/z calcd for C26H37NO2 [M+H]+ 396.2824. found 396.2897.
  • Figure US20150238473A1-20150827-C00149
    • KSC-352-069 (1-(4-aminophenethyl)piperidin-4-yl)diphenylmethanol
  • To a vial was added the (1-(4-nitrophenethyl) piperidin-4-yl)diphenylmethanol (KSC-352-060) (0.135 g, 0.324 mmol) with MeOH (1 mL) and DCM (1 mL). The reaction was cooled to 0° C. and the Raney Nickel (1.902 mg, 0.032 mmol) was added. The sodium borohydride (0.031 g, 0.810 mmol) was then added portionwise and the reaction stirred at rt for 28 h and the Raney Nickel filtered through celite. The reaction was diluted with DCM and washed with water and the DCM layer was dried with MgSO4, filtered and adsorbed to silica then purified by MPLC (0-15% MeOH:DCM) to produce pure (1-(4-aminophenethyl)piperidin-4-yl)diphenylmethanol (0.077 g, 0.199 mmol, 61% yield). 1H NMR (400 MHz, CDCl3): δ 7.51-7.47 (m, 4H), 7.32-7.27 (m, 4H), 7.18 (tt, J=7.3 Hz, 1.8 Hz, 2H), 6.97 (d, J=8.3 Hz, 2H), 6.61 (d, J=8.3 Hz, 2H), 3.52 (br s, 2H), 3.07-3.01 (m, 2H), 2.70-2.65 (m, 2H), 2.54-2.41 (m, 3H), 2.22 (br s, 1H), 2.07-1.98 (m, 2H), 1.56-1.49 (m, 4H). 13C NMR (125 MHz, CDCl3): δ 145.9, 144.4, 130.4, 129.4, 128.1, 126.5, 125.8, 115.2, 79.5, 61.2, 54.1, 44.2, 32.8, 26.4, 21.0. LCMS Retention time: 3.328 min. LCMS purity 93.1%. HRMS (ESI): m/z calcd for C26H30N2O [M+H]+ 387.2358. found 387.2431.
  • Figure US20150238473A1-20150827-C00150
    • KSC-352-075 (1-(4-(Dimethylamino)phenethyl)piperidin-4-yl)diphenylmethanol
  • To a vial was added the (1-(4-aminophenethyl)piperidin-4-yl)diphenylmethanol (KSC-352-069) (0.030 g, 0.078 mmol) and acetic acid (1 mL). The paraformaldehyde (0.058 mL, 0.776 mmol) solution in water followed by sodium cyanoborohydride (0.015 g, 0.233 mmol) was then added and the reaction stirred at rt for 20 h. The reaction was concentrated and diluted with saturated NaHCO3 and extracted with EtOAc (3×5 mL). The EtOAc layer was dried with MgSO4, filtered and concentrated. The product was purified by reverse-phase MPLC (10-100% MeCN:water) to produce (1-(4-(dimethylamino)phenethyl)piperidin-4-yl)diphenylmethanol (0.027 g, 0.065 mmol, 84% yield). 1H NMR (400 MHz, CDCl3): δ 7.50-7.46 (m, 4H), 7.31-7.26 (m, 4H), 7.17 (tt, J=7.3 Hz, 1.8 Hz, 2H), 7.06 (d, J=8.3 Hz, 2H), 6.68 (d, J=8.3 Hz, 2H), 3.08-3.02 (m, 2H), 2.90 (s, 6H), 2.72-2.67 (m, 2H), 2.56-2.50 (m, 2H), 2.48-2.42 (m, 1H), 2.30 (br s, 1H), 2.07-2.00 (m, 2H), 1.56-1.51 (m, 4H). 13C NMR (125 MHz, CDCl3): δ 149.1, 146.0, 129.2, 128.4, 128.1, 126.4, 125.8, 112.9, 79.4, 61.1, 54.0, 44.2, 41.0, 40.8, 32.6, 26.4. LCMS Retention time: 2.50 min. LCMS purity 96.1%. HRMS (ESI): m/z calcd for C28H34N2O [M+H]+ 415.2671. found 415.2744.
  • Figure US20150238473A1-20150827-C00151
    • KSC-352-082 Diphenyl(1-(4-(trifluoromethyl)phenethyl)piperidin-4-yl)methanol
  • To a vial was added the diphenyl(piperidin-4-yl)methanol (0.100 g, 0.374 mmol), 1-(2-bromoethyl)-4-(trifluoromethyl)benzene (0.057 ml, 0.340 mmol) and acetonitrile (10 mL). The TEA (0.071 mL, 0.510 mmol) was then added and the reaction stirred at 85° C. for 18 h. The reaction was diluted with water and extracted with EtOAc (3×15 mL). The EtOAc layer was collected and dried with MgSO4, filtered and adsorbed to silica then purified by MPLC (15 min, 0-10% MeOH:DCM) to produce pure diphenyl(1-(4-(trifluoromethyl)phenethyl)piperidin-4-yl)methanol (0.074 g, 0.168 mmol, 49% yield) as an oil. 1H NMR (400 MHz, CDCl3): δ 7.54-7.47 (m, 4H), 7.33-7.27 (m, 6H), 7.19 (tt, J=7.3 Hz, 1.8 Hz, 2H), 3.06-3.00 (m, 2H), 2.86-2.80 (m, 2H), 2.60-2.55 (m, 2H), 2.51-2.42 (m, 1H), 2.14 (br s, 1H), 2.10-2.03 (m, 2H), 1.57-1.47 (m, 4H). 13C NMR (125 MHz, CDCl3): δ 145.9, 144.6, 129.0, 128.3 (q, J=32 Hz), 128.2, 126.5, 125.8, 125.2 (q, 3.8 Hz), 124.2 (q, J=271.8 Hz), 79.5, 60.2, 54.1, 44.1, 33.6, 26.4, 21.0. LCMS Retention time: 3.877 min. LCMS purity 99.1%. HRMS (ESI): m/z calcd for C27H28F3NO [M+H]+ 440.2123. found 440.2196.
  • Figure US20150238473A1-20150827-C00152
    • KSC-352-088 (1-(4-Fluorophenethyl)piperidin-4-yl)diphenylmethanol
  • To a vial was added the diphenyl(piperidin-4-yl)methanol (0.099 g, 0.370 mmol), 1-(2-bromoethyl)-4-fluorobenzene (0.047 mL, 0.337 mmol) and acetonitrile (10 mL). The TEA (0.070 mL, 0.505 mmol) was then added and the reaction stirred at 85° C. at for 19 h and was cooled to rt. The reaction was diluted with water and extracted with EtOAc (3×15 mL). The EtOAc layer was collected and dried with MgSO4, filtered and adsorbed to silica then purified by MPLC (15 min, 0-10% MeOH:DCM) to produce pure (1-(4-fluorophenethyl)piperidin-4-yl)diphenylmethanol (0.123 g, 0.316 mmol, 94% yield). 1H NMR (400 MHz, CDCl3): δ 7.51-7.47 (m, 4H), 7.32-7.27 (m, 4H), 7.21-7.11 (m, 4H), 6.98-6.92 (m, 2H), 3.06-3.00 (m, 2H), 2.78-2.72 (m, 2H), 2.56-2.51 (m, 2H), 2.50-2.42 (m, 1H), 2.21 (br s, 1H), 2.08-1.99 (m, 2H), 1.57-1.48 (m, 4H). 13C NMR (125 MHz, CDCl3): δ 161.2 (d, J=243.6 Hz), 145.9, 136.5 (d, J=3.2 Hz), 129.9 (d, J=7.9 Hz), 128.1, 126.5, 125.8, 115.0 (d, J=21.2 Hz), 79.5, 60.8, 54.1, 44.2, 33.0, 26.4, 21.0. LCMS Retention time: 3.733 min. LCMS purity 96.8%. HRMS (ESI): m/z calcd for C26H28FNO [M+H]+ 390.2155. found 390.2228.
  • Figure US20150238473A1-20150827-C00153
    • KSC-352-090 2-(3-(Tert-butyl)phenyl)ethanol
  • To a vial was added the 1-bromo-3-(tert-butyl)benzene (0.107 g, 0.502 mmol) and dry THF. The reaction was then cooled to −78° C. and the BuLi (0.221 mL, 0.552 mmol) (2.5 M in hexanes) was added dropwise and the reaction stirred for 30 min at −78° C. and then ethylene oxide (0.502 mL, 1.255 mmol) (2.5-3.3M solution in THF) was added dropwise and the reaction stirred for 10 minutes at −78° C. then warmed to rt and stirred for 1 h. The reaction was then quenched with 1.0 M HCl (2 mL) and extracted with EtOAc (3×5 mL). The EtOAc layer was combined, concentrated and purified by reverse-phase MPLC (10-100% MeCN:water) to produce pure 2-(3-(tert-butyl)phenyl)ethanol (0.035 g, 0.196 mmol, 39% yield). 1H NMR (400 MHz, CDCl3): δ 7.31-7.27 (m, 3H), 7.10-7.07 (m, 1H), 3.90 (t, J=6.6 Hz, 2H), 2.91 (t, J=6.5 Hz, 2H), 1.52 (br s, 1H), 1.36 (s, 9H).
  • Figure US20150238473A1-20150827-C00154
    • KSC-352-093 3-(Tert-butyl)phenethyl 4-methylbenzenesulfonate
  • To a vial was added the 2-(3-(tert-butyl)phenyl)ethanol (KSC-352-090) (0.035 g, 0.196 mmol), TEA (0.082 mL, 0.589 mmol) and DCM (2 mL) followed by p-toluenesulfonyl chloride (0.056 g, 0.294 mmol). The reaction began to stir at rt for 20 h and was then diluted with saturated NaHCO3 and extracted with EtOAc. The EtOAc was then dried with MgSO4, filtered and concentrated then purified by reverse-phase MPLC (10-100% MeCN:water) to provide pure 3-(tert-butyl)phenethyl 4-methylbenzenesulfonate (0.060 g, 0.180 mmol, 92% yield). 1H NMR (400 MHz, CDCl3): δ 7.70 (d, J=8.4 Hz, 2H), 7.30-7.24 (m, 3H), 7.19 (t, J=7.52 Hz, 1H), 7.14-7.12 (m, 1H), 4.22 (t, J=7.2 Hz, 2H), 2.96 (t, J=7.2 Hz, 2H), 2.43 (s, 3H), 1.29 (s, 9H).
  • Figure US20150238473A1-20150827-C00155
    • KSC-352-097 (1-(3-(Tert-butyl)phenethyl)piperidin-4-yl)diphenylmethanol
  • To a vial was added the 3-(tert-butyl)phenethyl 4-methylbenzenesulfonate (KSC-352-093) (0.060 g, 0.180 mmol), diphenyl(piperidin-4-yl)methanol (0.048 g, 0.180 mmol) and acetonitrile (1 mL). The TEA (0.038 mL, 0.271 mmol) was added and the reaction stirred at 85° C. for 18 h and was cooled to rt then diluted with water and extracted with EtOAc. The EtOAc layer was concentrated and the crude product was purified by reverse-phase MPLC (10-100% MeCN:water) to produce the pure (1-(3-(tert-butyl)phenethyl)piperidin-4-yl)diphenylmethanol (0.065 g, 0.152 mmol, 84% yield). 1H NMR (400 MHz, CDCl3): δ 7.51-7.47 (m, 4H), 7.32-7.27 (m, 4H), 7.23-7.16 (m, 5H), 7.01-6.98 (m, 1H), 3.09-3.04 (m, 2H), 2.81-2.76 (m, 2H), 2.61-2.55 (m, 2H), 2.51-2.43 (m, 1H), 2.28 (br s, 1H), 2.10-2.02 (m, 2H), 1.30 (s, 9H), 1.32-1.26 (m, 4H). 13C NMR (125 MHz, CDCl3): δ 151.2, 145.9, 140.0, 128.1, 128.0, 126.5, 125.8, 125.71, 125.68, 123.0, 79.5, 54.1, 44.2, 34.6, 34.0, 31.6, 31.4, 26.4, 22.6. LCMS Retention time: 4.214 min. LCMS purity 96.4%. HRMS (ESI): m/z calcd for C30H37NO [M+H]+ 428.2875. found 428.2948.
  • Figure US20150238473A1-20150827-C00156
    • KSC-352-099 3-((Phenylsulfonyl)methylene)oxetane
  • To an oven-dried vial was added (methylsulfonyl)benzene (0.570 g, 3.65 mmol) and the vial was evacuated with argon 3 times. The dry THF (17 mL) was added and the reaction was cooled to 0° C. The 2.5 M BuLi in hexanes (3.21 mL, 8.03 mmol) was added dropwise and the reaction began to stir at 0° C. and stirred for 45 minutes. The diethyl chlorophosphate (0.528 mL, 3.65 mmol) was then added at 0° C. and the reaction stirred for 30 minutes. The reaction was then cooled to −78° C. and the oxetan-3-one (0.330 mL, 5.15 mmol) was then added dropwise and the reaction stirred for 2 h. The reaction was then warmed to rt and filtered through a silica plug. The reaction was then concentrated onto silica and purified by MPLC (20 min, 0-40% EtOAc:hex) to provide pure 3-((phenylsulfonyl)methylene)oxetane (0.579 g, 2.75 mmol, 75% yield). 1H NMR (400 MHz, CDCl3): δ 7.91-7.87 (m, 2H), 7.69-7.64 (m, 1H), 7.60-7.55 (m, 2H), 6.12 (quintet, J=2.3 Hz, 1H), 5.66-5.63 (m, 2H), 5.30-5.27 (m, 2H).
  • Figure US20150238473A1-20150827-C00157
    • KSC-367-003 2-(4-(3-((Phenylsulfonyl)methyl)oxetan-3-yl)phenyl)ethanol
  • To a vial was added the chloro(1,5-cyclooctadiene)rhodium(I), dimer (0.012 g, 0.025 mmol) and 1,4-dioxane (10 mL). The 1.5 M aqueous KOH (0.496 mL, 0.745 mmol) was then added and the reaction stirred for 1 minute at rt. Then the (4-(2-hydroxyethyl)phenyl)boronic acid (0.103 g, 0.621 mmol) and 3-((phenylsulfonyl)methylene)oxetane (KSC-352-099) (0.052 g, 0.248 mmol) in 1 mL dioxane was added and the reaction stirred for 30 minutes at 100° C. in μwaves. The reaction was then cooled to rt and diluted with EtOAc and washed with 1.0 M HCl. The water layer was extracted with EtOAc (3×15 mL). The EtOAc layer was collected and the water was extracted with EtOAc again. The EtOAc layers were combined and dried with MgSO4, filtered and concentrated then purified by reverse-phase MPLC (30 min, 10-100% MeCN:water) to produce pure 2-(4-(3-((phenylsulfonyl)methyl) oxetan-3-yl)phenyl)ethanol (0.063 g, 0.190 mmol, 76% yield). 1H NMR (400 MHz, CDCl3): δ 7.55-7.52 (m, 2H), 7.50-7.46 (m, 1H), 7.36-7.31 (m, 2H), 7.09 (d, J=8.4 Hz, 2H), 7.01 (d, J=8.3 Hz, 2H), 5.03 (d, J=6.4 Hz, 2H), 4.93 (d, J=6.4 Hz, 2H), 4.03 (s, 2H), 3.82 (t, J=7.3 Hz, 2H), 2.80 (t, J=7.3 Hz, 2H).
  • Figure US20150238473A1-20150827-C00158
    • KSC-367-027 4-(diphenylmethylene)piperidine
  • To a vial was added the diphenyl(piperidin-4-yl)methanol (0.514 g, 1.922 mmol) and TFA (4 mL). The reaction stirred at 75° C. at for 24 h and was concentrated in vacuo. The residue was then dissolved in DCM (5 mL) and washed with water (4 mL). The DCM layer was collected and washed with water (1×5 mL), dried with MgSO4, filtered concentrated then purified by reverse-phase MPLC (10-100% MeCN:Hex) to produce pure 4-(diphenylmethylene)piperidine (0.296 g, 1.187 mmol, 62% yield). 1H NMR (400 MHz, CDCl3): δ 7.34-7.28 (m, 4H), 7.25-7.20 (m, 2H), 7.18-7.14 (m, 4H), 2.96-2.92 (m, 4H), 2.37-2.33 (m, 4H), 1.75 (br s, 1H).
  • Figure US20150238473A1-20150827-C00159
    • KSC-367-032 4-(4-Benzylpiperidin-1-yl)-1-(4-(tert-butyl)phenyl)butan-1-one
  • To a vial was added the 4-benzylpiperidine (0.25 ml, 1.422 mmol), 1-(4-(tert-butyl)phenyl)-4-chlorobutan-1-one (0.407 g, 1.707 mmol), acetonitrile and TEA (0.297 mL, 2.133 mmol). The reaction stirred at 85° C. for 17 h. The reaction was cooled to rt and diluted with saturated NaHCO3 then extracted with EtOAc. The EtOAc was dried with MgSO4, filtered and concentrated. The crude material was purified by reverse-phase MPLC (10-100% MeCN:water) to produce 4-(4-benzylpiperidin-1-yl)-1-(4-(tert-butyl)phenyl)butan-1-one (0.291 g, 0.771 mmol, 54% yield). 1H NMR (400 MHz, CDCl3): δ 7.91 (d, J=8.6 Hz, 2H), 7.47 (d, J=8.5 Hz, 2H), 7.29-7.24 (m, 2H), 7.20-7.16 (m, 1H), 7.14-7.11 (m, 2H), 2.96 (t, J=7.2 Hz, 2H), 2.90-2.84 (m, 2H), 2.50 (d, J=7.0 Hz, 2H), 2.36 (t, J=7.3 Hz, 2H), 1.96-1.82 (m, 4H), 1.63-1.56 (m, 2H), 1.53-1.46 (m, 1H), 1.34 (s, 9H), 1.28-1.18 (m, 2H).
  • Figure US20150238473A1-20150827-C00160
    • KSC-367-033 3-(4-(Hydroxydiphenylmethyl)piperidin-1-yl)propan-1-ol
  • To a vial was added the diphenyl(piperidin-4-yl)methanol (0.502 g, 1.878 mmol), 3-bromopropan-1-ol (0.204 mL, 2.253 mmol), acetonitrile and TEA (0.393 mL, 2.82 mmol). The reaction stirred at 85° C. for 3 h. The reaction was cooled to rt and diluted with saturated NaHCO3 and extracted with EtOAc. The EtOAc layer was concentrated and purified by reverse-phase MPLC (10-100% MeCN:water) to provide 3-(4-(hydroxydiphenylmethyl)piperidin-1-yl)propan-1-ol (0.395 g, 1.214 mmol, 65% yield) as a white solid. 1H NMR (400 MHz, CDCl3): δ 7.48-7.44 (m, 4H), 7.31-7.27 (m, 4H), 7.20-7.15 (m, 2H), 5.45 (br s, 1H), 3.75 (t, J=5.2 Hz, 2H), 3.12-3.06 (m, 2H), 2.57 (t, J=5.7 Hz, 2H), 2.47-2.36 (m, 1H), 1.98-1.91 (m, 2H), 1.70-1.65 (m, 3H), 1.54-1.42 (m, 4H).
  • Figure US20150238473A1-20150827-C00161
    • KSC-367-036 3-(4-(Hydroxydiphenylmethyl)piperidin-1-yl)propyl 4-methylbenzenesulfonate
  • Prepared with same method at KSC-352-093 using 3-(4-(hydroxydiphenylmethyl)piperidin-1-yl)propan-1-ol (KSC-367-033) (0.395 g, 1.214 mmol), 4-methylbenzene-1-sulfonyl chloride (0.347 g, 1.821 mmol), DCM (5 mL) and TEA (0.508 mL, 3.64 mmol) to produce pure 3-(4-(hydroxydiphenylmethyl)piperidin-1-yl)propyl 4-methylbenzenesulfonate (0.193 g, 0.402 mmol, 33% yield). 1H NMR (400 MHz, CDCl3): δ 7.69-7.66 (m, 2H), 7.46-7.41 (m, 4H), 7.24-7.19 (m, 4H), 7.15-7.05 (m, 4H), 4.26-4.12 (m, 4H), 3.73-3.65 (m, 2H), 3.27-3.18 (m, 2H), 2.68-2.60 (m, 1H), 2.47-2.37 (m, 2H), 2.30 (s, 3H), 1.88-1.76 (m, 2H), 1.52-1.43 (m, 2H).
  • Figure US20150238473A1-20150827-C00162
    • KSC-367-039 4-(4-Benzylpiperidin-1-yl)-1-(4-(tert-butyl)phenyl)butan-1-ol
  • Method B: 4-(4-benzylpiperidin-1-yl)-1-(4-(tert-butyl)phenyl)butan-1-one (KSC-367-032) (0.291 g, 0.771 mmol) and MeOH (5 mL) and sodium borohydride (0.117 g, 3.08 mmol) to produce pure 4-(4-benzylpiperidin-1-yl)-1-(4-(tert-butyl)phenyl)butan-1-ol (0.232 g, 0.611 mmol, 79% yield). 1H NMR (400 MHz, CDCl3): δ 7.35-7.25 (m, 6H), 7.21-7.12 (m, 3H), 4.64-4.60 (m, 1H), 3.13-3.07 (m, 1H), 2.94-2.88 (m, 1H), 2.54 (d, J=7.0 Hz, 2H), 2.44-2.34 (m, 2H), 2.03-1.93 (m, 2H), 1.90-1.38 (m, 10H), 1.31 (s, 9H). 13C NMR (125 MHz, CDCl3): δ 149.4, 142.9, 140.7, 129.1, 128.2, 125.8, 125.4, 125.0, 73.5, 59.0, 54.6, 52.9, 42.9, 40.1, 38.0, 34.4, 31.8, 31.6, 31.4, 24.3. LCMS Retention time: 4.330 min. LCMS purity 99.1%. HRMS (ESI): m/z calcd for C26H37NO [M+H]+ 380.2875. found 380.2948.
  • Figure US20150238473A1-20150827-C00163
    • KSC-367-043 (1-(3-((4-(Tert-butyl)phenyl)amino)propyl)piperidin-4-yl)diphenylmethanol
  • To a vial was added the 3-(4-(hydroxydiphenylmethyl)piperidin-1-yl)propyl 4-methylbenzenesulfonate (KSC-367-036) (0.088 g, 0.183 mmol), 4-(tert-butyl)aniline (0.035 mL, 0.220 mmol) and TEA (0.038 mL, 0.275 mmol) with acetonitrile (3 mL). The reaction began to stir at 85° C. for 18 h and was then cooled to rt and diluted with saturated NaHCO3 then extracted with EtOAc. The EtOAc was concentrated and purified by reverse-phase MPLC (10-100% MeCN:water) to produce pure (1-(3-((4-(tert-butyl)phenyl)amino) propyl)piperidin-4-yl)diphenylmethanol (0.038 g, 0.083 mmol, 45% yield). 1H NMR (400 MHz, CDCl3): δ 7.50-7.46 (m, 4H), 7.33-7.28 (m, 4H), 7.21-7.16 (m, 4H), 6.51 (d, J=8.7 Hz, 2H), 3.13 (t, J=6.4 Hz, 2H), 3.02-2.96 (m, 2H), 2.49-2.41 (m, 3H), 2.15 (br s, 1H), 2.00-1.93 (m, 2H), 1.80-1.73 (m, 2H), 1.57-1.43 (m, 5H), 1.27 (s, 9H). 13C NMR (125 MHz, CDCl3): δ 146.4, 145.9, 139.7, 128.2, 126.5, 125.9, 125.8, 112.4, 79.6, 57.4, 54.2, 44.2, 43.7, 33.8, 31.5, 26.6, 26.2. LCMS Retention time: 4.208 min. LCMS purity 100%. HRMS (ESI): m/z calcd for C30H38N2O [M+H]+ 457.6620. found 457.3194.
  • Figure US20150238473A1-20150827-C00164
    • KSC-367-044 (1-(3-(4-(Tert-butyl)phenoxy)propyl)piperidin-4-yl)diphenylmethanol
  • To a vial was added the 3-(4-(hydroxydiphenylmethyl)piperidin-1-yl)propyl 4-methylbenzenesulfonate (KSC-367-036) (0.105 g, 0.219 mmol), 4-(tert-butyl)phenol (0.039 g, 0.263 mmol) and TEA (0.046 mL, 0.328 mmol) with acetonitrile (3 mL). The reaction stirred at 85° C. for 18 h then diluted with saturated NaHCO3 and extracted with EtOAc. The EtOAc layer was concentrated and purified by RP MPLC (10-100% MeCN:water) to produce pure (1-(3-(4-(tert-butyl)phenoxy)propyl)piperidin-4-yl)diphenylmethanol (0.015 g, 0.033 mmol, 15% yield). 1H NMR (400 MHz, CDCl3): δ 7.49-7.46 (m, 4H), 7.31-7.26 (m, 6H), 7.19-7.14 (m, 2H), 6.81 (d, J=8.8 Hz, 2H), 3.96 (t, J=6.4 Hz, 2H), 3.01-2.94 (m, 2H), 2.51-2.40 (m, 3H), 1.99-1.89 (m, 5H), 1.52-1.45 (m, 4H), 1.28 (s, 9H). 13C NMR (125 MHz, CDCl3): δ 156.7, 145.9, 143.2, 128.1, 126.5, 126.1, 125.7, 116.3, 113.9, 79.5, 66.3, 60.4, 55.4, 54.1, 44.1, 34.0, 31.5, 29.7, 27.0, 26.4. LCMS Retention time: 4.293 min. LCMS purity 95.2%. HRMS (ESI): m/z calcd for C30H37NO2 [M+H]+ 458.6470. found 458.3068.
  • Figure US20150238473A1-20150827-C00165
    • KSC-367-047 2-(6-(tert-butyl)pyridin-3-yl)ethanol
  • Prepared by same method as KSC-352-090 with 5-bromo-2-(tert-butyl)pyridine (0.303 g, 1.415 mmol), dry THF (10 mL), 2.5 M BuLi in hexanes (0.623 mL, 1.557 mmol) and ethylene oxide (1.415 ml, 3.54 mmol) (2.5-3.3M solution in THF) to produce pure 2-(6-(tert-butyl)pyridin-3-yl)ethanol (0.211 g, 1.177 mmol, 83% yield).). 1H NMR (400 MHz, CDCl3): δ 8.40 (br d, J=2.4 Hz, 1H), 7.48 (dd, J=8.2 Hz, 2.4 Hz, 1H), 7.26 (dd, J=8.2 Hz, 0.8 Hz, 1H), 3.85 (br t, J=6.0 Hz, 2H), 2.82 (t, J=6.5 Hz, 2H), 2.29 (br s, 1H), 1.33 (s, 9H).
  • Figure US20150238473A1-20150827-C00166
    • KSC-367-049 2-(6-(tert-butyl)pyridin-3-yl)ethyl 4-methylbenzenesulfonate
  • Prepared by same method at KSC-352-093 with 2-(6-(tert-butyl)pyridin-3-yl)ethanol (KSC-367-047) (0.211 g, 1.177 mmol), TEA (0.492 mL, 3.53 mmol) and DCM (2 mL) followed by p-toluenesulfonyl chloride (0.337 g, 1.766 mmol) to provide pure 2-(6-(tert-butyl)pyridin-3-yl)ethyl 4-methylbenzenesulfonate (0.260 g, 0.780 mmol, 66% yield). 1H NMR (400 MHz, CDCl3): δ 8.29 (br d, J=2.4 Hz, 1H), 7.69 (d, J=8.3 Hz, 2H), 7.40 (dd, J=8.2 Hz, 2.4 Hz, 1H), 7.30-7.27 (m, 2H), 7.23 (dd, J=8.2 Hz, 0.8 Hz, 1H), 4.19 (t, J=6.9 Hz, 2H), 2.92 (t, J=6.8 Hz, 2H), 2.43 (s, 3H), 1.34 (s, 9H).
  • Figure US20150238473A1-20150827-C00167
    • KSC-367-052 (1-(2-(6-(Tert-butyl)pyridin-3-yl)ethyl)piperidin-4-yl)diphenylmethanol
  • To a vial was added the diphenyl(piperidin-4-yl)methanol (0.250 g, 0.936 mmol), 2-(6-(tert-butyl)pyridin-3-yl)ethyl 4-methylbenzenesulfonate (KSC-367-049) (0.260 g, 0.780 mmol) and acetonitrile (5 mL). The TEA (0.163 mL, 1.170 mmol) was then added and the reaction stirred at 50° C. for 20 h and was then cooled to rt and diluted with saturated NaHCO3 then extracted with DCM. The DCM layer was concentrated and purified by reverse-phase MPLC (10-100% MeCN:water) to produce pure (1-(2-(6-(tert-butyl)pyridin-3-yl)ethyl)piperidin-4-yl)diphenylmethanol (0.308 g, 0.719 mmol, 92% yield). 1H NMR (400 MHz, CDCl3): δ 8.39-8.38 (m, 1H), 7.51-7.48 (m, 4H), 7.42 (dd, J=8.1 Hz, 2.4 Hz, 1H), 7.32-7.27 (m, 4H), 7.25-7.22 (m, 1H), 7.20-7.15 (m, 2H), 3.07-3.01 (m, 2H), 2.76-2.71 (m, 2H), 2.57-2.52 (m, 2H), 2.50-2.42 (m, 1H), 2.31 (br s, 1H), 2.09-2.01 (m, 2H), 1.57-1.48 (m, 4H), 1.35 (s, 9H). 13C NMR (125 MHz, CDCl3): δ 166.9, 148.7, 145.9, 136.3, 132.3, 128.1, 126.5, 125.8, 118.6, 79.4, 60.2, 54.0, 44.1, 37.0, 30.3, 30.2, 26.4. LCMS Retention time: 3.802 min. LCMS purity 99.5%. HRMS (ESI): m/z calcd for C29H36N2O [M+H]+ 429.2828. found 429.2900.
  • Figure US20150238473A1-20150827-C00168
    • KSC-367-053 1-(4-(Tert-butyl)phenyl)-4-(4-(diphenylmethylene)piperidin-1-yl)butan-1-one
  • To a vial was added the 4-(diphenylmethylene)piperidin-1- ium 2,2,2-trifluoroacetate (KSC-367-027) (0.0475 g, 0.131 mmol), 1-(4-(tert-butyl)phenyl)-4-chlorobutan-1-one (0.037 g, 0.157 mmol) and TEA (0.046 mL, 0.327 mmol) in acetonitrile. The reaction stirred at 75° C. for 20 h. The reaction was removed from heat and diluted with saturated NaHCO3, extracted with EtOAc. The EtOAc layer was concentrated and purified by reverse-phase MPLC (10-100% MeCN:water) to produce pure 1-(4-(tert-butyl)phenyl)-4-(4-(diphenylmethylene)piperidin-1-yl)butan-1-one (0.019 g, 0.042 mmol, 32% yield). 1H NMR (400 MHz, CDCl3): δ 7.91 (d, J=8.2 Hz, 2H), 7.46 (d, J=8.3 Hz, 2H), 7.30-7.25 (m, 4H), 7.21-7.17 (m, 2H), 7.13-7.10 (m, 4H), 2.99 (t, J=7.2 Hz, 2H), 2.51-2.32 (m, 10H), 1.98-1.91 (m, 2H), 1.34 (s, 9H).
  • Figure US20150238473A1-20150827-C00169
    • KSC-367-055 (1-(4-Chlorophenethyl)piperidin-4-yl)diphenylmethanol
  • To a vial was added the diphenyl(piperidin-4-yl)methanol (0.221 g, 0.827 mmol), 1-(2-bromoethyl)-4-chlorobenzene (0.165 g, 0.752 mmol), acetonitrile (4 mL) and TEA (0.157 mL, 1.128 mmol). The reaction stirred at 75° C. for 18 h then was cooled to rt and diluted with saturated NaHCO3 and extracted with EtOAc. The EtOAc layer was concentrated and purified by reverse-phase MPLC (10-100% MeCN:water) to produce pure (1-(4-chlorophenethyl)piperidin-4-yl)diphenylmethanol (0.224 g, 0.552 mmol, 73% yield). 1H NMR (400 MHz, CDCl3): δ 7.39-7.36 (m, 4H), 7.20-7.15 (m, 4H), 7.12-7.09 (m, 2H), 7.08-7.03 (m, 2H), 6.99-6.96 (m, 2H), 2.92-2.87 (m, 2H), 2.64-2.58 (m, 2H), 2.43-2.38 (m, 2H), 2.37-2.30 (m, 1H), 2.22 (br s, 1H), 1.95-1.88 (m, 2H), 1.44-1.35 (m, 4H). 13C NMR (125 MHz, CDCl3): δ 145.9, 145.8, 138.9, 131.6, 129.9, 128.3, 128.0, 126.4, 125.7, 79.4, 79.3, 60.4, 57.0, 44.1, 33.0, 26.4. LCMS Retention time: 3.903 min. LCMS purity 99.6%. HRMS (ESI): m/z calcd for C26H28ClNO [M+H]+ 406.1859. found 406.1932.
  • Figure US20150238473A1-20150827-C00170
    • KSC-367-058 1-(4-(Tert-butyl)phenyl)-4-(4-(diphenylmethylene)piperidin-1-yl)butan-1-ol
  • Method B: 1-(4-(tert-butyl)phenyl)-4-(4-(diphenylmethylene)piperidin-1-yl)butan-1-one (KSC-367-053) (0.019 g, 0.042 mmol) and sodium borohydride (6.37 mg, 0.168 mmol) to produce pure 1-(4-(tert-butyl)phenyl)-4-(4-(diphenylmethylene)piperidin-1-yl)butan-1-ol (0.010 g, 0.022 mmol, 52% yield). 1H NMR (400 MHz, CDCl3): δ 7.35-7.26 (m, 8H), 7.23-7.18 (m, 2H), 7.13-7.10 (m, 4H), 4.68-4.65 (m, 1H), 2.66-2.60 (m, 2H), 2.55-2.42 (m, 8H), 2.00-1.94 (m, 1H), 1.90-1.81 (m, 1H), 1.73-1.63 (m, 3H), 1.30 (s, 9H). 13C NMR (125 MHz, CDCl3): δ 149.5, 142.7, 142.3, 136.4, 134.6, 129.7, 128.0, 126.4, 125.3, 125.0, 73.3, 58.7, 55.0, 39.6, 34.4, 31.6, 31.4, 31.1, 24.0, 22.6. LCMS Retention time: 4.454 min. LCMS purity 97.1%. HRMS (ESI): m/z calcd for C32H39NO [M+H]+ 454.3032. found 454.3104.
  • Figure US20150238473A1-20150827-C00171
    • KSC-367-066 4-(3-((phenylsulfonyl)methyl)oxetan-3-yl)phenethyl 4-methylbenzenesulfonate
  • Prepared by the same method as KSC-352-093 with 2-(4-(3-((phenylsulfonyl)methyl)oxetan-3-yl)phenyl)ethanol (KSC-367-003) (0.104 g, 0.313 mmol), TEA (0.131 mL, 0.939 mmol) and DCM (2 mL) followed by p-toluenesulfonyl chloride (0.089 g, 0.469 mmol) to produce 4-(3-((phenylsulfonyl)methyl)oxetan-3-yl)phenethyl 4-methylbenzenesulfonate (0.041 g, 0.084 mmol, 27% yield). 1H NMR (400 MHz, CDCl3): δ 7.75 (d, J=8.3 Hz, 2H), 7.57-7.46 (m, 4H), 7.36-7.32 (m, 4H), 7.02-6.96 (m, 3H), 5.00 (d, J=6.4 Hz, 2H), 4.93 (d, J=6.4 Hz, 2H), 4.17 (t, J=7.0 Hz, 2H), 4.01 (s, 2H), 2.90 (t, J=7.0 Hz, 2H), 2.45 (s, 3H).
  • Figure US20150238473A1-20150827-C00172
    • KSC-367-069 Diphenyl(1-(4-(3-((phenylsulfonyl)methyl)oxetan-3-yl)phenethyl)piperidin-4-yl)methanol
  • To a vial was added the 4-(3-((phenylsulfonyl)methyl)oxetan-3-yl)phenethyl 4-methylbenzenesulfonate (KSC-367-066) (0.041 g, 0.084 mmol) and diphenyl(piperidin-4-yl)methanol (0.025 g, 0.093 mmol) in acetonitrile. The TEA (0.018 ml, 0.126 mmol) was then added and the reaction stirred at 50° C. for 18 h. The reaction was removed from heat and cooled to rt then diluted with saturated NaHCO3. The reaction was then extracted with EtOAc (3×5 mL) and the EtOAc layer was dried with MgSO4, filtered and concentrated. The crude residue was purified by reverse-phase MPLC (15 min, 10-100% MeCN:water) to produce diphenyl(1-(4-(3 ((phenylsulfonyl)methyl)oxetan-3-yl)phenethyl)piperidin-4-yl)methanol (0.024 g, 0.041 mmol, 49% yield). 1H NMR (400 MHz, CDCl3): δ 7.53-7.43 (m, 6H), 7.33-7.27 (m, 7H), 7.21-7.16 (m, 2H), 7.04 (d, J=8.2 Hz, 2H), 6.96 (d, J=8.2 Hz, 2H), 5.02 (d, J=6.4 Hz, 2H), 4.92 (d, J=6.4 Hz, 2H), 4.01 (s, 2H), 3.08-3.02 (m, 2H), 2.74-2.69 (m, 2H), 2.56-2.44 (m, 3H), 2.10-2.02 (m, 2H), 1.60-1.50 (m, 5H).
  • Figure US20150238473A1-20150827-C00173
    • KSC-367-072 (1-(4-(3-Methyloxetan-3-yl)phenethyl)piperidin-4-yl)diphenylmethanol
  • To a vial was added the diphenyl(1-(4-(3-((phenylsulfonyl)methyl)oxetan-3-yl)phenethyl)piperidin-4-yl)methanol (KSC-367-069) (0.024 g, 0.041 mmol) and MeOH (10 mL) and the reaction as heated to 50° C. The magnesium was added in 3 additions (0.016 g, 0.066 mmol, 16 equiv) 1.5 h apart. The reaction was removed from heat 1.5 h after the final magnesium addition, cooled to rt and poured into 1.0 M HCl with ice. The aqueous layer was then extracted with DCM (3×10 mL) and the organic layers were combined and dried with MgSO4, filtered and concentrated then purified by reverse-phase MPLC (15 min, 10-100% MeCN:water). To produce (1-(4-(3-methyloxetan-3-yl)phenethyl)piperidin-4-yl)diphenylmethanol (0.0045 g, 10.19 μmol, 24.70% yield) as a light brown solid. 1H NMR (400 MHz, CDCl3): δ 7.51-7.47 (m, 4H), 7.32-7.27 (m, 4H), 7.21-7.16 (m, 4H), 7.13-7.10 (m, 2H), 4.95 (d, J=5.5 Hz, 2H), 4.61 (d, J=5.5 Hz, 2H), 3.09-3.02 (m, 2H), 2.81-2.75 (m, 2H), 2.59-2.54 (m, 2H), 2.50-2.42 (m, 1H), 2.16 (br s, 1H), 2.09-2.00 (m, 2H), 1.71 (s, 3H), 1.56-1.48 (m, 4H). 13C NMR (125 MHz, CDCl3): δ 145.9, 144.1, 138.4, 128.8, 128.2, 126.5, 125.8, 125.1, 83.8, 79.5, 60.7, 54.1, 44.1, 43.1, 33.3, 27.8, 26.4. LCMS Retention time: 3.652 min. LCMS purity 97.9%. HRMS (ESI): m/z calcd for C30H35NO2 [M+H]+ 442.2668. found 442.2741.
  • Figure US20150238473A1-20150827-C00174
    • KSC-367-088 2-(Tert-butyl)phenyl trifluoromethanesulfonate
  • To a vial was added the 2-(tert-butyl)phenol (1.0 ml, 6.51 mmol) and DCM (4 mL) followed by pyridine (1.053 mL, 13.02 mmol). The reaction was then cooled to 0° C. and the triflic anhydride (1.320 mL, 7.81 mmol) was added dropwise and the reaction stirred for 2 h. The reaction was then allowed to warm to rt and was diluted with DCM and quenched with 1.0 M HCl. The DCM layer was collected and washed with saturated NaHCO3 and brine. The organic layer was then dried (MgSO4), filtered and adsorbed to silica and purified by MPLC (0-25% EtOAc:hex) to produce pure 2-(tert-butyl)phenyl trifluoromethanesulfonate (1.66 g, 5.88 mmol, 90% yield). 1H NMR (400 MHz, CDCl3): δ 7.49-7.46 (m, 1H), 7.37-7.34 (m, 1H), 7.31-7.27 (m, 2H), 1.43 (s, 9H).
  • Figure US20150238473A1-20150827-C00175
    • KSC-381-009 2-(2-(Tert-butyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
  • To a flame-dried vial was added molecular sieves and 2-(tert-butyl)phenyl trifluoromethanesulfonate (KSC-367-088) (0.475 g, 1.683 mmol) and 1,1′-Bis(diphenylphosphino)ferrocenedichloropalladium(II) (0.042 g, 0.050 mmol). The vial was evacuated with argon 3 times and then dioxane (1 mL), TEA (0.704 mL, 5.05 mmol) and 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.732 mL, 5.05 mmol) were added via syringe. The reaction stirred at reflux (100° C.) for 2 h. The reaction was then removed from heat and diluted with water then extracted with DCM (3×5 mL). The DCM layer was then washed again with water (3×10 mL). The DCM layer was dried with MgSO4, filtered and concentrated. The residue was diluted with hexanes and filtered through MgSO4 to remove the residual Pd complex. The hexanes layer was then concentrated to produce pure 2-(2-(tert-butyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.093 g, 0.357 mmol, 86% yield). 1H NMR (400 MHz, CDCl3): δ 7.45 (dd, J=7.2 Hz, 1.2 Hz, 1H), 7.41-7.39 (m, 1H), 7.29 (td, J=7.6 Hz, 2.0 Hz, 1H), 7.14 (td, J=7.6 Hz, 2.0 Hz, 1H), 1.41 (s, 9H), 1.38 (s, 12H).
  • Figure US20150238473A1-20150827-C00176
    • KSC-381-011 1-Bromo-2-(tert-butyl)benzene
  • To a vial was added the 2-(2-(tert-butyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (KSC-381-009) (0.180 g, 0.692 mmol) and MeOH (1.5 mL). The copper (II) bromide (0.464 g, 2.075 mmol) was then dissolved in water and added to the reaction then stirred at 80° C. for 24 h. The reaction was then removed from heat and diluted with water and extracted with EtOAc. The EtOAc was dried with MgSO4, filtered and concentrated to produce 1-bromo-2-(tert-butyl)benzene (0.103 g, 0.483 mmol, 70% yield) as a brown liquid. 1H NMR (400 MHz, CDCl3): δ 7.59 (dd, J=8.0 Hz, 1.6 Hz, 1H), 7.44 (dd, J=8.0 Hz, 1.6 Hz, 1H), 7.24 (td, J=7.6 Hz, 2.0 Hz, 1H), 7.02 (td, J=7.6 Hz, 2.0 Hz, 1H), 1.51 (s, 9H).
  • Figure US20150238473A1-20150827-C00177
    • KSC-381-015 2-(2-(Tert-butyl)phenyl)ethanol
  • Prepared by same method as KSC-352-090 with 1-bromo-2-(tert-butyl)benzene (KSC-381-011) (0.147 g, 0.690 mmol), dry THF, 2.5 M BuLi in hexanes (0.303 ml, 0.759 mmol) and then ethylene oxide (0.690 ml, 1.724 mmol) (2.5-3.3M solution in THF) to produce pure 2-(2-(tert-butyl)phenyl)ethanol (0.018 g, 0.101 mmol, 14.64% yield) as a clear oil. 1H NMR (400 MHz, CDCl3): δ 7.43-7.37 (m, 1H), 7.23-7.19 (m, 1H), 7.18-7.14 (m, 2H), 3.90 (t, J=7.6 Hz, 2H), 3.19 (t, J=7.6 Hz, 2H), 1.44 (s, 9H).
  • Figure US20150238473A1-20150827-C00178
    • KSC-381-018 2-(Tert-butyl)phenethyl 4-methylbenzenesulfonate
  • Prepared according to same procedure as KSC-352-093 with 2-(2-(tert-butyl)phenyl)ethanol (KSC-381-015) (0.018 g, 0.101 mmol), TEA (0.042 mL, 0.303 mmol) and DCM (2 mL) followed by p-toluenesulfonyl chloride (0.029 g, 0.151 mmol) to provide pure 2-(tert-butyl)phenethyl 4-methylbenzenesulfonate (0.022 g, 0.066 mmol, 66% yield) and a clear oil. 1H NMR (400 MHz, CDCl3): δ 7.76 (d, J=8.0 Hz, 2H), 7.37-7.31 (m, 3H), 7.17-7.04 (m, 3H), 4.19 (t, J=7.6 Hz, 2H), 3.25 (t, J=7.6 Hz, 2H), 2.44 (s, 3H), 1.33 (s, 9H).
  • Figure US20150238473A1-20150827-C00179
    • KSC-381-020 (1-(2-(Tert-butyl)phenethyl)piperidin-4-yl)diphenylmethanol
  • To a vial was added the 2-(tert-butyl)phenethyl 4-methylbenzenesulfonate (KSC-381-018) (0.022 g, 0.066 mmol), diphenyl(piperidin-4-yl)methanol (0.018 g, 0.066 mmol) and acetonitrile. The TEA (0.014 mL, 0.099 mmol) was added and the reaction stirred at 85° C. for 20 h. The reaction was cooled to rt and diluted with water then extracted with EtOAc. The EtOAc layer was concentrated and the crude product was purified by reverse-phase MPLC (10-100% MeCN:water) to produce the pure (1-(2-(tert-butyl)phenethyl) piperidin-4-yl)diphenylmethanol (0.013 g, 0.030 mmol, 46% yield). 1H NMR (400 MHz, CDCl3): δ 7.51-7.48 (m, 4H), 7.37-7.28 (m, 5H), 7.21-7.09 (m, 5H), 3.15-3.04 (m, 4H), 2.65-2.60 (m, 2H), 2.52-2.42 (m, 1H), 2.17-2.08 (m, 3H), 1.60-1.53 (m, 4H), 1.41 (s. 9H). 13C NMR (125 MHz, CDCl3): δ 147.7, 145.9, 138.5, 132.1, 128.2, 126.5, 126.1, 125.9, 125.84, 125.79, 79.5, 61.7, 54.2, 44.2, 35.7, 31.7, 29.7, 26.4. LCMS Retention time: 4.200 min. LCMS purity 99.3%. HRMS (ESI): m/z calcd for C30H37NO [M+H]+ 428.2875. found 428.2948.
    • Bacterial Strains and Conditions
  • All strains used to evaluate the antimicrobial activity of terfenadine and corresponding structural derivatives are shown below in Table 5. S. aureus strain UAMS-1 is an osteomyelitis clinical isolate (Gillaspy et al. “Role of the accessory gene regulator (agr) in pathogenesis of staphylococcal osteomyelitis. Infect. Immun. 63:3373-3380 (1995)), whereas ciprofloxacin-resistant strains CRC118 and CRC61 are spontaneous ciprofloxacin-resistant derivatives of UAMS-1 that were selected by growth on Mueller-Hinton agar (MHA) (Becton, Dickinson & Company, Franklin Lakes, N.J.) at 1.5×MIC ciprofloxacin (0.75 μg/ml).
  • TABLE 5
    Bacterial Strains Used in Terfenadine Study
    Species Strain Source
    S. aureus UAMS-1 1
    CRC61 Dunman Lab, URMC
    CRC118 Dunman Lab, URMC
    • Minimum Inhibitory Concentration (MIC) Testing
  • Minimum Inhibitory Concentration (MIC) testing was performed to determine the minimum concentration of test compound that is necessary to inhibit visible growth of bacteria according to Clinical and Laboratory Standards (CLSI) guidelines (Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Ninth Edition. CLSI document M07-A9. 2012. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pa. 19087-1898 USA.) To do so, 105 colony forming units of an overnight bacterial culture were seeded into individual wells of 96-well round-bottom microtiter plates containing 88 μl of MHB medium. To the first column, 2 μl of the test compound's corresponding solvent was also added to each well (negative control). To the next ten columms, 2 μl of the test compound (dissolved in DMSO for terfenadine and its derivatives or sterile water for ciprofloxacin) was added in increasing 2-fold increments of 0.5 μg/ml to 256 μg/ml to each successive well. Each test compound was evaluated in duplicate. Plates were incubated at 37° C. incubator for 16 h at which point the minimum inhibitory concentration was determined to be the lowest concentration of test compound that inhibited bacterial growth, as judged by the unaided eye.
  • S. aureus DNA Gyrase Supercoiling Assay (TopoGEN)
  • The gyrase supercoiling assays were performed to determine if test compounds interfered with S. aureus DNA gyrase activity, following the manufacturer's recommendations (TopoGEN). Reactions (20 μl) contained kit provided assay buffer, ATP, potassium glutamate, relaxed plasmid DNA (0.4 μg/ml), 2 Units of S. aureus DNA gyrase, and various amounts of test compound. Reactions were incubated at 37° C. for 30 min and then stopped by the addition of 10% SDS, filtered through 0.025 μm Millipore membrane filters in a 10 mM Tris-HCl buffer (pH 8), and electrophoresed in a 1% agarose TAE gel. Gels were stained with 0.5 μg/ml ethidium bromide and images were analyzed using densitometry (Image J, NIH). The IC50 values for each test compound was determined to be the compound concentration that inhibited S. aureus DNA gyrase activity by 50%.
  • S. aureus Topoisomerase IV Decatenation Assay (Inspiralis)
  • A Topoisomerase IV assay was performed on test compounds to determine if they interfered with the ability of S. aureus topoisomerase IV to decatenate kDNA, according to the recommendations of the manufacturer (Inspiralis). To do so, 0.25 U S. aureus topoisomerase IV enzyme was mixed with 200 ng kDNA in kit provided reaction buffer, in the absence or presence of various concentrations of test compounds at 37° C. for 30 min. The reaction was stopped by the addition of STEB stop buffer and 30 μl of 24:1 chlorform:isoamyl alcohol (total volume 90 μl). Reaction products then electrophoresed in a 1% agarose TAE gel, stained with 0.5 μg/ml ethidium bromide and images were analyzed using densitometry (Image J, NIH). The IC50 value for each test compound was determined as the compound concentration that inhibited S. aureus topoisomerase IV activity by 50%. The results are set forth in Table 6.
  • TABLE 6
    ¶    
    Figure US20150238473A1-20150827-P00899
    Mole- Topo-
    Com- KUC- cular- MIC- Gyrase- isomeras-
    pound- Registry- Weight- (μg/ IC50 iv-IC50-
    #o Numbero (g/mol)o Structureo mL)o (μM)o (μM)o
    Terfena- dineo N/Ao 471.673
    Figure US20150238473A1-20150827-P00899
    Figure US20150238473A1-20150827-C00180
         		 16o  190.00o  206.67o
     1o KSC- 335- 012o 457.647
    Figure US20150238473A1-20150827-P00899
    Figure US20150238473A1-20150827-C00181
         		 16o  126.67o  273.33o
     2o KSC- 335- 013o 485.7o
    Figure US20150238473A1-20150827-C00182
         		 16o  100.00o  133.33o
     3o KSC- 335- 014o 471.673¶
    Figure US20150238473A1-20150827-P00899
    Figure US20150238473A1-20150827-C00183
         		  8o  330.00o  103.33o
     4o KSC- 335-015o 450.12o
    Figure US20150238473A1-20150827-C00184
         		 64o  133.33o >333o
     5o KSC- 335- 016o 457.647o
    Figure US20150238473A1-20150827-C00185
         		  8o  133.33o  333.88o
     6o KSC- 335- 021o 415.567o
    Figure US20150238473A1-20150827-C00186
         		 256o >500o >333o
     7o KSC- 335-030o 445.593o
    Figure US20150238473A1-20150827-C00187
         		 256o >500o >333o
     8o KSC- 335- 031o 433.558o
    Figure US20150238473A1-20150827-C00188
         		 128o >500o >333o
     9o KSC- 335- 032o 494.463o
    Figure US20150238473A1-20150827-C00189
         		  32o >500o >333o
    10o KSC- 335- 041o 455.674o
    Figure US20150238473A1-20150827-C00190
         		  8o 93.33o 320.00o
    11o KSC- 335- 007o 469.658o
    Figure US20150238473A1-20150827-C00191
         		  8o  93.33o  110.00o
    12o KSC- 335- 069o 471.673o
    Figure US20150238473A1-20150827-C00192
         		 16o  126.67o  100.00o
    13o KSC- 335- 070o 471.673o
    Figure US20150238473A1-20150827-C00193
         		 16o  410.00o  110.00o
    14o KSC- 335- 077o 429.594o
    Figure US20150238473A1-20150827-C00194
         		 128o >500o >333o
    15o KSC- 335- 080o 515.683o
    Figure US20150238473A1-20150827-C00195
         		 128o >500o >333o
    16o KSC- 335- 081o 501.656o
    Figure US20150238473A1-20150827-C00196
         		>256o >500o >333o
    17o KSC- 342- 010o 443.62o
    Figure US20150238473A1-20150827-C00197
         		 16o  73.33o  100.00o
    18c KSC- 342- 017o
    Figure US20150238473A1-20150827-P00899
      ¶ 473.603
    Figure US20150238473A1-20150827-C00198
         		 256o  440.00o >333o
    19 KSC- 342- 021 459.577
    Figure US20150238473A1-20150827-C00199
         		>256 >500 >333
    20 KSC- 342- 006 441.604
    Figure US20150238473A1-20150827-C00200
         		>256  73.33  246.67
    21 KSC- 335- 008 455.631
    Figure US20150238473A1-20150827-C00201
         		 32  90.00  133.33
    22 KSC- 342- 080 441.647
    Figure US20150238473A1-20150827-C00202
         		  8  93.33  100.00
    23 KSC- 342- 081 427.621
    Figure US20150238473A1-20150827-C00203
         		  8  93.33  146.67
    24 KSC- 342- 088 470.689
    Figure US20150238473A1-20150827-C00204
         		 16 >500 >333
    25 KSC- 348- 002 491.663
    Figure US20150238473A1-20150827-C00205
         		  8  13.33  100.00
    26 KSC- 348- 050 413.595
    Figure US20150238473A1-20150827-C00206
         		  8  90.00  213.33
    27 KSC- 348- 049 427.578
    Figure US20150238473A1-20150827-C00207
         		>256  93.33 >333
    28 KSC- 348- 058 401.541
    Figure US20150238473A1-20150827-C00208
         		 256 >333 >333
    29 KSC- 352- 060 416.512
    Figure US20150238473A1-20150827-C00209
         		 64  263.33 >333
    30 KSC- 352- 061 450.411
    Figure US20150238473A1-20150827-C00210
         		 16  246.67  260.00
    31 KSC- 352- 066 395.577
    Figure US20150238473A1-20150827-C00211
         		 128 >333 >333
    32 KSC- 352- 063 447.611
    Figure US20150238473A1-20150827-C00212
         		  8  80.00  133.33
    33 KSC- 352- 064 448.599
    Figure US20150238473A1-20150827-C00213
         		 32  93.33  226.67
    34 KSC- 352- 069 386.529
    Figure US20150238473A1-20150827-C00214
         		 256  93.33 >333
    35 KSC- 352- 065 448.599
    Figure US20150238473A1-20150827-C00215
         		 32  250.00  280.00
    36 KSC- 352- 075 414.582
    Figure US20150238473A1-20150827-C00216
         		 256 >333 >333
    37 KSC- 352- 082 439.513
    Figure US20150238473A1-20150827-C00217
         		 16  16.67 >333
    38 KSC- 352- 088 389.505
    Figure US20150238473A1-20150827-C00218
         		 128 >333 >333
    39 KSC- 352- 097 427.621
    Figure US20150238473A1-20150827-C00219
         		 16  93.33 >333
    40 KSC- 367- 039 379.578
    Figure US20150238473A1-20150827-C00220
         		 64 >333 >333
    41 KSC- 367- 043 456.662
    Figure US20150238473A1-20150827-C00221
         		  8  193.33  250.00
    42 KSC- 367- 044 457.647
    Figure US20150238473A1-20150827-C00222
         		  8  100.00 >333
    43 KSC- 367- 052 428.609
    Figure US20150238473A1-20150827-C00223
         		 64 >333 >333
    44 KSC- 367- 055 405.96
    Figure US20150238473A1-20150827-C00224
         		 32  260.00  266.67
    45 KSC- 367- 072 441.604
    Figure US20150238473A1-20150827-C00225
         		>256 >333 >333
    Figure US20150238473A1-20150827-P00899
    indicates data missing or illegible when filed

Claims (15)

1. A method of treating or preventing an infection in a subject with or at risk of developing an infection, the method comprising administering to the subject a
a compound of Formula I
Figure US20150238473A1-20150827-C00226
wherein R represents hydrogen or hydroxyl and R1 represents hydrogen, or R and R1 taken together form a second bond between the carbon atoms bearing R and R1; R2 represents hydrogen or phenyl; n is zero or a positive whole integer of from 1 to 4; X represents CH2, CHOH, NH, C═O, CHNR3R4, where R3 and R4 independently are hydrogen or lower alkyl; and Z represents thienyl, pyridinyl, substituted pyridinyl, phenyl or substituted phenyl wherein the substituents on the substituted pyridinyl or substituted phenyl are selected from phenyl, pyridinyl, nitro, a halogen atom, such as chlorine, fluorine, bromine, or iodine, a straight or branched lower alkyl chain of from 1 to 4 carbon atoms, a lower alkoxy group of from 1 to 4 carbon atoms, amino, a mono or di(lower)alkylamino group, a saturated monocyclic heterocyclic group such as pyrrolidino, piperidino, morpholino, or N-(lower)alkylpiperazino, or a group having the structure —COOR5, —CR6R7COOR5, —CF3, CHF2, CH2F, or
Figure US20150238473A1-20150827-C00227
where R5 is hydrogen or lower alkyl, and R6 and R7 independently are hydrogen or methyl or a pharmaceutically acceptable salt thereof.
2-4. (canceled)
5. The method of claim 1, wherein the infection is a bacterial infection, a viral infection, a parasitic infection or a fungal infection.
6. The method of claim 1, wherein the infection is a respiratory infection.
7. The method of claim 1, wherein the infection is a gastrointestinal infection.
8. The method of claim 1, wherein the infection is a skin infection.
9. The method of claim 5 wherein the bacterial infection is selected from the group consisting of Enterobacterium faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinebacter baumannii, Pseudomonas aeruginosa and Enterobacter sp.
10. The method of claim 5, wherein the bacterial infection is a small colony variant bacterial infection.
11. A method of treating or preventing a bacterial infection in a subject with or at risk of developing a bacterial infection, the method comprising administering terfenadine to the subject.
12. (canceled)
13. A method of removing or preventing biofilm formation on a surface, the method comprising administering to a biofilm containing surface or a surface susceptible to biofilm formation an effective amount of a compound of Formula I
Figure US20150238473A1-20150827-C00228
wherein R represents hydrogen or hydroxyl and R1 represents hydrogen, or R and R1 taken together form a second bond between the carbon atoms bearing R and R1; R2 represents hydrogen or phenyl; n is zero or a positive whole integer of from 1 to 4; X represents CH2, CHOH, NH, C═O, CHNR3R4, where R3 and R4 independently are hydrogen or lower alkyl; and Z represents thienyl, pyridinyl, substituted pyridinyl, phenyl or substituted phenyl wherein the substituents on the substituted pyridinyl or substituted phenyl are selected from phenyl, pyridinyl, nitro, a halogen atom, such as chlorine, fluorine, bromine, or iodine, a straight or branched lower alkyl chain of from 1 to 4 carbon atoms, a lower alkoxy group of from 1 to 4 carbon atoms, amino, a mono or di(lower)alkylamino group, a saturated monocyclic heterocyclic group such as pyrrolidino, piperidino, morpholino, or N-(lower)alkylpiperazino, or a group having the structure —COOR5, —CR6R7COOR5, —CF3, CHF2, CH2F, or
Figure US20150238473A1-20150827-C00229
where R5 is hydrogen or lower alkyl, and R6 and R7 independently are hydrogen or methyl or a pharmaceutically acceptable salt thereof.
14. The method of claim 13, wherein the biofilm comprises one or more of Staphylococcus aureus, Pseudomonas aeuroginosa, Staphylococcus epidermidis, Escherichia coli or Acinetobacter baummanii.
15. A method of identifying an antimicrobial agent comprising:
a) contacting a bacterial culture with a test agent;
b) and measuring adenylate kinase release in the supernatant of the bacterial culture, wherein an increase in adenylate kinase release as compared to a control indicates that the test compound is an antimicrobial agent.
16. The method of claim 15, wherein the bacterial culture is selected from the group consisting of Staphylococcus aureus, Pseudomonas aeuroginosa, Staphylococcus epidermidis, Escherichia coli or Acinetobacter baummanii.
17. The method of claim 5, wherein the parasitic infection is not malaria.
US14/431,031 2012-09-27 2013-09-27 Methods and compositions for treating infection Abandoned US20150238473A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/431,031 US20150238473A1 (en) 2012-09-27 2013-09-27 Methods and compositions for treating infection

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261706492P 2012-09-27 2012-09-27
PCT/US2013/062309 WO2014052836A2 (en) 2012-09-27 2013-09-27 Methods and compositions for treating infection
US14/431,031 US20150238473A1 (en) 2012-09-27 2013-09-27 Methods and compositions for treating infection

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/062309 A-371-Of-International WO2014052836A2 (en) 2012-09-27 2013-09-27 Methods and compositions for treating infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/356,940 Division US10004701B2 (en) 2012-09-27 2016-11-21 Methods and compositions for treating infection

Publications (1)

Publication Number Publication Date
US20150238473A1 true US20150238473A1 (en) 2015-08-27

Family

ID=50389149

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/431,031 Abandoned US20150238473A1 (en) 2012-09-27 2013-09-27 Methods and compositions for treating infection
US15/356,940 Expired - Fee Related US10004701B2 (en) 2012-09-27 2016-11-21 Methods and compositions for treating infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/356,940 Expired - Fee Related US10004701B2 (en) 2012-09-27 2016-11-21 Methods and compositions for treating infection

Country Status (2)

Country Link
US (2) US20150238473A1 (en)
WO (1) WO2014052836A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106859800A (en) * 2017-02-27 2017-06-20 滨州医学院 A kind of tumor planting device
US20200000742A1 (en) * 2016-10-05 2020-01-02 Helperby Therapeutics Limited Combination
CN111000841A (en) * 2020-01-03 2020-04-14 陕西科技大学 Application of luteolin in inhibition of growth of multiple drug-resistant enterobacter cloacae
CN113318115A (en) * 2021-06-22 2021-08-31 山东省农业科学院畜牧兽医研究所 Application of metacycline in preparation of medicine for preventing and treating bovine parainfluenza virus type 3 virus infection
US20210361621A1 (en) * 2018-07-16 2021-11-25 The Medical College Of Wisconsin, Inc. Compositions and Methods for Reducing Weight Gain
CN114456983A (en) * 2022-03-03 2022-05-10 云南农业大学 Acinetobacter lofei AL202103 strain for degrading alpha-solanine and preparation method and application thereof
CN115177617A (en) * 2015-03-31 2022-10-14 麦姆德制药公司 Methods of treating cancer, autoimmune disorders, and other conditions associated with chronic inflammation
US20230036304A1 (en) * 2021-07-28 2023-02-02 Subhash Dhawan Therapeutic swabs for treating upper respiratory infections
CN115737628A (en) * 2022-02-23 2023-03-07 安阳工学院 Application of bergenin sulfonate derivative in resisting activity of drug-resistant bacteria

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015289126A1 (en) * 2014-07-16 2017-02-02 C.N.C.C.S. S.C.A.R.L. Collezione Nazionale Dei Composti Chimici E Centro Screening Use of Perhexiline
US10335454B2 (en) * 2014-12-18 2019-07-02 Helperby Therapeutics Limited Combination and use
CN108459094A (en) * 2017-12-07 2018-08-28 广东东阳光药业有限公司 A kind of evaluation method of rats'liver CYP450 enzyme inductions
EP3524237A1 (en) 2018-02-13 2019-08-14 European Molecular Biology Laboratory Repurposing compounds for the treatment of infections and for modulating the composition of the gut microbiome
US11338010B2 (en) 2020-03-30 2022-05-24 Suzhou Kintor Pharmaceuticals, Inc. Systems, methods, and kits for diagnostics and treatment of viral respiratory infection
WO2021202014A1 (en) * 2020-03-30 2021-10-07 Applied Biology, Inc. Anti-androgen or an androgen receptor antagonist for treatment of a viral respiratory infection
US20240002935A1 (en) * 2020-04-11 2024-01-04 Geneticure Inc. Genetic method for diagnosis and treatment of pre and post coronavirus infections
EP3939585A4 (en) * 2020-05-20 2022-03-02 Syntekabio, Inc. Preventive or therapeutic composition for severe acute respiratory syndrome coronavirus type 2 infectious disease
WO2021252709A1 (en) * 2020-06-10 2021-12-16 Rutgers, The State University Of New Jersey Compounds, compositions, and methods for treating, ameliorating, and/or preventing sigma receptor related diseases and/or disorders
US11857551B1 (en) 2020-07-10 2024-01-02 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss
CN112156089A (en) * 2020-09-27 2021-01-01 天津国际生物医药联合研究院 Application of benzbromarone in resisting mycobacterium tuberculosis infection
CN114601822A (en) * 2020-12-09 2022-06-10 润佳（苏州）医药科技有限公司 Pharmaceutical use of condensed ring phenolic compounds
CN115068454A (en) * 2021-03-15 2022-09-20 中国医学科学院药物研究所 Application of salmeterol medicine for preventing and treating coronavirus infection
CN114259485A (en) * 2021-12-14 2022-04-01 华中科技大学协和深圳医院 Application of benzbromarone in resisting staphylococcus aureus and biofilm infection thereof
CN114224891B (en) * 2021-12-29 2023-04-18 佛山科学技术学院 Application of clofazimine in preparation of medicines for preventing and treating Porcine Reproductive and Respiratory Syndrome (PRRSV)
CN118496647B (en) * 2024-07-19 2024-09-27 泰州泽钰新材料科技有限公司 Modified polylactic acid heat-resistant degradable composite material and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1214937A2 (en) * 1992-08-03 2002-06-19 Sepracor Inc. Terfenadine carboxylate and the treatment of dermal irritation
WO2003020274A1 (en) * 2001-08-30 2003-03-13 Aventis Pharmaceuticals Inc. Treatment of atopic dermatitis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3689646A (en) 1969-09-04 1972-09-05 Univ Pennsylvania Antimutagenic treatment of bacteria
US5261896A (en) 1990-01-10 1993-11-16 Rochester Medical Corporation Sustained release bactericidal cannula
US5610198A (en) 1994-03-18 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases
ZA952521B (en) * 1994-03-28 1996-03-15 Univ Columbia Composition for inactivating irritants in fluids
KR100550839B1 (en) 1997-09-17 2006-02-10 에자이 가부시키가이샤 Antimicrobials
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
AR031135A1 (en) 2000-10-10 2003-09-10 Upjohn Co TOPIC ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF OCULAR INFECTIONS
US20110092488A1 (en) 2005-10-28 2011-04-21 Geoffrey Dow Quninoline Methanol Compounds for the Treatment and Prevention of Parasitic Infections
CN101511430A (en) 2006-08-03 2009-08-19 普罗森萨技术有限公司 Antibiotic composition
WO2008033466A2 (en) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
CA2669591A1 (en) 2006-11-16 2008-05-22 E-Therapeutics Limited Treatment of multi-drug resistant bacterial infections
WO2009143309A2 (en) * 2008-05-21 2009-11-26 Trustees Of Dartmouth College Female reproductive tract and anal prophylaxes
GB0813211D0 (en) 2008-07-18 2008-08-27 E Therapeutics Plc Antibacterial combination therapy for the treatment of gram positive bacterial infections
WO2011137376A2 (en) * 2010-04-30 2011-11-03 University Of Rochester Compounds for anti-fungal treatment
HUE048859T2 (en) 2010-08-10 2020-08-28 Rempex Pharmaceuticals Inc Cyclic boronic acid ester derivatives, method for the preparation and therapeutic uses thereof
GB201015079D0 (en) * 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1214937A2 (en) * 1992-08-03 2002-06-19 Sepracor Inc. Terfenadine carboxylate and the treatment of dermal irritation
WO2003020274A1 (en) * 2001-08-30 2003-03-13 Aventis Pharmaceuticals Inc. Treatment of atopic dermatitis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Lubbe "Secondary Infections in Patients with Atopic Dermatitis," Am. J. Clin. Dermatol. 2003, Vol. 4, No. 9, pp 641-654 *
Rigoni et al. "Treatment of histamine-dependent allergic dermatoses with 120-mg terfenadine tablet once a day," Giornale italiano di dermatologia e venerologia: organo ufficiale, Societa Italiana di dermatologia e sifilografia, 1989, Vol. 124, No. 9, pp XXXIX-XLI. Medline abstract, AN 1990243318. *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115177617A (en) * 2015-03-31 2022-10-14 麦姆德制药公司 Methods of treating cancer, autoimmune disorders, and other conditions associated with chronic inflammation
US20200000742A1 (en) * 2016-10-05 2020-01-02 Helperby Therapeutics Limited Combination
CN106859800A (en) * 2017-02-27 2017-06-20 滨州医学院 A kind of tumor planting device
US20210361621A1 (en) * 2018-07-16 2021-11-25 The Medical College Of Wisconsin, Inc. Compositions and Methods for Reducing Weight Gain
CN111000841A (en) * 2020-01-03 2020-04-14 陕西科技大学 Application of luteolin in inhibition of growth of multiple drug-resistant enterobacter cloacae
CN113318115A (en) * 2021-06-22 2021-08-31 山东省农业科学院畜牧兽医研究所 Application of metacycline in preparation of medicine for preventing and treating bovine parainfluenza virus type 3 virus infection
US20230036304A1 (en) * 2021-07-28 2023-02-02 Subhash Dhawan Therapeutic swabs for treating upper respiratory infections
US11724077B2 (en) * 2021-07-28 2023-08-15 Subhash Dhawan Therapeutic swabs for treating upper respiratory infections
CN115737628A (en) * 2022-02-23 2023-03-07 安阳工学院 Application of bergenin sulfonate derivative in resisting activity of drug-resistant bacteria
CN114456983A (en) * 2022-03-03 2022-05-10 云南农业大学 Acinetobacter lofei AL202103 strain for degrading alpha-solanine and preparation method and application thereof

Also Published As

Publication number Publication date
US20170065540A1 (en) 2017-03-09
WO2014052836A2 (en) 2014-04-03
WO2014052836A3 (en) 2014-05-22
US10004701B2 (en) 2018-06-26

Similar Documents

Publication Publication Date Title
US10004701B2 (en) Methods and compositions for treating infection
ES2585262T3 (en) Hexahydropyran [3,4-d] [1,3] thiazin-2-amine heterocyclic compounds substituted as inhibitors of PPA, BACE1 and BACE2
US20110160223A1 (en) NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders
TWI692465B (en) Prodrugs of phenolic trpv1 agonists
US20120220564A1 (en) Selective calcium channel modulators
US20070161690A1 (en) Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
JP4584534B2 (en) Materials for the treatment of gastroesophageal reflux disease
JP2011500577A (en) Pharmaceutical formulation of valsartan
EP1146790A1 (en) Compounds and methods
JP2022525856A (en) Charged ion channel blockers and usage
AU2018392985A1 (en) Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
JP2023500890A (en) Charged ion channel blockers and methods of use
WO2004010942A2 (en) Substituted heterocyclic compounds as modulators of the ccr5 receptor
EA021224B1 (en) Piperidinyl derivative as a modulator of chemokine receptor activity
KR20110017452A (en) Novel compounds active as muscarinic receptor antagonists
CN115279731A (en) Charged ion channel blockers and methods of use thereof
EP3233799B1 (en) Dopamine d2 receptor ligands
JP5165166B1 (en) Novel piperazine as an antimalarial drug
CN108440446B (en) Benzothiazine-4-ketone compound containing oximino fragment and preparation method thereof
US8507482B2 (en) Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
WO2020142657A1 (en) Charged ion channel blockers and methods for use thereof
US11731947B2 (en) Deuterated antimicrobial compounds
US7618986B2 (en) Method of treating latent tuberculosis
JP2006526633A (en) Anti-HIV benzamide compound
WO1996031472A1 (en) Novel heterocyclic compounds

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIVERSITY OF ROCHESTER, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DUNMAN, PAUL M.;KRYSAN, DAMIAN J.;REEL/FRAME:032038/0798

Effective date: 20140122

Owner name: UNIVERSITY OF KANSAS, KANSAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FLAHERTY, DANIEL P.;REEL/FRAME:032038/0633

Effective date: 20131009

AS Assignment

Owner name: UNIVERSITY OF ROCHESTER, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DUNMAN, PAUL M.;KRYSAN, DAMIAN J.;REEL/FRAME:035251/0357

Effective date: 20140122

Owner name: UNIVERSITY OF KANSAS, KANSAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FLAHERTY, DANIEL P.;REEL/FRAME:035251/0433

Effective date: 20131009

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF ROCHESTER;REEL/FRAME:044209/0308

Effective date: 20171012